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ABSTRACT 
The exceptional capacity for regeneration of olfactory sensory neurons in the olfactory epithelium 
and their axonal projections into the central nervous system (CNS) has led to extensive 
investigation of olfactory ensheathing cell (OEC) transplantation as a therapy to promote repair 
within the injured CNS.  In those studies that report enhanced anatomical and functional recovery, 
the beneficial effects of OECs have been variously attributed to OECs re-myelinating axons, 
forming a supportive tract for axon growth across the boundary between the peripheral and 
central nervous systems or producing growth factors, cell adhesion molecules and extracellular 
matrix proteins that promote axon growth. This thesis investigates the possibility that OECs 
modulate the inflammatory activation of astrocytes and could thereby contribute to CNS injury 
repair after therapeutic transplantation.  
 
Following CNS injury, factors released by damaged cells, activated microglia and invading 
peripheral immune cells activate surviving astrocytes in the lesion penumbra. The activated 
astrocytes undergo reactive astrogliosis and become another important source of inflammatory 
mediators. These inflammatory responses often lead to delayed secondary neuronal loss and 
tissue damage that can exceed the initial traumatic damage. In addition, astrogliosis leads to the 
development of a glial scar around the lesion that is a barrier to axonal regeneration. Therefore, 
moderation of astrocyte activation by transplanted OECs could potentially both protect neurons 
by moderating inflammation and promote axon regeneration by moderating astrogliosis and glial 
scarring. 
 
The transcription factor nuclear factor-kappaB (NF-κB) is a key regulator of inflammatory 
responses, including many of the protein expression changes that characterize astrogliosis. NF-κB 
exists as inactive dimers in the cytoplasm of most cells and must translocate to the nucleus in 
order to regulate gene transcription. Phorbol myristate acetate (PMA) and calcium ionophore 
(PMA/ionophore) stimulation was found to induce rapid robust translocation of NF-κB to 
astrocyte nuclei (p < 0.001), providing an in vitro model of astrocyte inflammatory activation. 
NF-κB translocation was readily detectable by immunocytochemistry, providing a relatively 
simple, direct, unambiguous measure of this early key event in astrocyte activation. Subsequently, 
soluble factors released by microglia were found to similarly induce NF-κB translocation in 
astrocytes (p < 0.001), illustrating that this detection method can be utilised to investigate other 
inflammatory stimuli. 
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Most importantly, soluble factors released by OECs moderated the NF-κB translocation induced 
in astrocytes by either PMA/calcium ionophore or the microglia-derived factors (p < 0.001). 
Immunostaining confirmed that insulin-like growth factor-1 (IGF-1) was expressed by the 
cultured OECs and may have contributed to the moderation of astrocyte activation, since IGF-1 
also significantly moderated (p < 0.05) the NF-κB translocation induced by either stimulus, albeit 
insufficiently (p < 0.01) to account in full for the OEC-induced moderation. OECs also 
significantly moderated the increased transcription of the NF-κB-regulated pro-inflammatory 
cytokine, granulocyte macrophage-colony stimulating factor (GM-CSF) in the activated 
astrocytes (p < 0.01). High levels of GM-CSF released by astrocytes can stimulate microglia to 
produce cytotoxic levels of pro-inflammatory cytokines that may further amplify and prolong 
inflammation. More severe inflammation leads to more severe astrogliosis, increased secondary 
neuronal damage and more extensive glial scarring, accompanied by increased deposition of axon 
growth-inhibitory extracellular matrix molecules. Hence, the identified moderation of astrocyte 
activation by OECs represents a plausible mechanism whereby transplanted OECs could facilitate 
neural repair after CNS injury. Furthermore, PMA/ionophore and the microglia-derived factors 
did not induce NF-κB translocation in OECs, suggesting that OECs transplanted into CNS injury 
sites could be resistant to pro-inflammatory stimuli and may be able to maintain the in vitro 
phenotype associated here with the amelioration of astrocyte activation.  
 
CNS injury and the associated ischemia induces increases in intracellular calcium levels that can 
initiate inflammatory responses via NF-κB or, when excessive, cell death by necrosis or apoptosis. 
Calcium ionophore alone activated significantly more astrocytes than PMA alone (p < 0.001), 
with only a relatively small additive effect attributable to PMA, when astrocytes were treated 
simultaneously with PMA and ionophore. TUNEL assay demonstrated that at higher doses 
(250nM-1μM), calcium ionophore dose-dependently (R2 = 0.9996) induced significant (p < 0.001) 
apoptosis of astrocytes. OECs did not appear to protect astrocytes against the ionophore-induced 
apoptosis and they became apoptotic more rapidly and at lower ionophore doses (125nM) than 
astrocytes. Consequently, OECs could become apoptotic due to excessive calcium influx if 
transplanted into ischemic regions of CNS lesions where there are high levels of extracellular 
calcium ions, glutamate and ATP. Disruption of the surviving vasculature during OEC 
transplantation could re-initiate ischemia and in vivo research may be required to determine the 
optimal timing and location for transplanting OECs. Both the OEC moderation of astrocyte 
activation and the absence of OEC inflammatory activation imply that if transplanted OECs 
survive, they are likely to enhance neuronal survival by moderating inflammation. 
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In summary, this thesis provides evidence that OECs moderate the inflammatory activation of 
astrocytes, thus providing a plausible mechanism that could contribute to improved 
neuroprotection and tissue regeneration in response to therapeutic OEC transplantation after CNS 
injury. IGF-1 was identified as soluble factor that may have contributed to the anti-inflammatory 
effects of the cultured OECs. Further research to identify and isolate the responsible soluble 
factors released by the OECs could lead to more precisely targeted molecular therapies. The in 
vitro model of astrocyte activation established during the thesis could be further utilised to 
investigate other CNS injury therapies. 
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CHAPTER 1: Introduction 
 
1.0 Central nervous system injury 
1.00 Neurons are vulnerable to injury 
1.00.0 Central nervous system function depends on adequate blood supply 
The structural and functional integrity of the central nervous system (CNS) depends on a 
continuous supply of oxygen and glucose from the cerebral vasculature (Iadecola and 
Nedergaard, 2007; Doyle et al., 2008; Candelario-Jalil, 2009). The disruption of this 
metabolite supply because of vascular damage is the major underlying cause of the 
neuronal and glial cell death resulting from CNS injury. Although constituting only about 
2% of adult body weight, the brain consumes around 20% of the available oxygen and 
glucose in order to maintain the necessary activity of ion pumps for regulating neuronal 
membrane potentials and the constant synthesis of neurotransmitters and other signalling 
molecules (Gulbenkian et al., 2001; Edvinsson, 2006; Girouard and Iadecola, 2006; 
Zlokovic, 2008; del Zoppo, 2010). Brain tissue is highly perfused to cater for this high 
energy demand and the brain capillary density displays a remarkably heterogeneity that 
correlates with regional blood flow and energy use (Iadecola and Nedergaard, 2007). 
Changes in neural activity can induce highly localised changes in cerebral blood flow 
within seconds to match the oxygen and glucose supply to the local metabolic 
requirements. CNS blood vessels, neurons and glia constitute a functional ‘neurovascular 
unit’ (Fig. 1.0) where the close proximity of the different cells allows the necessary 
metabolite exchange and regulatory paracrine signalling (Iadecola and Nedergaard, 2007; 
Zlokovic, 2008; del Zoppo, 2010). The endothelial cells of arterioles and capillaries have 
a continuous basal lamina and a layer of contractile pericytes that regulate blood vessel 
diameter (Kida et al., 1993; Girouard and Iadecola, 2006; Zlokovic, 2008). Tight 
junctions between brain capillary endothelial cells together with the continuous basal 
lamina constitute the blood-brain barrier (BBB), which prevents potentially harmful 
macromolecules and pathogens in the blood from entering brain tissue (Abbott, 2002; 
Curin et al., 2006; Iadecola and Nedergaard, 2007; Zlokovic, 2008). The flattened end-
feet of astrocyte processes are closely apposed on the basal lamina and interact with the 
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endothelial cells to regulate BBB permeability. The regulated movement of water, ions, 
glucose and other nutrients across the BBB between the capillary endothelial cells and 
the astrocyte end-feet is crucial to maintaining a suitable environment for normal 
neuronal function (Verkhratsky et al., 1998; Verkhratsky and Steinhauser, 2000; 
Zlokovic, 2008; Kwon et al., 2009). 
 
1.00.1 Ischemia causes rapid neuronal death 
Ischemia resulting from traumatic injury, stroke or cardiac arrest interrupts the supply of 
oxygen and glucose required for ATP production by glycolysis and oxidative 
phosphorylation, causing neuronal death within minutes (Johnston, 2005; Curin et al., 
2006; Doyle et al., 2008; Candelario-Jalil, 2009). The glucose-dependent metabolism, 
high energy requirements and cellular specialisation of neurons makes them particularly 
sensitive to ischemic damage, although astrocytes and other glial cells are also 
susceptible (Xu et al., 2001; Swanson et al., 2004; Chen et al., 2005b; Giffard and 
Swanson, 2005). The CNS damage caused by ischemia is largely irreversible and often 
has fatal or severely disabling consequences depending on the location and extent of the 
neuronal damage (Stys, 2004; Ennis and Keep, 2006; Oechmichen and Meissner, 2006; 
Yamashima et al., 2007; Doyle et al., 2008; Segura et al., 2008; Candelario-Jalil, 2009). 
Following the initial cell death from ischemia and physical damage, a sequence of events 
leads to excessive glutamate-induced excitation culminating in ‘excitotoxic’ neuronal 
death (Coyle and Puttfarcken, 1993; Kannurpatti et al., 2000; Johnston, 2005; Villmann 
and Becker, 2007; Fernandez-Gomez et al., 2008). Without ATP, the membrane sodium 
and potassium pumps cannot maintain ionic gradients and membrane depolarisation 
occurs in neurons and astrocytes, releasing large amounts of glutamate, ATP and other 
neurotransmitters. Glutamate is the major excitatory neurotransmitter and the excessive 
extracellular levels initiate a positive feedback loop, causing further membrane 
depolarisation, ATP consumption and glutamate release. Blood glutamate levels are 
several fold higher than normal levels in the brain extracellular fluid and make an 
important additional contribution to excessive glutamate receptor activation following 
injury (Wagner, 2007). Activation of glutamate receptors on neurons and astrocytes 
releases calcium ions (Ca2+) from intracellular stores (Lipton, 2001; Pivovarova et al., 
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Figure 1.0 Astrocytes interact with synapses and blood vessels. Grey matter astrocytes extend 
fine processes that surround most synapses and large processes (end-feet) that are closely apposed 
on blood vessel walls. Pial arteries rest on the glia limitans, which envelops the brain surface. 
Astrocytes support synaptic transmission by taking up and recycling glutamate for re-use by 
neurons. Astrocytes also produce metabolic substrates for neuronal function and synapse 
formation. Grey matter astrocytes occupy exclusive spatial domains and consequently all of the 
~160,000 synapses in an astrocytic domain are covered by processes from a single astrocyte. The 
end-feet of astrocytes cover >99% of the vascular surface facing capillary endothelial cells or the 
contractile pericytes. Vascular end-feet express several specialized proteins including the glucose 
transporter 2 for the rapid transfer of glucose from blood to neurons. Ion channels (e.g. potassium; 
K+) , aquaporin 4 (Aqp4) and gap junction proteins in the end-feet regulate CNS extracellular 
homeostasis and may also be involved in the regulation of blood-flow to match neuronal demand, 
which could be signalled by glutamate stimulation of intracellular calcium (Ca2+) signalling 
(adapted from Iadecola et al, 2007). 
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2004; Swanson et al., 2004; Smith et al., 2005; Wagner, 2007; Candelario-Jalil, 2009). 
Mitochondria attempt to take up the excess Ca2+ until high Ca2+ levels damage 
mitochondrial membranes and calcium is released back into the cytosol, together with 
cytochrome C and reactive oxygen species (ROS) from the mitochondrial respiratory 
chain (Dugan et al., 1995; Swanson et al., 2004; Blomgren and Hagberg, 2006; Wagner, 
2007; Lai et al., 2009; Niizuma et al., 2009; Wang et al., 2009b). Cytochrome C then 
activates cytosolic proteases, initiating a cascade of cellular damage leading to neuronal 
apoptosis. Hypoxia also interrupts the respiratory chain of oxidative phosphorylation 
causing increased ROS generation, which is further catalysed by iron released from blood 
and damaged cellular proteins (Choi et al., 2005; Blomgren and Hagberg, 2006; Loh et al., 
2006; Valko et al., 2007). The high levels of ROS including superoxide, nitric oxide and 
peroxynitrite generated by neurons and surrounding glia contribute to anoxic neuronal 
death by directly damaging neuronal proteins and membranes (Casetta et al., 2005; 
Blomgren and Hagberg, 2006; Forder and Tymianski, 2009; Niizuma et al., 2009).  
 
1.00.2 Cerebral oedema is a consequence of blood brain barrier damage  
Blood brain barrier (BBB) damage resulting from injury causes cerebral oedema due to 
the excessive influx of water from the blood into the extracellular space of the CNS 
(Lynch et al., 2002; Ishida et al., 2006; Ostrowski et al., 2006; Doyle et al., 2008; Risher 
et al., 2009; Zador et al., 2009). Cerebral oedema can be further increased by obstruction 
of the flow or drainage of the cerebrospinal fluid by the initial damage or subsequent 
haematoma development (Go, 1997; Lohdia et al, 2006).  Oedema elevates intra-cranial 
pressure and restricts vascular perfusion and therefore exacerbates hypoxia and the 
related tissue damage. The clotting responses that limit systemic blood loss disrupt the 
supply of oxygen and metabolites leading to further cell death. Astrocyte swelling is a 
prominent early response to injury as a result of the inactivation of ion pumps in the 
hypoxic conditions and the excess water moving into astrocytes by osmosis (Panickar and 
Norenberg, 2005; Gunnarson et al., 2008; Laird et al., 2008; Sinke et al., 2008; Panickar 
et al., 2009; Risher et al., 2009; Zador et al., 2009). Astrocytes upregulate aquaporin 
water transport proteins in response to injury, assisting in the uptake and redistribution of 
excess water via gap junctions into the ventricular cerebrospinal fluid or the vascular 
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blood in undamaged CNS regions. However, excessive swelling can also rupture 
astrocyte plasma membranes causing necrotic cell death and releasing cellular contents 
into the extracellular space (Kimelberg, 2005; Panickar and Norenberg, 2005). Neurons 
also swell during oedema adding to neuronal damage and death because neurons do not 
express aquaporins to regulate water uptake (Risher et al., 2009).  
 
1.01 The inflammatory response to CNS injury 
1.01.0 CNS tissue damage initiates inflammation  
The initial responses to CNS injury are followed by longer term changes involving 
complex cellular and molecular interactions extending well beyond the lesion site that 
may have systemic components (Fawcett and Asher, 1999; Chen and Swanson, 2003; 
Harukuni and Bhardwaj, 2006; Lucas et al., 2006; Floyd and Lyeth, 2007; Ayer and 
Zhang, 2008; Doyle et al., 2008; Fitch and Silver, 2008). Neurons and glia that die 
immediately, due to physical damage and ischemia, release ATP, glutamate, cytokines, 
prostaglandins, heat shock proteins, calcium and cellular debris. The entry of blood 
components and pathogens into the CNS following BBB damage can directly induce 
inflammation and generate neurotoxic products at injury sites (Stys, 2004; Choi et al., 
2005; Ray, 2006; Whitney et al., 2009; Goldshmit et al., 2010). Inflammation is a 
stereotypical response of tissues to injury that has evolved to degrade toxic stimuli and 
restore tissue integrity in what is usually a beneficial and self-limiting healing process 
(Kracht and Saklatvala, 2002; Schwartz et al., 2006; Farooqui et al., 2007). Surrounding 
cells attempt to limit the injury and repair the damage (Ellison et al., 1999; Kracht and 
Saklatvala, 2002; Farooqui et al., 2007; Whitney et al., 2009). Dependent on the extent of 
injury, the acute inflammation resolves with wound healing and the restoration of tissue 
integrity. Although a similar sequence of events occurs following injury to the adult 
mammalian CNS, there is never a substantial restoration of normal tissue structure and 
function, even after relatively mild tissue damage. Removal of pathogens and damaged 
tissue usually requires some sacrifice of surrounding tissue prior to tissue regeneration for 
wound-healing (Schwartz, 2003, 2010). In the CNS, this tissue sacrifice is a particularly 
critical determinant of the capacity for recovery of normal function. The complex, precise 
network of neural connections required for motor and cognitive functions together with 
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the low inherent capacity for neurogenesis and axon regrowth in the adult CNS, decreases 
the likelihood of tissue repair and restoration of normal function (Schwartz et al., 1989; 
Yagita et al., 2001; Schwab, 2002; Nieto-Sampedro, 2003; Lie et al., 2004; Fawcett, 
2006b; Das and Basu, 2008; Ruitenberg and Vukovic, 2008; Whitney et al., 2009).  
 
1.01.1 Inflammation causes neuronal damage 
Although the inflammation following CNS injury resembles that resulting from injury to 
any vascularised tissue (Ellison et al., 1999; Farooqui et al., 2007; Whitney et al., 2009; 
del Zoppo, 2010), the immune protection provided by the BBB and the highly specialised 
functions of CNS tissue ensure that there are also important differences (Whitney et al, 
2009). Activated neurons and glia release cytokines and chemokines that recruit 
microglia, the resident CNS immune cells, and peripheral leukocytes to the injury site, 
where they proliferate and can differentiate into macrophages to phagocytose and remove 
pathogens and damaged tissue (Fawcett and Asher, 1999; Frangogiannis, 2007; Chen and 
Palmer, 2008; Matsumoto et al., 2008). Upregulation of adhesion molecules promotes 
leukocyte infiltration through capillary endothelial cells and retention in the damaged 
tissue. Local blood flow is augmented by increased production of prostaglandins and 
nitric oxide (NO) following induction of their respective enzymes, cyclooxygenase-2 
(COX-2) and inducible NO synthase (iNOS) (Kracht and Saklatvala, 2002; Kim and de 
Vellis, 2005; Kim and Dustin, 2006; Kim et al., 2006).  Under normal conditions only 
relatively low numbers of macrophages, T-cells and dendritic cells can enter the CNS 
parenchyma from the blood. BBB damage and altered permeability after injury (del 
Zoppo, 2010) allows the recruitment of large numbers of peripheral neutrophils, 
monocytes and lymphocytes to the lesion (Toews et al., 1998; Bush et al., 1999; 
Proescholdt et al., 2002; Babcock et al., 2003; Popovich et al., 2003;  Frangogiannis, 
2007; Gee et al., 2007; Longbrake et al., 2007; Matsumoto et al., 2007). Pro-
inflammatory cytokines and other factors stimulate innate immune responses in both the 
recruited peripheral immune cells and resident microglia in the damaged tissue. Adaptive 
immune responses are triggered when lymphocytes that enter the lesion encounter novel 
CNS antigens. Following exposure to abnormal CNS proteins or molecules from blood in 
the altered post-injury environment, activated microglia can also participate in adaptive 
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immune responses, including antigen presentation (Stollg and Jander, 1999; Town et al., 
2005; Hanisch and Kettenmann, 2007; Wagner, 2007; Yang et al., 2010). This activation 
of the immune cells initiates a massive release of pro-inflammatory and neurotoxic 
molecules from resident and invading cells (Feuerstein et al., 1994; Ellison et al., 1999; 
John et al., 2005; Kim and de Vellis, 2005; Mehta et al., 2007; Yagita et al., 2008; Pineau 
and Lacroix, 2009). 
NO and other ROS generated by the activated immune cells can destroy invading micro-
organisms but may also damage resident CNS cells that are compromised by injury or 
infection (Kim and Dustin, 2006). The injury and tissue repair responses continue over 
days and up to months and are associated with continuing apoptotic death of neurons 
because of their vulnerability to the cytotoxic effects of NO and other ROS (Profyris et 
al., 2004; Swanson et al., 2004; Casetta et al., 2005; Oechmichen and Meissner, 2006; 
Szeto, 2006; Mehta et al., 2007). The extent to which tissue repair is possible depends on 
the location and size of the region of damaged tissue. Growth factors, cytokines and other 
molecules released by activated astrocytes, microglia, macrophages, fibroblasts and 
endothelial cells during mild acute inflammation can stimulate neurogenesis and axon 
growth (Bregman et al., 1997; Namiki et al., 2000; Le and Esquenazi, 2002; Graef et al., 
2003; Furukawa and Furukawa, 2007; Bunge, 2008). However, more severe and 
prolonged inflammation after CNS injury typically leads to increased secondary neuronal 
damage, increased infarct size, decreased neurogenesis and worse functional deficits 
(Bethea, 2000; Brahmachari et al., 2006; Yang et al., 2007; Jiang et al., 2008; Laird et al., 
2008).  
 
1.01.2 Four intracellular signalling pathways regulate inflammatory gene expression 
The progress of inflammation and wound healing is determined by complex interactions 
involving inflammatory mediators produced by astrocytes, microglia, peripheral immune 
cells, neurons, progenitor cells, fibroblasts and endothelial cells (Chen and Swanson, 
2003; Sandvig et al., 2004; Fawcett, 2006a; Farooqui et al., 2007; Chen and Palmer, 
2008). The inflammation and wound healing involve extensive reorganisation of cells and 
tissues requiring the altered transcription of hundreds of genes to regulate the necessary 
protein synthesis (Ellison et al., 1999). Astrocytes, microglia and recruited immune cells 
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produce a variety of growth factors, cytokines and other factors that regulate cell survival, 
proliferation and differentiation for wound-healing (Ellison et al., 1999; Hernandez et al., 
2002; Lu et al., 2004; Yang et al., 2004; John et al., 2005; Yang et al., 2007). Expression 
of most of these inflammatory genes is co-ordinated through the activation of four 
intracellular signalling pathways leading to transcriptional activation (Fig. 1.1) 
(Yamamoto and Gaynor, 2001; Kracht and Saklatvala, 2002; Saklatvala, 2007; Yang et 
al., 2007). These are the pathways leading to activation of the transcriptional regulator, 
nuclear factor-kappaB (NF-κB) and the phosphorylation cascades of the three types of 
mitogen-activated protein kinase (MAPK), the Jun N-terminal kinases (JNKs), the p38 
MAPKs and the extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Kyriakis and 
Avruch, 2001; Saklatvala, 2007; Wolter et al., 2008). Activation of the three MAPKs can 
promote inflammatory gene expression both through activation of NF-κB and other 
transcription factor families. While NF-κB translocation is necessary for robust 
inflammatory responses, full activation of inflammatory genes appears to require the 
assembly of a multi-protein activation complex at gene promoter regions associated with 
the synchronous activation of both NF-κB and a mitogen-activated (MAP) kinase 
pathway (Kracht and Saklatvala, 2002; Chen and Greene, 2004a). NF-κB like other 
"rapid-acting" primary transcription factors, including c-JUN, nuclear factor of activated 
T-cells (NFAT), and signal transducers and activators of transcription (STATs), facilitate 
the rapid inflammatory responses required for protection of cells against potentially 
harmful stimuli, since being present in cells in an inactive state, they do not require new 
protein synthesis before activation (Gilmore, 1999; Wolter et al., 2008). Amplification of 
the inflammatory response to injury can occur through signalling interactions between 
cells, within the intracellular signalling cascades and through the multiple complementary 
mechanisms for transcriptional regulation (Baeuerle and Henkel, 1994; Kracht and 
Saklatvala, 2002; Chen and Greene, 2004b).  
 
1.01.3 Increased cytokine production can amplify inflammation 
MAPK and NF-κB pathway activation (Fig. 1.2) by the initial injury leads to an 
inflammatory cascade that stimulates production of a range of cytokines, chemokines, 
adhesion molecules, extracellular matrix proteins, proteases and growth factors required  
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Figure 1.1 Flow chart of inflammatory gene regulation. Expression of most inflammatory 
genes is regulated through the activation of four intracellular signalling pathways leading to 
transcriptional activation. These are the pathways leading to activation of the transcriptional 
regulator, nuclear factor-kappaB (NF-κB) and the protein kinase phosphorylation cascades of the 
three types of mitogen-activated protein kinase (MAPK), the Jun N-terminal kinases (JNKs), the 
p38 MAPKs and the extracellular signal-regulated kinases 1 and 2 (ERK1/2). Inflammatory 
stimuli, including cytokines, chemokines, pathogens and excessive levels of neurotransmitters 
stimulate specific membrane receptors. Complex interactions follow within intracellular 
signalling pathways that lead to activation of the protein kinase cascades of the four major 
inflammatory signalling pathways. Gene transcription is followed by mRNA translation and 
increased protein expression (adapted from Kracht and Saklatvala, 2002). 
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Abbreviations: AP-1, activating protein 1 CAM, cell adhesion molecule; Ca2+BP, calcium binding 
protein; CCL, chemokine; COX, cyclo-oxygenase; ERK, extracellular-regulated kinase; IκB, inhibitor 
of NF-κB; IKK, IκB kinase; IL-1, interleukin-1; iNOS, inducible nitric oxide synthase; IP3, inositol 
trisphosphate; JNK, JUN-N-terminal kinase; MAPK, mitogen-activated protein kinase; mGluR, 
metabotropic glutamate receptor; MKK, MAPK kinase; MMP, matrix metalloproteinase; Na/Ca, 
sodium/calcium ion exchanger; NFAT, nuclear factor of activated T-cells; NF-κB, nuclear factor-κB; 
P, phosphorylation; PKC, calcium-dependent protein kinase; PKs, protein kinases; PLC, 
phospholipase C; P2Y, metabotropic purinergic receptor; ROS, reactive oxygen species; RTK, 
receptor tyrosine kinase; TLR, toll-like receptor; TNF, tumour necrosis factor. 
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Figure 1.2 The regulation of cellular inflammatory responses. Pro-inflammatory mediators 
including, IL-1, TNF, ATP, glutamate and pathogens trigger specific receptor activation leading 
to activation of protein kinases, elevation of intracellular calcium ion (Ca2+)  levels and indirectly 
via increased metabolism, to increased intracellular ROS and RNS production. Extracellular Ca2+ 
can also enter through membrane ion channels, while ROS and RNS released from nearby cells 
can diffuse through membranes. These factors lead to activation of the IκB kinase, ERK, JNK and 
p38 MAPK signalling pathways. These kinases phosphorylate either IκB and NF-κB, or the 
transactivation domains of AP-1 proteins, resulting in activation of both NF-κB and AP-1. Purine 
and glutamate stimulation of metabotropic receptors can release Ca2+ from internal stores, which 
activate NF-κB and MAPKs via PKC and other transcription factors, such as NFAT via Ca2+ 
binding proteins, such as calcineurin. Activation of at least one MAP kinase pathway is required 
in addition to NF-κB to promote strong transcription. Signals from these pathways converge at 
gene promoters by promoting chromatin remodelling via histone acetylation and phosphorylation. 
This is followed by the formation of multi-protein complexes, known as enhanceosomes. Within 
an enhanceosome, NF-κB and AP-1 interact with DNA, other transcription factors such as NFAT, 
co-activators and RNA polymerase. Variations within the enhanceosome composition result in 
activation of specific genes followed by mRNA translation and increased inflammatory protein 
expression. NF-κB promotes transcription of its own gene and its inhibitor (IκB), while many of 
the other inflammatory proteins are stimulators of the MAPK and NF-κB pathways. Increased 
intracellular calcium and growth factors can stimulate mitochondrial production of ATP to 
provide energy for the increased protein synthesis (adapted from Kracht and Saklatvala, 2002 and 
Carafoli, 2002). 
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for inflammation and subsequent wound-healing (Ellison et al., 1999; Meeuwsen et al., 
2003a; Raghavendra Rao et al., 2003; John et al., 2005; Zhang et al., 2006). IL-1β and 
TNF-α are major initiating cytokines involved in inflammatory responses in the CNS and 
other tissues (Siren et al., 2001a; John et al., 2005; Panickar and Norenberg, 2005; 
Farooqui et al., 2007; Lambertsen et al., 2009). Transcription of both cytokines is 
promoted by NF-κB activation and their upregulation has been detected within an hour of  
CNS injury (John et al., 2005; Laird et al., 2008). IL-1β and TNF-α are also important 
secondary amplifiers of inflammation that promote their own production by macrophages 
and activated glia through their strong activation of NF-κB and the MAPKs (John et al., 
2005; Saklatvala, 2007). Cytokines such as IL-6, IL-15 and interferon-γ (IFN-γ) can 
synergise with other stimuli to amplify the response (John et al., 2005; Satriotomo et al., 
2006; Saklatvala, 2007; Gomez-Nicola et al., 2008; Gomez-Nicola et al., 2010). 
 
1.02 Astrocyte activation has a crucial role in CNS injury responses 
1.02.0 Reactive astrocytes are a major source of inflammatory mediators 
Altered gene transcription following the inflammatory activation of astrocytes in vivo 
leads to a phenotype change known as astrogliosis, which is a prominent feature of CNS 
inflammation (Silver and Miller, 2004; Sofroniew, 2005; Fawcett, 2006a; Fernandez et 
al., 2007a; Fitch and Silver, 2008). Due to their size and abundance, the activated 
astrocytes are a major source of cytokines, chemokines, adhesion factors, extracellular 
matrix proteins, growth factors and other inflammatory mediators (Ellison et al., 1999; 
Panenka et al., 2001; Meeuwsen et al., 2003a; John et al., 2005; Khorooshi et al., 2008).  
Astrocytes are also the main contributors to wound healing and restoration of the 
extracellular matrix after CNS injuries (Hertel et al., 2000; Muir et al., 2002; Bundesen et 
al., 2003; Zhang et al., 2006; Gris et al., 2007). The high levels of extracellular glutamate, 
ATP, Ca2+ and many other factors in the hypoxic conditions after CNS injury, activate 
inflammatory gene transcription in astrocytes through the NF-κB and MAPK pathways 
(Neary and Kang, 2005; O'Riordan et al., 2006; Zeng et al., 2008b), with an increase in 
intracellular Ca2+ levels being an early event in the astrocyte activation (Neary and Kang, 
2005; Smith et al., 2005; Weisman et al., 2005) (Fig. 1.2). Activated microglia release 
ROS, IL-1β, TNF-α and IL-6 (Giulian et al., 1994; Streit, 2000; Aloisi, 2001; Hanisch, 
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2002; Kim and de Vellis, 2005; Gosselin and Rivest, 2007), which also activate 
astrocytes via NF-κB to promote the expression of chemokines, including monocyte 
chemoattractant protein (MCP)-1, macrophage inflammatory proteins (MIPs) 1α and 2α, 
Gro and fractalkine as well as their respective receptors (Hughes et al, 2002; Babcock et 
al., 2003; Meeuwsen et al., 2003a; Bolin et al., 2005; John et al., 2005; Khorooshi et al., 
2008; Held-Feindt et al., 2010; Schwartz et al., 2010). The location of reactive astrocytes 
in the injury penumbra and their proximity to the BBB enables them to generate a 
gradient of chemokines that attract resident microglia and circulating leukocytes towards 
the injured tissue (Ellison et al., 1999; Babcock et al., 2003; Meeuwsen et al., 2003a; 
John et al., 2005). The chemokines and adhesion molecules also promote the migration of 
neural progenitor cells, which further contribute to the complexity of the inflammatory 
signalling as they proliferate and differentiate in the lesion (Okada et al., 2004; Alonso, 
2005; John et al., 2005; Faijerson et al., 2006; Tatsumi et al., 2008).  
 
1.02.1 Reactive astrocytes form a protective glial scar  
Over several days post-injury the GFAP-rich processes of reactive astrocytes are major 
contributors to the formation of a ‘glial scar’ (Figs. 1.3, 1.4) around the lesion that 
separates the core region of severely damaged tissue from the lesion penumbra (Fawcett 
and Asher, 1999; Silver and Miller, 2004; Sofroniew, 2005; Fitch and Silver, 2008). The 
increased immunoreactivity for GFAP exhibited by reactive astrocytes surrounding CNS 
lesions (Fig. 1.4) is a prominent feature of astrogliosis that is often used as an indication 
of the severity of inflammation (Krohn et al., 1999; Brahmachari et al., 2006). Although 
the functional significance of the increased GFAP immunoreactivity remains uncertain, it 
has been suggested that increased expression of GFAP could provide more binding sites 
for aquaporins, glutamate transporters and ion channels to help restore post-injury 
extracellular homeostasis (Wilhelmsson et al., 2006; Sullivan et al., 2007; Gunnarson et 
al., 2008). The glial scar is a dense tissue with many tightly interwoven astrocyte 
processes (Fig. 1.4B) and other cells surrounded by a specialised extracellular matrix 
with little extracellular space (Fawcett and Asher, 1999; Fitch and Silver, 2008). Neural 
progenitor cells are induced to proliferate and differentiate in the lesion where they make 
a major contribution to the population of reactive astrocytes that form the glial scar 
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(Alonso, 2005; Shen et al., 2010). A robust inflammatory response within the lesion may 
allow the removal of cellular debris and pathogens by migratory and resident phagocytes 
without compromising cells outside the glial scar (Faulkner et al., 2004; Sofroniew, 
2005). The more moderate inflammatory responses of astrocytes in the penumbra (Fig. 
1.4E) may then initiate processes leading to wound healing and tissue regeneration 
involving angiogenesis, gliogenesis, neurogenesis and the re-establishment of the BBB 
and a glial-pial boundary (Chen and Swanson, 2003; Faulkner et al., 2004; Sofroniew, 
2005). Thus, as with scarring in other organs and tissues the glial scar may be an adaptive 
component of wound healing with protective functions. Any neurogenesis is more likely 
to occur outside the glial scar, in the perilesional penumbra, where inflammation is less 
severe (Kernie et al., 2001; Chen and Swanson, 2003; Panickar and Norenberg, 2005; Ito 
et al., 2006c; Doyle et al., 2008).  
 
1.02.2 The glial scar is a barrier to axonal regeneration 
Although the glial scar could limit tissue damage by protecting the penumbral tissue from 
excessive inflammation, it simultaneously presents a major barrier to the axon regrowth 
across the lesion required for the restoration of functional neural networks by surviving 
or regenerating penumbral neurons (Qiu et al., 2000; Silver and Miller, 2004; Fawcett, 
2006b). The altered expression of chemokines, adhesion molecules, proteases, 
extracellular matrix components and cell surface receptors by reactive astrocytes serves 
to attract and retain microglia, neural progenitors and peripheral macrophages at injury 
sites (Babcock et al., 2003; Chen and Swanson, 2003; John et al., 2005). Since the 
motility of all cells is regulated by similar pathways affecting cytoskeletal dynamics 
(Suter and Forscher, 2000; Gallo and Letourneau, 2004; Hall, 2005), many of these same 
factors expressed by reactive astrocytes may also restrict regenerating axons to the lesion 
periphery (Sandvig et al., 2004; Goldshmit et al., 2006; Gross et al., 2007). While this 
could protect regenerating neurons from the cytotoxic conditions of the lesion it also 
prevents the re-establishment of neuronal connectivity for the recovery of normal CNS 
function.  
 
 
 15
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Reactive astrocytes and the glial scar. Severe reactive astrogliosis and glial 
scarring develop on the boundary of the lesion core, involving astrocyte proliferation (with 
red nuclei in figure) and invading meningeal fibroblasts (with grey nuclei in figure). 
Progenitor cells proliferate and differentiate into reactive astrocytes adding to the scar tissue. 
Reactive astrocytes in the scar have overlapping domains, extend long thickened GFAP-
expressing processes towards the lesion and secrete axon-growth inhibitory chondroitin 
sulphate proteoglycans (CSPGs). Mature glial scars tend to persist for long periods and act as 
barriers not only to axon regeneration but also to inflammatory cells and so protect healthy 
tissue from the cytotoxic conditions of the lesion core. Astrocytes in the lesion penumbra 
exhibit mild to moderate reactive astrogliosis and remain in their exclusive domains although 
having thickened processes. Penumbral astrocytes show alterations in molecular expression 
and functional activity that vary with insult severity and may return to normal if inflammation 
resolves (adapted from Sofroniew, 2009). 
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Figure 1.4 Reactive astrocytes surround a focal cortical injury lesion. A: 7 days after a 
1.5mm deep, 22 gauge needle-stick injury in adult rat cortex, 50μm sagittal cryostat sections 
were immunostained for GFAP (green) to show astrocytes and ferritin (red) as a marker for 
activated macrophages. Nuclei were counterstained with Hoechst blue DNA stain (HB). 
Activated macrophages occupy the needle-stick injury lesion surrounded by reactive astrocytes 
with high intensity GFAP immunoreactivity. GFAP immunoreactivity gradually diminishes 
away from the lesion until reaching the usual low levels found in adult cortical astrocytes. Scale 
bar is 250μm. B: Enlargement of lesion and glial scar region from A. Most activated 
macrophages are confined to the lesion with some also appearing amongst the reactive 
astrocytes of the scar tissue (asterisks). Overlapping processes extend from the reactive 
astrocytes and surround the lesion. C: Small astrocytes with intense GFAP immunoreactivity on 
the lesion border are probably proliferating astrocytes that have differentiated from progenitor 
cells, which migrate to lesions. D: Astrocytes about 1mm from the lesion show normal adult 
cortical morphology with weak immunoreactivity for GFAP creating the appearance of spindly 
processes, which can be seen wrapped around a small descending blood vessel in the centre of 
the image (arrows).  E: Astrocytes in the injury penumbra have processes showing thickened 
regions of strong GFAP immunoreactivity but remain predominantly within their exclusive 
domains. Scale bar is 50μm. 
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1.02.3 Extracellular matrix proteins and basal laminae inhibit axon-growth 
The glial scar often appears to be a disorganised accumulation of reactive astrocytes, 
activated microglia, macrophages and fibroblasts surrounded by extracellular matrix 
(Fawcett and Asher, 1999; Nieto-Sampedro, 2003; Teng et al., 2008). Meningeal 
fibroblasts often contribute to the development of glial scar tissue (Fig. 1.3) by invading 
lesions where they proliferate and interact with reactive astrocytes (Lagord et al., 2002; 
Sandvig et al., 2004; Teng et al., 2008). The fibroblasts and reactive astrocytes secrete 
glycoproteins and proteoglycans to form layers of extracellular matrix in the glial scar. 
Deposition of chondroitin sulphate proteoglycans (CSPGs), particularly phosphacan, 
versican and brevican, by reactive astrocytes and fibroblasts into the extracellular matrix 
of the glial scar is considered to be a major factor in the inhibition of axon growth at the 
glial scar boundary of CNS lesions (Silver, 1994; Gilbert et al., 2005; Laabs et al., 2005; 
Smith and Strunz, 2005; Galtrey and Fawcett, 2007). Digestion of the CSPGs with the 
enzyme chondroitinase ABC has improved axon regrowth in several CNS injury models 
(Chau et al., 2004; Del Rio and Soriano, 2007; Bunge, 2008). The extracellular matrix 
layers resemble basal laminae with separate networks of type IV collagen and laminin 
cross-linked by fibronectin (Berry et al., 1983; Hermanns et al., 2006; Teng et al., 2008). 
The end-feet of astrocytes form a glia limitans-like structure against the basal laminae 
similar to the interaction with fibroblasts and blood vessel endothelial cells during 
developmental glia limitans formation. The glia limitans re-establishes a BBB around the 
lesion and walls off the fibrotic scar tissue preventing further penetration of the CNS by 
fibroblasts and blood cells. Extensive revascularisation also occurs in the lesion following 
the infiltration of endothelial cells, which proliferate and form new capillaries and there is 
often a permanent increase in capillary density within the damaged region (Jaeger and 
Blight, 1997; Stichel and Muller, 1998; Lagord et al., 2002). Reactive astrocytes interact 
with the endothelial cells to form basal laminae and a BBB around the capillaries, further 
increasing the complexity of the scar environment.  
 
1.02.4 Glial scarring is more extensive in the spinal cord 
The nature and extent of glial scarring varies considerably with differences in the relative 
contributions of perilesional astrocytes, migrating progenitor cells and invading  
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Figure 1.5 Spinal cord after injury. Schematic sagittal view through a region of cervical spinal 
cord injury (SCI), depicting a combination of features from different types of injury. Many cells 
die immediately, and progressively, after SCI. Cystic cavities usually form after contusion injury. 
After penetrating injury, cells from the peripheral nervous system (PNS) often invade the injury 
site and, in conjunction with CNS glial cells, form a connective tissue scar incorporating 
astrocytes, progenitor cells, meningeal fibroblasts and microglia, which presents a permanent 
barrier to axon regrowth. Many ascending and descending axons are interrupted and fail to 
regenerate over long distances. Some axons form new circuits via interneurons with collateral 
motor neurons in spared tissue. At the site of cyst formation, axons can sprout into trabeculae that 
are formed from ependymal cells. Disconnected myelinated axon segments are phagocytosed by 
macrophages. Some spontaneous remyelination occurs, largely by invasive PNS Schwann cells, 
to maintain motor function in some muscles, while denervated (non-spastic) muscles atrophy 
(adapted from Thuret, 2006). 
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fibroblasts that result from different injuries (Nieto-Sampedro, 2003; Silver and Miller, 
2004; Fawcett, 2006b; Thuret et al., 2006; Teng et al., 2008). Glial scarring is usually less 
extensive in cortical grey matter injuries (Fig. 1.4) than in spinal cord (Fig. 1.5) and white 
matter injuries where there are more axons and high GFAP-expressing fibrous astrocytes 
predominate. In addition, the axon-growth inhibitory extracellular matrix components, 
brevican, versican, phosphacan and tenascin are more abundant in white matter (Bekku et 
al., 2009). Meningeal fibroblasts and Schwann cells often invade spinal cord injuries 
following glia limitans damage, while cystic cavities formed in the lesion core present an 
impassable physical barrier to axon regrowth (Fawcett, 2006b; Thuret et al., 2006). 
However, spinal cord injuries do not always completely sever the cord and some 
functional recovery may occur through stimulation of axonal sprouting or plasticity in 
spared collateral tracts (Li and Raisman, 1995; Raineteau and Schwab, 2001; Chuah et al., 
2004). 
 
1.03 Microglia are rapidly activated following CNS injury  
1.03.0 Microglia are the resident CNS immune cells 
Microglia are the principal immune effector cells of the CNS (Schwartz, 2003; Davalos et 
al., 2005; Hanisch and Kettenmann, 2007). Quiescent microglia are small cells with many 
long, fine highly-branched processes that appear to be actively sampling the environment 
of their exclusive domains within the healthy brain (Kloss et al., 1997; Davalos et al., 
2005; Hanisch and Kettenmann, 2007). The most immediate activator of microglia 
following injury may be the physical disruption of ‘calming’ signals from neurons and 
astrocytes mediated by membrane-bound factors, such as fractalkine, which maintain a 
quiescent state in microglia (Hanisch and Kettenmann, 2007; Held-Feindt et al., 2010; 
Lauro et al., 2010). Fractalkine (or CX3CL1) is expressed by neurons and astrocytes 
(Hughes et al, 2002; Mizuno et al., 2003) and can promote leukocyte recruitment by 
increasing their adhesion to capillary endothelial cells (Ruitenberg et al., 2008; Schwartz 
et al., 2010). Binding of constitutively-expressed neuronal fractalkine to the specific 
CX3CR1 receptors on microglia has recently been shown to exert neuroprotective 
‘calming’ effects that ameliorate microglial expression of pro-inflammatory cytokines 
(Cardona et al., 2006; Held-Feindt et al., 2010; Lauro et al., 2010). Microglia respond to 
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specific antigens through immune receptors, including toll-like receptors, and to non-
specific indicators of damage through chemokine receptors (Davalos et al., 2005; Haynes 
et al., 2006; Block et al., 2007). Hence, a wide variety of inflammatory or antigenic 
signals can stimulate the transformation of microglia to a variety of reactive phenotypes, 
including a macrophage-like phenotype. There is a massive release of ATP and other 
purines, mainly from astrocytes damaged by traumatic or ischemic CNS injury, which 
rapidly activates microglia (Haynes et al., 2006; Kurpius et al., 2007; Pineau and Lacroix, 
2009). Glutamate released from injured neurons and astrocytes can also activate 
microglia through metabotropic glutamate receptors and activation of NF-κB (Kaushal 
and Schlichter, 2008; Kataoka et al., 2009; Pineau and Lacroix, 2009). Toll-like receptor 
activation by heat shock proteins or extracellular matrix components released by 
proteases is another mechanism for the rapid activation of microglia by CNS injury (Lee 
and Lee, 2002; Hanisch et al., 2008; Pineau and Lacroix, 2009). Traumatic CNS injury 
immediately provokes targeted movement of microglial processes towards the injury site 
and increased transcription of inflammatory chemokines and cytokines occurs within five 
minutes (Davalos et al., 2005; Haynes et al., 2006; Hanisch and Kettenmann, 2007). 
Reactive microglia also upregulate their expression of proteins involved in immune 
complement cascades, membrane transport, cell motility and protein degradation (Gasque 
et al., 1997; Kurpius et al., 2007). Activated microglia adopt an amoeboid morphology 
and migrate to injury sites within hours where they proliferate and phagocytose cellular 
debris, including degenerating axons, dendrites and myelin (Davalos et al., 2005; Haynes 
et al., 2006; Hanisch and Kettenmann, 2007; Kurpius et al., 2007). While activated 
microglia may have a prominent role in immune responses in the penumbral region, the 
majority of immune cells that accumulate in the lesion (Fig. 1.3) within hours of injury 
appear to be peripheral leukocytes that enter from the blood (Liu et al., 1994; Fawcett and 
Asher, 1999; Babcock et al., 2003; Frangogiannis, 2007; Pineau et al., 2009). In the first 
24 hours, chemokine expression by astrocytes recruits mainly neutrophils, with 
increasing numbers of monocyte-derived macrophages and lymphocytes being recruited 
over the following days and weeks. The peripheral immune cell recruitment is more 
extensive and is more likely to involve immune cell infiltration into the perilesional 
parenchyma following spinal cord injuries than for brain injuries (Schnell et al., 1999; 
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Schwartz, 2001; reviewed by Donnelly and Popovich, 2008). Immune activation of both 
the resident microglia and peripheral immune cells has conflicting effects on the injured 
CNS. The activated immune cells can protect against pathogenic invasion, phagocytose 
cellular debris and secrete a variety of neuroprotective and growth-promoting factors. 
However, they can also release pro-inflammatory cytokines, matrix metalloproteinases 
and toxic free radicals that can exacerbate inflammation and increase blood-brain barrier 
permeability leading to increased secondary neuronal and glial cell damage. The majority 
of microglia and peripheral monocytes recruited to CNS injury sites are rapidly induced 
to differentiate into activated macrophages that participate in robust immune responses 
with neurotoxic effects (Longbrake et al., 2007; Kigerl et al., 2009; Schechter et al., 2009; 
Schwartz, 2009, 2010). A more transient response may involve differentiation of 
macrophages into an anti-inflammatory phenotype with neuroprotective and regenerative 
activities. Invading T and B lymphocytes can react to CNS antigens to induce 
pathological autoimmune responses that can amplify macrophage activity to increase 
blood-brain barrier damage, oedema and neuronal injury (Ankeny et al., 2009; Ankeny 
and Popovich, 2009).  There may also be a protective form of autoimmunity mediated by 
autoreactive T cells (Schwartz, 2001, 2009) and both T and B cells can secrete the 
neurotrophin BDNF (Donnelly and Popovich, 2008).  
 
1.03.1 Phagocytic activity may increase cellular damage 
Activated microglia, monocyte-derived macrophages and neutrophils all participate in the 
production of potentially neurotoxic levels of free radicals at CNS injury sites (Block et 
al., 2007; Wagner, 2007; Donnelly and Popovich, 2009; Yang et al., 2010). The 
membrane-bound enzyme NADPH oxidase, which catalyses the generation of superoxide 
free radicals, is the primary source of extracellular ROS released by activated microglia 
and other macrophages (Forman and Torres, 2001; Iles and Forman, 2002; Block et al., 
2007; Sun et al., 2007; Wagner, 2007). NO generated by iNOS reacts with superoxide to 
form highly reactive and toxic peroxynitrite (Forman et al., 1998; Forman and Torres, 
2001). Superoxide, NO and peroxynitrite can diffuse into micro-organisms and kill them 
by inactivating essential enzymes. ROS and reactive nitrogen species (RNS) along with 
lytic enzymes are also released into phagolysosomes to degrade phagocytosed antigens 
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and remnants of apoptotic and necrotic cells both after injury and during normal tissue 
maintenance (Forman and Torres, 2001; Farooqui et al., 2007; Harting et al., 2008). At 
high levels, ROS and RNS can induce apoptosis in intact cells by damaging proteins, 
lipids and nucleic acids (Forman and Torres, 2001; Chen and Palmer, 2008; Reed et al., 
2009). High extracellular levels of NO and peryoxynitrite are particularly detrimental 
because their greater stability enhances diffusion through cell membranes to cause 
intracellular damage (Forman and Torres, 2001). Tissue remodelling is necessary for 
injury repair and the cytotoxic and phagocytic activities of macrophages removes 
compromised cells and debris, including injured axons and dendrites to provide space for 
regrowth and the establishment of new neural connections (Shih et al., 2006; Hanisch and 
Kettenmann, 2007). However, persisting high levels of ROS and RNS associated with 
macrophage activation in the lesion, can continue secondary neuronal damage for weeks 
after an injury (Si et al., 1997; Jia-Yi et al., 2006; Shih et al., 2006; Block et al., 2007; 
Hanisch and Kettenmann, 2007). The glial scar could protect penumbral tissue by 
confining severe neurotoxic macrophage activity to the lesion core (Sofroniew, 2008; 
Yang et al., 2010; Schwartz, 2010), because the instability of ROS and RNS ensures that 
they cannot diffuse far before being inactivated by reacting with other molecules (Forman 
and Torres, 2001). Glial scar extracellular matrix components, such as chondroitin 
sulphate proteoglycans, and possibly other factors produced by reactive astrocytes, may 
attract peripheral macrophages to the lesion border and direct their differentiation 
towards the phenotype with more neuroprotective and wound healing activity (Rolls et al., 
2008; Schwartz, 2010). Following recruitment to the perilesional glial scar region, the 
complementary actions of these peripheral macrophages and activated microglia may be 
required for effective wound healing. 
 
1.03.2 Microglia have concentration-dependent responses to ATP  
The actions of activated microglia are thought to be generally neuroprotective although 
they can be neurotoxic depending on the phenotype adopted and the injury environment 
context (Schilling et al., 2001; Re et al., 2002; Schwartz, 2003; Hanisch and Kettenmann, 
2007). Different modes of microglial activation may be regulated by microglial 
metabotropic (P2Y) and ionotropic (P2X) purinergic receptors that have concentration-
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dependent responses to extracellular ATP (Re et al., 2002; Lai and Todd, 2006, 2008). 
Microglial P2Y activation by low to moderate ATP levels has been associated with 
neuroprotective IL-6 production, glutamate uptake and degradation, chemotaxis and 
phagocytic activity. However, at the high ATP levels associated with the lesion core and 
severe injuries, activation of P2X receptors induces expression of immediate early genes 
c-fos and c-jun and activates NF-κB and NFAT leading to expression of pro-
inflammatory cytokines such as IL-1β, TNF-α and IFN-γ as well as prostaglandins, 
glutamate, NO, RNS and ROS (Kaya et al., 2002; Kim and de Vellis, 2005; Block et al., 
2007; Kataoka et al., 2009). Excessive glutamate, TNF-α, RNS and ROS can all be 
neurotoxic while IL-1β and TNF-α can alter adhesion molecule expression in the 
endothelial tight junctions of the BBB promoting leukocyte and potentially pathogen 
entry to the brain parenchyma. P2X activation also induces microglial production of 
chemokines, such as MCP-1, MIP-1α and microglial response factor-1 that continue 
recruitment of leukocytes and microglia to the injury site (Kaya et al., 2002; Kataoka et 
al., 2009). Glutamate stimulation of microglial metabotropic glutamate receptors 
activates NF-κB resulting in increased TNF-α secretion. Activation of neuronal NF-κB 
by the ensuing high levels of TNF-α can induce caspase-dependent apoptosis (Kaushal 
and Schlichter, 2008). The P2Y mediated microglial activities may predominate in the 
lesion penumbra, where, because there is less cell damage, extracellular purine levels are 
likely to be lower than in the lesion infarct. P2Y activation by gradients of released 
purines may induce chemotaxis of microglia in the penumbra towards locally damaged 
cells or the lesion core. Higher purine levels in more severely damaged tissue could 
induce more robust and potentially neurotoxic activation of microglia through P2X 
receptors. 
 
1.03.3 Interaction between astrocytes and microglia can amplify inflammation 
Complex interaction between astrocytes and microglia regulates the severity, progression 
and resolution of inflammation (Hanisch, 2002; Kim and de Vellis, 2005; Block et al., 
2007). Damaged astrocytes release ATP and other factors that activate microglia, which 
then, dependent on the degree of activation, release a variety of cytokines, chemokines, 
ROS and other inflammatory mediators. High levels of the pro-inflammatory cytokines 
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IL-1β, IL-6 and TNF-α, produced by microglia and other macrophages, induce more 
severe astrogliosis (Oh et al., 1993; Okada et al., 2004; John et al., 2005; Weisman et al., 
2005; Kim et al., 2006). The reactive astrocytes increase their production of pro-
inflammatory cytokines, including more IL-1β and TNF-α, chemokines, matrix 
metalloproteases, COX and iNOS (John et al., 2005; Kim et al., 2006; Laird et al., 2008). 
The consequent increase in astrocytic prostaglandins and NO production results in 
amplification of inflammation with further IL-1β and TNF-α production, increased BBB 
disruption, more secondary neuronal damage and increased infarct size (Schneider et al., 
1999; Bethea, 2000; Brambilla et al., 2005b; Canellada et al., 2008). In addition, more 
severe astrogliosis leads to more extensive glial scarring with increased deposition of 
axon growth-inhibitory CSPGs (Lemons et al., 1999; Sandvig et al., 2004; Properzi et al., 
2005). TNF-α induces increased expression of toll-like receptors (TLRs) by astrocytes 
and blood entering after CNS damage generates antigens that bind the TLRs, inducing 
further increases in IL-1β, TNF-α, iNOS and NO production (Konat et al., 2006; 
Phulwani et al., 2008). Activated astrocytes produce granulocyte macrophage-colony 
stimulating factor (GM-CSF) (Zaheer et al., 2002; Henze et al., 2005), which induces 
proliferation and immune activation of microglia to potentially further amplify the 
inflammatory response (Giulian et al., 1994; Fujita et al., 1996; Schilling et al., 2001).  
 
1.04 The severity of astrocyte inflammation affects the potential for CNS repair 
1.04.0 Reactive astrocytes have neuroprotective and regenerative actions 
Neuronal viability after CNS injury is obviously dependent on the survival of astrocytes 
because of their normal physiological roles of providing metabolic support for neurons 
and maintaining extracellular homeostasis. As a consequence of these roles, astrocytes 
have large stores of metabolic substrates and high levels of anti-oxidant enzymes, which 
provide protection against ischemic damage (Swanson et al., 2004; Kintner et al., 2007) 
(Zhang et al, 2007; Takuma et al, 2004; Yu et al, 2007). Upregulation of glutamate 
transporters (Duan et al., 1999; Sullivan et al., 2007; Li et al., 2008a; Arranz et al., 2010) 
and increased production of anti-oxidants, such as ascorbate, glutathione and 
metallothionein by reactive astrocytes (Eddleston and Mucke, 1993; Penkowa et al., 1997; 
Aschner, 1998; Shih et al., 2003; Swanson et al., 2004; Chen et al., 2006b) may limit 
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neuronal excitotoxic damage by enhancing uptake of extracellular glutamate and 
detoxifying ROS. Lower levels of IL-1β and TNF-α, associated with the progression 
towards the resolution of inflammation, greater distance from the lesion core or less 
severe injuries, may favour astrocytic production of factors such as metallothionein 
(Wakida et al., 2007; Chung et al., 2008), erythropoietin (Li et al., 2008b), IL-6 
(Penkowa et al., 2003; Bolin et al., 2005), transforming growth factor (TGF)β1 (Lin et al., 
2006), ciliary neurotrophic factor (CNTF) (Albrecht et al., 2002), fibroblast growth factor 
(FGF) (Furukawa and Furukawa, 2007), brain derived neurotrophic factor (BDNF) (Giehl 
and Tetzlaff, 1996), vascular endothelial growth factor (VEGF) (Kalaria et al., 1998), 
nerve growth factor (NGF) (Oudega and Hagg, 1996) and insulin-like growth factor-1 
(IGF-1) (Fernandez et al., 2007b) that have more neuroprotective and regenerative effects. 
Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) produced by 
astrocytes promote neuron survival and axon outgrowth (Zafra et al., 1992; Namiki et al., 
2000; Meeuwsen et al., 2003a; Vargas et al., 2004). IGF-1 has anti-inflammatory actions 
(Pons and Torres-Aleman, 2000; Fernandez et al., 2007b) and together with FGF and 
VEGF promotes angiogenesis, proliferation of astrocytes and neurogenesis (Fernandez et 
al., 1999; Albrecht et al., 2002; Jung et al., 2006; Wang et al., 2006; Furukawa and 
Furukawa, 2007). TGFβ1 promotes angiogenesis (Vinals and Pouyssegur, 2001; Lagord 
et al., 2002; Gomes et al., 2005) and differentiation of neural progenitors into neurons 
(Chen and Palmer, 2008) or astrocytes (Lagord et al., 2002; Stipursky and Gomes, 2007). 
Erythropoietin is a neuroprotective factor that moderates astrogliosis, promotes 
angiogenesis and limits BBB disruption and oedema (Siren et al., 2001b; Diaz et al., 2005; 
Kretz et al., 2005; Li et al., 2008b) resulting in less tissue damage and improved 
functional recovery from CNS injury (Wakida et al., 2007; Li et al., 2008b). 
Metallothioneins are ubiquitous, small, zinc-binding proteins with anti-oxidant actions 
that are strongly upregulated by reactive astrocytes after injury (Hidalgo et al., 1994; 
Carrasco et al., 2000b; Wakida et al., 2007; Chung et al., 2008). Metallothionein 1/2 
produced by reactive astrocytes protects neurons by binding excess zinc released from 
injured neurons and detoxifying ROS, (Dalton et al., 1994; Kumari et al., 2000; Katakai 
et al., 2001; Frederickson et al., 2004; Kruczek et al., 2009) while exogenous 
metallothionein 2A strongly promotes axon regeneration (Chung et al., 2003). Il-6 
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activation of the receptor associated janus tyrosine kinase (JAK), signal transducer and 
activator of transcription (STAT) and MAPK pathways promotes differentiation of neural 
progenitors into astrocytes (Fan et al., 2005; He et al., 2005; Nakanishi et al., 2007) and 
the transformation of astrocytes to a reactive phenotype (Justicia et al., 2000; Bolin et al., 
2005), thereby contributing to glial scar development.  
 
1.04.1 Moderation of astrogliosis can improve recovery from CNS injury 
CNS injuries can vary from transient ischemic attacks or diffuse brain injuries where 
there may be only selective neuron and axonal damage without detectable functional 
consequences to severe traumatic injuries and stroke causing permanent serious 
functional deficits or death (Singleton and Povlishock, 2004; Panickar and Norenberg, 
2005; Wagner, 2007; Doyle et al., 2008; Sofroniew, 2008). A similar variation in the 
degree of damage also occurs in individual injuries with distance from the lesion (Figs. 
1.3, 1.4). At the lesion core there may be permanently damaged tissue or even a cell-free 
void following death of neurons and glia, whereas in the injury penumbra, the 
inflammatory responses of surviving astrocytes may enable some restoration of neuronal 
function. While reactive astrocytes produce neuroprotective and neurotrophic factors, 
more severe inflammation is associated with more severe astrogliosis, increased neuronal 
damage and glial scarring that is more inhibitory to regenerating axons (John et al., 2005; 
Fawcett, 2006a; Fernandez et al., 2007a; Laird et al., 2008). Numerous studies on anti-
inflammatory treatments have produced evidence for improved neuronal survival and 
regeneration (Chen et al, 2008; Kunz et al, 2008; Zhang et al, 2008; Yenari and Han, 
2006; Jatana et al, 2006; Kauppinen et al, 2008; Ginis et al, 2002) that has often been 
associated with the moderation of astrogliosis and glial scarring (Schneider et al., 1999; 
Fernandez et al., 2007a; Khorooshi et al., 2008; Phulwani et al., 2008; Sinke et al., 2008). 
However, differentiation and proliferation of astrocytes to establish the glial scar and 
close the lesion is an essential step in wound healing and may protect surviving neurons 
from the severe inflammatory responses in the lesion core (Sofroniew, 2005). 
Consequently, selective ablation of proliferating astrocytes after CNS injury results in a 
less organised glial scar that allows increased axonal regrowth into the lesion, but 
ultimately leads to increased oedema, inflammation and neuronal damage (Bush et al., 
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1999; Horner and Gage, 2000; Faulkner et al., 2004). However, suppression of the 
inflammatory activation of astrocytes, rather than ablation of the scar-forming astrocytes, 
can ameliorate CNS injury damage and improve functional recovery (Brambilla et al., 
2005b).   
 
1.1 Olfactory ensheathing cells as a therapy for CNS injury 
1.10 The olfactory neuronal pathway 
The primary olfactory pathway (Fig. 1.6) has a remarkable capacity for continuous post-
developmental neurogenesis and de novo growth of axons from the peripheral olfactory 
epithelium into the CNS (Doucette et al., 1983; Doucette, 1991; Calof et al., 1996; 
reviewed by Chuah et al., 2010). Dendritic receptors of individual olfactory sensory 
neurons are partly exposed on the surface of the olfactory epithelium and their axons 
course through the cribriform plate into the CNS, where they synapse with second order 
neurons in the olfactory bulbs. The olfactory sensory neurons are regularly replaced by 
differentiation of neurons from stem cells in the olfactory epithelium necessitating axonal 
regrowth from the peripheral epithelium into the CNS (Doucette et al., 1983; Mackay-Sim 
and Kittel, 1991; Chuah et al., 2003). Olfactory sensory neuron axons will continue to 
grow from the olfactory epithelium into the brain after removal of an olfactory bulb and the 
bulbectomy strongly stimulates olfactory sensory neuron renewal (Graziadei and Graziadei, 
1979; Hendricks et al., 1994; Bauer et al., 2003).  
 
1.11 Olfactory ensheathing cells 
1.11.0 Olfactory ensheathing cells ensheath olfactory sensory neuron axons  
Olfactory sensory neurons are closely associated with equally remarkable glial cells, the 
olfactory ensheathing cells (OECs) (Doucette, 1984; Doucette, 1989; Chuah and Au, 
1993; Li et al., 2005b). Unlike other glial cells, OECs are found in both the peripheral 
and CNS regions of the olfactory system (Figure 1.6). OECs are asymmetrical, spindle-
shaped cells (Fig. 1.7A) that extend thin sheet-like cytoplasmic processes to ensheath the 
small fascicles of the unmyelinated olfactory neuron axons (Fig. 1.7B) along their entire 
trajectories from the peripheral lamina propria into the olfactory nerve layers of the 
olfactory bulbs in the brain (Doucette, 1990; Chuah and West, 2002). OECs, like the  
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Figure 1.6 The olfactory nervous system. Schematic sagittal section through the 
human head, showing the olfactory nervous system (right), with a section of the 
olfactory nervous system depicted in greater detail (inset). Stem cells at the base of 
the olfactory epithelium generate new olfactory receptor neurons throughout life, 
which then extend de novo axons to the olfactory bulb. These axons are ensheathed 
by olfactory ensheathing cells throughout their entire trajectories from the lamina 
propria of the olfactory mucosa in the peripheral nervous system (PNS) and into the 
olfactory nerve layer of the olfactory bulbs in the central nervous system (CNS) via 
the cribriform plate. The axons emerge from the olfactory ensheathing cells to 
synapse with second order neurons in odorant-specific glomeruli in the bulbs, from 
where nerve fibres extend to the brain via the olfactory tract (adapted from Thuret, 
2006). 
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Figure 1.7 Olfactory ensheathing cells. A: Immunostaining of olfactory ensheathing cells 
(OECs) from an in vitro purified culture derived from neonatal rat olfactory bulbs. OECs are 
asymmetrical cells that show immunoreactivity for the low affinity neurotrophin receptor 
(green, p75NTR) on the plasma membrane throughout the cell bodies and the long spindly 
processes. Nuclei have been counter-stained with Hoechst blue DNA dye (HB). Scale bar is 
50μM. B: OEC folding for axon ensheathment. Morphologically, the OECs have an epithelial 
origin. A single OEC in represented (a) as an asymmetrical cell with a basal lamina-lined 
inner surface (left of the cell), which faces the mesenchymal fibroblasts and an outer, naked 
surface (to the right), which apposes the olfactory nerve fibres. Progressive curling over of 
the cell (b to e) shows the formation of an enclosed channel to ensheath the olfactory nerve 
axons, which are partially divided into interconnecting territories by thin cytoplasmic sheets 
arising from the inner, naked surface of the OECs. Overall cell diameter ~10μm (adapted 
from Li et al, 2005). C: Fascicular ensheathment. The end-to-end apposition of individual 
OECs forms long continuous channels that ensheath olfactory neuron axon fascicles. Overall 
diameter ~10μm (adapted from Li et al, 2005).   
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olfactory sensory neurons, originate from the olfactory placode on the ectodermal surface 
(Chuah and Au, 1993; Li et al., 2005b).  As development proceeds, the OECs migrate 
inwards through the mesoderm and into the neuroectoderm of the neural tube in 
association with the sensory neuron axons as they grow from the peripheral epithelium to 
the olfactory bulbs in the CNS (Chuah and Au, 1991; Tennent and Chuah, 1996). A basal 
lamina covers the outer surface of OECs and is then encircled by layers formed by the 
thin processes of mesodermal fibroblasts (Doucette, 1990; Chuah, 2003; Li et al., 2005b). 
In the lamina propria single OECs form cylindrical sheaths around axon fascicles (Fig. 
1.7B). The cylinders formed by individual OECs are arranged end to end creating a 
continuous passage for nerve fibre growth. Further along the olfactory nerve pathway, 
two or more OECS combine to form larger cylinders (Fig. 1.7C) surrounded by a 
common basal lamina. Surrounding fibroblasts interact with the OECs to generate basal 
laminae and collagen fibres which probably help maintain the integrity of the nerve 
fascicle passages during phases of olfactory neuron degeneration and regeneration. At the 
olfactory bulb the basal lamina and surrounding fibroblasts separate from the nerve fibre 
fascicles and OEC sheaths to form the pial surface of the bulb. OECs near the pial surface 
extend end-feet that interact with surrounding fibroblasts to form the glia limitans around 
the olfactory bulbs (Doucette, 1993b; Boyd et al., 2003; Li et al., 2005b). Similar 
astrocyte interactions with fibroblasts form the glia limitans elsewhere in the CNS (Berry 
et al., 1983; Abbott et al., 1992; Bundesen et al., 2003). Within the olfactory nerve layer 
of the olfactory bulb the ensheathed nerve fascicles separate and continue to their target 
glomeruli (Valverde et al., 1992; Doucette, 1993b; Dynes and Ngai, 1998; Treloar et al., 
1999). OECs are present throughout the olfactory nerve layer of the bulb but are not 
found deeper in the bulbs, while astrocytes are present throughout the olfactory nerve 
layer and deeper layers. The ensheathing cylinders open at the glomerular layer to allow 
individual olfactory sensory neuron axons to synapse with the dendrites of second-order 
neurons. OEC processes intermingle with the processes of CNS astrocytes in the 
olfactory glomeruli and this association of OECs and astrocytes without any intervening 
basal laminae or fibroblasts may be crucial for directing regenerating olfactory sensory 
neuron axons to the correct synaptic targets. This pathway for regenerating olfactory 
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sensory neuron axons growing from the periphery into the CNS remains open throughout 
life (Doucette et al., 1983; Doucette, 1991; Li et al., 2005b).  
 
1.11.1 OECs are specialised glial cells 
OECs have morphological, protein expression and functional similarities with both 
peripheral Schwann cells and CNS astrocytes (Tennent and Chuah, 1996; Chuah and 
West, 2002; Fairless et al., 2005; Li et al., 2005b; Vincent et al., 2005b). All three glial 
cell types express neurotrophins and neuregulins which promote their proliferation, 
differentiation and survival (Thompson et al., 2000; Woodhall et al., 2001). Although 
OECs and astrocytes both express GFAP there are only sparse scattered filaments in 
OECs, whereas astrocytes have multiple dense bundles of the intermediate filaments 
(Chuah and West, 2002; Fairless et al., 2005; Li et al., 2005b; Vincent et al., 2005b). 
Genetic profiling and morphology indicate that OECs constitute a distinct cell type with 
more similarity to Schwann cells than astrocytes, although OEC morphology exhibits 
variability and plasticity (Vincent et al., 2003; Vincent et al., 2005b; Franssen et al., 
2008). The different glia have separate developmental origins, with OECs arising from 
the olfactory placode, Schwann cells from the neural crest (Doucette, 1993a; Chuah and 
West, 2002; Richter et al., 2005; Leaver et al., 2006) and olfactory bulbar astrocytes from 
progenitors that migrate to the bulbs from the subventricular zone in the brain (Barnett et 
al., 1993; Li et al., 2005b; Vergara et al., 2005; Parent et al., 2006).  
 
1.12 OECs and neuronal regeneration  
In mammals, both the exceptionally high neuronal turnover rate and the regrowth of axons 
from the periphery into the brain are unique to the olfactory nervous system (Doucette et 
al., 1983; Doucette, 1990; Richter and Roskams, 2008). Axons fail to elongate from the 
periphery into the CNS and are therefore unable to re-establish appropriate synaptic 
connections following neuronal damage elsewhere in the nervous system (Li et al., 1997; 
Li et al., 2004; Ruitenberg et al., 2006). The close association of OECs with regenerating 
olfactory sensory neuron axons suggested that OECs may be important contributors to the 
capability for neuronal regeneration and axon regrowth in the olfactory system (Doucette, 
1990, 1993b; Li et al., 2004; Richter and Roskams, 2008). Radial glia stimulate and guide 
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early neurite outgrowth in the developing CNS (Parnavelas and Nadarajah, 2001; 
Campbell, 2003). OECs and other specialised glia such as hypothalamic tanycytes and 
hypophyseal pituicytes have similar functions to radial glia in CNS regions where axon 
regeneration occurs throughout life (Gudino-Cabrera and Nieto-Sampedro, 1999; Boyd et 
al., 2003). These cells sometimes referred to as aldynoglia, have similar morphologies in 
culture and share immunological markers, including the p75 low affinity neurotrophin 
receptor, O4 antigen and insulin-like growth factor. Increased expression of the cytokine, 
leukaemia inhibitory factor (LIF), in the olfactory epithelium precedes olfactory sensory 
neuron renewal induced by bulbectomy (Bauer et al., 2003). LIF appears to be expressed 
by the degenerating olfactory neurons and glia-like sustentacular cells (Bauer et al., 2003), 
while OECs also upregulate their expression of the LIF receptor at 3 days post-bulbectomy 
(Nan et al., 2001). Exogenous LIF also stimulates cellular proliferation in the olfactory 
epithelium and LIF expression by astrocytes promotes neural stem cell renewal in the brain 
(Bauer et al., 2003; Bauer and Patterson, 2006; Dell'Albani, 2008). Furthermore, OECs 
express a variety of neurotrophins and other molecules that support axon growth and 
guidance, including NGF, BDNF, glial cell line-derived neurotrophic factor (GDNF), 
CNTF, neuregulins, integrins, cell adhesion molecules, cadherins and laminin (Kafitz and 
Greer, 1999; Wewetzer et al., 2001; Woodhall et al., 2001; Asan et al., 2003; Lipson et al., 
2003; Franssen et al., 2008). The unique capacity for renewal of olfactory neurons and the 
substantial evidence for OECs providing trophic support for this neurogenesis and de novo 
axon growth (Kafitz and Greer, 1999; Christensen et al., 2001; Woodhall et al., 2001; 
Lipson et al., 2003; Schwob, 2005) has led to extensive research to determine whether 
transplanted OECs could similarly promote neuronal regeneration after spinal cord and 
brain injuries (reviewed by Chuah et al., 2010). A particular advantage of OECs for 
cellular transplantation therapy is the relative accessibility of OECs in the olfactory 
mucosa of live donors for autologous transplant into the CNS of the donors (Barnett and 
Chang, 2004; Feron et al., 2005; Dewar et al., 2007; Mackay-Sim et al., 2008). Autologous 
transplantation eliminates the need for immunosuppression and the attendant increased risk 
of pathogenic infection.  
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1.13 OEC transplantation therapy 
1.13.0 Different CNS injury models have variable therapeutic outcomes  
OEC transplantation into the injured CNS has been associated with decreased tissue and 
neuronal damage (Ruitenberg et al., 2003, 2005; Ramer et al., 2004b; Sasaki et al., 2006; 
Toft et al., 2007), improved axon sprouting and regrowth (Li et al., 1998b; Guntinas-
Lichius et al., 2001; Deumens et al., 2006b), remyelination of spinal cord axons (Barnett 
et al., 2000; Akiyama et al., 2004), angiogenesis (Richter et al., 2003) and enhanced 
functional recovery (Imaizumi et al., 2000a; Lu et al., 2002; Keyvan-Fouladi et al., 2003; 
Li et al., 2003; Johansson et al., 2005; reviewed by Chuah et al., 2010) although some 
studies have not found therapeutic benefits (Gomez et al., 2003; Deumens et al., 2006a; 
Lu et al., 2006). Understandably, much of the research has focussed on the capacity of 
OECs to induce regeneration of injured axons (Bartolomei and Greer, 2000; Guntinas-
Lichius et al., 2001; Deumens et al., 2006c). Spinal cord injury models to investigate the 
regenerative effects of OEC transplantation have included electrolytic lesions (Li and 
Raisman, 1995; Li et al., 1998b; Keyvan-Fouladi et al., 2003), photochemical lesions 
(Verdu et al., 2003), partial dorsal column (Chuah et al., 2004; Ramer et al., 2004b; 
Ruitenberg et al., 2005) or complete spinal cord transections (Ramon-Cueto et al., 2000; 
Lopez-Vales et al., 2006a;  Toft et al., 2007) dorsal rhizotomy (Gomez et al., 2003; Li et 
al., 2004; Ramer et al., 2004a; Riddell et al, 2004)  and contusion lesions (Takami et al., 
2002; Plant et al., 2003; Collazos-Castro et al., 2005). Although the majority of studies 
report enhanced axon regrowth and some functional recovery there are also inconsistent 
results that can be partly attributed to marked variations in the extent and anatomical 
features of the injuries arising from the different injury models (reviewed by Bartolomei 
and Greer, 2000; Nieto-Sampedro, 2003; Barnett and Riddell, 2004; Ruitenberg et al., 
2006; Ruitenberg and Vukovic, 2008; Chuah et al., 2010). There is also considerable 
variation in the severity and nature of clinical traumatic CNS injuries and the different 
injury models may provide insight into the type of injuries most likely to benefit from 
OEC transplantation. Discrepancies between the reported therapeutic outcomes of the 
injury models could also have arisen from differences in the experimental protocols 
affecting the timing and location of transplantation, the composition of the transplanted 
OEC cultures and the severity of inflammation and glial scarring. In comparison to brain 
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injuries, where severe injury is more likely to be fatal, spinal cord injuries are associated 
with stronger inflammatory responses and more extensive glial scarring, with large 
cavities often developing in the lesion. There is no unequivocal evidence for axon 
regrowth across these large spinal cord lesion cavities or of improvements in functional 
recovery due to axonal regeneration following complete transection of the spinal cord 
(Plant et al., 2003; Verdu et al., 2003; Deumens et al., 2006a, c; Sasaki et al., 2006; 
Barnett and Riddell, 2007; Toft et al., 2007; Ruitenberg and Vukovic, 2008). Any 
therapeutic benefits of OECs for these severe spinal cord injuries are probably mediated 
by neuroprotective effects that ameliorate secondary neuronal and axonal damage. 
However, there is evidence of transplanted OECs promoting limited axonal regeneration 
into spinal cord lesions, including the regrowth of severed dorsal roots into the spinal 
cord. OECs have also been reported to promote the regeneration of peripheral axons 
(Guntinas-Lichius et al., 2001; Radtke et al., 2009) and of transected nigrostriatal axons 
in the brain (Teng et al., 2008).  
 
1.13.1 Do OECs remyelinate axons? 
Transplants of Schwann cells (Richardson et al., 1980; Martin et al., 1996; Xu et al., 1997) 
and OECs (Franklin et al., 1996; Kato et al., 2000; Sasaki et al., 2006; Barnett and 
Riddell, 2007) have both been postulated to mediate repair of spinal cord lesions by 
promoting axon growth and re-myelination. Both cell types promote and guide axon 
growth and express similar neurotrophic factors, cell adhesion molecules and 
extracellular matrix proteins (Vincent et al., 2005b; Franssen et al., 2008). OECs only 
ensheath unmyelinated axons in the olfactory system and it may seem improbable that 
transplanted OECs could remyelinate damaged or regenerating axons after spinal cord 
injury, as suggested by some studies (Imaizumi et al., 2000b; Kato et al., 2000; Akiyama 
et al, 2004). However, Schwann cells ensheath small diameter unmyelinated axons in a 
similar manner to OECs and only form myelinated sheaths around larger diameter axons 
with longer nerve fibres where action potential conduction speed becomes more 
physiologically important. In vitro experiments and in vivo transplantation of OECs into 
demyelinated regions of the CNS suggest that OECs can also form myelin sheaths around 
axons of suitable diameter (Kato et al., 2000; Franklin, 2003; Lakatos et al., 2003b; Boyd 
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et al., 2004; Sasaki et al., 2007). However, remyelination by OECs could be restricted to 
demyelinating lesions and was not replicated in other injury models (Boyd et al., 2004; 
Ramer et al., 2004a; Richter et al., 2005). Schwann cell integrins binding to fibronectin 
secreted by fibroblasts promotes myelination (Mirsky and Jessen, 1999; Previtali et al., 
2003). Similar interactions between OECs and fibronectin and other extracellular matrix 
proteins expressed by meningeal fibroblasts may enhance re-myelination by transplanted 
OECs (Lakatos et al., 2000; Lakatos et al., 2003b). The presence of meningeal fibroblasts 
in OEC cultures transplanted into demyelinated lesions increased both the remyelination 
of axons and the number of myelinating cells in the lesions. OECs appeared to form 
myelin sheaths around the large diameter axons in the demyelinated spinal cords, while 
surrounding fibronectin-expressing fibroblasts separated them into fascicles. Growth 
factors such as fibroblast growth factor 2 secreted by the fibroblasts may also have 
promoted OEC proliferation, survival and migration along axon tracts in the lesion (Hsu 
et al., 2001; Yan et al., 2001; Barraud et al., 2007; Santos-Silva et al., 2007). It is also 
possible that contaminating Schwann cells in the OEC or neuronal cultures were 
responsible for the in vitro remyelination (Plant et al., 2002; Li et al., 2005b). Schwann 
cells can often invade spinal cord lesions along with meningeal fibroblasts and may also 
have been responsible for the in vivo remyelination, with fibroblast growth factor 2 or 
other factors produced by the transplanted fibroblasts and OECs possibly promoting 
Schwann cell migration into the lesion (Boyd et al., 2004; Ramer et al., 2004a; Richter et 
al., 2005).  
 
1.13.2 OEC migration in vitro and after transplantation 
Other research shows that transplanted Schwann cells are less able than OECs to migrate 
and survive in the CNS and only remyelinate axons in astrocyte-free regions (Fairless et 
al., 2005; Santos-Silva et al., 2007). Schwann cells also fail to migrate among astrocytes 
in vitro, instead forming discrete boundaries and inducing a hypertrophic reactive 
phenotype characterised by increased expression of GFAP and axon growth inhibitory 
CSPGs, in the astrocytes. In contrast OECs intermingle and migrate amongst astrocytes 
in vitro without forming boundaries or inducing astrocyte activation (Lakatos et al., 2000; 
Li et al., 2005b; O'Toole et al., 2007). Although several studies have reported that OECs 
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are capable of migrating from the injection site, over white matter tracts and grey matter 
(Ramon-Cueto et al., 1998; Ramon-Cueto et al., 2000; Resnick et al., 2003), the 
possibility of dye leakage or the engulfment of dead pre-labelled OECs by macrophages 
have cast doubt on these claims.  Labelling of OECs by viral vector-mediated expression 
of green fluorescent protein has revealed a more conservative migratory capability, while 
others have suggested that the eventual localization of OECs was more likely due to 
passive spreading rather than active migration (Ruitenberg et al., 2002; Lu et al., 2006).  
Recent in vitro experiments have revealed that TNF-α secreted by activated astrocytes 
stimulates OEC chemotaxis and a linear expression gradient of TNF-α has been detected 
in the glial scar after spinal hemisection that could conceivably regulate the migration of 
transplanted OECs (Su et al., 2009).  TNF-α levels peaked at 7 days after injury and in 
studies that failed to show OEC migration, the timing or location of OEC transplantation 
may not have coincided with the TNF-α levels required for chemotaxis (Chuah et al., 
2010).  
 
1.13.3 Regulation of OEC migration 
Comparative gene expression profiling (Vincent et al., 2005b; Franssen et al., 2008) 
indicates that OECs express distinct additional genes associated with tissue repair and 
angiogenesis, which may confer the reported advantages of OECs over Schwann cells as 
therapeutic transplants. The differences between Schwann cell and OEC migration 
amongst astrocytes may be due to stronger neuronal cadherin-mediated adhesion between 
Schwann cells and astrocytes than between OECs and astrocytes (Fairless et al., 2005). 
Suppression of neuronal cadherin activity enhances Schwann cell migration and reduces 
boundary formation in co-cultures with astrocytes but does not alter the intermingling of 
OECs and astrocytes in co-cultures. An additional possible component of the mechanism 
for these differences involves fibroblast growth factor 2, which is expressed by reactive 
astrocytes and invasive fibroblasts after CNS injury and heparan sulphate proteoglycans 
produced by Schwann cells (Santos-Silva et al., 2007). Soluble heparan sulphate 
proteoglycans may induce astrogliosis by enhancing binding of fibroblast growth factors 
to receptors on astrocytes and Schwann cells to promote boundary formation between the 
two cell types. Digestion of heparan sulphate proteoglycans inhibits this boundary 
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formation and promotes Schwann cell migration in co-cultures with astrocytes, while 
addition of fibroblast growth factor 2 and heparin induces boundary formation in 
OEC/astrocyte co-cultures. While the molecules mediating the superior spatial integration 
of OECs and astrocytes are unknown, the repertoire of cadherins (cadherin-3, cadherin-5 
and MT-protocadherin) and integrins (alpha 1, alpha 6, alpha 7 and beta 4) expressed by 
OECs are likely candidates for future investigation (Franssen et al., 2008). 
 
1.13.4 The ‘pathway hypothesis’ 
The compatibility of OECs and astrocytes in co-culture has similarities with their 
interaction in the olfactory bulbs (Fairless et al., 2005; Li et al., 2005b; Santos-Silva et al., 
2007). No discrete boundary forms between OECs in the outer layer of the olfactory bulb 
and astrocytes of the inner layers and there is no inhibition of olfactory sensory neuron 
axon growth at the transition between the OEC and astrocyte dominated regions. 
Following neuronal damage in peripheral regions where axons are ensheathed by 
Schwann cells there is no regeneration of nerve fibres into the CNS as occurs with the 
olfactory sensory axons (Carlstedt, 1997; Chong et al., 1999; Li et al., 2005b).  Except in 
the olfactory system, astrocytes interact with invading fibroblasts and capillary 
endothelial cells to form basal laminae and a glia limitans around CNS sites of neuronal 
damage that are impenetrable to regenerating axons. If dorsal root axons are severed near 
their entry zone to the spinal cord (dorsal rhizotomy), reactive astrocytes reform a 
continuous glial-pial membrane with an outward facing basal lamina that excludes the 
peripheral Schwann cells and is impenetrable to regenerating axons (Liuzzi and Lasek, 
1987; Wroblewski et al., 2000; Pascual et al., 2002; Li et al., 2005b). When OECs were 
transplanted into the entry zone after rhizotomy there was extensive outgrowth of 
astrocyte processes, which interwove with OEC and Schwann cell processes, forming 
bridges that allowed dorsal root axons to regenerate into the spinal cord (Li et al., 2004). 
This research led to the ‘pathway hypothesis’, which proposes that favourable 
interactions between astrocytes and transplanted OECs after injury in the CNS may 
inhibit the formation of an inhibitory glial scar boundary and establish a permissive 
pathway for regenerating axons similar to that existing in the olfactory system (Nieto-
Sampedro, 2003; Li et al., 2005b; Teng et al., 2008). The inclusion of fibroblasts in the 
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transplants (Li et al., 1998b; Li et al., 2003; Teng et al., 2008) may further enhance the 
regenerative properties of OECs, possibly by producing growth factors and extracellular 
matrix proteins that regulate OEC migration (Raisman, 2001; Teng et al., 2008). 
Transplantation of mixed OEC and meningeal fibroblasts into electrolytic lesions in the 
adult rat corticospinal tract led to growth of neuronal sprouts across the lesion and into 
the spinal cord caudal of the lesion (Li et al., 1997, 1998b). Functional recovery in 
response to this treatment appears to depend on precise location of OECs that allows their 
interaction with the processes of reactive astrocytes (Keyvan-Fouladi et al., 2003). 
Restoration of axonal connectivity in the olfactory system does not involve regrowth 
from existing neurons as is required for the repair of spinal cord injuries. Instead, 
olfactory axon replacement depends on neurogenesis from globose basal progenitor cells 
in the olfactory epithelium and de novo axon growth to reconnect with the olfactory bulbs 
(Verhaagen et al., 1990; Christensen et al., 2002; Schwob, 2002). While normal 
innervation and function is restored by olfactory neuron renewal following peripheral 
deafferentation of the olfactory epithelium, reinnervation is abnormal and incomplete 
following transection of the olfactory nerve. Although unilateral bulbectomy strongly 
stimulates proliferation and differentiation of progenitor cells in the olfactory epithelium, 
in the absence of the target tissue, most of the newly formed olfactory neurons remain 
immature and die within a few weeks. Apoptosis and degradation of the olfactory sensory 
neurons and the subsequent axonal renewal appears to occur within intact ensheathment 
channels formed by OECs and the surrounding fibroblasts, supporting the view that 
OECs may have neurotrophic and axon guidance functions. However, the injury 
responses in the olfactory tract also imply that OECs may need to be transplanted at or be 
capable of migrating to suitable locations to induce regrowth of axons towards the 
required targets. These requirements may explain why other groups have found no 
benefit from OEC transplantation after rhizotomy (Gomez et al., 2003; Ramer et al., 
2004a; Riddell et al., 2004) or that transplanted OECs suppressed astrogliosis and 
promoted neurite sprouting, but not in the required direction to repair the injury (Ramon-
Cueto and Nieto-Sampedro, 1994; Nieto-Sampedro, 2003). Subsequently, it was 
proposed that OECs may only be able to promote regeneration when the preferred 
direction of OEC migration coincides with the alignment of new axonal sprouts. This 
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view is supported by experiments involving the implantation of encapsulated OECs into 
the injured spinal cord where regenerating corticospinal collateral nerve fibres were 
directed towards the capsules (Chuah et al., 2004). OECs that were free to migrate after 
direct injection into the injured spinal cord induced significantly more sprouting of 
collateral branches than the encapsulated OEC implants. Adenoviral transduction to 
increase neurotrophin expression in transplanted OECs augmented axonal sprouting but 
the associated improvements in functional recovery were attributed to enhanced 
neuroprotection leading to smaller lesion sizes and more axons spared from secondary 
damage rather than being a consequence of axonal regeneration (Ruitenberg et al., 2003, 
2005). The failure of these and other therapies to promote substantial axonal regeneration 
has led to the view that some form of aligned substrate to support axon growth across 
large lesions is an essential requirement for the repair of spinal cord injuries (reviewed by 
Bunge, 2001; Ruitenberg et al., 2006; Ruitenberg and Vukovic, 2008).  A combination 
treatment using OECs and olfactory nerve fibroblasts aligned on biomatrix bridges did 
increase axon growth into the lesion but the regrowth still did not extend across the lesion 
(Deumens et al., 2006). OEC implantation has also been associated with decreased 
astrogliosis and reduced glial scarring around the lesion in many CNS injury models 
(Ramon-Cueto et al., 2000; Takami et al., 2002; Nieto-Sampedro, 2003; Plant, 2003; 
Ramer et al., 2004b; Teng et al., 2008). Since OEC transplantation has been associated 
with neuroprotective effects (Toft et al., 2007; Ruitenberg and Vukovic, 2008) and 
decreased lesion size, it could be argued that the less severe astrogliosis was an indirect 
effect of a reduction in secondary neuronal damage. However, some of the studies 
reporting improved neuronal survival involved genetically-modified OECs (Ruitenberg et 
al., 2003, 2005) and it is also plausible that the moderation of astrogliosis could have 
initiated the neuroprotective effects. Some evidence suggests that glial scar 
transformation by transplanted OECs is crucial for promoting axonal sprouting (Ramer et 
al., 2004b; Teng et al., 2008) and transplants of OECs combined with Schwann cells to 
bridge the lesion and chondroitinase, to digest growth-inhibitory chondroitin sulphate 
proetoglycans in the glial scar, induced significantly more axonal sparing and functional 
recovery than a variety of other combination treatments (Bunge, 2008). However, other 
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studies have reported improved axonal regeneration independent of effects on astrogliosis 
(Lopez-Vales et al., 2006a; López-Vales et al., 2007). 
 
1.2 Research rationale 
Although the numerous studies on OEC transplantation therapy for CNS injury have 
produced considerable evidence for improved neuronal regeneration and some functional 
recovery, the results have been inconsistent and the mechanisms for the reported 
beneficial effects remain debatable (reviewed by Bunge, 2008; Ruitenberg and Vukovic, 
2008; Chuah et al., 2010). While there is evidence for enhanced neuronal survival and 
decreased lesion size in response to OEC transplantation it is uncertain how OECs 
mediate these effects. Primary neuronal and glial cell death caused by the initial physical 
trauma and ischemia of CNS injury stimulates an inflammatory response that, when 
severe, can lead to extensive secondary neuronal damage (Lenzlinger et al., 2001; 
Morganti-Kossmann et al., 2002; Block et al., 2007; Doyle et al., 2008). Activated 
astrocytes make a major contribution to the inflammatory mediators that regulate the 
severity, duration and resolution of the CNS inflammation (Chen and Swanson, 2003; 
John et al., 2005; Fawcett, 2006b; Floyd and Lyeth, 2007; Fitch and Silver, 2008; Laird et 
al., 2008). Strongly activated astrocytes on the lesion perimeter form a glial scar that 
protects penumbral tissue from more severe inflammation in the lesion core but presents 
a barrier to axon regeneration. More severe inflammation is associated with increased 
neuronal damage, more severe glial scarring and worse functional deficits. Moderation of 
astrocyte activation could therefore enhance neuronal survival and axonal regeneration. 
Many studies report moderation of astrogliosis and glial scarring as a consequence of 
OEC implantation and OECs appear able to migrate freely amongst astrocytes in the 
olfactory bulbs, injured CNS tissue and in vitro (reviewed by Chuah et al., 2010). 
However, partly because of the different injury models used and the complexity of 
cellular interactions in vivo, the effects of OEC implantation have been inconsistent and 
inconclusive. There has been additional uncertainty related to possible contributions to 
the effects of OECs by Schwann cells and fibroblasts that either invade lesions or are 
introduced with the OEC transplants. In vitro research utilising purified cultures of OECs 
and other relevant cell types could provide some insight into the cellular interactions and 
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mechanisms that affect the success of OEC transplantation therapy. Hence, this PhD 
research is an in vitro study to investigate the possibility that OECs moderate astrocyte 
inflammatory activation and could thereby contribute to the beneficial effects of OEC 
implantation therapy. This hypothetical OEC moderation of astrocyte activation has not 
been the specific topic of previous research. In order to research this topic it is first 
necessary to establish a suitable in vitro model of astrocyte activation, which can then be 
utilised to investigate the effects of OECs. Strong inflammatory stimuli can lead to 
astrocyte apoptosis and astrocyte survival is essential for neuronal survival and axon 
regeneration (Swanson et al., 2004; Giffard and Swanson, 2005; Matute et al., 2006; 
Laird et al., 2008; Broughton et al., 2009). Consequently, it was considered advisable to 
also investigate whether the inflammatory stimuli used for the in vitro model induced 
astrocyte apoptosis and whether OECs could modulate any such apoptotic effect. 
 
1.3 Specific aims 
 
1. Establish an in vitro model of astrocyte inflammatory activation. 
 
2. Determine whether OECs inhibit in vitro astrocyte inflammatory activation.  
 
3. Determine whether the inflammatory activation induces astrocyte apoptosis. 
  
4. Determine whether OECs modulate astrocyte apoptosis. 
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CHAPTER 2: Materials and Methods 
 
2.0 Ethics 
All animal procedures were approved by the Animal Experimentation Ethics Committee 
of the University of Tasmania and are consistent with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes. Hooded Wistar rats were used for 
all experimental procedures involving animals and all cell types were harvested from 2 
day-old rats. 
 
2.1 Cell culture 
2.10 Culture media and incubation 
Following harvesting from 2 day-old Hooded Wistar rats, all cell types were plated at 
densities of 2 x 104 cells/cm2 and cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Invitrogen) supplemented with 10% foetal bovine serum (JRH Biosciences) and 
1% penicillin-streptomycin-amphotericin B solution (Invitrogen). All media and reagents 
for use with cell cultures were made up with sterile distilled or milliQ water, filter 
sterilised and stored at 40C or -200C. The serum-supplemented culture medium (DMEM-
10S) was replaced with serum-free DMEM (supplemented only with the 1% 
antibiotic/antimycotic) 24 hours prior to and throughout experiments. Medium 
conditioned by OECs, astrocytes, microglia or fibroblasts was collected from confluent 
cultures in culture flasks after 24 hours of culture in serum-free DMEM. All cultures 
were maintained in an incubator (Forma Scientific) at 370C in a humid atmosphere 
containing 5% carbon dioxide. 
 
2.11 Astrocytes   
Cortical astrocytes were cultured as previously described (McCarthy and De Vellis, 1980; 
Vincent et al., 2005b) with some modifications. Briefly, each rat pup was anaesthetized 
in ice for 10 minutes, the head removed, sterilized with 70% ethanol and transferred to a 
Petri dish, containing warm (370C) DMEM-10S, in a laminar flow hood to maintain 
sterile conditions. The skin and skull above the cerebral hemispheres was removed, the 
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cerebral hemispheres separated from the olfactory bulbs and hindbrain, removed into a 
separate Petri dish containing warm (370C) Modified Eagle’s Medium with HEPES 
(MEM-H; Sigma), hemispheres separated down the midline and the remaining hindbrain 
removed from each cortical lobe. The meninges were carefully peeled from each cortical 
lobe and cortices then transferred to another Petri dish containing 2.5mL warm (370C) 
Hank’s Balanced Salt Solution (HBSS; Sigma) and finely macerated with scissors. The 
macerated neocortical tissues from two rats were then digested in 0.25% trypsin (Gibco) 
at 370C for 20 minutes, excess trypsin removed and trypsinisation inhibited by re-
suspension in DMEM-10S. The cell suspension was filtered through a 60µm pore mesh, 
plated and cells grown to confluence over ~6 days in 1:25 poly-L-lysine (PLL; Sigma)-
coated 75 cm2 flasks (TRP, Switzerland), purified by shaking at 250 rpm on an oscillating 
shaker for 24 hours (McCarthy and De Vellis, 1980) to remove microglia, 
oligodendrocytes and progenitor cells, followed by 4 days with a  20 μM addition to the 
culture medium of the mitotic inhibitor, cytosine-β-D-arabinofuranoside (AraC; Sigma) 
to remove rapidly dividing cells such as fibroblasts or remaining progenitor cells. 
Astrocyte cultures were then passaged twice and grown to confluence after each passage. 
Astrocytes were harvested from flasks by washing with 2mM ethylenediamine 
tetraacetate (EDTA; Sigma) in 0.1M PBS (Versene) to inhibit cell adherence by chelating 
calcium ions, followed by trypsinisation (0.25%) and re-plated onto PLL-coated 18-mm 
diameter acid-washed glass coverslips (Nunc) in 12-well culture plates or, for PCR 
samples, directly into PLL-coated 6-well culture plates. This method yielded cultures 
containing ~95% GFAP-positive astrocytes. 
 
2.12 Olfactory ensheathing cells  
2.12.0 OEC source tissue 
Different researchers have cultured OECs from peripheral olfactory mucosal tissue 
(Barber and Lindsay, 1982; Chuah and Au, 1991; Pixley, 1992), the olfactory nerve layer 
of the olfactory bulbs in the CNS (Chuah and Au, 1993; Franceschini and Barnett, 1996; 
Li et al., 1998a) or pooled tissues from both locations (Chuah et al., 2004; Vincent et al., 
2005b) using a variety of purification techniques and culture conditions. These different 
culture techniques may in part have led to the divergent views on the antigenic profile 
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and identity of OECs, as well as the variable efficacies reported for OECs as therapeutic 
transplants for CNS injury. OEC cultures are subject to contamination by Schwann cells 
that surround some peripheral axons in the olfactory mucosa, astrocytes from the deeper 
layers of the olfactory bulbs and by fibroblasts that surround the OECs of the olfactory 
nerve fascicles and the glia limitans of the olfactory bulbs. Initially, OECs were prepared 
following protocols from previous research that utilised pooled tissue dissected from the 
nasal septum and olfactory bulbs (Chuah and Teague, 1999; Vincent et al., 2003). 
Dissecting the tissue from both the nasal septum and olfactory bulbs was time-consuming 
and risked introducing contaminating Schwann cells (Kawaja et al., 2009), which are 
difficult to distinguish from OECs since they have similar morphology and 
immunoreactivity for p75NTR and S100 in culture (Boyd et al, 2003). In addition, 
inclusion of the peripheral olfactory tissue led to an increase in the percentage of 
contaminating fibroblasts to levels that prevented their elimination from the cultures. 
Sufficient OECs were obtained for later experiments and collection of conditioned 
medium by culturing entirely from olfactory bulb tissue with further modifications of the 
previous culturing protocols. Differences between cultures of mucosal and bulbar OECs 
appear to arise predominantly from the different proportions of contaminating cells, with 
purified mature OECs from either source tissue having similar antigenic profiles and 
abilities to promote neurite growth in vitro (Jani and Raisman, 2004; Kumar et al., 2005; 
Krudewig et al., 2006). Therefore, although bulbar OECs cannot be harvested from living 
donors for autologous transplantation, this choice of source tissue was not considered to 
be a serious impediment to the generalisability of this research. The research implications 
of the source tissues for OEC cultures are discussed further in Chapter 6. 
  
2.12.1 OEC culture from olfactory bulbs 
Briefly, following removal of cerebral hemispheres for astrocyte culture, the olfactory 
bulbs were carefully removed from rat pup skulls using fine forceps and transferred to a 
Petri dish containing warm (370C) MEM-H. The outer layer of each olfactory bulb was 
carefully peeled away and held using a hypodermic syringe with the needle bent at 900 
while any adhering tissue from the inner layers was scraped free using a second 
hypodermic syringe with the needle bent at 450. The tissue harvested from the outer 
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layers of 6-8 olfactory bulbs were pooled and digested in 0.25% trypsin (Gibco) at 370C 
for 30 minutes, excess trypsin solution removed and trypsinisation inhibited by re-
suspension in DMEM-10S. The tissue was then partially dissociated by syringing through 
a 23-gauge needle and pelleted by centrifugation at 500g for 10 minutes. Cells were then 
resuspended in DMEM-10S and plated without filtering onto 1:25 PLL-coated 18 mm 
acid-washed coverslips (Nunc) in 12-well culture plates, PLL-coated 25 cm2 culture 
flasks (TRP, Switzerland) or Falcon™ cell culture inserts incorporating polyethylene 
terephthalate membranes with 400nm pores (Becton Dickinson). Cells were purified for 3 
days with 100μM AraC and expanded for four days using 100 µg/ml bovine pituitary 
extract (Sigma). Cultures with ~95% low affinity neurotrophin receptor (p75NTR)-positive 
OECs were obtained for experiments by this method. 
 
2.13 Microglia  
Microglia were cultured by plating the medium collected from astrocyte cultures after 30 
minutes of shaking onto uncoated 25 cm2 flasks or 18 mm coverslips in 12-well culture 
plates. Microglia tended to proliferate cyclically and detach spontaneously from cortical 
cell cultures. Higher yields were therefore obtained by monitoring cultures under phase 
contrast and commencing shaking when large numbers of microglia were visible on the 
upper surface of the cortical cell cultures. Shaking for less than 45 minutes minimised 
detachment of cell types other than microglia. The cultures were placed in the incubator 
for about 20 minutes to allow microglia to adhere and then the cultures were swirled and 
gently tapped to remove any oligodendrocytes or progenitor cells (which adhered less 
readily than microglia) before changing the medium and returning the purified microglia 
cultures to the incubator. Microglia are an abundant CNS cell type (Yang et al., 2010) 
and this procedure immediately yielded large numbers of microglia, which proliferated 
slowly over three to five days to produce dense cultures. These cultures contained ~95% 
CD11b-positive microglia with astrocytes as the predominant contaminating cells.  
 
2.14 Meningeal fibroblasts  
Fibroblasts were cultured from meningeal tissue separated from cerebral hemispheres 
during astrocyte culture preparation. The meningeal tissue was treated as for astrocyte 
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culture except that it was not filtered prior to plating into 75 cm2 flasks. Cultures were 
grown to confluence and passaged several times in flasks before plating onto PLL-coated 
18 mm coverslips in 12-well culture plates. These cultures contained ~95% fibronectin-
positive/GFAP-negative fibroblasts. The meningeal fibroblast monocultures contained 
few contaminating cells without requiring any specific procedure for their elimination 
due to the rapid proliferation rate of the fibroblasts. Fibroblasts are present in most tissues 
and their rapid proliferation rate confers a propensity for contaminating cultures of other 
cells (Gibbons et al., 2007). 
 
2.2 Immunocytochemistry 
2.20 Immunostaining 
Cultures on coverslips were fixed in 4% paraformaldehyde, washed with 0.1M PBS 
containing 0.3% Triton X-100 (Sigma) to permeabilise cell membranes and incubated 
with serum-free protein block (Dako) for 5 minutes to block non-specific binding of 
antibodies. Primary antibodies were applied for 1 hour at room temperature at the 
concentrations shown below (Table 2.0), in 0.1M PBS containing 0.3% Triton X-100. In 
most instances, a rabbit and mouse primary antibody were applied simultaneously in the 
same solution. A no primary antibody control sample was included for all experiments. 
Following washing with PBS, the secondary antibodies, goat anti-rabbit Alexa Fluor 594 
and goat anti-mouse Alexa Fluor 488 (both Molecular Probes) were each diluted at 
1:1000 in 0.1M PBS containing 0.3% Triton X-100, in the same solution, for 
simultaneous incubation, for 1 hour in the dark. When required cells, were delineated 
with Alexa Fluor 488 phalloidin staining (1:40 in 0.1M PBS for 20 minutes in the dark; 
Molecular Probes) of cytoskeletal actin filaments in place of a mouse primary antibody 
and the goat anti-mouse Alexa Fluor 488 secondary antibody. Nuclei were counter-
stained by incubating with Hoechst blue DNA dye 33342 (200 ng/mL in 0.1M PBS; 
Molecular Probes) for 30 minutes in the dark. Coverslips were placed on wax-filled 
culture plate lids for antibody incubations to enable the use of small volumes of antibody 
solution (100μL/coverslip) and then returned to culture plate wells for PBS washes and 
Hoechst staining of nuclei. Coverslips were washed in 0.1M PBS, rinsed in distilled 
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water and mounted on glass slides using Permafluor™ aqueous mounting medium 
(Immunotech, France) and stored in the dark. 
 
2.21 Fluorescence imaging 
Specimens were viewed on an Olympus BX50 fluorescence microscope using Olympus 
UplanF1 10X, 20X and 40X lenses or a Leica 60X oil immersion lens for image capture 
with an Optronics Magnafire camera. Images were usually taken at the same 
magnification and location on the coverslip for the Hoechst nuclear stain and each 
antibody. Image locations on the coverslip were selected randomly, commencing with a 
central location and separated by two to three microscope fields. Where possible, images 
for the same primary antibody and magnification were taken at the same exposure. Sets 
of 3 images were merged using Adobe Photoshop 7.0 © (Adobe Systems, San Jose, CA, 
USA) when required, for example, to show immunoreactivity for NF-κB, a cell-specific 
protein (astrocytes: GFAP; OECs: p75NTR; microglia: CD11b) and Hoechst blue nuclear 
staining. 
 
Table 2.0 Primary antibodies for immunocytochemistry 
 
Antibody Concentration  Host species/clonality Manufacturer 
anti-p65 NF-κB 1:100 rabbit polyclonal Santa Cruz 
anti-c-Rel NF-κB 1:100 rabbit polyclonal Santa Cruz 
anti-GFAP 1:1000 rabbit polyclonal Dako 
anti-GFAP 1:1000 mouse monoclonal Millipore 
anti-fibronectin  1:100 rabbit polyclonal Abcam 
anti-ferritin 1:1000 rabbit polyclonal Abcam 
anti-S100 1:500 rabbit polyclonal Dako 
anti-p75NTR 1:100 rabbit polyclonal Upstate 
anti-p75NTR 1:100 mouse monoclonal Millipore 
anti-CD11b 1:500 mouse monoclonal Sigma 
anti-IGF-1 1:100 mouse monoclonal Millipore 
anti-Iba1 1:1000 rabbit polyclonal Wako 
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2.3 Identification of cell types 
2.30 Monitoring the cellular composition of live cultures  
The progress, cellular composition and viability of cell cultures were monitored daily by 
observing the live cultures on an Olympus CK2 bifocal microscope under phase contrast 
and imaging, when required, with an Olympus DP10 camera (Figs. 2.0, 2.1). To enable 
identification of cells from the observed morphologies in the live cultures, sample 
cultures were compared after immunostaining for cell-specific marker proteins (Figs. 2.2-
2.12). Live cultures of astrocytes (Fig. 2.0A-C), fibroblasts (Fig. 2.0D), OECs (Fig. 2.1A, 
B) and microglia (Fig. 2.1C, D) displayed distinctive morphologies under phase contrast.  
 
2.30.0 Astrocyte morphology  
Astrocytes in serum-supplemented medium (Fig. 2.0A) appeared as large flat cells that 
formed dense confluent monocultures. Astrocytes had large oval nuclei and variably 
shaped cell bodies from which long broad processes extended, typically arranged in a 
distinctive radial ‘star-like’ distribution (McCarthy and De Vellis, 1980). Ingredients of 
serum such as thrombin, lysophosphatidic acid and fibronectin promote attachment to 
culture substrates by activating the cytoskeletal regulator, RhoA leading to downstream 
assembly of actin stress fibres and their attachment at focal adhesions (Goldman and 
Abramson, 1990; Suidan et al., 1997; Ramakers and Moolenaar, 1998; Safavi-Abbasi et 
al., 2001; Peters et al., 2005). Consequently astrocytes in serum-supplemented media 
have focal adhesions linked to radially arranged actin stress fibres resulting in large 
flattened cell bodies (Fig. 2.0A) while those growing in serum-free conditions have 
smaller cell bodies and longer processes (Fig. 2.0B). Cyclic AMP analogues such as 
dibutyryl-cyclic AMP (db-cAMP) strongly inactivate RhoA resulting in rapid retraction 
of cytoplasm to produce stellate astrocyte morphologies with small cell bodies and long 
narrow radially distributed processes (Fig. 2.0C), independent of any synthesis of 
cytoskeletal proteins.  
 
2.30.1 Meningeal fibroblast morphology 
Meningeal fibroblasts (Fig. 2.0D) form dense confluent cultures that, although 
resembling astrocytes, are morphologically distinct (Hanson et al., 1982; Grumet and 
Edelman, 1988; Deloulme et al., 1997; Niclou et al., 2003). Fibroblasts are more uniform  
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Figure 2.0 Phase contrast live images of astrocyte and fibroblast cultures. Astrocytes (A-C) 
and fibroblasts (D) cultured in 75cm2 culture flasks were imaged live under phase contrast. 
Astrocytes formed dense confluent cultures and although displaying highly variable size and 
morphology, when cultured in DMEM supplemented with 10% foetal calf serum (DMEM-10S) 
they tended to have flattened, epitheloid cell bodies with long broad processes (A). Culture in 
serum-free conditions promoted a gradual change to more process-bearing stellate astrocyte 
morphologies (B) while treatment of astrocytes with the cyclic-AMP analogue dibutyryl-cyclic-
AMP (db-cAMP) strongly and rapidly induced these stellate process-bearing morphologies (C). 
Fibroblasts also formed dense confluent cultures (D) with cells of variable size but with 
relatively uniform epitheloid morphologies usually having much shorter processes than 
astrocytes. Scale bar is 200μm. 
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Figure 2.1 Phase contrast live images of OEC and microglia cultures. OECs (A, B) and 
microglia (C, D) cultured in 25cm2 culture flasks were imaged live under phase contrast.  
Cultures of both OECs and microglia varied from cultures that appeared to contain a mixture of 
cell types (A, C) to those that were predominantly monocultures (B, D). In the OEC 
monocultures (B) dense clusters of small high-contrast cell bodies extended a dense network of 
long thin processes. In other OEC cultures (A) these high contrast cells and process networks 
were more sparse with an underlying layer of large, flat, low-contrast cells with short processes 
(asterisks in A) that resembled fibroblasts. Microglia monocultures (D) contained rounded 
high-contrast cells with mainly short processes, although there was often a single long process 
(arrows in D) sometimes terminating in a fan-shaped structure resembling an axonal growth 
cone. Microglia tended to occupy discrete domains in these cultures with relatively little 
overlapping of adjoining cells compared with cultures of the other cell types. In other microglia 
cultures (C) the high-contrast rounded microglia (plus signs in C) were on a basal layer of large 
flattened low-contrast cells (asterisks in C) while other cells had small dark cell bodies with 
long thin processes (arrows in C). Cells resembling microglia were also occasionally seen in the 
OEC cultures (plus sign in A). Scale bar is 200μm. 
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in shape than astrocytes, tend to align along parallel bipolar axes rather than having the 
random distribution of astrocytes and usually have shorter and fewer processes.   
 
2.30.2 OEC morphology 
OECs (Fig. 2.1B) appear as medium to dark grey, high-contrast, spindly bipolar cells 
with oval cell bodies that are smaller than most astrocyte cell bodies and long processes 
that are much thinner than astrocyte processes (Chuah and Au, 1993; Vincent, 2003; 
Vincent et al., 2005a). OECs often occurred in dense clusters of small high-contrast cell 
bodies that extended dense networks of long thin processes that tended to align in parallel. 
Some OECs had larger more polygonal cell bodies with a more radial distribution of 
processes. The OEC cultures (Fig. 2.1A) were subject to contamination by fibroblasts 
(asterisks in Fig. 2.1A) and occasionally microglia (plus sign in Fig. 2.1A). 
 
2.30.3 Microglial morphology 
Microglia (Fig. 2.1D) appeared as small medium to dark grey, high-contrast cells with 
irregular outlines having many short fine processes and sometimes one or several larger 
processes (arrows in Fig. 2.1D), that sometimes terminated in a fan-shaped structure 
resembling an axonal growth cone. Overall cell-shape varies remarkably (Dobrenis, 1998; 
Frank et al., 2006) including small rounded cells resembling the activated amoeboid in 
vivo phenotype, relatively large rounded flat cells, long irregular rod-shaped cells and 
very irregular cells resembling the ramified quiescent in vivo phenotype.  Microglia 
tended to occupy discrete domains in these cultures with relatively little overlapping of 
adjoining cells compared with cultures of the other cell types. Cultures of microglia (plus 
signs in Fig. 2.1C) sometimes contained contaminating fibroblasts (asterisks in Fig. 2.1C) 
and progenitor cells (arrows in Fig. 2.1C) that appear as small, dark cells occupying 
separate domains with radially-distributed, highly-branched processes (McCarthy and De 
Vellis, 1980; Itoh, 2002).  
 
2.31 Determination of cell type and culture purity by immunoreactivity 
Cultures were imaged after immunostaining for protein markers of the intended culture 
cell type (Table 2.1) and probable contaminating cell types, together with Alexa Fluor 
488 phalloidin staining of cytoskeletal actin filaments to delineate cell morphologies and 
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Hoechst blue counter-staining of nuclei. Unfortunately, it is rarely possible to find marker 
proteins that are expressed exclusively by a specific cell type. For this reason, cell type 
was identified using the expression of marker proteins in conjunction with the 
intracellular distribution of immunoreactivity for the marker proteins and cell 
morphology. The reliability of identification using this methodology is discussed below 
for each cell type.  
 
Table 2.1 Marker proteins for identifying cell type 
 
Cell type Marker protein 
astrocyte GFAP 
microglia CD11b 
fibroblast fibronectin 
OEC p75NTR
 
 
2.31.0 Astrocyte cultures 
Astrocytes (Fig. 2.2) are commonly identified by their expression of the intermediate 
filament protein, glial fibrillary acidic protein (GFAP) (Reeves et al., 1989; Goldman and 
Abramson, 1990; De Groot et al., 1997; Reilly et al., 1998; Silva et al., 1998; Gomes et 
al., 1999; Brahmachari et al., 2006; Cebolla and Vallejo, 2006; Tramontina et al., 2007). 
Although other glial cells express some GFAP, only astrocytes have distinctive 
prominent cytoplasmic bundles of GFAP. In common with other glial cells, astrocytes 
also express S100, a cytoplasmic calcium-binding protein (Goncalves et al., 1997; Sorci 
et al., 1998; Raponi et al., 2007). GFAP immunoreactivity (Fig. 2.2A, D, G and green in 
Fig. 2.2C, F, I) revealed a dense network of the intermediate filaments throughout 
astrocyte cell bodies and processes while S100 (Fig. 2.2B and red in Fig. 2.2C) appeared 
as diffuse bright immunoreactivity throughout cell bodies and processes. Nuclei were 
large and oval-shaped (blue in Fig. 2.2C, F) while cytoskeletal actin filaments (Fig. 2.2E 
and red in Fig. 2.2F) were radially distributed around centres in the cell bodies (asterisks 
in Fig. 2.2D-F) away from nuclei and not obviously aligned with the processes delineated 
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Figure 2.2 Immunostaining characterisation of astrocytes. Cultured astrocytes were 
maintained in serum-free DMEM for 24 hours prior to immunostaining for GFAP (A, D, G and 
green in C, F, I) and S100 (B and red in C). Cytoskeletal actin filaments (F-actin) were stained 
with Alexa fluor 488-conjugated phalloidin (E, H and red in F, I) and nuclei were stained with 
Hoechst blue (HB; blue in C, F, I). GFAP immunoreactivity is prominent in astrocytes as a 
dense network of the intermediate filaments throughout cell bodies and processes. Cultured 
astrocytes also showed diffuse bright immunoreactivity for S100 throughout cell bodies and 
processes. After 24 hours in serum-free conditions astrocytes tended to stellate morphologies 
with flattened epitheloid cell bodies and radially distributed processes. Nuclei were large and 
oval-shaped (blue in C, F) while cytoskeletal actin filaments (E and red in F) were radially 
distributed around centres in the cell bodies (asterisks in D-F) away from nuclei and not 
obviously aligned with the processes delineated by GFAP filaments (D and green in F). 
Treatment with 1mM db-cAMP induced strong stellation of astrocytes within 1 hour (G-I). The 
db-cAMP treated astrocytes had small cell bodies with radially distributed long thin processes 
that formed dense interwoven networks. The rapid compression of cytoplasm into cell bodies 
and narrow processes is associated with intensification of immunoreactivity. Substantial 
depolymerisation of actin filaments, which are radially distributed around nuclei and aligned 
with GFAP filaments in processes (H and red in I), accompanied the cytoplasmic compression. 
Nuclei were also compressed and became more rounded (blue in I). Scale bar is 50μm. 
 
 
 54
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Contaminating cells in astrocyte cultures. Astrocytes were identified by 
immunoreactivity for GFAP (A, D and green in C, I). Contaminating microglia were identified by 
immunoreactivity for CD11b (B, E and red in C, F) and fibroblasts by immunoreactivity for 
fibronectin (H, K and red in I, L). Nuclei were stained with Hoechst blue (HB; blue in C, F, I, L). 
Cytoskeletal actin filaments (F-actin) were stained with Alexa fluor 488-conjugated phalloidin (D, 
J and green in F, L) to facilitate comparisons of cell morphologies with live cultures viewed 
under phase contrast (Fig. 3.0). CD11b-positive microglia (asterisks in A-F) were rarely found in 
the astrocyte cultures. Microglia had irregular morphologies with numerous short processes (B, E) 
and were negative for GFAP (asterisks in A). Actin filaments in microglia (asterisks in D) were 
not discernible against the dense background of radially arranged astrocyte actin filaments. 
Although astrocyte cultures appeared to usually be of high purity (G-I) there were occasionally 
dense patches of contaminating fibroblasts (lower section of J-L). Astrocytes and fibroblasts both 
expressed fibronectin in a perinuclear punctate distribution (H, K and red in I, L), but 
immunoreactivity was usually more intense in fibroblasts (lower section of K, L) and networks of 
secreted fibronectin (arrows in K, L) appeared to be associated only with fibroblasts. Actin 
filaments in fibroblasts were sparser and more randomly distributed (lower section of J) than in 
astrocytes (D, J). Some fibroblasts appeared to be growing on a basal layer of astrocytes (asterisk 
in J-L) with secreted fibronectin extending out from the boundary (arrows in J-L and asterisk in 
G-I). Scale bar is 100μm. 
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by GFAP filaments (Fig. 2.2D and green in Fig. 2.2F). The rapid compression of 
cytoplasm into cell bodies and narrow processes, associated with db-cAMP induced 
astrocyte stellation (Fig. 2.2G-I), resulted in intensification of immunoreactivity and 
depolymerisation of cytoskeletal actin filaments, which became radially distributed 
around nuclei and aligned with GFAP filaments in processes (Fig. 2.2H and red in Fig. 
2.2I). Nuclei were also compressed and became more rounded (blue in Fig. 2.2I). 
Occasional contaminating microglia in astrocyte cultures (asterisks in Fig. 2.3A-F) were 
identified by positive immunoreactivity for the complement receptor, CD11b (Fig. 2.3B, 
E and red in Fig. 2.3C, F) and although negative for GFAP (asterisks in Fig. 2.3A), this 
would be difficult to discern within dense GFAP-positive astrocyte cultures without 
counter-staining for CD11b to locate the microglia. There were also occasionally dense 
patches of contaminating fibroblasts in the astrocyte cultures (Fig. 2.3J-L). Although 
immunoreactivity for the extracellular matrix protein, fibronectin, was usually more 
intense in fibroblasts (Fig. 2.3K, L) and networks of secreted fibronectin were associated 
only with fibroblasts (arrows in Fig. 2.3K, L), both astrocytes and fibroblasts expressed 
fibronectin in a perinuclear punctate distribution (Fig. 2.3H, K and red in Fig. 2.3I, L). 
Although fibroblasts were negative for GFAP, this would again be difficult to discern in 
dense astrocyte cultures, particularly where fibroblasts were growing on or under a layer 
of astrocytes (asterisk in Fig. 2.3J-L). Careful removal of meningeal tissue during 
cerebral hemisphere dissection helped to ensure that fibroblasts remained within the 
acceptable limits of 5% of cells in the astrocyte cultures. 
 
2.31.1 Microglial cultures 
Microglia were identified by immunostaining for the integrin, CD11b (Fig. 2.4B, D, K, 
M, green in Fig. 2.4C, L and red in Fig. 2.4F, O), a component of complement receptor 3 
(Koguchi et al., 2003; Frank et al., 2006; Garcao et al., 2006; Haynes et al., 2006; 
Vincent et al., 2007). Peripheral macrophages also express CD11b (Haynes et al., 2006; 
Farber et al., 2009) but these are usually only present in very low numbers within healthy 
brain parenchyma (Dobrenis, 1998; Frank et al., 2006). Although outer meningeal tissue 
was removed during culture preparation, it is not possible to separate the pia mater, which 
has been reported to contain a large population of monocyte-derived macrophages in 
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adult rodents (Chinnery et al., 2010). These macrophages could represent a remaining 
source of contaminating cells in the microglia cultures. However, they would only be 
likely to make a minor contribution to the cultures because of the small volume of pial 
tissue relative to the cerebral hemispheres. In addition, large numbers of microglia could 
also be expected in the outer meninges and pia mater in the tissue from neonatal rats used 
for this current research, since circulating microglia precursors derived from mesodermal 
hematopoietic cells enter the developing brain through the meninges during perinatal 
stages and transform into microglia (Boya et al., 1987; Cuadros and Navascues, 1998; 
Dobrenis, 1998; Monier et al., 2006; Yang et al., 2010). In the perinatal brain, microglia 
predominantly adopt amoeboid phagocytic morphologies and transform into ramified 
resting microglia during development. These microglia cannot readily be distinguished 
from monocyte-derived macrophages on the basis of either morphology or immunology 
(Rolls et al., 2008; Yang et al., 2010; Schwartz et al., 2010). Chinnery et al., 2010 use 
major histocompatiblity complex Class II (MHCII) expression to distinguish pial 
macrophages from microglia, despite the known expression of MHCII by activated 
microglia (Sasaki and Nakazato, 1992; Longbrake et al., 2007; Yang et al. 2010). 
Furthermore, Chinnery et al., 2010 only present low resolution out-of-focus images of 
microglia that, as far as can be discerned, morphologically resemble the monocyte-
derived macrophages. All microglia also showed positive immunostaining for the iron-
storage protein, ferritin (Fig. 2.4A, G, J and red in Fig. 2.4C, I, L), which has been used 
to identify activated microglia and other immune cells in vivo after CNS injury (Huang 
and Ong, 2005). However, ferritin is the major intracellular iron storage protein in all 
animals and was not specific to microglia. Astrocytes, fibroblasts, OECs (data not shown) 
and progenitor cells (asterisks in Fig. 2.4G-O) were all positive for ferritin but negative 
for CD11b immunostaining. Contaminating astrocytes (Fig. 2.5A-F) and fibroblasts (Fig. 
2.5G-I) could be identified by positive immunostaining for GFAP and fibronectin 
respectively and negative immunostaining for CD11b, although CD11b-positive 
microglia sometimes exhibited weak staining for both GFAP (plus sign Fig. 2.5D-F) and 
fibronectin (plus signs Fig. 2.5G-I). Microglia, astrocytes and fibroblasts could also be 
distinguished by their morphologies and distributions of cytoskeletal actin filaments (Fig. 
2.5J-R). 
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Figure 2.4 Immunostaining characterisation of microglia. Microglia were identified by 
immunoreactivity for CD11b (B, D, K, M, green in C, L and red in F, O) and ferritin (A, G, J and 
red in C, I, L). Nuclei were stained with Hoechst blue (HB; blue in C, F, I, L, O). Cytoskeletal 
actin filaments (F-actin) were stained with Alex fluor 488-conjugated phalloidin (E, H, N and 
green in F, I, O) to facilitate comparisons of cell morphologies with live cultures viewed under 
phase contrast (Fig. 3.1). Microglia were all positive for ferritin and CD11b and had rounded to 
irregular morphologies with numerous short processes. There was little difference in the 
appearance of microglial morphologies revealed by staining for ferritin, CD11b or actin filaments 
(D-I). Contaminating progenitor cells in the microglia cultures had small cell bodies and long thin 
processes (asterisks in G-O), and were positive for ferritin but negative for CD11b 
immunoreactivity. Scale bar is 100μm. 
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Figure 2.5 Contaminating cells in microglia cultures. Microglia were identified by immunoreactivity for 
CD11b (A, D, G, J, M, green in C, F, I and red in L, O). Contaminating astrocytes were identified by 
immunoreactivity for GFAP (B, E and red in C, F) and fibroblasts by immunoreactivity for fibronectin (H, 
Q and red in I, R). Nuclei were stained with Hoechst blue (HB; blue in C, F, I, L, O, R). Cytoskeletal actin 
filaments (F-actin) were stained with Alex fluor 488-conjugated phalloidin (K, N, P and green in L, O, R) 
for morphological comparisons with live cultures viewed under phase contrast (Figs. 3.0, 3.1). GFAP 
positive astrocytes varied from small cells with long thin processes (asterisks in A-C) to large flattened 
cells with shorter processes (E and red in F) and were all CD11b-negative (A, D). Large flattened 
astrocytes had stronger GFAP immunoreactivity. GFAP immunoreactivity was imaged at 2x exposure in B 
and was otherwise only very faint in these progenitor-like astrocytes (arrow in D-F; cell underlying the 
large astrocyte). There was some background nuclear and peri-nuclear immunoreactivity and occasionally 
bright (plus sign D-F) immunoreactivity in microglia with the polyclonal GFAP antibody (Dako). Most 
microglia had rounded to irregular morphologies with short processes and occasionally a larger process, 
terminating in a fan-shaped structure (asterisks D-F). There was also some background staining in 
microglia (plus signs G-I) with the fibronectin antibody but immunoreactivity was much stronger in the 
CD11b-negative contaminating fibroblasts (asterisks in G-I). Contaminating fibronectin-positive fibroblasts 
(arrows in Q-R) had sheet-like distributions of thick parallel actin filaments (arrows in J- R) whereas the 
irregularly-shaped microglia had a relatively diffuse distribution of actin filaments (asterisks M-R). 
Contaminating astrocytes had finer actin filaments that extended into radially arranged processes (asterisks 
J-L) and were distinguishable from actin filaments of fibroblasts (arrows in J-L) and CD11b-positive 
microglia (plus signs J-L). Scale bar is 100μm. 
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Figure 2.6 Contaminating progenitor cells in microglia cultures. Progenitor cells (A, C, E) 
were separated from astrocytes in confluent cortical cell cultures by 23 hours of shaking 
following earlier removal of microglia after 1 hour of shaking. Immunostaining for GFAP 
indicated that in monoculture the progenitor cells differentiated into astrocytes. After 24 hours 
most cells in these cultures had small cell bodies with two or three short branched processes. By 
48 hours most cells had numerous longer, highly-branched processes. After 6 days the majority of 
cells were mature astrocytes with flattened epitheloid morphologies, although there were still 
numerous cells present similar to those seen in the earlier cultures (asterisks in E). Some 
progenitors with highly branched interwoven processes may have been differentiating into 
oligodendrocytes (arrows in E). Contaminating GFAP-positive progenitors (red in B, D, F) 
showed a similar progression of differentiation into astrocytes within cultures of CD11b-positive 
microglia (green in B, D, F). After 48 hours (B) the contaminating progenitors had long thin 
processes similar to those seen in monoculture after the same time in culture (C). By three days 
the GFAP-positive processes had thickened to form tract-like networks through the culture (D). 
Hoechst blue-stained nuclei (HB; blue in B, D, F) revealed there were some contaminating cells 
that were negative for GFAP and CD11b (plus signs in D). By 6 days (F) the contaminating cells 
were mainly mature astrocytes although there were also some still immature progenitors present 
(asterisk in F). Scale bar is 100μm. 
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2.31.2 Progenitor cells 
Neural progenitor cells that express NG2, a chondroitin sulphate proteoglycan, generate 
oligodendrocytes during development (Nishiyama et al., 2005; Wigley et al., 2007) and 
can differentiate into astrocytes or oligodendrocytes, depending on the growth factor 
environment, in culture (Raff et al., 1983; Franklin et al., 1995; Parnavelas, 1999). 
Microglia and progenitor cells were both removed from cortical cell cultures by shaking 
during preparation of astrocyte cultures and therefore, progenitor cells were a likely 
contaminating cell in microglia cultures. Progenitor cells (Fig. 2.6) cultured in the 
presence of serum appear to rapidly differentiate into GFAP-positive astrocytes within 48 
hours and then gradually develop more mature astrocyte morphologies over several days 
(Fawcett and Asher, 1999; Rhodes et al., 2006), whether cultured separately (Fig. 2.6A, C, 
E) or as contaminating cells (red in Fig. 2.6B, D, F) in the microglia (green in Fig. 2.6B, 
D, F) cultures. Hence, any progenitor cells remaining in astrocyte cultures would be 
unlikely to affect the purity of the astrocyte cultures by the time of experimentation. 
Although not observed, there may have been small numbers of quiescent progenitors in 
the astrocyte cultures (Crang and Blakemore, 1997) that could contribute to the continued 
proliferation of astrocytes in confluent cultures (Faijerson et al., 2006; Sergent-Tanguy et 
al., 2006). Gradual differentiation of progenitors into astrocytes could account for some 
of the observed morphological heterogeneity of astrocytes in the cultures. Rarely, 
progenitors may have been differentiating into oligodendrocytes (arrows in Fig. 2.6E) 
and there were also some contaminating cells negative for GFAP and CD11b (plus signs 
in Fig. 2.6D) that were most likely to have been fibroblasts. 
 
2.31.3 Fibroblast cultures 
Fibroblasts all showed positive immunostaining for the extracellular matrix protein, 
fibronectin (Hirsch et al., 1995; Lakatos et al., 2003b; Mulsow et al., 2005; Ito et al., 
2006a; Gibbons et al., 2007; Ibanez et al., 2007) with stronger perinuclear staining  in 
more isolated cells (Fig. 2.7D-F) and interlocking networks of secreted fibronectin 
forming over dense patches of fibroblasts (Fig. 2.7A-C, G-I). Fibroblasts had shorter 
processes that, unlike astrocyte processes, were not radially arranged and oval nuclei that 
tended to be larger than astrocyte nuclei. Fibroblasts were negative for GFAP showing 
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only faint background staining (Fig. 2.7B) with the monoclonal GFAP antibody 
(Chemicon). The coarse sheet-like parallel actin filaments of fibroblasts could be 
distinguished from the interwoven dense networks of fine radially distributed actin 
filaments in S100-positive astrocytes (Fig. 2.7). Fibroblasts showed only nuclear and 
faint perinuclear S100 immunoreactivity. Contaminating cells, which were identified as 
GFAP-positive astrocytes (asterisks in Fig. 2.8A) and CD11b-positive microglia 
(asterisks in Fig. 2.8B), were rare in the fibroblast cultures (Fig. 2.8) with the majority of 
Hoechst blue-stained nuclei belonging to GFAP/CD11b-negative fibroblasts.  
 
2.31.4 OEC cultures 
OECs were identified by immunostaining for the low affinity nerve growth factor 
receptor, p75NTR (Fig. 2.9A, D, G, green in Fig. 2.9C, F and red in Fig. 2.9I). All OECs 
also showed immunoreactivity for S100 (Fig. 2.9B, E and red in Fig. 2.9C, F). Schwann 
cells also express p75NTR and in culture are very similar in appearance to OECs (Lakatos 
et al., 2000; Vincent et al., 2005b; Franssen et al., 2008). Therefore, to exclude Schwann 
cells from the cultures, OECs were cultured from the only from olfactory bulb tissue for 
this research. The p75NTR-positive OECs corresponded with those seen under phase 
contrast (Fig. 2.1) including both those with small cell bodies and long thin processes and 
more flattened cells. Consistent with previous research (Alexander et al., 2002; Chuah 
and West, 2002; Vincent et al., 2005b), immunostaining showed that the transition 
towards the more flattened, epitheloid, astrocyte-like morphologies with multiple 
radially-arranged processes was accompanied by a corresponding transition towards 
decreasing intensity of p75NTR immunoreactivity and increasing intensity of GFAP 
immunoreactivity (Fig. 2.10). GFAP immunoreactivity appeared as weak, diffuse 
staining in the more Schwann cell-like spindly bipolar OECs and as fibrous bundles of 
GFAP in astrocyte-like OECs. Neural stem cells and multipotent progenitor cells that can 
differentiate into neurons and astrocytes are present in large numbers in the olfactory 
bulbs during development and continue to migrate from the subventricular zone of the 
brain into the olfactory bulbs in the adult CNS (Barnett, 1993; Liu and Rao, 2003; 
Vergara et al., 2005; Parent et al., 2006; Maurer et al., 2008). The progenitor cells 
differentiate into granule cell and periglomerular second order neurons (Hack et al., 2005;  
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Figure 2.7 Immunostaining characterisation of fibroblasts. Fibroblasts were identified by 
immunoreactivity for fibronectin (A, D, G and red in C, F, I) and nuclei were stained with 
Hoechst blue (HB; blue in C, F, I, L). Cytoskeletal actin filaments (F-actin) were stained with 
Alex fluor 488-conjugated phalloidin (E, H, K and green in F, I, L) to facilitate comparisons of 
cell morphologies with live cultures viewed under phase contrast (Fig. 3.0). Fibroblasts were all 
fibronectin positive with stronger perinuclear staining  in more isolated cells (D-F) and 
interlocking networks of secreted fibronectin forming over dense patches of fibroblasts (A-C, G-
I). Fibroblasts were negative for GFAP showing only faint background staining (B) with the 
monoclonal GFAP antibody (Chemicon). Actin filaments in fibroblasts formed sheet-like 
structures with thick parallel fibres (D-F). In dense fibroblast cultures with secreted networks of 
fibronectin, the actin filaments formed a sparse criss-crossed network (G-I). The sheet-like 
parallel actin filaments of fibroblasts were distinct (asterisk in J-L) from the interwoven dense 
networks of fine radially distributed actin filaments in S100-positive (J, red in L) astrocytes. 
Fibroblasts showed only nuclear and faint perinuclear S100 immunoreactivity. Scale bar is 50μm 
(A-C, G-I) or 100μm (D-F, J-L). 
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Figure 2.8 Contaminating cells in fibroblast cultures. 
Contaminating astrocytes (asterisks in A) and microglia (asterisks in B) 
in fibroblast cultures were identified by immunoreactivity for GFAP 
(green) and CD11b (red) respectively (A, B). Nuclei were stained with 
Hoechst blue (HB; blue). Contaminating cells were rare and the 
majority of nuclei belonged to GFAP/CD11b-negative fibroblasts. 
Scale bar is 50μm. 
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Figure 2.9 Immunostaining characterisation of OECs. OECs were identified by 
immunoreactivity for p75NTR (A, D, G, green in C, F and red in I) and S100 (B, E and red in 
C, F). Nuclei were stained with Hoechst blue (HB; blue in C, F, I). All OECs were p75NTR 
and S100-positive although staining intensity was more variable for S100. Cytoskeletal 
actin filaments (F-actin) were stained with Alex fluor 488-conjugated phalloidin (H and 
green in I) to facilitate comparisons of cell morphologies with live cultures viewed under 
phase contrast (Fig. 3.1). OECs had sheet-like arrangements of sparse fine actin filaments 
(G-I). Scale bar is 100μm. 
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Figure 2.10 Contaminating cells in OEC cultures. OECs were identified by immunoreactivity 
for p75NTR (A, D, G, J and green in C, F, I, L) while contaminating astrocytes and microglia in 
OEC cultures were identified by immunoreactivity for GFAP (B, E, H, K, N and red in C, F, I, L, 
O) and CD11b (M and green in O) respectively. Nuclei were stained with Hoechst blue (HB; blue 
in C, F, I, L, O). There were some small astrocytes with fine processes (asterisks in A-C) 
resembling the astrocytes differentiating from progenitors in microglia cultures (Fig. 3.6). 
Occasional patches of mature astrocytes (M-O) had bright GFAP immunoreactivity and were 
p75NTR-negative (A-C, M-O). Microglia were rare (asterisk in M-O). OECs were GFAP-negative 
(plus signs in A-C). unless imaged at 3x longer exposures (E, H, K), which revealed faint diffuse 
GFAP immunoreactivity in many p75NTR-positive OECs (asterisks in D-L). There were also some 
p75NTR-positive cells that showed fibrous GFAP immunoreactivity (arrows and arrowheads in D-I) 
that increased in intensity in larger more flattened cells with lower intensity p75NTR 
immunoreactivity (arrowheads in D-I). There were other contaminating cells identified by 
Hoechst stained nuclei (C, F, I, L, O) in cells that were negative for p75NTR, GFAP and CD11b 
although they sometimes had faint perinuclear p75NTR immunoreactivity (A, D, G, J) and at 
longer exposures moderate nuclear and faint perinuclear GFAP immunoreactivity at similar levels 
to many OECs (E, H, K). Scale bar is 100μm. 
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Brill et al., 2008), and presumably astrocytes in the olfactory bulbs. Hence, it is possible 
that the variable OEC phenotypes observed in the cultures, derived from progenitor cells 
with the potential to differentiate into neurons, astrocytes or OECs, similar to the 
differentiation of neurons, astrocytes or oligodendrocytes from progenitors in the cortex. 
However, OECs are thought to originate from glial progenitors in the peripheral olfactory 
placode and migrate ahead of regenerating olfactory neuron axons into the olfactory 
bulbs (Doucette and Devon, 1993; Chuah and West, 2002; Li et al., 2005b; Richter et al., 
2005). OEC differentiation in the cultures may instead have been affected by local 
biochemical environments before or after dissection. OECs had sheet-like arrangements 
of sparse fine actin filaments (Fig. 2.9G-I and Fig. 2.11G-I) similar to fibroblasts, 
although actin filaments in fibroblasts appeared thicker with more intense 
immunoreactivity (plus signs Fig. 2.11G-I). Rare contaminating microglia could be 
distinguished by their irregular morphologies and immunoreactivity for CD11b. The 
OEC cultures sometimes contained small astrocytes with numerous fine processes 
(asterisks in Fig. 2.10A-C) that resembled the astrocytes differentiating from progenitor 
cells seen in microglia cultures (Fig. 2.6). There were also occasional patches of mature 
astrocytes (Fig. 2.10M-O) that had bright GFAP immunoreactivity and were negative for 
p75NTR (Fig. 2.10A-C, Fig. 2.10M-O).  
 
2.31.5 Contaminating fibroblasts in OEC cultures 
Fibroblasts that presumably derived from the meningeal layers surrounding the olfactory 
bulbs and olfactory axon fascicles were the most prevalent contaminating cells in the 
OEC cultures (Fig. 2.10). Fibroblasts were best distinguished from OECs by the absence 
of p75NTR immunoreactivity in fibroblasts, although they sometimes had faint perinuclear 
p75NTR immunoreactivity (Fig. 2.11A, D, G, J and Os in Fig. 2.12D-F). OECs (arrows in 
Fig. 2.12A-C) and fibroblasts (Os in Fig. 2.12A-I) both expressed fibronectin although 
networks of secreted fibronectin only appeared to be associated with fibroblasts (Fig. 
2.12D-F). The fibroblasts could proliferate rapidly, resulting in some cultures where 
OECs grew on dense layers of fibroblasts (Fig. 2.11D-F). This potential for 
contamination of OEC cultures by fibroblasts necessitated the confirmation of cell 
identity in experiments, by immunoreactivity for the cell-specific marker proteins. OEC  
 67
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Contaminating fibroblasts in OEC cultures. OECs were identified by 
immunoreactivity for p75NTR (A, D, G, green in C, F and red in I) and S100 (B, E and red in 
C, F). Nuclei were stained with Hoechst blue (HB; blue in C, F, I). Cytoskeletal actin 
filaments (F-actin) were stained with Alex fluor 488-conjugated phalloidin (H and green in I) 
to facilitate comparisons of cell morphologies with live cultures viewed under phase contrast 
(Figs. 3.0, 3.1). Clusters of p75NTR and S100-positive OECs in cultures were often 
accompanied by fibroblasts showing faint nuclear and perinuclear background p75NTR and 
S100 immunoreactivity (asterisks A-C). The fibroblasts could proliferate rapidly, resulting in 
cultures where OECs grew on dense layers of fibroblasts (D-F). OECs had sheet-like 
distributions of fine parallel actin filaments (asterisks G-I). Actin filaments in fibroblasts had 
similar distributions but were thicker with more intense staining (plus signs G-I). Scale bar is 
100μm. 
 
 
 
 
 
 68
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 Fibronectin immunoreactivity in OEC cultures. OECs were identified by 
immunoreactivity for p75NTR (A, D, and green in C, F) and fibroblasts by immunoreactivity for 
fibronectin (B, E, H and red in C, F, I). Nuclei were stained with Hoechst blue (HB; blue in C, 
F, I). Cytoskeletal actin filaments (F-actin) were stained with Alexafluor 488-conjugated 
phalloidin (G and green in I) to facilitate comparisons of cell morphologies with live cultures 
viewed under phase contrast (Figs. 3.0, 3.1). P75NTR-positive OECs (asterisks in A-I) also 
expressed fibronectin with immunoreactivity that was sometimes of similar intensity (arrows in 
A-C) to that in fibroblasts (Os in A-I) which had only faint background p75NTR 
immunoreactivity (Os in D-F). Networks of secreted fibronectin appeared to be associated with 
fibroblasts and not OECs (D-F).  Fibronectin and actin filaments had similar distributions in 
OECs (asterisks in G-I) and fibroblasts (Os in G-I) but immunoreactivity was usually more 
intense in fibroblasts. Scale bar is 100μm. 
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cultures for later experiments were prepared using only olfactory bulb tissue, which 
consisted predominantly of Schwann-cell like OECs and had fewer contaminating 
fibroblasts and astrocytes. 
 
2.4 Western blotting 
2.40 Cell lysis 
Lysis buffer:  
20 mM Tris-HCl pH 7.5 
150 mM NaCl 
1 mM EDTA  
0.5 % sodium deoxycholate 
1 % Nonidet P-40 
1:10 000 protease inhibitor cocktail (Sigma), added immediately before lysis. 
 
Astrocytes were cultured in 12-well culture plates as previously described and treatments 
performed in triplicate on cultures in separate wells. Medium was removed from wells at 
the end of treatments and cultures were rinsed twice with ice-cold PBS. 200μL of ice-
cold lysis buffer was added to each well, then cells were scraped and the cell suspension 
incubated for 30 minutes on ice. Lysate was collected into eppendorfs, centrifuged at 13 
000 rpm for 30 minutes at 4OC and the resulting supernatant lysate samples stored at 
minus 80OC. 
 
2.41 Lysis sample protein quantification 
Total protein concentration of lysis samples was determined prior to storage of samples, 
to enable loading equal amounts of total protein from samples onto gels for 
electrophoresis and Western blotting. Protein concentration was determined using the 
BioRad protein assay, which is based on the Bradford protein assay whereby protein is 
quantified by comparison to a standard curve prepared using serial dilutions of bovine 
serum albumin. BioRad protein assay reagent was diluted 1:5 in MilliQ water. Bovine 
serum albumin (BSA; New England Biolabs) dilutions of 10μg/mL, 20μg/mL, 50μg/mL, 
100μg/mL and 500μg/mL were prepared, 10μL of each dilution added to 990μL of the 
diluted BioRad assay reagent, mixed and incubated at room temperature for 5 minutes, 
 70
before absorbance was measured at 595nm with a SmartSpec 3000 spectrophotometer 
(BioRad). A standard curve was prepared from the measured absorbances of the BSA 
dilutions. 10μL of each sample (diluted 1:10 in MilliQ water for samples with high 
protein content) was added to 990μL of diluted assay reagent, mixed, incubated and 
absorbances read as for the BSA standards. The protein concentration of each sample was 
then determined from the standard curve. 
 
2.42 SDS-PAGE 
Samples for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
were used undiluted or diluted with sufficient milliQ water for a total protein content of 
~0.5 to 5mg/mL in a total volume of 18μL. Lower concentrations were used for Western 
blots for abundant proteins such as GFAP and higher concentrations for less abundant 
proteins such as metallothionein. Separate samples for each SDS-PAGE gel and 
subsequent Western blot were diluted according to the protein content of the sample such 
that the same amount of total protein was loaded into each sample lane of the gel. 7μL of 
4x NuPAGE LDS sample buffer (Invitrogen), which contained SDS to denature and 
negatively charge proteins, and 3μL of sample reducing agent (Invitrogen) to reduce 
disulphide bonds between cysteine residues, was then added to the samples, which were 
then mixed by vortexing, pulse-centrifuged to consolidate, heated at 85-95OC for 10 
minutes to denature proteins, vortexed and again pulse-centrifuged. SDS-PAGE was 
performed using an Xcell Surelock Mini-cell (Invitrogen) with ~500mL of 1x NuPage 
MES SDS running buffer (Invitrogen) in the outer chamber and ~200mL of 1x MES 
buffer (Invitrogen)  with 0.5mL of NuPAGE antioxidant (Invitrogen) to minimise sample 
oxidation, in the inner chamber. Samples were loaded into a NuPAGE 10% Bis-Tris gel 
(Invitrogen) and 10μL SeeBlue Plus2 protein markers (Invitrogen) were loaded adjacent 
to the sample lanes as a size reference for sample protein bands. A constant voltage of 
200V was applied to the gel for 40 minutes to separate the denatured proteins in samples 
according to size by electrophoresis. Gels were then removed from cassettes and 
processed for Western blotting or Coomassie staining.  
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2.43 Coomassie blue staining of SDS-PAGE gels 
Coomassie blue staining solution: 
250mL methanol (Ajax Chemicals) 
0.25g Coomassie brilliant blue R-250 (Sigma0 
50mL glacial acetic acid (Ajax Chemicals) 
Made to 500mL with dH2O and filtered through filter paper 
Destaining solution: 
400mL methanol (Ajax Chemicals) 
100mL acetic acid (Ajax Chemicals) 
Made to 1L with dH2O 
 
Following separation of proteins by SDS-PAGE, the gel was submerged in Coomassie 
blue staining solution on an orbital shaker until stained protein bands were visible. The 
gel was then destained by covering with destaining solution on an orbital shaker until 
(usually overnight) protein bands could be clearly distinguished from background 
staining. The gel was then rehydrated, heat-sealed in plastic and imaged with a scanner 
(Epson Perfection 1650). 
 
2.44 Protein assay by Western blotting 
2.44.0 Protein transfer from SDS-PAGE gels to nitrocellulose membranes 
Transfer buffer: 
50mL 20x NuPAGE transfer buffer (Invitrogen) 
100mL methanol 
Made to 1L with dH2O 
 
Following separation of proteins by electrophoresis, proteins from the gel were 
transferred to a nitrocellulose membrane (Micro Filtration Systems) using an X-cell II 
blot module (Novagen), to allow later identification of protein bands by probing with 
antibodies. A nitrocellulose membrane (Micro Filtration Systems) pre-soaked in transfer 
buffer was placed on the gel containing electrophoresed samples while the gel was still 
on one side of the opened gel cassette. Two layers of pre-soaked blotting paper were then 
placed on the nitrocellulose, the gel carefully separated from the cassette and another two 
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layers of pre-soaked blotting paper placed on the underside of the gel. The 
gel/nitrocellulose/ blotting paper sandwich was then rolled with a glass rod to remove 
bubbles before placing in the blot module inner chamber with the nitrocellulose 
membrane closer to the module cathode (+) and two or three pre-soaked sponges on 
either side of the blotting paper layers to ensure a tight fit. The inner chamber was placed 
in the transfer module and filled with transfer buffer and the outer chamber was filled 
with dH2O. A constant voltage of 30V was applied to the blot module overnight at 4OC to 
transfer proteins to the nitrocellulose membrane. 
 
2.44.1 Blocking and probing of the nitrocellulose membrane 
PBS-T: 
1mL Tween 20 (Ajax Chemicals) 
999mL 0.01M PBS 
 
X% blocking solution: 
Xg skimmed milk powder (Diploma) 
100mL PBS-T 
 
 Following transfer, the nitrocellulose membrane was removed from the module and 
washed for 5 minutes three times in PBS-T on an orbital shaker. Unbound regions of the 
membrane were then blocked by incubating with a 5% blocking solution for one hour on 
the shaker at room temperature, followed by another three 5 minute washes with PBS-T. 
The blot was then incubated with primary antibody at the required dilution (Table 2.2) in 
10mL of 2.5% blocking solution in a heat-sealed plastic bag, on the shaker, for 1-2 hours 
at room temperature, followed by another three 5 minute washes in PBS-T. The 
membrane was then incubated with the appropriate secondary antibody, goat anti-rabbit 
IgG or goat anti-mouse IgG conjugated to horseradish peroxidase (Dako), diluted 1:1000-
2000 in 2.5% blocking solution in a heat-sealed plastic bag for one hour at room 
temperature on the shaker, followed by three 5 minute washes in PBS-T. Primary 
antibodies were used at the concentrations shown below (Table 2.2). 
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Table 2.2 Primary antibody concentrations for Western blotting 
Antibody Concentration  Host species/clonality Manufacturer 
anti-GFAP 1:20 000 rabbit polyclonal Dako 
anti-GFAP 1:20 000 mouse monoclonal Millipore 
anti-GAPDH 1:5000 mouse monoclonal Santa Cruz 
anti-β-actin 1:10 000 mouse monoclonal Abcam 
 
2.44.2 Antibody detection 
Detection solution:  
5mL SuperSignal West Pico Stable Peroxide solution (Pierce) 
5mL SuperSignal West Pico Luminol/Enhancer solution (Pierce) 
 
After probing with antibodies the membrane was incubated with 10mL of detection 
solution in a heat-sealed plastic bag for 5 minutes on a shaker. Detection solution was 
then poured off and the excess rolled out of the plastic bag with a glass rod. The 
membrane was placed in a photographic cassette with fluorescent stickers to later enable 
correct alignment of detected protein bands. Photographic film (Hyperfilm, Amersham 
Pharmacia Biotech) was then exposed to the membrane for suitable time intervals for 
optimal visualisation of protein bands. The film was developed (Ilford) until protein 
bands were sufficiently visible, washed, fixed (Ilford) until the unexposed regions of the 
film were transparent, washed and dried, before imaging on a scanner (Epson Perfection 
1650). The size of proteins in detected bands in the imaged blots could then be estimated 
from the known size of proteins in the SeeBlue Plus 2 marker protein bands. The size of 
the protein and the relevant primary antibody probe allowed identification of detected 
proteins and determination of the specificity of the antibody for the correct protein. Since 
the same amount of total protein was loaded into each lane of the SDS-PAGE gel, the 
relative strength of protein bands in the lanes corresponding to separate samples, 
provided an indication of the relative amount of the protein represented by the band, in 
each sample. Blots were washed and re-probed for multiple proteins, including GFAP to 
confirm that samples were from astrocytes and because GFAP is a commonly used 
indicator of astrogliosis. Blots were also probed for loading control proteins, β actin and 
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GAPDH that are not usually altered by physiological changes to confirm equal loading of 
total protein in each lane of the SDS-PAGE gels and consistent migration and transfer of 
protein bands during electrophoresis and blotting. 
 
2.5 In vivo cortical needle-stick injury and OEC implantation  
2.50 OEC culture and staining for implantation 
OECs for implantation in cortical injury sites were cultured as described above in 25cm2 
tissue culture flasks. OECs were labelled with carboxy-fluorescein diacetate succinimidyl 
ester (CFDA-SE; Vybrant® CFDA SE Cell Tracer Kit, Molecular Probes) to enable 
identification and confirm viability of OECs after implantation. CFDA-SE passively 
diffuses into cells and remains non-fluorescent until its acetate groups are cleaved by 
intracellular esterases to yield highly fluorescent, amine-reactive carboxyfluorescein 
succinimidyl ester (Lyons and Parish, 1994; De Boer et al., 2006; Callard and Hodgkin, 
2007; Wu et al., 2009). The succinimidyl ester group reacts with intracellular amines, 
forming fluorescent conjugates that are well-retained and can be fixed with 
paraformaldehyde. Excess unconjugated reagent and by-products passively diffuse to the 
extracellular medium, where they can be washed away. The dye-protein adducts that 
form in labelled cells are retained by the cells throughout development, meiosis and in 
vivo tracing (Fujioka et al., 1994; De Boer et al., 2006; Hawkins et al., 2007; Ishii et al., 
2007; Hua et al., 2008). The label is inherited by daughter cells after cell division and is 
not transferred to adjacent cells in a population (Lyons and Parish, 1994; Bracher et al., 
2007; Quah et al., 2007; Weischenfeldt and Porse, 2008). Lymphocytes labelled with 
CFDA-SE have been detected up to eight weeks after injection into mice (Quah et al., 
2007) and CFDA-SE labelled hepatocytes were easily located by fluorescence 
microscopy up to 14 days after transplantation (Fujioka et al., 1994; Spinelli et al., 2002; 
Wu et al., 2009), while CFDA-SE labelled skin fibroblasts were detectable for at least 7 
days after implantation into rats (Mian et al., 2001). A 10mM stock solution of CFDA-SE 
in dimethyl sulphoxide (DMSO; Sigma) was diluted to 10μM in PBS for labelling OECs. 
Culture medium was removed from flasks and OECs were incubated in the 10μM CFDA-
SE solution for 15 minutes in the incubator at 37OC for 15 minutes. The CFDA-SE 
solution was then removed and the OECs returned to the incubator in fresh culture 
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medium for at least 30 minutes. When required for implantation, OECs were removed 
from flasks by trypsinisation (using 0.25% trypsin in PBS) after removing medium and 
two washes with Versene. Trypsinisation was halted with the addition of DMEM-10FCS, 
OECs spun down at 2500 rpm for 10 minutes and re-suspended in 10μL of 0.9% sterile 
saline and kept on ice until implantation.  
 
2.51 Surgery and cortical needle-stick injury 
A cortical needle-stick injury model (King et al., 2000; Chung et al., 2003), involving 
surgery to produce a controlled mild brain injury, was used for in vivo investigation of the 
effects of OEC transplantation on brain injury in rats.  240-260g adult male rats were 
initially anaesthetised for surgery in a container filled with 95% oxygen / 5% isoflurane 
gas (Bomac, Australia), delivered through a Stinger anaesthetic system (AAS, Australia). 
To control post-operative pain, rats were injected subcutaneously with 3mg/kg of the 
analgesic, meloxicam (Boehringer Ingelheim) using an insulin syringe. Hair was shaved 
from the scalp from in front of the ears to just behind the eyes using electric clippers and 
the rat then secured in a stereotaxic device (Stoelting, USA) with clamped ear bars and a 
nose mask. A constant supply of 97% oxygen / 3% isoflurane gas at 0.8L/minute was 
delivered to the nose and mouth of the rat through the nose mask.  The exposed scalp of 
the rat was wiped clean with isopropanol wipes and the rat’s eyes kept moist throughout 
the procedure by periodically applying drops of 0.1M PBS. The scalp was incised with a 
sterile scalpel blade (No. 10, Swann-Morton) to expose the midline of the skull where the 
left and right parietal plates fuse. A drill with a 1mm bit (Dremel) attached to an adapter 
arm on the stereotax was aligned with the bit positioned above the skull reference point, 
lambda, where the left and right parietal plates fuse with the interparietal plate. A Vernier 
scale on the stereotax arm was then used to realign the drill and bit over a specific region 
of the right somatosensory cortical hemisphere by moving 5mm anterior and 4.5 mm to 
the right. The membrane over the skull was scraped away with a scalpel blade from the 
area below the position of the drill bit and the skin and membrane held clear with a 
haemostat while carefully lowering the drill, set on high speed, to drill through the skull 
without penetrating the underlying meninges. The drill was raised and a 1μL 22 gauge 
(outer diameter 0.711 mm) bevelled-end Hamilton syringe (Supelco, USA), containing 
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1μL of OECs suspended in sterile saline (0.9%) for transplantation treatments or saline 
only for controls, was fitted to the adapter arm and lowered 1.5mm into the brain.  The 
syringe was left in the brain for 10 minutes and raised 1mm after 7 minutes for injection 
of the syringe contents into the injury site. After removing the syringe, a piece of gel 
foam (Upjohn, USA) was used to fill the hole in the skull and the wound was sutured 
with a single stitch. 1μL of saline alone or approximately 1000 OECs suspended in 1μL 
of saline was injected into the cortical injury site with the Hamilton syringe, which was 
sterilised with 70% ethanol, followed by several washes with milliQ water, between 
treatments on separate rats. This relatively low number of cells for injection was 
considered appropriate for the small lesion size, ease of injection and to possibly improve 
the low survivability found in previous research utilising implantation of  ~100,000 to 
millions of cells (Richter et al., 2005; Hill et al., 2007; Vukovic et al., 2007). After 
surgery, each rat was placed in a warm cage, monitored until it regained consciousness 
and then kept in a cage with ample food and water until being euthanized 1, 4 or 7 days 
later for assessment of the cortical injury responses. A total of 14 rats were used for this 
preliminary in vivo study. 4 rats were used for each post-treatment euthanasia time-point; 
2 receiving OEC implantations and 2 controls receiving saline injections, with another 2 
rats used as uninjured controls. One brain from each pair of rats was used for injury 
assessment by immunocytochemistry with the other brain being used for protein assay by 
Western blotting. 
 
2.52 Rat perfusion and brain dissection for immunocytochemistry 
Rats were euthanized by intraperitoneal injection with 60mg/kg of sodium pentobarbitone 
(Boehinger Inglelheim) using an insulin syringe. A series of reflex tests were 
administered after rats became unconscious to ensure that rats were unresponsive to 
stimuli and therefore sufficiently anaesthetised before commencing surgery for perfusion.  
Surgery was then conducted efficiently to enable perfusion to commence while there was 
still a heartbeat. The abdominal cavity was opened with a lateral incision below the 
sternum using scissors.  The chest cavity was entered by cutting through the diaphragm 
with scissors, parallel incisions made upwards through each ribcage on either side of the 
solar plexus and the heart fully exposed by lifting the ribcage towards the head with a 
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clamp attached to the sternum.  The base of the heart was held with forceps, a small 
incision made into the lower left ventricle with fine scissors, a catheter inserted into the 
ventricle through the incision and the catheter clamped with a haemostat to seal the 
incision, ensuring that perfusate delivered through the catheter would travel through the 
circulatory system via the aorta.  Ice-cold PBS was gravity fed through the catheter and 
the right atrium of the heart cut to allow circulation of the PBS (150-200mL/rat) to flush 
blood from the rat’s circulatory system. When blood was sufficiently cleared as indicated 
by loss of liver colouration, perfusion was continued with ice-cold 4% paraformaldehyde 
solution (100-150mL/rat) to fix tissues until muscular twitching in response to the 
paraformaldehyde ceased and the rat was rigid.  Following perfusion, rats were 
decapitated, skin and flesh removed with scissors and the skull carefully snapped away 
from the brain with bone scissors. The whole brain was carefully removed with a spatula 
and post-fixed in 4% paraformaldehyde for 1-2 days before storing in PBS containing 
0.03% (w/v) sodium azide (PBS-azide) solution at 4ºC, until sectioning for 
immunocytochemistry. 
 
2.53 Cortical sectioning for immunocytochemistry 
Brains were removed from PBS-azide solution, washed twice with PBS, sagittally 
trimmed 2mm anterior and posterior of the injury site and embedded in 5% (w/v)   
agarose. The brains were squared off at the front and rear by making a sagittal incision 
1mm anterior and 1mm posterior of the injury site with a flat blade. Multiple 50μm 
coronal sections were cut through the injury site across the whole brain, so that each 
section contained injured and uninjured cortical hemisphere portions. Sectioning 
commenced anterior to the injury site and 2-3 sections were stored in each well of 12-
well culture plates in order of sectioning in PBS-azide at 4OC. 
 
2.54 Immunostaining of cortical sections 
Brain sections were immunostained and imaged following the same procedures described 
above for immunostaining of cell cultures except that antibodies were applied to sections 
in 12-well culture plates. Primary antibodies were applied at the concentrations shown 
below (Table 2.3). For samples that had been implanted with OECs labelled with CFDA-
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SE, only one primary antibody for conjugation to either goat anti-rabbit Alexa Fluor 594 
or goat anti-mouse Alexa Fluor 594 (Molecular Probes) could be used, since the CFDA-
SE had similar fluorescence to Alexa Fluor 488. 
 
Table 2.3 Primary antibodies for immunostaining tissue sections 
 
Antibody Concentration  Host species/clonality Manufacturer 
anti-GFAP 1:1000 rabbit polyclonal Dako 
anti-GFAP 1:1000 mouse monoclonal Millipore 
anti-EphA4 1:250 rabbit polyclonal Santa Cruz 
anti-ferritin 1:1000 rabbit polyclonal Santa Cruz 
anti-metallothionein 1/2 1:500  mouse monoclonal Abcam 
anti-phosphorylated 
neurofilament (SMI312) 
1:1000 mouse monoclonal Sternberger 
       
2.55 Rat brain dissection for Western blotting 
For Western blot samples, rats were euthanized and whole brains removed as described 
above, without perfusion or fixation. The brain was placed on ice in a Petri dish lid and a 
4mm sagittal section, 2mm either side of the injury site was made through the whole 
brain using a scalpel blade (No. 10, Swann-Morton). The cortex was separated from the 
hindbrain portion of the section, the injured cortical hemisphere separated from the 
uninjured hemisphere, the injured hemisphere portion trimmed to 2mm each side of the 
injury site at right angles to the initial sagittal section and the uninjured hemisphere 
similarly trimmed to provide an equivalent sample. The two samples were placed in 
separate eppendorfs and snap frozen in liquid nitrogen before storage at -80OC. 
 
2.56 Lysis of cortical samples and Western blotting 
Frozen tissue samples were crushed under liquid nitrogen using a cold mortar and pestle, 
then diluted in 500μL of lysis buffer (recipe as described above for lysis of cultured cells) 
and transferred to a 15mL Falcon tube. Samples were homogenised on ice with several 
brief pulses using an Ultra-Turrax T25 (Janke & Kunkel, IKA® Labortechnik), 
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centrifuged for 20 minutes at 13 000 rpm at 4OC and the supernatant samples stored at 
minus 80OC. Western blotting was conducted on samples as described above for cell 
culture samples. 
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CHAPTER 3:  
Nuclear factor-κB translocation and astrocyte activation 
 
3.0 Introduction 
3.00 Why measure astrocyte activation?  
Brain tissue viability after injury depends on astrocyte survival because of their critical 
roles in the active uptake of glutamate and its conversion to glutamine, buffering of 
extracellular potassium ions (K+) and calcium ions (Ca2+), maintenance of extracellular 
pH and provision of lactate and pyruvate to neurons as alternative energy sources under 
the hypoxic and hyperglycaemic conditions (Swanson and Benington, 1996; Chen and 
Swanson, 2003; Swanson et al., 2004; Laird et al., 2008). In particular, the uptake of 
excess extracellular glutamate through the astrocyte excitatory amino acid transporters 
(EAAT) 1 and 2, (also known as the glutamate/aspartate transporter (GLAST) and 
glutamate transporter-1 (GLT-1) respectively) is essential for protecting neurons from 
glutamate-induced excitotoxicity and enabling their survival in the injury penumbra 
(Chen and Swanson, 2003; Vermeiren et al., 2005; Sullivan et al., 2007; Arranz et al., 
2010). However, as described in Chapter 1 the inflammatory activation of astrocytes 
eventually leads to reactive astrogliosis and the development of the glial scar. Although 
the glial scar may protect penumbral tissue from cytotoxic conditions in the lesion core it 
also appears to be a barrier to axon regrowth across the lesion. Similarly, reactive 
astrocytes produce growth factors and cytokines that can promote wound-healing and the 
resolution of inflammation, while more severe astrogliosis is associated with increased 
tissue damage due to the production of factors that amplify and prolong inflammation. It 
follows that measurement of the severity of astrocyte inflammatory activation, within the 
context of an experimental model enabling equivalent initial injuries, could provide a 
useful indication of the likely efficacy of OEC implantation and other potential therapies 
for CNS injury. Although it could be argued that any moderation of astrocyte reactivity 
was a consequence rather than a cause of decreased neuronal damage, these are likely to 
be mutually complementary events.  Reactive astrocytes are a major source of cytokines 
and chemokines that regulate the extent of immune cell recruitment and the consequent 
inflammation that causes secondary neuronal damage. Secondary neuronal death can then 
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initiate further inflammation and astrocyte activation. Furthermore, glutamate uptake, 
free radical scavenging and the production of metabolites by astrocytes can protect 
neurons against the cytotoxic conditions arising from injury and inflammation. 
 
3.01 Glial fibrillary acidic protein (GFAP) and astrocyte activation 
3.01.0 GFAP is upregulated in response to CNS inflammation 
GFAP expression in astrocytes is sensitive to a wide variety of even mild CNS 
disturbances and consequently is frequently used as an indicator of the severity of 
astrogliosis that is assumed to correlate with the severity of inflammation and related 
CNS tissue damage (Oh et al., 1993; Yu et al., 1993; Krohn et al., 1999; Brahmachari et 
al., 2006; O'Toole et al., 2007; Tramontina et al., 2007; Wanner et al., 2008). This may be 
problematic, particularly for in vitro models, since GFAP expression varies with 
astrocyte type and brain region and may be differently regulated by a variety of 
inflammatory mediators (Wofchuk and Rodnight, 1994; Rodnight et al., 1997; Gomes et 
al., 1999; Kommers et al., 2002; Sousa Vde et al., 2004; Sullivan et al., 2010b).  
 
3.01.1 Progenitor differentiation contributes to GFAP upregulation 
The GFAP gene promoter region contains binding sites for nuclear factor-κB (NF-κB), 
nuclear factor (NF) 1, AP-1, STAT, Smad proteins and response elements for cAMP, 
transforming growth factor (TGF)β, glucocorticoids and hormones and many of these 
factors regulate GFAP expression during astrocyte development (Reeves et al., 1989; 
Gomes et al., 1999; Krohn et al., 1999; Cebolla and Vallejo, 2006). Many of these 
regulators of astrogliogenesis are upregulated following CNS injury, provoking research 
into their possible roles in promoting injury-induced GFAP upregulation and the 
associated astrogliosis. There have been some conflicting results from this research that 
may be partly because astrogliosis and glial scar formation involves both mature 
astrocytes and immature astrocytes that differentiate from progenitor cells at injury sites 
(Yang et al., 1997; Fawcett and Asher, 1999; Alonso, 2005; Panickar and Norenberg, 
2005; Faijerson et al., 2006). For example, although IL-1β and TNF-α activate NF-κB 
and inflammatory gene expression leading to astrogliosis (Taupin et al., 1993; Feuerstein 
et al., 1994; Lee et al., 1995) they do not necessarily induce GFAP upregulation in vitro 
 82
(Oh et al., 1993). However, IL-1B and TNF-α induce NF-κB-dependent production of 
IL-6 (Meeuwsen et al., 2003a; Aronica et al., 2005; John et al., 2005; Fernandes et al., 
2006), which has structural similarities with CNTF and activates the JAK/STAT1/3 and 
MAPK pathways to promote differentiation of neural progenitors into astrocytes (Rajan 
and McKay, 1998; Justicia et al., 2000; Fan et al., 2005; He et al., 2005; Nakanishi et al., 
2007) and the transformation of astrocytes to a reactive phenotype (Korzus et al., 1997; 
Okada et al., 2004; Bolin et al., 2005; Na et al., 2007).   
 
3.01.2 Astrocyte swelling induces GFAP upregulation 
GFAP is normally expressed at only low levels in mature cortical astrocytes but 
following injury it is dramatically upregulated in mature astrocytes, particularly in the 
glial scar region (Fawcett and Asher, 1999; Panickar and Norenberg, 2005; Wilhelmsson 
et al., 2006). GFAP upregulation also occurs over a wide area in the injury penumbra and 
surrounding undamaged tissue (Fig. 1.4). The mature astrocytes away from the lesion 
border substantially retain their normal morphology and their increased GFAP expression 
may be associated with astrocyte swelling and upregulation of the aquaporin 4 (AQP4) 
water channel to facilitate the uptake of excess water, extracellular potassium ions and 
glutamate resulting from the vasogenic oedema that follows BBB damage during CNS 
injury (Wilhelmsson et al., 2006; Gunnarson et al., 2008; Nesic et al., 2008; 
Papadopoulos and Verkman, 2008). The upregulation of GFAP and astrocyte process 
growth after injury could provide additional binding sites and structural stability for 
additional membrane receptors, transport proteins and ion channels required for restoring 
homeostasis (Wilhelmsson et al., 2004; Lee et al., 2007; Sullivan et al., 2007; Saadoun 
and Papadopoulos, 2009; Wang and Hatton, 2009).  
 
3.01.3 Depolymerisation may alter GFAP immunoreactivity 
The variety of stimuli and the involvement of mature astrocytes and progenitor cells in 
GFAP upregulation after CNS injury make the interpretation of the pathological 
implications of GFAP expression levels difficult, especially for in vitro studies. Further 
ambiguities can arise from measuring expression levels by immunocytochemistry. GFAP 
may be less accessible to antibody binding when in the de-phosphorylated polymerised 
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form than when in phosphorylated monomeric form and glutamate-induced increases in 
intracellular Ca2+ following CNS injury can rapidly induce phosphorylation and 
depolymerisation of GFAP (Rodnight et al., 1997; Tramontina et al., 2007; Sullivan et al., 
2010b). Ca2+ influx also activates the Ca2+-dependent protease, calpain (Robles et al., 
2003) resulting in depolymerisation and degradation of GFAP (Du et al., 1999; Stys, 
2004). Furthermore, while GFAP levels may provide an indication of the severity of the 
astrogliosis that results from astrocyte inflammatory activation it would be useful to have 
an earlier measure of the intensity of astrocyte activation for assessing the efficacy of 
anti-inflammatory therapies. 
   
3.02 NF-κB translocation as a measure of astrocyte inflammatory activation 
3.02.0 NF-κB is a key early regulator of inflammation 
NF-κB is a key regulator of inflammatory gene expression that has a major role in CNS 
injury responses (Wagner, 2007; Yang et al., 2007; Ridder and Schwaninger, 2009). 
Many of the factors elevated by CNS injury activate NF-κB, including cytokines, 
glutamate, ROS and increases in intracellular Ca2+. Activated NF-κB then promotes the 
transcription of many genes involved in the pathogenesis of CNS injury and 
inflammation, including cytokines, chemokines, adhesion molecules, iNOS, which 
generates NO and inducible cyclooxygenase-2 (COX-2), which generates prostaglandins 
(Bethea et al., 1998; Schneider et al., 1999; Yamamoto and Gaynor, 2001). The cytokines 
IL-1β, TNF-α, IL-6 and IFN-γ have crucial roles in the inflammatory response to CNS 
injury (Ballestas and Benveniste, 1995; Tzeng et al., 1999; Lenzlinger et al., 2001; 
Meeuwsen et al., 2003a; John et al., 2005) and they all regulate gene expression via NF-
κB (Baldwin, 1996; O'Neill and Kaltschmidt, 1997; Bethea et al., 1998; Tak and Firestein, 
2001; Yamamoto and Gaynor, 2001). These NF-κB-activating cytokines are also induced 
by NF-κB and the resultant positive autoregulation can increase the amplitude and 
duration of inflammation (Yamamoto and Gaynor, 2001; Tian et al., 2005). The extent of 
the inflammatory response affects the progression of pathogenesis and secondary damage 
following the initial injury (Schneider et al., 1999; Bethea, 2000; Brambilla et al., 2009). 
Consequently, NF-κB activation could provide an effective early measure of the severity 
of inflammation relevant to CNS injury responses. 
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Figure 3.0 Activation of nuclear factor-κB. Nuclear factor-κB (NF-κB) dimers exist 
predominantly in the cytoplasm of unstimulated cells where they are bound to inhibitor of 
κB (IκB) family proteins. Translocation of dimers to the nucleus is essential for NF-κB 
promotion of gene transcription. Signal-mediated phosphorylation of IκBs by IκB kinase 
(IKK) leads to ubiquitination of IκB and subsequent degradation by the proteasome. 
Removal of IκBs promotes translocation of the free NF-κB dimers to the nucleus where 
they bind specific sequences in the promoter and enhancer regions of genes. NF-κB 
activation, mainly involving the p50/p65 dimers, regulates transcription of many genes 
involved in CNS inflammatory responses to injury and can thereby induce increased 
expression of cytokines, chemokines, adhesion molecules, iNOS, aquaporins, GFAP and 
growth factors.    
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3.02.1 Translocation to nuclei is essential for NF-κB activity  
NF-κB is a ubiquitous dimeric transcription factor with five mammalian subunits, p65 
(also known as RelA), Rel-B, c-Rel, p50 and p52 that are expressed in most cells 
(Baeuerle and Henkel, 1994; Baeuerle, 1998; Hayden and Ghosh, 2004). NF-κB homo- 
or heterodimers exist predominantly in the cytoplasm of unstimulated cells where they 
are bound to inhibitor of κB (IκB) family proteins (Fig. 3.0). Inflammatory stimuli induce 
phosphorylation of IκBs by IκB kinase (IKK) causing IκB to dissociate from NF-κB and 
marking IκB for polyubiquitination and proteosomal degradation. Removal of IκBs 
promotes translocation of the free NF-κB dimers to the nucleus where they bind specific 
DNA sequences in the promoter and enhancer regions of genes. NF-κB proteins share a 
300–amino acid Rel homology domain that mediates the DNA binding, dimerisation, and 
nuclear transport of the proteins (Baeuerle, 1998; Yamamoto and Gaynor, 2001; Chen 
and Greene, 2004a; Hayden and Ghosh, 2004). In addition to the Rel homology domain, 
the NF-κB family members, c-Rel, RelB, and p65 (also known as RelA) contain 
transactivation domains, which interact with components of the basal transcription 
apparatus. Although the NF-κB subunits p50 and p52, which are derived from the 
inactive precursors, p105 and p100, respectively, possess DNA binding and dimerisation 
properties through their Rel domains, they do not have strong transactivation domains. In 
addition to the inflammatory gene targets, NF-κB also promotes transcription of its own 
primary regulators, the IκBs (Baeuerle, 1998; Ghosh et al, 1998; Hoffman et al., 2002; 
O’Dea et al., 2007). Newly formed IκBs translocate to the nucleus where they bind NF-
κB and mask its nuclear localization signals. The NF-κB:IκB complex is then exported to 
the cytoplasm to complete a cycle of NF-κB activation and deactivation. Due to this 
autoregulatory mechanism, NF-κB transcriptional activity is usually transient, lasting 
only between 1 and 4 hours in most cells and deletion of IκB expression results in 
persistent NF-κB activation, leading to postnatal lethality (Hertlein et al., 2005). The 
synthesis and degradation rates of IκBs are critical controlling factors of NF-κB activity.  
NF-κB activation is Ca2+- and PKC-dependent and resynthesis of IκBs is favoured by 
decreased concentrations of these factors either in the absence of activating stimuli or 
during prolonged exposure, which may deplete intracellular calcium stores and 
simultaneously inhibit the ATP production required for their replenishment (Carafoli, 
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2002; Fisher et al., 2006; Hoffman et al., 2002; Hertlein et al., 2005; Sorriento et al., 
2008). The three isoforms of IκB have differing regulatory effects on NF-κB (Hoffman et 
al., 2002; O’Dea et al, 2007). IκBα synthesis is controlled by a highly NF-κB responsive 
promoter and consequently, provides strong negative feedback resulting in an oscillatory 
NF-κB response. The slower responses of IκBβ and IκBε can dampen the oscillations so 
that they gradually diminish in amplitude over about 6 hours as NF-κB activity returns to 
basal levels. However, in the absence of IκBα, IκBβ and IκBε can induce sustained NF-
κB activation. Translocation of dimers is essential for NF-κB activation and promotion of 
gene transcription is associated with the subsequent binding of co-activators to the NF-κB 
transactivation domains. NF-κB activity, mainly involving the p50/p65 dimers (Schneider 
et al., 1999; Hang et al., 2006; Ridder and Schwaninger, 2009), is increased in neurons, 
microglia and astrocytes within hours of CNS injury and remains elevated for months 
(Bethea et al., 1998; Bethea, 2000; Domanska-Janik et al., 2001; Tak and Firestein, 2001; 
Zhang et al., 2007). Translocation of NF-κB from the cytoplasm to nuclei can be 
measured by relatively simple techniques including, immunostaining of intact cells, 
Western blotting of nuclear and cytoplasmic fractions, electrophoretic mobility shift 
assay (EMSA) and chromatin immunoprecipitation (CHIP) assay, thus providing a 
convenient measure of the inflammatory activation (Bethea et al., 1998; Brettingham-
Moore et al., 2005a; Vincent et al., 2007; Zhang et al., 2007). 
 
3.02.2 Regulation of the NF-κB signalling pathway is complex 
NF-κB family subunit differences in expression, nuclear translocation, ability to 
heterodimerise with other subunits and interaction with components of the transcription 
apparatus contribute to the diverse effects of NF-κB pathway activation (Tak and 
Firestein, 2001; Chen and Greene, 2004a; Johansen et al., 2005; Brettingham-Moore et 
al., 2008; Pizzi et al., 2009). Transcription can be further enhanced by phosphorylation 
and acetylation of NF-κB subunits and interactions with the MAPK inflammatory 
signalling pathways (Fig. 1.2) and associated transcription factors (Chan and Riches, 
2001; Hayden and Ghosh, 2004; Chen et al., 2007; Brettingham-Moore et al., 2008; 
Wolter et al., 2008). Genomic screening has identified 154 positive and 88 negative 
modulators of NF-κB signalling, with most of the positive modulators converging on 
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activation of the IκB kinases and a number of negative modulators providing an 
additional downstream layer of control (Halsey et al., 2007). The differential tissue 
distribution of these modulators together with the downstream negative regulation 
enables NF-κB to mediate different responses to different stimuli.  The complexity of the 
NF-κB signalling pathway can result in either monophasic or oscillatory cycles of 
transcriptional activation and de-activation involving multiple activating stimuli, the 
recruitment of co-activators to gene promoter regions, interactions between NF-κB 
subunits and enhanced transcription of both NF-κB subunit and inhibitor of NF-κB (IκB) 
genes as well as other genes that promote or inhibit NF-κB activity (Baeuerle, 1998; 
Chen and Greene, 2004b; Hayden and Ghosh, 2004; Tian et al., 2005; Wietek and O'Neill, 
2007; Hertlein et al., 2005).  NF-κB also regulates transcription of the NF-κB subunit and 
IκB genes to respectively prolong or resolve inflammation. The modulation of NF-κB 
activation by these multiple factors allows the integration of signalling and feedback from 
the diversity of inflammatory mediators. NF-κB activation is thereby a sensitive and 
immediate indicator of the severity of inflammatory activation.  
 
3.02.3 NF-κB activation promotes astrogliosis 
Most of the protein expression changes that characterize astrogliosis are regulated by NF-
κB, including the increased expression of cytokines and chemokines (Schwaninger et al., 
1999; Meeuwsen et al., 2003a; Neary and Kang, 2005; Khorooshi et al., 2008), adhesion 
molecules (Ballestas and Benveniste, 1995; Ellison et al., 1999), iNOS (Zhang et al., 
2007; Sinke et al., 2008), AQP4 (Ito et al., 2006b; Gunnarson et al., 2008), granulocyte 
macrophage-colony stimulating factor (GM-CSF) (Zaheer et al., 2002), GFAP (Bae et al., 
2006), insulin-like growth factor (Ye et al., 2004), NGF, GDNF and BDNF (Meeuwsen 
et al., 2003a; Kuno et al., 2006). The NF-κB-dependent protein expression changes are 
associated with a change to a neurite growth inhibitory astrocyte phenotype accompanied 
by increased GFAP expression and the development of a glial scar around the lesion 
(Stichel and Muller, 1998; de Freitas et al., 2002; Sandvig et al., 2004; Fawcett, 2006a; 
Wilhelmsson et al., 2006). The chemokines, adhesion molecules and increased nitric 
oxide (NO) production promote recruitment of microglia and leukocytes to the lesion 
(Babcock et al., 2003; Meeuwsen et al., 2003a; Panickar and Norenberg, 2005; 
 88
Khorooshi et al., 2008). GM-CSF together with other growth factors and cytokines 
induce NF-κB-regulated proliferation and activation of the recruited microglia and 
leukocytes (Liva et al., 1999; Koguchi et al., 2003; Henze et al., 2005; Suh et al., 2005) 
resulting in enhanced secretion of inflammatory cytokines (Hanisch, 2002; Zaheer et al., 
2002) and increases in the production of NO and ROS to potentially neurotoxic levels 
(Block et al., 2007; Hanisch and Kettenmann, 2007). Hence, NF-κB activation in 
astrocytes appears to be a highly relevant determinant of astrocyte inflammatory 
responses and consequently, the extent of neuronal damage and the potential for axonal 
regeneration after CNS injury.  
 
3.02.4 Increased intracellular calcium activates NF-κB via PKC in astrocytes 
An increase in intracellular Ca2+ levels in asytrocytes is an early event in the activation of 
inflammatory gene transcription through the NF-κB and MAPK pathways (Fig. 1.2) by 
the high levels of extracellular glutamate, ATP, Ca2+ following CNS injury (Neary and 
Kang, 2005; Smith et al., 2005; Weisman et al., 2005; O'Riordan et al., 2006; Zeng et al., 
2008b). ATP can increase Ca2+ influx due to activation of ionotropic (P2X) or by release 
from internal stores due to activation of metabotropic (P2Y) purinergic receptors (Sun et 
al., 1999; Zeng et al., 2008b). Activation of G protein-linked receptors by glutamate and 
ATP (Fig. 1.2) can activate calcium-dependent protein kinase (PKC) (Norris et al., 1994; 
Haak et al., 1997), an important signalling molecule in the NF-κB and MAPK pathways 
(Akita et al., 1990; Ballestas and Benveniste, 1995; McCarthy et al., 1998; Silberman et 
al., 2005; Gonczi et al., 2008). PKC activates NF-κB by phosphorylation of IκB, allowing 
translocation of NF-κB dimers to the nucleus. The inflammatory cytokines, IL-1β and 
TNF-α, activate PKC in astrocytes to increase expression of IL-6 (Norris et al., 1994), 
ICAM-1 (Ballestas and Benveniste, 1995; Chen et al., 2001b) and COX-2 (Huang et al., 
2003). Chemokine upregulation by reactive astrocytes in response to TNF-α and IFN-γ is 
also regulated by PKC activation (Ludwig et al., 2005). ROS generation by NADPH 
oxidase in astrocytes is regulated by PKC (Abramov et al., 2005) and the novel PKC 
isoform, PKCη activates NF-κB to upregulate iNOS and increase NO production in 
astrocytes (Chen et al., 1998). PKC has also been reported to both promote (Zhu et al., 
2009) and inhibit (Tang et al., 2007) AQP4 expression by reactive astrocytes.  
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3.02.5 Other calcium signalling pathways modulate NF-κB activity in astrocytes 
Increases in intracellular free Ca2+ also activate the Ca2+-dependent phosphatase, 
calcineurin, which dephosphorylates inactive cytosolic NFAT promoting its translocation 
to the nucleus where it forms complexes with NF-κB and other transcription factors to 
regulate transcription of specific inflammatory  genes (Canellada et al., 2008; Perez-Ortiz 
et al., 2008). In lymphocytes, simultaneous Ca2+- and calcineurin-dependent activation of 
NF-κB and NFAT is required to achieve the high rate of proliferation necessary for 
inflammatory responses (Baldwin, 1996; Brettingham-Moore et al., 2005a; Winslow and 
Crabtree, 2005). Calcineurin also regulates the calcium-dependent initiation and 
resolution of inflammation through its activation of NF-κB and NFAT  in astrocytes 
(Morita et al., 2003; Norris et al., 2005; Fernandez et al., 2007a; Perez-Ortiz et al., 2008; 
Sama et al., 2008). In astrocytes, calcium influx induced by glutamate stimulation of 
calcineurin via metabotropic glutamate receptors activates the NFATc3 isoform, while 
ATP activation of P2Y receptors promotes activation of NFATc1 by calcineurin 
(Canellada et al., 2008; Perez-Ortiz et al., 2008). Glutamate-induced increases in 
intracellular Ca2+ can also activate calcium/calmodulin-dependent protein kinase 
(CaMKII) and iNOS to upregulate the water channel, AQP4, and promote astrocyte 
swelling in response to oedema following CNS injury (Gunnarson et al., 2008).  
 
3.03 PMA and ionophore activate NF-κB via calcium signals and PKC 
3.03.0 PMA is an analogue of diacylglycerol 
Phorbol esters, including phorbol myristate acetate (PMA), are analogues of 
diacylglycerol (DAG) and can therefore activate conventional and novel PKC isoforms 
(Zalewski et al., 1990; Obeid et al., 1992; Quest and Bell, 1994; Newton, 1997; Medkova 
and Cho, 1999). Unlike DAG, phorbol esters are not readily metabolised following 
binding to PKC and induce chronic PKC activation (Newton, 1997). This prolonged 
activation accounts for the tumorigenic effects of phorbol esters and led to the 
identification of PKC as the intracellular effector molecule (Marquez et al., 1992; Szallasi 
et al., 1996; Ventura and Maioli, 2001). Phorbol esters have consequently been used 
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extensively in research on PKC biochemistry (Zalewski et al., 1990; James and Olson, 
1992; Obeid et al., 1992; Quest and Bell, 1994; Newton, 1997; Medkova and Cho, 1999), 
gene expression (Ventura and Maioli, 2001; Suh et al., 2004; Brettingham-Moore et al., 
2005a) tumorigenesis (Correale et al., 1997; Gopalakrishna et al., 1997; Chen et al., 2000; 
Esteve et al., 2002), inflammation (Genot et al., 1995; Han et al., 2003; Abramov et al., 
2005; Hull et al., 2006; Hashioka et al., 2007), cytoskeletal regulation (Wilms et al., 1997; 
Abe and Saito, 1999; Cheng et al., 2000; Kobayashi et al., 2001) and other effects 
(Kermorgant et al., 2003; Michel et al., 2005; Kheifets et al., 2006) mediated by PKC. 
The phorbol ester research includes numerous studies on the intracellular targets of PKC, 
including NF-κB (Baldwin, 1996; Schwaninger et al., 1999; Huang et al., 2003; 
Brettingham-Moore et al., 2005a), in a variety of cell types including astrocytes (Abe and 
Saito, 2000; Suh et al., 2004; Amos et al., 2005; Ludwig et al., 2005; Vermeiren et al., 
2005; Hull et al., 2006) and microglia (Han et al., 2003; Hashioka et al., 2007; Moon-
Sook et al., 2008; Woo et al., 2008).  
 
3.03.1 Ionophores induce intracellular calcium ion influx 
As described above, calcium ions are important second messengers in intracellular 
signalling pathways and increases in intracellular calcium ion concentration regulate 
many of the cellular responses to CNS injury. Ionophores, such as ionomycin or calcium 
ionophore (also known as calcimycin or A23187), can transport divalent cations across 
cell membranes down electrochemical gradients (Kolber and Haynes, 1981; Fasolato and 
Pozzan, 1989; Bergling et al., 1998). Since intracellular calcium ion (Ca2+) concentration 
is actively maintained by cells at much lower levels than extracellular levels (Carafoli, 
2002; Clapham, 2007), ionophores induce Ca2+ influx that can initiate calcium transients 
under normal physiological and cell culture conditions (Venance et al., 1997; Calegari et 
al., 1999). The increased intracellular Ca2+ can promote activation of NF-κB through 
conventional PKC isoform activation (Nishizuka, 1988; Ahmed et al., 1991; Li et al., 
2005a) and other calcium signalling pathways (Tsuboi et al., 1994; Baldwin, 1996; 
Abramov et al., 2005; Belcheva et al., 2005; Brettingham-Moore et al., 2005a; Silberman 
et al., 2005). Smooth endoplasmic reticulum calcium (SERCA) pumps and other Ca2+-
ATPases actively transport calcium into intracellular calcium stores that are 
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predominantly located in the endoplasmic reticulum and mitochondria (Kannurpatti et al., 
2000; Guerini et al., 2002; Beech et al., 2003; Paschen and Mengesdorf, 2003). Blocking 
these Ca2+-ATPase transporters with thapsigargin, can also elevate intracellular calcium 
ion concentrations (Lampe et al., 1995; Bergling et al., 1998; Brunig et al., 2004) leading 
to PKC and NF-κB activation (Pahl and Baeuerle, 1996; Paria et al., 2003).  
 
3.03.2 Combined PMA and ionophore activation of NF-κB  
Full activation of inflammatory genes requires interactions between NF-κB and other 
transcription factors (Chan et al., 2001; Grassl et al., 2003; Hayden and Ghosh, 2004; 
Chen et al., 2007; Wolter et al., 2008). Consequently, combined treatment with PMA and 
calcium ionophore has commonly been used to stimulate expression of NF-κB-regulated 
inflammatory genes in lymphocytes (Tsuboi et al., 1994; Baldwin, 1996; Schwaninger et 
al., 1999; Brettingham-Moore et al., 2005a; Silberman et al., 2005). Combined PMA and 
calcium ionophore also stimulated PKC-dependent production of IL-6 (Norris et al., 1994) 
and ICAM-1 expression (Ballestas and Benveniste, 1995) in astrocytes in a similar 
manner to the inflammatory cytokines, IL-1β and TNF-α. Furthermore, PMA and 
ionomycin-induced calcium influx promoted ROS generation by NADPH oxidase in 
astrocytes (Abramov et al., 2005) and activated NF-κB to induce COX-2 and subsequent 
prostaglandin production in an astroglial cell line (Rael et al., 2004a). However, the 
effects of these reagents are not always synergistic, with nerve growth factor production 
in astrocytes being promoted by PMA and inhibited by calcium ionophore- or 
thapsigargin-induced intracellular Ca2+ elevation (Jehan et al., 1995). As described above, 
both PKC and calcium signalling are involved in activating NF-κB to promote production 
of inflammatory mediators in astrocytes. Therefore, since PMA stimulates PKC and 
ionophore stimulates calcium signalling, NF-κB translocation to astrocyte nuclei in 
response to combined PMA and ionophore treatment was investigated in this Chapter as 
an in vitro model of astrocyte inflammatory activation.                                                                                       
 
3.04 Research rationale  
The aim of this Chapter was to establish a model of astrocyte inflammatory activation 
relevant to CNS injury, as required for the following research on the possible moderation 
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of this activation by OECs. To investigate activation, NF-κB translocation to astrocyte 
nuclei in vitro was measured by immunocytochemistry following stimulation with PMA 
and calcium ionophore. Translocation of NF-κB to astrocyte nuclei was chosen as a 
suitable relevant measure of astrocyte activation, since NF-κB is a key transcriptional 
regulator of inflammatory genes including many of the inflammatory genes involved in 
astrogliosis. Translocation of the p65 (or RelA) subunit was measured since it is the most 
potent transcriptional activator of the NF-κB family (Baeuerle and Henkel, 1994; 
Baldwin, 1996; Wang and Baldwin, 1998; Madrid et al., 2001; Ridder and Schwaninger, 
2009) and most NF-κB activity in response to CNS injury involves the p50/p65 dimers 
(Schneider et al., 1999; Hang et al., 2006; Ridder and Schwaninger, 2009). The combined 
treatment with PMA and calcium ionophore is an established, well-characterised 
treatment that induces NF-κB translocation via activation of the PKC and calcium 
signalling pathways, both of which regulate astrocyte responses to CNS injury. GFAP 
expression was measured in response to stimulation with PMA and calcium ionophore 
since it is upregulated by reactive astrocytes following CNS injury.  
 
3.05 Specific aims 
 
 1. Investigate PMA and calcium ionophore stimulation of p65 NF-κB translocation to 
 astrocyte nuclei as a measure of inflammatory activation. 
 
2. Investigate GFAP expression in astrocytes following stimulation with PMA and 
calcium ionophore. 
 
3.1 Materials and Methods 
3.10 Quantitative analysis of astrocyte activation using NF-κB immunoreactivity 
Sets of 3 images showing immunostaining for p65 NF-κB (Fig. 3.1C), GFAP (Fig. 3.1E) 
and Hoechst blue nuclear staining (Fig. 3.1A) were taken at the same exposure (for each 
fluorophore) and magnification (200x). Image locations on the coverslip were selected 
randomly, commencing with a central location and separated by two to three microscope 
fields. Image sets were then merged using Adobe Photoshop© (Fig. 3.1F). Images 
containing any contaminating non-GFAP positive cells were excluded from analysis to  
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Figure 3.1 Quantitative analysis of astrocyte activation. GFAP immunoreactivity (E, green in 
F) identified astrocytes while NF-κB immunoreactivity (C, red in F) identified activated 
astrocytes. Nuclei were counterstained with Hoechst blue (HB; A, blue in F. Images of Hoechst 
blue-stained astrocyte nuclei (A) were batch processed with HCA-Vision© to generate images of 
nuclei that were thresholded using Adobe Photoshop© (B). The thresholded nuclear images (B) 
masked cytoplasmic immunoreactivity when blended with the corresponding image of astrocyte 
NF-κB immunoreactivity (C) in Adobe Photoshop©. This masking process resulted in images 
showing only nuclear NF-κB immunoreactivity (D), which were again batch processed with  
HCA-Vision© to generate result images with accompanying intensity measurements for each 
nucleus (numbers in D) and a count of total cells/image. Astrocytes having nuclei with mean 
intensity above an arbitrary level (>125) were deemed activated (plus signs in C and F) for 
calculating the mean percentage of activated astrocytes for each image. Asterisks and arrows (C, 
D and F) respectively indicate nuclei just below (intensity 120 and 116 in D) and above (intensity 
126 and 129 in D) this arbitrary intensity level used to measure activation. Scale bar is 50 μm. 
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assure the homogeneity of cultures for treatment comparisons and to avoid any unknown 
confounding effects of interactions with other unidentified cell types. In addition, the 
automated quantitation method described below would not have distinguished between 
astrocytes and other cell types. The nuclear staining images were batch processed using 
HCA-Vision© software (CSIRO, North Ryde, Australia) to generate thresholded images 
of nuclear regions that were used as masks for merging with the NF-κB immunostaining 
images (Fig. 3.1). This produced images showing NF-κB staining only in the nuclear 
regions, which was not altered by the masking process, allowing them to be batch 
processed using HCA-Vision©. HCA-Vision© could not batch process the whole cell 
NF-κB images (Fig. 3.1C) prior to the masking process, because it could not identify 
individual cells or separate nuclear regions from cytoplasmic regions in these images. 
The batch processing allowed simultaneous processing of hundreds of images to generate 
Excel files listing nuclear NF-κB immunoreactivity intensity measurements for every 
astrocyte in the images. Astrocytes having nuclei with mean NF-κB immunoreactivity 
intensity above an arbitrary level (>125) were deemed activated and used to calculate the 
mean percentage of activated astrocytes for each image. This choice of minimum 
intensity level ensured that astrocytes were scored as activated only when their nuclear 
NF-κB immunoreactivity was visibly more intense than the cytoplasmic NF-κB 
immunoreactivity (plus signs in Fig. 3.1C, D and F), to preclude the possibility of false 
positives due to overlapping stronger cytoplasmic NF-κB immunoreactivity in quiescent 
astrocytes (e.g. arrows, Fig. 3.2A-H). This method may have resulted in some 
underestimation of activation due to false negatives. This possible underestimation was 
considered preferable to an overestimation, with some error being unavoidable due to the 
variability of both cytoplasmic and nuclear NF-κB immunoreactivity intensity. At least 8 
images showing ~120 cells/image from 2-3 cell cultures from the pooled tissue of 2-4 
neonatal rats on separate coverslips were analysed to generate means for each treatment 
group. Data were analysed for significant differences between treatment group means by 
ANOVA and post-hoc Tukey tests.  
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3.11 Comparisons of NF-κB translocation 
Astrocytes were cultured on 18mm diameter coverslips in 12-well culture plates, as 
described previously. Fluorescence microscope images of immunostained astrocytes were 
used for comparisons of nuclear NF-κB immunoreactivity intensity in astrocytes that 
were untreated or stimulated with the following reagents:  
 
1.  phorbol-12-myristate-13-acetate (PMA; Calbiochem) 
 
2. calcium ionophore (antibiotic A23187 or calcimycin, free acid from Streptomyces 
chartreusensis, Calbiochem)  
  
3. thapsigargin (Alamone Labs) 
 
Astrocytes were usually incubated in serum-free DMEM for 24 hours prior to and during 
experiments. Comparisons of astrocyte activation were also made using cultures 
incubated in serum- and calcium-free DMEM or serum- and calcium-free DMEM 
supplemented with 200μM EDTA. 
 
3.12 Comparisons of GFAP expression 
3.12.0 GFAP immunoreactivity and morphology 
Following 24 hours of treatment of astrocyte cultures with 1μM ionophore, 
immunocytochemistry was conducted and the intensity of GFAP immunoreactivity was 
measured within astrocytes using the Adobe Photoshop© selection and histogram 
functions.  The area of the same astrocytes revealed by the GFAP immunoreactivity was 
then measured using ImageJ to enable comparison of astrocyte area relative to the 
intensity of GFAP immunoreactivity. 
 
3.12.1 Western blotting 
Western blotting was used to compare GFAP expression in untreated astrocytes and 
astrocytes treated with PMA and ionophore for 48 hours, to allow time for protein 
expression changes in response to activation, in: 
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1. serum-free DMEM 
 
2. serum- and calcium-free DMEM 
 
3. serum- and calcium-free DMEM supplemented with 5mM calcium chloride. 
 
3.2 Results 
 
3.20 PMA and ionophore activate astrocytes  
The relative effects of 20ng/mL PMA, 500nM ionophore and combined PMA/ionophore 
on astrocyte activation were compared by measuring the intensity of p65 NF-κB nuclear 
immunoreactivity. Combined PMA/ionophore was the most effective treatment for 
activating astrocytes as illustrated by the shift from cytoplasm to nucleus of the 
predominant location of the more intense NF-κB immunoreactivity (Fig. 3.2A-H). Prior 
to PMA and ionophore treatment (Fig. 3.2A, B) only about 5% of astrocytes were 
activated (Fig. 3.2E). PMA and ionophore both rapidly activated astrocytes with large 
significant increases in the percentage of activated astrocytes (p < 0.001) within 30 
minutes of treatment. The maximum response to PMA occurred after 30 minutes of 
treatment with activation of 25.45±3.14% of astrocytes. Ionophore was a stronger 
activator than PMA, inducing activation of significantly more astrocytes at 30 minutes 
(37.21±3.09%; p < 0.05) and 1 hour (38.39±3.63%; p < 0.001). Combining the PMA and 
ionophore treatments induced an additional significant increase in activated astrocytes to 
a maximum by 1 hour (55.7±3.1 %; p < 0.01). By 2 hours, the percentage of activated 
astrocytes had diminished to near basal untreated levels (p > 0.05) and remained 
unchanged at 3, 4 and 24 hours (data not shown).  
 
3.21 Optimisation of PMA/ionophore activation of astrocytes 
3.21.0 Ionophore concentration 
To determine the optimal ionophore concentration for astrocyte activation, NF-κB 
translocation was compared for 125nM, 250nM, 500nM and 1μM ionophore combined 
with 20ng/mL PMA (Fig. 3.3). The percentage of activated astrocytes was not 
significantly different across the range of tested ionophore concentrations (p > 0.05), 
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however after only 1 hour of treatment with 1μM ionophore (Fig. 3.3D) there appeared to 
be some apoptotic astrocytes with condensed nuclei (arrows in Fig. 3.3D) and condensed 
cytoplasm, resulting in more intense GFAP immunoreactivity. This increase in 
immunoreactivity was too soon for GFAP upregulation and was presumably due to the 
morphological alteration. After 24 hours at this 1μM dose of ionophore, about half the 
astrocytes appeared apoptotic, with blebby morphologies, partial detachment from the 
substrate and condensed nuclei (Fig. 3.3F-G). The astrocytes apparently displaying 
condensed cytoplasm had much higher intensity immunostaining than the astrocytes with 
flattened morphologies and normal nuclei. Comparison of the area of astrocytes 
displaying high (150.79±3.82) or low (68.63±7.07) intensity GFAP immunoreactivity 
showed that the more intense GFAP immunoreactivity was associated with astrocytes of 
significantly smaller mean area (p < 0.001), again implying that the increased intensity 
was due to the morphological alterations associated with apoptosis rather than an 
upregulation of GFAP expression. Ionophore was used at 500nM or less in later 
experiments on astrocyte activation to minimise possible confounding effects due to the 
induction of apoptosis. 
 
3.21.1 PMA concentration 
To determine the optimal PMA concentration for astrocyte activation, NF-κB 
translocation was compared for 20ng/mL, 100ng/mL and 200ng/mL PMA combined with 
125nM ionophore (Fig. 3.4). The percentage of activated astrocytes was not significantly 
different across the range of tested PMA concentrations (p > 0.05). PMA had already 
been shown to contribute significantly less to astrocyte activation than ionophore and was 
therefore used at the minimum concentration tested of 20ng/mL for remaining 
experiments to minimise possible unknown confounding effects. 
 
3.22 Calcium-dependence of NF-κB-mediated astrocyte activation 
3.22.0 Astrocyte activation in calcium-free medium 
Since ionophore was responsible for the major proportion of PMA/ionophore-induced 
astrocyte activation, NF-κB translocation in astrocytes was further investigated to 
determine whether the activation was dependent on calcium ions. Surprisingly, 1 hour  
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Figure 3.2 PMA and ionophore activation of astrocytes. Astrocytes were treated with either   
20ng/mL PMA (C, D), 500nM ionophore (E, F) or both (PMA/ionophore; G, H) for 30 minutes, 1 
hour or 2 hours, with untreated astrocytes (A, B) providing control comparisons.  Immunostaining 
for GFAP (green) was used to identify astrocytes, NF-κB (red) to identify activated astrocytes 
and nuclei were counterstained with Hoechst blue (HB). Images show NF-κB (A, C, E, G) or 
combined immunoreactivity (B, D, F, H) after 1 hour. NF-κB immunoreactivity was 
predominantly cytoplasmic in untreated astrocytes (A, B) and translocated to nuclei following 
activation with PMA and ionophore (C-H). NF-κB translocation was apparent from the more 
intense nuclear than cytoplasmic NF-κB immunoreactivity in the activated astrocytes (C, E, G) 
compared with untreated astrocytes (A). Astrocytes scored as activated had mean nuclear NF-κB 
immunoreactivity intensity noticeably above the background cytoplasmic immunoreactivity (e.g. 
arrow-heads in A-H). Due to variations in the position of cells relative to the image plane of focus, 
astrocytes deemed quiescent included those with nuclei where NF-κB was clearly absent (e.g. 
asterisks in A-H) and others where nuclear regions (e.g. arrows in A-H) had staining intensity 
similar to cytoplasmic levels and may have represented overlapping cytoplasmic staining. Scale 
bar is 50 μm. I: Quantitative analysis of astrocyte activation by PMA and ionophore. Separate or 
combined treatment with PMA and ionophore induced significant increases in the percentage of 
activated astrocytes (p < 0.001) within 30 minutes. Activation was significantly greater in the 
presence of ionophore than for PMA alone at both 30 minutes (p < 0.05) and 1 hour (p < 0.001) 
after treatment. The maximum response to separate PMA or ionophore treatment occurred by 30 
minutes whereas with combined PMA/ionophore there was a further significant increase (p < 
0.01) by 1 hour. By 2 hours after treatments the percentage of activated astrocytes had diminished 
to near basal untreated levels (p > 0.05). Data were analysed by 2-way ANOVA and post-hoc 
Tukey’s multiple comparison test. Results are means ± SEM, n = 15. Asterisks denote significant 
differences: * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 3.3 Ionophore dose and astrocyte activation. Astrocytes were treated for 1 hour with 
20ng/mL PMA combined with 125nM (A), 250nM (B), 500nM (C) or 1μM (D) ionophore. A-D: 
Immunostaining for GFAP (green) was used to identify astrocytes and NF-κB (red) to identify 
activated astrocytes. Nuclei were counterstained with Hoechst blue (HB). Similar astrocyte 
activation appeared to be induced across the range of ionophore concentrations. 1μM ionophore 
appeared to induce some apoptosis as indicated by bright GFAP immunoreactivity suggesting 
cytoplasmic and nuclear condensation (arrows in D). Scale bar is 100 μm.  E: Quantitative 
analysis of astrocyte activation. The percentage of astrocytes activated by PMA/ionophore was 
not significantly altered by varying the ionophore dose from 125nM to 1μM (p > 0.05). Data were 
analysed by ANOVA and post-hoc Tukey’s multiple comparison test. Results are means ± SEM, 
n = 8. F-G: After 24 hours of treatment with 1μM ionophore about 50% of astrocytes appeared to 
be apoptotic, displaying condensed nuclei (arrows), intense GFAP immunostaining (A) and faint 
or absent NF-κB immunostaining (G). H: Quantitative comparison of cell area for astrocytes 
displaying high or low intensity GFAP immunostaining following 24 hours of treatment with 
1μM ionophore. Astrocytes with high intensity GFAP immunostaining presented a significantly 
smaller mean area on the coverslip/image plane. Data were analysed by ANOVA. Results are 
means ± SEM, n = 50. Asterisks denote significant differences: *** p < 0.001. 
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Figure 3.4 PMA dose and astrocyte activation. Astrocytes were treated for 1 hour with 
125nM ionophore combined with 20ng/mL (A), 100ng/mL (B) or 200ng/mL (C) PMA. A-
C: Immunostaining for GFAP (green) was used to identify astrocytes and NF-κB (red) to 
identify activated astrocytes. Nuclei were counterstained with Hoechst blue (HB). Similar 
astrocyte activation appeared to be induced across the range of PMA concentrations. Scale 
bar is 50 μm.  E: Quantitative analysis of astrocyte activation. The percentage of astrocytes 
activated by PMA/ionophore was not significantly altered by varying the PMA dose from 
20ng/mL to 200ng/mL (p > 0.05). Data were analysed by ANOVA and post-hoc Tukey’s 
multiple comparison test. Results are means ± SEM, n = 8. 
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after a change of culture medium from DMEM to calcium-free DMEM (Fig. 3.5D, H), 
NF-κB had translocated to astrocyte nuclei indicating significant activation 
(62.10±4.78%; p < 0.001), similar to that induced by 1 hour of PMA/ionophore treatment 
in DMEM (Fig. 3.5C, H). Combining the change to calcium-free medium with 
PMA/ionophore treatment induced a further significant increase in astrocyte activation 
(72.86±2.94%; p < 0.05; Fig. 3.5E, H). However, when astrocytes were pre-incubated for 
4 hours in calcium-free DMEM supplemented with 200μM EDTA, to chelate any 
calcium ions that may have been released from astrocyte intracellular stores, there was 
significantly less astrocyte activation 1 hour after a subsequent change of this EDTA-
supplemented calcium-free DMEM (1.24±0.81%; p < 0.05; Fig. 3.5F, H) compared with 
a change of normal DMEM (6.28±0.92%; Fig. 3.5B, H), which contains 1.8mM calcium 
chloride. In addition, significantly less astrocyte activation was induced by 
PMA/ionophore when combined with the EDTA-supplemented calcium-free DMEM 
following the 4 hour pre-incubation (14.1±1.87%; p < 0.001; Fig. 3.5G, H). The total of 5 
hours incubation in calcium-free conditions resulted in a noticeable change in astrocyte 
morphology to a more elongated bipolar form with sparse GFAP fibres (Fig. 3.5F, G).  
 
3.22.1 Thapsigargin activates astrocytes 
As described above, intracellular Ca2+ can also be increased by blocking intracellular 
storage calcium pumps with thapsigargin. Therefore, the effect of thapsigargin on 
activation was compared for astrocytes in DMEM and EDTA-supplemented calcium-free 
DMEM (Fig. 3.6). 1μM thapsigargin induced significant activation of astrocytes in 
DMEM (60.85±2.77%; p < 0.001; Fig. 3.6B, F) that was not significantly different from 
the activation induced by PMA/ionophore (p > 0.05; Fig. 3.6D, F). However, in calcium-
free medium, thapsigargin only increased activation (6.48±1.04%; p < 0.05; Fig. 3.6C, F) 
to the basal levels of untreated astrocytes in DMEM. In the calcium-free conditions, 
PMA/ionophore activated significantly more astrocytes (14.1±1.87%) than thapsigargin 
(p < 0.05) and combining the treatments induced a further significant additive effect 
(22.66±2.11%; p < 0.05; Fig. 3.6E, F), however the activation in both cases remained 
significantly less than for similarly treated astrocytes in DMEM (p < 0.001; Fig. 3.6F). 
The elongated bipolar astrocyte morphology with sparse GFAP fibres induced by  
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Figure 3.5 Calcium-dependence of NF-κB mediated astrocyte activation. A: Activation was 
compared for astrocytes treated for 1 hour with 20ng/mL PMA/500nM ionophore in DMEM, 
calcium-free DMEM or in calcium-free DMEM supplemented with 200μM EDTA after 4 hours 
pre-incubation in this medium, with untreated astrocytes 1 hour after a change of DMEM or 
calcium-free DMEM with EDTA or from DMEM to calcium-free DMEM for comparison 
controls. B-G: Immunostaining for GFAP (green) was used to identify astrocytes and NF-κB (red) 
to identify activated astrocytes. Nuclei were counterstained with Hoechst blue (HB). A change 
from DMEM (B) to calcium-free medium induced astrocyte activation (D) similarly to treatment 
with PMA/ionophore (C, E). Incubation of astrocytes in calcium-free medium supplemented with 
the chelating agent EDTA resulted in more elongated astrocyte morphologies with only sparse 
GFAP fibres (F, G). In these conditions astrocytes were not activated by medium change (F) and 
only a low percentage were activated by PMA/ionophore (G). Scale bar is 50 μm. H: Quantitative 
analysis of astrocyte activation. Incubation in calcium-free DMEM induced a significant increase 
in astrocyte activation (p < 0.001) that was not significantly different (p > 0.05) from the increase 
induced by PMA/ionophore for astrocytes in DMEM. However, compared to untreated astrocytes 
in DMEM, there were significantly less activated astrocytes 1 hour after a change to fresh 
calcium-free DMEM supplemented with EDTA following 4 hours pre-incubation in the same 
medium conditions (p < 0.05). Although PMA/ionophore induced a significant increase in 
activation for the pre-incubated astrocytes in EDTA-supplemented calcium-free DMEM (p < 
0.01), the increase was significantly less than for astrocytes in DMEM (p < 0.001). In contrast 
there were significantly more activated astrocytes after PMA/ionophore treatment in calcium-free 
DMEM without pre-incubation than for astrocytes in DMEM (p < 0.05). Data were analysed by 
2-way ANOVA and post-hoc Tukey’s multiple comparison test. Results are means ± SEM, n = 8. 
Asterisks denote significant differences: * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 3.6 Thapsigargin activates astrocytes. A: Activation was compared for astrocytes 
treated for 1 hour with PMA/ionophore and/or the specific internal store Ca2+-ATPase blocker, 
thapsigargin (1μM) in DMEM or calcium-free DMEM supplemented with 200μM EDTA (after 4 
hours pre-incubation in this medium) with untreated astrocytes in the same media as comparison 
controls. B-E: Immunostaining for GFAP (green) was used to identify astrocytes and NF-κB (red) 
to identify activated astrocytes. Nuclei were counterstained with Hoechst blue (HB). 
Thapsigargin activated astrocytes in DMEM (B) to a similar extent as PMA/ionophore (D) but 
not when astrocytes were incubated in calcium-free conditions (C). Calcium-free medium 
induced an elongated astrocyte morphology with sparse GFAP fibres (Figs. 3.4F, 3.5A) that was 
not altered by thapsigargin treatment (C). However when thapsigargin was combined with 
PMA/ionophore, astrocytes adopted a spindly morphology with compressed GFAP fibres and 
some were activated (E). Scale bar is 50 μm. F: Quantitative analysis of astrocyte activation. 
Thapsigargin induced significant activation of astrocytes in DMEM (p < 0.001) that was not 
significantly different from the activation induced by PMA/ionophore (p > 0.05). However, for 
astrocytes in calcium-free medium, thapsigargin only increased activation (p < 0.05) to the basal 
levels of untreated astrocytes in DMEM. Although PMA/ionophore activated significantly more 
astrocytes than thapsigargin (p < 0.05) and combining the treatments induced a further significant 
additive effect (p < 0.05) in the calcium-free conditions, the activation remained significantly less 
than for similarly treated astrocytes in DMEM (p < 0.001). Data were analysed by 2-way 
ANOVA and post-hoc Tukey’s multiple comparison test. Results are means ± SEM, n = 8. 
Asterisks denote significant differences: * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 3.7 Calcium-dependent effects of PMA/ionophore on astrocyte morphology 
and GFAP expression. A: PMA induced some stellation of astrocytes but did not alter GFAP 
immunoreactivity. B: Ionophore induced some apoptosis of astrocytes that was associated with 
decreased intensity of GFAP immunoreactivity in relatively intact cells and more intense 
immunoreactivity in detached cells displaying GFAP depolymerisation (arrows) and cytoplasmic 
condensation (asterisks). C: The apoptosis and depolymerisation were accentuated by combined 
PMA/ionophore treatment. Scale bar is 50μm. D: GFAP expression was analysed by Western blot 
for untreated astrocytes (lane 1) and astrocytes treated for 48 hours with 20ng/mL PMA (lane 2), 
500nM ionophore (lane 3) and combined PMA/ionophore (lane 4). Protein bands were obtained 
at about 55kDa with the anti-GFAP primary antibody. GFAP levels appeared to be highest for 
untreated astrocytes with slightly lower expression levels following PMA treatment. GFAP levels 
decreased a little further in ionophore-treated astrocytes and were noticeably much lower 
following combined PMA/ionophore treatment. Equal quantities of total protein were loaded for 
each lane as confirmed by similar intensity immunoreactivity in each lane for the β actin (~ 
42kDa) loading control. E: Calcium and ionophore dose dependence of GFAP expression. GFAP 
expression was analysed by Western blot for untreated astrocytes in calcium-free DMEM (lane 1) 
or calcium-free DMEM with a 5mM addition of calcium chloride (lane 5), astrocytes treated with 
250nM ionophore in calcium-free DMEM (lane 2) or calcium-free DMEM with 5mM calcium 
chloride (lane 6), astrocytes treated with 500nM ionophore in calcium-free DMEM (lane 3) or 
calcium-free DMEM with 5mM calcium chloride (lane 7) and astrocytes treated with 1μM 
ionophore in calcium-free DMEM (lane 4) or calcium-free DMEM with 5mM calcium chloride 
(lane 8). All treatments were for 48 hours. The blot image is representative of 4 blots performed 
on separate samples. There was little difference in GFAP expression for untreated astrocytes in 
DMEM with 5mM calcium chloride (lane 5) and astrocytes treated with 250nM or 500nM 
ionophore in either medium condition (lanes 2-3 and 6-7). There was possibly slightly lower 
GFAP expression for untreated astrocytes (lane 1) and 1μM ionophore treated astrocytes (lane 4) 
in calcium-free DMEM and noticeably much less GFAP expression for astrocytes treated with 
1μM ionophore in calcium-free DMEM with 5mM calcium chloride (lane 8). All differences 
between lanes seen for the GFAP bands corresponded with similar differences for the bands for β 
actin and GAPDH loading controls. 
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calcium-free medium conditions (Figs. 3.5) was not altered by thapsigargin treatment 
(Fig. 3.6C), however combining thapsigargin with PMA/ionophore in calcium-free 
medium induced an even more elongated, spindly astrocyte morphology with 
compression of the sparse GFAP fibres (Fig. 3.6E). 
 
3.23 PMA/ionophore decreases GFAP levels   
PMA alone induced some stellation of astrocytes but did not appreciably affect GFAP 
immunoreactivity (Fig. 3.7A) or expression levels (Fig. 3.7D lane 2). Ionophore appeared 
to induce dose-dependent detachment from the substrate and apoptosis of astrocytes (Figs. 
3.3 and 3.7B). This effect was accentuated by combined PMA/ionophore treatment (Fig. 
3.7C). These results were supported by Western blotting, with lower GFAP expression 
being detected following treatment with 500nM ionophore (Fig. 3.7D lane 3). Following 
combined PMA/ionophore treatment (Fig. 3.7D lane 4) much lower levels of GFAP were 
detected, consistent with the appearance of apoptotic cells showing condensed nuclei and 
protein degradation indicated by patchy, faint or absent immunoreactivity for GFAP in 
the immunocytochemistry images (Fig. 3.7C). Western blotting showed that the 
decreased levels of GFAP were dependent on Ca2+ influx since it was inhibited in 
calcium-free medium (Fig. 3.7E lane 4) and augmented by high levels of extracellular 
Ca2+ (5mM) (Fig. 3.7E lane 8). Despite equal protein loading in all lanes, GFAP and the 
loading controls β actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
all detected at much lower levels, in the samples from astrocytes treated with 500nM 
ionophore in medium supplemented with 5mM calcium chloride (Fig. 3.7E lane 8), 
probably due to high numbers of apoptotic cells and the associated degradation of 
proteins. 
 
3.24 Astrocyte morphology and NF-κB translocation 
3.24.0 Are astrocyte morphology changes associated with NF-κB activation? 
Results above show that PMA induces astrocyte stellation and moderate NF-κB 
activation while calcium ionophore strongly induces NF-κB activation without any 
noticeable astrocyte morphology change. To investigate the relationship between 
astrocyte morphology and activation further, dibutyryl cyclic AMP (db-cAMP), 
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lysophosphatidic acid (LPA), glutamate, metallothionein 2A were compared with PMA 
and ionophore for effects on astrocyte morphology and NF-κB translocation. As briefly 
described below, these reagents have all been previously reported to alter astrocyte 
morphology and induce astrogliosis. Cyclic-AMP analogues, such as db-cAMP, strongly 
inactivate the GTPase RhoA to induce actin depolymerisation and rapid rearrangements 
of focal adhesions that produce highly stellate morphologies (Goldman and Abramson, 
1990; Ramakers and Moolenaar, 1998; Safavi-Abbasi et al., 2001; Cechin et al., 2002). 
After injury, ingredients of serum such as endothelin, thrombin and LPA can enter the 
CNS where they induce inflammatory responses (Manning and Sontheimer, 1997; Steiner 
et al., 2002; Sorensen et al., 2003; Koh et al., 2005). In vitro these factors inhibit the 
effects of cAMP and induce flattened epitheloid astrocyte morphologies by activating 
RhoA, leading to downstream assembly of actin stress fibres and their attachment at focal 
adhesions (Koyama et al., 1993; Suidan et al., 1997; Ramakers and Moolenaar, 1998; 
Safavi-Abbasi et al., 2001). Excitatory amino acids, including glutamate can also activate 
RhoA to induce flattened morphologies in astrocytes (Chen et al., 2006a; Lau et al., 
2010). Metallothionein 1/2 is strongly upregulated by reactive astrocytes after CNS injury, 
prior to the peak in GFAP expression and glial scar development (Neal et al., 1996; 
Buniatian et al., 2001; Penkowa et al., 2002) and may have a role in regulating ROS-
mediated astrocyte swelling and inflammation (Wakida et al., 2007; Li et al., 2008a; 
Vitellaro-Zuccarello et al., 2008). Exogenous metallothionein 2A promotes neuronal 
survival and neurite outgrowth (Chung et al., 2003; Chung and West, 2004; Ambjorn et 
al., 2008) and induces astrogliosis with more process-bearing astrocyte morphologies and 
increased GFAP expression through the JAK/STAT pathway (Leung et al., 2010), which 
is downstream from NF-κB activation via IL-6.  
 
3.24.1 Rapid astrocyte morphology changes were independent of NF-κB translocation 
Of the additional agents tested only metallothionein 2A induced significant NF-κB 
translocation in astrocytes (Fig. 3.8A) with the response being similar to that induced by 
PMA and significantly less than the activation induced by ionophore (p < 0.01 at 1 hour). 
As expected, db-cAMP strongly induced the stellate morphologies (Fig. 3.8B-D) 
associated with RhoA inactivation while LPA (Fig. 3.8H) and glutamate (Fig. 3.8I)  
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Figure 3.8 Comparative effects of reagents on astrocyte activation, morphology and GFAP 
expression. A: Activation was compared for astrocytes treated for 30 minutes or 1 hour with 
1mM db-cAMP, 100μM sodium glutamate, 10μg/mL lysophosphatidic acid (LPA), 10μg/mL 
metallothionein 2A  (MT2A) and for comparison controls, 20ng/mL PMA and 500nM ionophore 
(see Fig. 3.2). Db-cAMP, glutamate and LPA did not significantly activate astrocytes (p > 0.05) 
above basal untreated levels (Fig. 3.2). Metallothionein significantly activated astrocytes (p < 
0.05) in a manner that was not significantly different from the activation induced by PMA (p > 
0.05), reaching a maximum by 30 minutes and being significantly less than for ionophore at both 
30 minutes (p < 0.05) and 1 hour (p < 0.01). Data were analysed by 2-way ANOVA and post-hoc 
Tukey’s multiple comparison test.  Results are means ± SEM, n = 8. Asterisks denote significant 
differences: * p < 0.05, ** p < 0.01, *** p < 0.001. B-J: Morphologies were compared for 
untreated astrocytes after 48 hours of treatment with the above reagents (A). Immunostaining for 
GFAP (C, F and green in D, G and H-J) identified astrocytes and actin filaments were stained 
with Alexa fluor 488 phalloidin (B, E and red in D, G). Nuclei were counterstained with Hoechst 
blue (HB, D, G and H-J). Untreated astrocytes (B-D) had flattened cell bodies and actin filaments 
that were radially distributed around rings (arrows in B, D) offset from nuclei. Db-cAMP (E-G) 
induced stellate morphologies characterised by compressed cell bodies, depolymerisation of actin 
filaments (E) and long, narrow, radially distributed processes. LPA (H) and glutamate (I) both 
induced broad flattened cell bodies with dense networks of GFAP and actin filaments (not shown) 
similar to those in the untreated astrocytes. Metallothionein induced flattened cell bodies with 
many long broad processes (J). Scale bar is 50 μm. K: Western blot of astrocyte samples after 48 
hour reagent treatments shows no substantial differences in GFAP expression between untreated 
astrocytes (lanes 1 and 7) and db-cAMP (lane 2), LPA (lane 3), glutamate (lane 4), MT2A (lane 5) 
and PMA (lane 6) treated astrocytes. GFAP expression for the treated astrocytes is within the 
limits of variation indicated by the B actin loading control bands and the untreated sample GFAP 
bands. The blot image is representative of 6 blots performed on separate samples. 
 
 
 
 
 
 
 114
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Metallothionein 1/2 immunoreactivity in astrocytes and progenitors. Progenitor 
cells after 24 hours, 48 hours or 6 days in culture and astrocyte cultures were immunostained for 
GFAP (A, D, G, J and red in C, F, I, L) to identify astrocytes and counter-stained for 
metallothionein 1/2  (B, E, H, K and green in C, F, I, L). Nuclei were stained with Hoechst blue 
(HB; blue in C, F, I, L). In 24- and 48-hour progenitor cell cultures metallothionein 1/2 
immunoreactivity occurred in the nuclei and very faintly in the processes of cells that had begun 
to extend GFAP-positive processes (asterisk in A-C). More intense metallothionein 1/2 
immunoreactivity occurred in astrocytes with more flattened morphologies (D-F). After 6 days 
most cells had differentiated into astrocytes with flattened morphologies and many exhibited 
metallothionein 1/2 immunoreactivity that was most intense in the nuclear region (G-I). 
Metallothionein 1/2 immunoreactivity was not detected in GFAP expressing cells with 
progenitor-like morphologies in the 6 day cultures (asterisks in G-I). Metallothionein 1/2 
expression was highly variable in mature astrocyte cultures (J-L). Some astrocytes had strong 
metallothionein 1/2 immunoreactivity while in others immunoreactivity was very faint or absent 
(asterisks in J-L). The metallothionein 1/2 immunoreactivity was more intense in the nuclear 
region of some astrocytes (plus signs in J-L) but was usually evenly distributed throughout cells. 
Scale bar is 100μm (A-I) or 50μm (J-L). 
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Figure 3.10 Metallothionein 1/2, excitatory amino acid transporter 2 and megalin 
immunoreactivity in astrocytes. Detail of merged images of immunostaining for 
metallothionein (MT) 1/2 (red in A), EAAT2 (red in B), megalin (red in C), GFAP (green 
in A and B) and Hoechst blue nuclear stain (blue in A-C) showed that punctate 
immunoreactivity for metallothionein 1/2 and excitatory amino acid transporter 2 (EAAT2; 
also known as glutamate/aspartate transporter) surrounded fibrous immunoreactivity for 
GFAP in astrocyte processes and cell bodies. Megalin immunoreactivity showed a similar 
punctate distribution, did not vary markedly between cells and occurred throughout 
astrocyte cell bodies, nuclear regions and processes. Scale bar is 15μm (A) or 40μm (B and 
C). D: Western blot analysis of megalin and metallothionein 1/2 (MT1/2) expression by 
astrocytes. Astrocytes were treated for 48 hours with 10μg/mL metallothionein (MT)2A 
(lane 1) and medium was collected from the MT2A-treated astrocytes and run as a control 
(lane 2) for the anti-metallothionein 1/2 primary antibody. Probing with the anti-megalin 
primary antibody detected protein bands at about 80kDa. Bands for GFAP, B actin and 
GAPDH were detected as controls. No bands were detected for metallothionein 1/2 from 
the astrocyte samples for exposures up to 10 minutes. However, a strong band at ~10kDa 
was detected for metallothionein 1/2 for the control medium sample after only a short 
exposure (~10 seconds). 
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induced the flattened morphologies associated with RhoA activation. Metallothionein 2A 
(Fig. 3.8J) induced morphologies intermediate between the extremes of RhoA activation 
and inactivation. It is possible that this intermediate state presents suitable conditions for 
growth, which requires co-ordinated activity of the various Rho family GTPases that 
regulate attachment, process extension and spreading of cell membranes (Weber et al., 
1998; Kuhn et al., 2000; Guan and Rao, 2003; Hall, 2005; Holtje et al., 2005). These 
morphological effects occurred within 30 minutes to one hour of treatment (data not 
shown) and were maintained 48 hours later (Fig. 3.8B-J). Western blotting (Fig. 3.8K) 
indicated that after 48 hours there no substantial change in GFAP expression resulted 
from the treatments and associated differences in astrocyte morphologies.  
 
3.24.2 Metallothionein 1/2 and megalin localised at astrocyte cell membranes 
Metallothionein 1/2 immunoreactivity occurred only in astrocytes and not in OECs, 
microglia or fibroblasts (data not shown). Progenitor cells did not appear to express 
metallothionein 1/2 before differentiating into astrocytes (asterisk in Fig. 3.9A-C) and 
expression increased with astrocyte maturation (Fig. 3.9D-F). Metallothionein expression 
was highly variable in mature astrocyte cultures (Fig. 3.9J-L). Some astrocytes had strong 
metallothionein immunoreactivity while in others immunoreactivity was very faint or 
absent (asterisks in Fig. 3.9J-L). The metallothionein immunoreactivity was more intense 
in the nuclear region of some astrocytes (plus signs in Fig. 3.9J-L) but usually expression 
was evenly distributed throughout cells and was not altered by reagent treatments (data 
not shown). Extracellular metallothionein 1/2 interacts with the low-density lipoprotein 
scavenger receptor, megalin, to facilitate zinc and cadmium transport in the kidney 
(Klassen et al., 2004; Wolff et al., 2006). Neurons and astrocytes also express megalin 
and it may be involved in a mechanism for the promotion of neurite outgrowth by 
astrocytic secretion of metallothionein 1/2 (Chung et al., 2003; Chung et al., 2008). 
Interestingly, metallothionein 1/2 and megalin immunoreactivity in astrocytes both 
showed a punctate distribution similar to that for the glutamate/aspartate transporter (also 
known as excitatory amino acid transporter 2), appearing to be located at astrocyte 
plasma membranes (Fig. 3.10A-C). Western blotting (Fig. 3.10D) and 
immunocytochemistry indicated that reagent treatments did not alter megalin expression 
 117
and distribution (data not shown). Metallothionein 1/2 could not be detected in the 
cultured astrocytes by Western blotting (Fig. 3.10D) even following exogenous 
metallothionein 2A treatment, although it was readily detectable in the culture medium 
from the treated astrocytes. This result implies that there was no substantial uptake of 
metallothionein 2A by astrocytes or that it was rapidly altered following uptake. 
 
3.3 Discussion 
3.30 PMA/ionophore induced NF-κB translocation to astrocyte nuclei 
3.30.0 Ionophore activated astrocytes more strongly than PMA  
PMA and ionophore both rapidly induced NF-κB translocation from the cytoplasm to 
nuclei in astrocytes that was readily detectable by immunocytochemistry. Utilising 
immunocytochemistry to detect p65 NF-κB translocation provided simple, direct, 
unambiguous evidence of these rapid robust activation responses in astrocytes and 
simultaneously enabled positive confirmation that the activated cells were astrocytes by 
counter-staining for GFAP. Consistent with the central role of increased intracellular 
calcium in glial responses to CNS injury, NF-κB translocation in astrocytes was induced 
more strongly by ionophore, with only a relatively small additive effect attributable to 
PMA, when astrocytes were treated simultaneously with PMA and ionophore. This result 
differs from PMA/ionophore stimulation of T cells, where NF-κB-mediated activation is 
more strongly induced (although still relatively weakly) through PMA activation of PKC 
and there is a strong synergistic increase in activation by combined PMA/ionophore 
treatment or other stimuli, such as TNF-α, that activate both calcium signalling and PKC 
(Baeuerle and Henkel, 1994; Brettingham-Moore et al., 2005a). 
 
3.30.1 NF-κB translocation was rapid and transient 
In the cultured astrocytes, NF-κB translocation was both rapid and transient reaching a 
peak by 1 hour after stimulation, followed by a significant decrease within the following 
hour. Although the time-course of this response was not atypical for NF-κB (Hertlein et 
al., 2005), a more sustained activation could have been expected in response to the 
reagent treatments, since ionophore promotes sustained elevation of intracellular calcium 
levels (Kolber and Haynes, 1981), while PMA induces chronic activation of PKC 
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(Newton, 1997). Both of these effects are likely to inhibit resynthesis of IκBs for 
subsequent binding and inactivation of NF-κB, which is favoured by lower intracellular 
concentrations of Ca2+ and PKC (Fisher et al., 2006). Cells are rapidly depleted of IκB in 
response to activating stimuli because they induce the required removal and proteolysis 
of IκB for activation of NF-κB (Baeuerle and Henkel, 1994; Hertlein et al., 2005; Fisher 
et al, 2006). Consequently, the autoregulatory upregulation of IκB transcription by NF-
κB can dramatically decrease the time required for inhibition of NF-κB by IκB in 
response to subsequent stimuli (Brown et al., 1993; Sun et al., 1993; Zabel et al., 1993; 
Baeuerle and Henkel, 1994). Hence, the relatively rapid transient activation of NF-κB by 
PMA/ionophore treatment suggests that IκB transcription may have already been 
upregulated in the astrocytes, possibly due to earlier NF-κB activation during culture 
preparation. This may have provided sufficient inhibition of NF-κB until the synthesis of 
more IκB was induced following stimulation by PMA/ionophore, thereby preventing an 
oscillatory NF-κB response. Although it is uncertain how long higher levels of IκB 
transcription and synthesis would persist after a phase of NF-κB activation, IκB levels 
appear to be dynamically regulated even in quiescent cells (O’Dea et al, 2007). IκBs still 
undergo constitutive degradation and synthesis in the absence of stimuli that induce 
proteasomal degradation of IκBs following their release from NF-κB dimers. The 
majority of newly synthesised IκB is probably degraded before ever binding to NF-κB 
dimers, because free IκB is degraded much more rapidly than IκB bound to NF-κB. This 
implies that constitutive synthesis of IκB would be required at a higher rate than would 
otherwise be predicted based on the relative stability of the IκB:NF-κB complex in 
unstimulated cells. Hence, the free IκB degradation pathway appears to be an important 
determinant of constitutive NF-κB activity and responsiveness to stimuli. Therefore, it 
could be informative to investigate IκB expression and localisation, in addition to NF-κB 
in the astrocytes, both in response to reagent treatments and at different stages of tissue 
dissection and astrocyte culture.   
 
3.30.2 Astrocyte activation may have been asynchronous 
Although no significant difference was detected in NF-κB translocation for ionophore 
doses from 125nM to 1μM and PMA doses from 20ng/mL to 200ng/mL, the protocol for 
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measuring NF-κB translocation did not take into account any differences in NF-κB 
immunoreactivity intensity in nuclei above an arbitrary threshold. Although it is uncertain 
whether there would be any functional importance to such differences, it is probable that 
more intense immunoreactivity would indicate more NF-κB had translocated to the 
nucleus and this could result in greater enhancement of transcription. For similar reasons, 
although nuclear NF-κB immunoreactivity intensity was lower than the arbitrary 
detection threshold at time-points following the peak response, nuclear NF-κB could have 
remained higher than levels prior to treatment and could have been sufficient to maintain 
increased gene transcription. Western blotting of nuclear and cytoplasmic fractions of 
astrocytes and/or chromatin immuno-precipitation assay for NF-κB subunits (Butler et al., 
2002; Hoffman et al., 2002; Brettingham-Moore et al., 2005a; Fan and Cooper, 2009) in 
conjunction with the immunocytochemistry could have provided a more accurate 
indication of relative activation levels in the cultures. If these alternative techniques using 
samples from whole culture lysates had been utilised it may have been assumed that NF-
κB activation was equally distributed in astrocytes throughout the cultures. This 
assumption could also arise from modeling of NF-κB activation, based on the 
dissociation rates of the most relevant molecular interactions, which predicts the 
maximum percentage of activated NF-κB dimers for different treatment conditions 
(Hoffman et al., 2002; Halsey et al., 2007). Furthermore, it could have been expected that 
subjecting the cultured astrocytes to soluble activating factors in the culture media would 
have simultaneously activated all astrocytes to the same extent within each culture. 
However, the differences in NF-κB activation between treatments, measured with the 
immunocytochemical method in this study, clearly represented differences in the 
percentages of synchronously-activated astrocytes in the cultures. It is likely that 
measured differences in NF-κB activity are also unequally distributed between cells in 
research using other methodologies and this has implications for explanations of NF-κB 
regulation and the related physiological effects. The observed effects in this study could 
have arisen from different rates of NF-κB activation in response to different treatments 
with higher activation rates resulting in more astrocytes simultaneously reaching the 
activation threshold at earlier time-points. Alternatively, the more inflammatory 
treatments may have been able to activate a greater percentage of astrocytes in the 
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cultures. It is also possible that the effects on the percentage of activated astrocytes were 
accompanied by corresponding unmeasured effects on the maximum percentage of 
activated NF-κB dimers in individual astrocytes. All of these explanations imply that 
there must have been uneven distributions of IκBs and/or other NF-κB signalling 
modulators between individual astrocytes in the cultures, possibly due to differences in 
maturity, cell cycle and growth phases between astrocytes or contact inhibition effects 
related to variations in cell density. These variables could be assumed to be equally 
distributed between cultures and would therefore not affect the validity or physiological 
relevance of the measured effects. However, a more detailed investigation of the 
sequence of events regulating NF-κB activation in individual astrocytes could provide 
valuable insight into the mechanisms that modulate inflammation and how they could 
limit the spread of secondary damage to neighbouring tissue. Fluorescence imaging of 
live astrocyte cultures could reveal the time-course of activation and deactivation of 
individual astrocytes within the cultures. 1μM ionophore did appear to induce apoptosis 
of astrocytes and ionophore was therefore used at lower doses in later experiments. High 
levels of intracellular calcium are known to induce apoptosis (Stys, 2004) and although 
NF-κB is considered to usually have growth-promoting and anti-apoptotic effects, it has 
been linked to apoptosis, particularly in neurons. Apoptosis in response to PMA and 
ionophore treatments are further investigated in Chapter 5.  
 
3.31 NF-κB translocation involved a calcium-dependent mechanism 
3.31.0 NF-κB translocation was sensitive to extracellular calcium levels 
The induction of NF-κB translocation by ionophore inferred a Ca2+-dependent 
mechanism. This result was as expected since many inflammatory stimuli activate NF-κB 
via PKC and other calcium dependent protein kinases (Fan and Cooper, 2009; Fisher et 
al., 2006; Gonczi et al., 2008). Interactions between calcium receptors, transporters and 
channels coordinate influx of extracellular Ca2+ with release from intracellular stores to 
create oscillations of intracellular Ca2+ concentration that act as a second messenger for 
intracellular signalling through a variety of calcium binding proteins (Gomez and Spitzer, 
1999; Carafoli, 2002; Robles et al., 2003; Clapham, 2007). Variations in the frequency of 
the Ca2+  concentration oscillations favour different protein interactions dependent on the 
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affinity of Ca2+ for the different calcium binding proteins and the binding dissociation 
rates of the subsequent protein interactions. Dissociation from NF-κB and degradation of 
IκB is favoured by high Ca2+ levels and modeling based on dissociation rates predicts that 
NF-κB is inactive at intracellular Ca2+ concentrations below 0.1μM with activity rising 
rapidly as intracellular Ca2+ increases across the physiological range from 0.1 to 0.5μM 
(Fisher et al., 2006). This model of NF-κB activation by calcium signalling was 
consistent with the rapid activation of NF-κB by ionophore in astrocytes, which reached a 
maximum within 30 minutes, as is predicted by the modeling, in response to low 
frequency Ca2+ oscillations across the physiological range. It was unlikely that the 
ionophore-induced translocation was PKC-dependent since there was not a synergistic 
increase in translocation when PMA was combined with ionophore treatment. However, 
the activation by PMA may have involved conventional Ca2+-dependent PKC or Ca2+-
independent novel PKC isoforms (Nishizuka, 1988; Deacon et al., 1997; Bright and 
Mochly-Rosen, 2005), which have both been implicated in astrogliosis (Ballestas and 
Benveniste, 1995; Pascale et al., 2004; Amos et al., 2005; Hung et al., 2005; Burgos et al., 
2007a). In T-cells, novel PKCε activated NFAT, AP-1 and NF-κB while conventional 
PKCα only activated NFAT and AP-1 and less effectively than PKCε (Genot et al., 1995). 
The translocation response in the cultured astrocytes was very sensitive to extracellular 
Ca2+ levels since a change to calcium-free medium induced NF-κB translocation as 
effectively as PMA/ionophore. Cells require a large gradient between intracellular and 
extracellular Ca2+ levels to maintain suitable ionic homeostasis for cellular functions 
(Carafoli, 2002; Clapham, 2007). Low extracellular Ca2+ would therefore lead to efflux 
of intracellular Ca2+ from astrocytes in an attempt to restore normal ionic gradients and 
simultaneous release of Ca2+ from internal stores to maintain normal intracellular levels. 
This perturbation of intracellular Ca2+ levels was apparently sufficient to stimulate 
calcium signalling leading to NF-κB translocation. 
 
3.31.1 Astrocyte attachment may affect activation 
There may also have been some cytoskeletal contribution to the stimulation of NF-κB 
translocation, since attachment of cells to substrates via integrins, adhesion molecules 
and cytoskeletal focal adhesions is Ca2+-dependent (Woods and Couchman, 1992; 
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Gottfried et al., 2003; Hall, 2005; Clapham, 2007). Astrocytes adopted spindly bipolar 
morphologies in the calcium-free conditions and this morphology change could have 
been associated with signalling through Rho GTPases that can lead to NF-κB activation 
(John et al., 2004; Kettritz et al., 2004; Hall, 2005). A cytoskeletal contribution to the 
induction of NF-κB translocation could provide an explanation for the significantly 
greater NF-κB translocation when astrocytes were treated with PMA/ionophore 
simultaneously with the change to calcium-free medium compared with PMA/ionophore 
or the medium change alone. Decreased cell to cell and cell to substrate attachment 
associated with the altered astrocyte morphologies in the calcium-free conditions could 
have limited a cytoskeleton-mediated inhibitory effect on astrocyte activation. Although 
cell density effects on NF-κB translocation were not specifically investigated, relatively 
less translocation did appear to occur among astrocytes in locally dense regions of the 
cultures under all treatment conditions. NF-κB translocation was not induced by a change 
of medium after astrocytes were pre-incubated for 4 hours in calcium-free DMEM 
supplemented with EDTA to chelate any free Ca2+ and the basal level of NF-κB 
activation was significantly less in these conditions than in DMEM, confirming the Ca2+-
dependence of the response to medium change. However, treatment with PMA/ionophore 
did still induce significant NF-κB translocation in these conditions, although the effect 
was significantly less than for ionophore or PMA treatment in normal DMEM, 
suggesting that there may have been a novel PKC component to the induction of 
translocation by PMA. Testing separate treatments with PMA and ionophore in the 
calcium-free conditions may help reveal the involvement of a novel PKC isoform, 
although conclusive evidence would require the use of inhibitors of specific PKC 
isoforms or experimental models involving knock-down or blocking of PKC isoforms. 
 
3.31.2 Thapsigargin confirmed the calcium-dependence of astrocyte activation 
Thapsigargin, which elevates intracellular Ca2+ levels by blocking active transport into 
intracellular stores (Pahl and Baeuerle, 1996; Araque et al., 1998; Chen et al., 2001a), 
induced similar levels of NF-κB translocation as PMA/ionophore, confirming that this 
translocation response in astrocytes was predominantly Ca2+-dependent. In addition, 
thapsigargin induced significantly less NF-κB translocation than PMA/ionophore in 
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astrocytes that had been pre-incubated in EDTA-supplemented calcium-free medium, 
providing further support for the possibility that a component of the translocation induced 
by PMA was mediated by a novel PKC isoform. Again, it could have been informative to 
test the effects of PMA and ionophore separately in combination with thapsigargin. 
Combining PMA/ionophore and thapsigargin treatments in the calcium-free conditions 
induced significantly more NF-κB translocation than PMA/ionophore alone in these 
conditions. Since ionophore transports Ca2+ down concentration gradients it could have 
induced some elevation of intracellular Ca2+, by transporting Ca2+ out of intracellular 
stores in the calcium-free medium conditions, when active transport back into the 
intracellular stores was blocked by thapsigargin. The resultant elevation of intracellular 
Ca2+ could have induced increased NF-κB translocation by augmenting a component of 
the translocation response mediated by a conventional PKC isoform or other calcium 
signalling pathways but significantly less so than for the same treatments in the presence 
of normal extracellular Ca2+ levels. A more sophisticated investigation of calcium 
signalling involvement in the NF-κB translocation response, utilising specific activators 
and inhibitors of the variety of Ca2+ channels and pumps together with the measurement 
of Ca2+ transients with Ca2+-sensitive fluorophores, could provide valuable information 
on the mechanisms of NF-κB translocation and the related inflammatory gene 
transcription responses in astrocytes. 
 
3.32 PMA and ionophore altered astrocyte morphology 
3.32.0 Astrocyte morphology and astrogliosis 
The NF-κB translocation induced by PMA, ionophore, thapsigargin and the change to 
calcium-free medium were all accompanied by morphological changes that were evident 
within 2 hours of stimulation. Changes in astrocyte morphology and motility associated 
with CNS injury and glial scar formation are often cited as characteristics of astrogliosis 
(Hou et al., 1995; Pindon et al., 1998; Rabchevsky et al., 1998; Panickar and Norenberg, 
2005). It has been proposed that Rho GTPase (Hall, 1998; Safavi-Abbasi et al., 2001) and 
calcium signalling (Gu and Spitzer, 1997; Doherty et al., 2000; Chierzi et al., 2005; 
Takenaga and Kozlova, 2006) stimulation of astrocyte cytoskeletal dynamics (Goldman 
and Abramson, 1990; Manning and Sontheimer, 1997; Suidan et al., 1997) in response to 
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CNS injury initiates activation of NF-κB and other inflammatory pathways (Steiner et al., 
2002; Sorensen et al., 2003; Hall, 2005; Koh et al., 2005) to stimulate the required ATP 
production (Carafoli, 2002; Cogswell et al., 2003; Clapham, 2007) and protein synthesis 
for growth (Ellison et al., 1999; Jacques-Silva et al., 2004; Hall, 2005) and differentiation 
to a reactive phenotype (Eddleston and Mucke, 1993; O'Neill and Kaltschmidt, 1997; 
Meeuwsen et al., 2003a; Sofroniew, 2005). 
 
3.32.1 Calcium-dependent alteration of astrocyte morphology 
 While it was possible that alterations in cytoskeletal dynamics associated with the 
morphology changes may have contributed to the NF-κB activation in response to some 
or all of the stimuli, it appeared unlikely that activation was predominantly initiated via 
the cytoskeleton. NF-κB translocation occurred within 30 minutes in response to 
activating stimuli, before morphological changes were apparent, except in calcium-free 
medium conditions, which induced almost immediate morphological changes. However, 
addition of 500μM-1mM calcium chloride prevented the morphology changes but did not 
eliminate the NF-κB translocation that was rapidly induced by briefly washing astrocytes 
with calcium-free medium. Furthermore, the morphological changes induced by 
ionophore were dose-dependent, with alteration to spindly bipolar morphologies only 
occurring at higher doses, while NF-κB activation was not dose-dependent, with similar 
levels of NF-κB translocation being induced across the 125nM to 1μm range of 
ionophore concentrations. The morphological changes induced by ionophore, 
thapsigargin and calcium-free medium were consistent with the disruption of Ca2+-
regulated cell-cell and cell-substrate attachment. Detachment of astrocytes was most 
evident in calcium-free conditions where blebby astrocytes with retracted, sinusoidal and 
coiled processes suggested a loss of tension due to disrupted cell-cell and cell-substrate 
attachment. At higher doses of ionophore, particularly in combination with PMA, 
astrocyte apoptosis appeared to contribute to the disruption of attachment and associated 
morphological changes. Although the morphological effects of ionophore and 
thapsigargin were accentuated by calcium-free conditions, NF-κB translocation in 
response to the reagents was moderated, again suggesting the morphological effects of 
disrupted calcium signalling were substantially independent of astrocyte activation. More 
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conclusively, pre-incubation in EDTA-supplemented calcium-free medium eliminated 
translocation of NF-κB in response to medium change, while the morphological effects 
were accentuated by the longer incubation in calcium-free conditions. 
 
3.32.2 Morphological effects were independent of NF-κB translocation 
The results were consistent with previous research that has revealed the role of RhoA in 
regulating astrocyte morphology. The flattened polygonal morphologies of the untreated 
astrocytes were accentuated by LPA and glutamate treatment and were accompanied by 
cytoplasmic networks of GFAP and radially arranged actin fibres that have been 
associated with RhoA activation (Suidan et al., 1997). Db-cAMP and PMA induced 
depolymerisation of actin fibres and the compression of cytoplasm and GFAP fibres into 
stellate morphologies that have been associated with inhibition of RhoA and disassembly 
of focal adhesions (Safavi-Abbasi et al., 2001). However, there was no evidence of a 
relationship between the inferred RhoA effects on astrocyte morphology and NF-κB 
activation or GFAP expression. There was no evidence of altered GFAP expression with 
any of the tested reagents. Untreated, LPA-treated and glutamate-treated astrocytes all 
had flattened polygonal morphologies consistent with RhoA activation and low levels of 
NF-κB activation. Flattened polygonal astrocyte morphologies were also maintained at 
the lower 125-250nM ionophore doses that induced NF-κB translocation as strongly as 
the higher ionophore doses that altered astrocyte morphology, probably by disrupting 
cell-cell and cell-substrate attachment and inducing apoptosis. The moderately more 
stellate process-bearing astrocyte morphologies induced by PMA and metallothionein 2A 
were associated with only moderate levels of NF-κB translocation, while the strong 
stellation induced by db-cAMP was not accompanied by any evidence of NF-κB 
translocation. Process extension by immature astrocytes differentiating from progenitors 
on the boundaries of CNS lesions may have led to the association of a process-bearing 
morphology with the reactive astrocyte phenotype. However, GFAP expression increases 
as the progenitors differentiate into astrocytes and develop broader processes.  
Consequently, the flattening of morphologies in response to inflammatory mediators such 
as LPA and thrombin from blood has also been cited as evidence for astrogliosis 
(Manning and Sontheimer, 1997; Steiner et al., 2002; Sorensen et al., 2003; Koh et al., 
 126
2005). In addition, analysis of the morphology changes are based mainly on 
immunostaining for GFAP and recent evidence shows that mature astrocytes substantially 
remain in their exclusive domains following injury (Wilhelmsson et al., 2006). The 
observed ‘hypertrophy’ and ‘stellation’ appears to be merely due to a thickening of the 
cytoplasmic GFAP bundles that already have a stellate distribution in mature astrocytes 
in normal tissue prior to injury. Mature astrocytes on the border of the lesion may extend 
GFAP-rich processes into the void created by cell death and progenitors that migrate into 
the lesion differentiate into astrocytes, grow and retain a highly process-bearing 
morphology that contributes to glial scar development (Fawcett and Asher, 1999; Alonso, 
2005; Sofroniew, 2008). Cytoskeleton-regulated morphology changes are essential (Hall, 
2005; Holtje et al., 2005) for the required cell migration, proliferation, growth and 
differentiation during inflammatory responses and wound-healing (Ellison et al., 1999; 
Emsley et al., 2005; John et al., 2005; Fawcett, 2006a). However, the results suggest that 
morphological evidence alone for the induction of astrogliosis has even more 
questionable validity than evidence based solely on GFAP expression. This study and 
previous research show that rapid changes between stellate and epitheloid extremes of 
astrocyte morphology can be induced in culture independent of any synthesis or 
degradation of cytoskeletal proteins (Safavi-Abbasi et al., 2001). Consequently, the 
implications of these morphology changes for astrogliosis remain uncertain (Goldman 
and Abramson, 1990; Pinto et al., 2000; Safavi-Abbasi et al., 2001; Koh et al., 2005; 
Chan et al., 2007).  
 
3.33 PMA/ionophore induced depolymerisation and decreased levels of GFAP 
3.33.0 Depolymerisation may have increased GFAP immunoreactivity  
It could have been expected that induction of inflammatory gene expression by NF-κB in 
the cultured astrocytes would have led to a detectable increase in GFAP expression, 
consistent with the development of astrogliosis. However, no apparent increase in GFAP 
expression was detected by immunohistochemistry or Western blot, within 48 hours of 
any of the investigated treatments, independent of whether they induced NF-κB 
translocation.  Immunoreactivity was already relatively intense in the cultured astrocytes 
in comparison to cortical astrocytes in healthy tissue in vivo and it may be that in these 
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circumstances any changes in GFAP expression were not sufficient to be detectable. The 
possibility that the cultured astrocytes had already undergone activation and astrogliosis 
during dissection and culture preparation is discussed further in Chapter 4. A consistent 
decrease in GFAP levels was detected by Western blot in response to prolonged 
treatments with higher doses of ionophore or combined PMA/ionophore. 
Immunocytochemistry on astrocyte cultures subjected to the same treatments revealed 
that these ionophore and PMA/ionophore treated cultures contained some astrocytes 
where GFAP appeared to be depolymerised, as evidenced by diffuse high intensity 
immunoreactivity, and other astrocytes that appeared to be apoptotic, with condensed 
nuclei and patchy, faint or absent immunoreactivity for GFAP. The much higher intensity 
GFAP immunoreactivity within 1 hour of treatment in astrocytes where GFAP appeared 
to be depolymerised, together with unchanged or decreased GFAP levels, after 48 hours, 
indicated by the corresponding Western blots, supported previous research showing that 
depolymerisation of GFAP increases accessibility to some antibodies resulting in rapid 
increases in immunoreactivity independent of increases in GFAP expression (Tramontina 
et al., 2007). The higher intensity GFAP immunoreactivity was demonstrated to be 
associated with the change to a blebby morphology in apoptotic astrocytes in cultures 
treated with 1μM ionophore for 24 hours. As could be expected for a cytoplasmic protein, 
NF-κB immunoreactivity appeared to be lost at an earlier time-point than 
immunoreactivity for the fibrous cytoskeletal GFAP, in these apoptotic astrocytes. The 
apparent GFAP depolymerisation in response to ionophore is consistent with the 
phosphorylation and depolymerisation of GFAP due to calcium influx following CNS 
injury (Rodnight et al., 1997; Robles et al., 2003; Sullivan et al., 2010b). The Ca2+-
dependence of the apoptotic effect of ionophore was demonstrated by moderation of the 
decrease in GFAP levels by incubation in calcium-free medium and a marked 
exacerbation of the decrease in GFAP levels, accompanied by similar decreases in β actin 
and GAPDH levels, by high extracellular Ca2+ levels. PMA activation of PKC could have 
enhanced depolymerisation of GFAP but it is uncertain why PMA appeared to augment 
the apoptotic effects of ionophore-induced Ca2+ influx. PMA directly activates PKC by 
binding the DAG activation site without inducing intracellular Ca2+ release by generating 
IP3, as occurs following activation of mGluRs by glutamate (Akita et al., 1990; Chen et 
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al., 2000; Cheng et al., 2000; Shindo et al., 2001). PMA may have activated PKC-
regulated growth and metabolic pathways (Huang et al., 1989; Chen et al., 2001c; 
Chattopadhyay et al., 2002; Nakashima, 2002) that possibly rendered astrocytes more 
susceptible to mitochondrial damage and consequent apoptosis in response to the 
ionophore-induced Ca2+ influx. 
 
3.33.1 Depolymerisation is necessary for redistribution of cytoskeletal proteins 
The NF-κB-regulated cytokines, TNF-α and IL-1β are rapidly upregulated after CNS 
injury and can inhibit GFAP transcription and expression (Selmaj et al., 1991; Oh et al., 
1993; Murphy et al., 1995; Krohn et al., 1999). In regions of severe cellular damage and 
decreased GFAP immunostaining 72 hours after hypoxic injury in pig brain, surviving 
astrocytes had abnormal morphologies, characterised by retraction of processes and 
bulbous swellings (Sullivan et al., 2010b, a), resembling the detached and apoptotic 
astrocytes following PMA/ionophore treatment in this study. GFAP immunoreactivity 
was increased in less damaged regions of the hypoxic pig brains and similar increases in 
GFAP following CNS injuries have been correlated with a thickening of cytoplasmic 
GFAP bundles and processes without any growth beyond the normal exclusive astrocyte 
domains (Wilhelmsson et al., 2006). The changes in cell morphology that accompany 
growth and motility require rapid redistribution of cytoskeletal proteins that is achieved 
by cycles of depolymerisation and polymerisation (Lin et al., 1994; Dickson, 2002). 
Mobilisation of cytoskeletal proteins by depolymerisation could therefore be expected 
following CNS injury, to allow cell growth and motility for inflammatory responses, 
tissue remodelling and wound healing. The large increase in immunoreactivity to an 
antibody specific for the phosphorylated depolymerised form of GFAP following hypoxic 
injury (Sullivan et al., 2010a) could have been a manifestation of a requirement for 
redistribution of GFAP to maintain or alter astrocyte morphologies following tissue 
damage. Since depolymerisation of GFAP can increase accessibility to other antibodies 
and thereby increase immunoreactivity intensity it may be that increased 
immunoreactivity for GFAP, particularly when they occur rapidly in response to 
treatments, may often represent depolymerisation and/or redistribution of GFAP within 
cells to allow cytoskeletal remodelling for morphology changes, separate from any 
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increased synthesis of new protein that would be required for cell growth. It would 
therefore be interesting to compare immunoreactivity using the anti-phosphorylated 
GFAP antibody and the anti-GFAP antibodies used for immunocytochemistry and 
Western blotting in this research, in response to PMA/ionophore and the other reagent 
treatments. 
 
3.33.2 Loss of GFAP immunoreactivity may be an initial effect of CNS injury 
IL-1β and TNF-α are the predominant cytokines promoting transcription of other pro-
inflammatory cytokines, chemokines and growth factors in the early response to CNS 
injury (Taupin et al., 1993; Chao et al., 1995; Meeuwsen et al., 2003a; John et al., 2005; 
Gosselin and Rivest, 2007; Clausen et al., 2008) and during this period of severe 
inflammation there may be a loss of GFAP due to death of astrocytes and transcriptional 
inhibition. The transcriptional effects of IL-1β and TNF-α are regulated by NF-κB and 
the strong activation of astrocytic NF-κB by PMA/ionophore and the associated apoptosis 
and decreased GFAP expression had similarities with the effects of these cytokines.  
However, the cytokines induced by IL-1β and TNF-α include TGFβ1 and IL-6, which 
activate the JAK/STAT pathway in astrocytes leading to astrogliosis and GFAP up-
regulation. GFAP up-regulation develops gradually following CNS injury and reaches a 
peak after about 7 days in the glial scar (Yang et al., 1997; Fawcett and Asher, 1999; 
Alonso, 2005; Sofroniew, 2008). Perhaps the balance between the inhibition of GFAP 
transcription by IL-1β and TNF-α and its promotion by TGFβ1 and IL-6 determines the 
location and timing of GFAP expression by reactive astrocytes during inflammatory 
responses. The widespread up-regulation of GFAP by mature astrocytes, in undamaged 
tissue away from the region of severe inflammation, may be related to astrocyte swelling 
in response to oedema (Wilhelmsson et al., 2006; Gunnarson et al., 2008; Laird et al., 
2008). Progenitor cells attracted to the lesion by chemokines may initially be stimulated 
to proliferate and then, over several days following injury, differentiate into GFAP-
expressing astrocytes that make a major contribution to development of the glial scar 
(Alonso, 2005; Tan et al., 2005). Surviving mature astrocytes in the injury penumbra may 
also extend GFAP-rich processes towards and around the lesion as inflammation subsides 
and wound healing progresses. Comparing NF-κB activation and GFAP expression in 
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response to PMA/ionophore and other reagents in cultures of constitutively active AQP4 
mutant astrocytes and AQP4 null astrocytes or with AQP4 knock-down could provide 
useful information on the relationship between astrocyte swelling and GFAP in 
astrogliosis.  
 
3.34 Metallothionein 1/2 and astrocyte activation 
There are some intriguing parallels and interactions between PKC and metallothionein 
that may be related to them having similar activating effects on astrocytes. PMA, which 
is known to activate PKC, and metallothionein 2A induced similar moderate levels of 
NF-κB translocation in the cultured astrocytes. If this response translated to a moderate 
level of inflammation and astrogliosis in vivo, it could provide suitable conditions for 
neuroprotection, neurogenesis and enhanced wound healing. Although metallothionein 
1/2 has been reported to strongly induce astrogliosis, this has been inferred from the 
upregulation of GFAP and related factors that may reflect an emphasis on the growth-
related wound healing components of astrogliosis (Chung et al., 2008; Leung et al, 2010). 
PKC activity is calcium and zinc dependent (Huang et al., 1989; Ahmed et al., 1991), 
while metallothionein 1/2 regulates zinc homeostasis (Maret, 2000; Coyle et al., 2002). 
Metallothionein 1/2 upregulation by astrocytes can be regulated by IL-6 and TNF-α 
(Carrasco et al., 1998; Penkowa and Hidalgo, 2000; Penkowa et al., 2001) and is 
dependent on a factor released by injured neurons, possibly glutamate (Chung et al., 2004; 
Chung and West, 2004) or zinc (McCormick et al., 1981; Coyle et al., 1993; Kruczek et 
al., 2009). Vesicular zinc is released during normal glutaminergic signalling and in 
massive amounts, together with protein-bound zinc after injury (Frederickson and Bush, 
2001; Kauppinen et al., 2008). The high levels of extracellular zinc can exacerbate 
neuronal damage by promoting inflammation and ROS production (Choi et al., 1988; 
Frederickson and Bush, 2001; Hellmich et al., 2004). ROS activation of PKC can then 
increase metallothionein 1/2 expression via NF-κB and increased transcription of metal 
transcription factor-1 (MTF-1) (Saydam et al., 2002; Rao et al., 2003; Spahl et al., 2003; 
Hara and Aizenman, 2004; Nakano et al., 2006). Metallothionein 1/2 can then bind the 
excess zinc to protect neurons. Astrocyte swelling following CNS injury also promotes 
ROS formation leading to cell damage,  the release of zinc ions from protein zinc-sulphur 
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complexes (Katakai et al., 2001; Kruczek et al., 2009) and increased aquaporin 
expression via NF-κB (Gunnarson et al., 2008). The elevation in extracellular zinc ions 
again leads to increased expression of metallothionein 1/2, which binds the excess zinc 
ions and scavenges ROS to provide protection against the oxidative stress (Dalton et al., 
1994; Kumari et al., 2000; Maret, 2003; Ebadi et al., 2005; Hashimoto et al., 2009). Zinc 
can also block Ca2+ entry into astrocytes in response to stimulation of metabotropic 
receptors by ATP and glutamate (Kresse et al., 2005). Ca2+ influx can promote glutamate 
uptake by astrocytes (Duan et al., 1999; Vermeiren et al., 2005; Verkhratsky, 2006) and 
induce astrogliosis via PKC and NF-κB activation (Ballestas and Benveniste, 1995; 
Ciccarelli et al., 2004; Abramov et al., 2005; Norris et al., 2005; Perez-Ortiz et al., 2008). 
The inhibition of Ca2+ influx by zinc could lead to increased neuronal damage due to 
higher extracellular and glutamate levels. Metallothionein 1/2 could protect neurons by 
binding the zinc and allowing Ca2+ and glutamate uptake by astrocytes, which could 
simultaneously lead to increased astrogliosis. This may explain why metallothionein 1/2 
null transgenic mice exhibit decreased gliosis but suffer more severe neuronal damage in 
response to kainic acid (Carrasco et al., 2000a). A further cyto-protective function of 
metallothionein 1/2 involves the regulation of mitochondrial zinc levels to maintain 
oxidative phosphorylation through alterations in metallothionein zinc-binding affinity 
resulting from interaction between ATP and metallothionein (Maret et al., 2002). 
Intracellular calcium ion levels similarly co-ordinate the mitochondrial production of 
ATP with the protein synthesis demands of growth and inflammatory responses 
stimulated through PKC, NF-κB and other calcium-dependent signalling pathways (Fig. 
1.1). Signalling complexes containing glutamate receptors and transporters, aquaporins, 
calcium channels and regulatory molecules, such as PKC are located at astrocyte cell 
membranes (Iadecola and Nedergaard, 2007; Sullivan et al., 2007; Gunnarson et al., 2008; 
Zeng et al., 2008a). Determining whether metallothionein 1/2 and megalin co-localise 
with these signalling complexes using confocal microscopy and co-immunoprecipitation 
could provide insight into the mechanisms for the effects of metallothionein 1/2 on 
astrogliosis and axon growth. 
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3.35 Conclusions 
The consistent rapid robust activation of NF-κB in astrocytes by PMA/ionophore 
established this treatment as a useful valid model for research on astrocyte inflammatory 
activation. Utilising immunocytochemistry to detect p65 NF-κB translocation provided 
simple, direct, unambiguous evidence of these rapid robust activation responses in 
astrocytes together with confirmation that the activated cells were astrocytes by counter-
staining for GFAP. The decreased GFAP levels and the apoptosis induced by high 
concentrations of ionophore and Ca2+ were consistent with previous research on the early 
responses of astrocytes to CNS injury, indicating that the PMA/ionophore treatment 
model was relevant for CNS injury research. Ionophore most potently activated NF-κB in 
astrocytes, with PMA inducing only moderate activation. 
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CHAPTER 4: 
 OECs moderate astrocyte inflammatory activation 
 
4.0 Introduction 
4.00 Moderation of inflammation may be therapeutic for CNS injury 
4.00.0 Methylprednisolone is the recommended treatment for acute spinal cord injury  
The association of more severe and prolonged inflammation with increased secondary 
neuronal damage has motivated research into adrenal and gonadal steroid hormones as 
anti-inflammatory treatments for CNS injury (for reviews see Garcia-Segura and 
Balthazart, 2009; Sorrels and Sapolsky, 2008). Glucocorticoids are adrenal steroid 
hormones that exert anti-inflammatory actions by inhibiting the adaptive immune activity 
of lymphocytes, T-cells and dendritic cells and at the molecular level, by directly 
inhibiting the transcriptional activity of NF-κB and activating protein 1 (AP-1) (reviewed 
by Sorrels and Sapolsky, 2008; Chen et al., 2007; MacNevin, et al., 2009). This inhibition 
of NF-κB and AP-1 results in decreased expression of chemoattractants for immune cells 
and of pro-inflammatory cytokines, including IL-1β, TNF-α and IL-6, while enhancing 
expression of anti-inflammatory cytokines such as IL-10 and TGF-β. In addition, there is 
decreased expression of other pro-inflammatory molecules, such as inducible COX-2 and 
prostaglandins. However, research into the therapeutic use of glucocorticoids in CNS 
injury and other conditions has shown that the anti-inflammatory effects are dose-
dependent. While basal levels of glucocorticoids can have anti-inflammatory, protective 
effects, higher levels, either administered therapeutically or due to chronic stress, can 
exacerbate inflammation and increase neuronal damage following injury. This is partly 
because glucocorticoids inhibit glucose uptake so that less energy is available to neurons 
and astrocytes to counter the effects of ischemia and excitotoxicity. Methylprednisolone 
is a synthetic glucocorticoid steroid that was developed for its enhanced anti-
inflammatory activity relative to the other effects of glucocorticoids (Donnelly and 
Popovich, 2008; Hall, 1992; Hall et al., 2010; Nash et al., 2002). In contrast to 
endogenous glucocorticoids, methylprednisolone has only been demonstrated to improve 
recovery from spinal cord injury when used at high doses. This is consistent with 
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evidence that, rather than the anti-inflammatory action, it is the anti-oxidant activity of 
methylprednisolone, particularly the amelioration of lipid peroxidation that is responsible 
for the therapeutic effects (Werner, 1997; Hall et al., 2010; Wu et al., 2010). Treatment is 
only considered effective if commenced within 8 hours of injury and is usually continued 
for 48 hours, covering the period of glucocorticoid receptor upregulation, strong 
excitotoxicity and high oxidative stress at injury sites.  Methylprednisolone is the only 
drug treatment advocated for acute spinal cord injury (O’Connor et al., 2003; Molloy et al, 
2002; Lee et al., 2007) and remains in widespread use, despite uncertainty about its 
efficacy and safety (Bracken and Holford, 2002; Kronvall et al., 2005; Aalborg et al, 
2008). High methylprednisolone doses have only provided modest improvements in 
neurological outcomes for some spinal cord injuries, while the systemic 
immunosuppression resulting from the treatment can result in worse patient outcomes 
due to infections. Subsequently, non-glucocorticoid steroids with enhanced antioxidant 
and less anti-inflammatory activity, such as tirilazad, have been found to have similar 
beneficial effects as methylprednisolone, without the adverse immunosuppressive effects 
(Werner, 1997; Nash et al., 2002; Hall et al., 2010). The endogenous adrenal steroids, 
progesterone, testosterone, oestrogen and estradiol, have also been reported to provide 
neuroprotection after traumatic brain injury and stroke by a variety of related mechanisms, 
including regulating astrocytic AQP4 expression to attenuate cerebral oedema, anti-
inflammatory effects and the reduction of lipid peroxidation, oxidative stress and 
apoptosis (Garcia-Segura and Balthazart, 2009; MacNevin et al., 2009; Samantaray et al., 
2010). These steroids and their metabolites can also be produced from cholesterol by 
neurons and glial cells and may thereby exert paracrine neuroprotective effects within the 
brain and spinal cord. Steroids are lipophilic and can therefore cross the BBB when 
administered systemically. However, their lipophilicity confers low aqueous solubility, 
which is problematic for intravenous delivery. Consequently water-soluble analogues of 
progesterone have been developed that reproduce some of its neuroprotective effects 
(MacNevin et al., 2009), while methylprednisolone is delivered as a succinated ester, 
which releases the free steroid following injection (Nash et al, 2002). 
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4.00.1 Inhibition of NF-κB moderates CNS injury damage 
Earlier Chapters explain how more severe inflammation following CNS injury typically 
leads to increased tissue damage, larger infarct area and more secondary post-ischemic 
neuronal damage. Since NF-κB is a key regulator of inflammation (Kracht and Saklatvala, 
2002; Chen and Greene, 2004a) that is robustly activated within 15 minutes of CNS 
injury (Yenari and Han, 2006; Zhao, 2007), limiting NF-κB activation has moderated 
inflammation with beneficial effects in a variety of CNS injury models (Schneider et al., 
1999; Fernandez et al., 2007a; Khorooshi et al., 2008). Furthermore, the moderation of 
post-CNS injury damage by diverse anti-inflammatory treatments appears to be 
dependent on the inhibition of NF-κB activation (Blondeau et al., 2001). For example, the 
attenuation of apoptotic cell death after cortical contusion in rats by progesterone 
administration was associated with down-regulation of toll-like receptor expression and 
the moderation of NF-κB activation that resulted in decreased expression of intercellular 
adhesion molecule-1 (ICAM-1) and the inflammatory cytokines IL-1β, TNF-α and IL-6 
(Chen et al., 2008). Similarly, NF-κB activation, neutrophil infiltration and astrogliosis 
were suppressed following cerebral artery occlusion in scavenger receptor CD36-null 
mice (Kunz et al., 2008). The neuroprotective effect of prostaglandin A after cerebral 
ischemia in rats also involved NF-κB inhibition (Zhang et al., 2008). In addition, the 
neuroprotection and suppression of post-ischemic inflammation by hypothermia (Yenari 
and Han, 2006), the inhibition of 5-lipoxygenase production of inflammatory leukotrienes 
(Jatana et al., 2006) and chelation of extracellular zinc released from damaged neurons 
(Kauppinen et al., 2008) all involved NF-κB inhibition. Finally, the development of 
tolerance to ischemia in cultured neurons and astrocytes following pre-conditioning with 
TNF-α treatment was dependent on inhibition of p65 NF-κB phosphorylation, thereby 
preventing binding to an adaptor protein, p300 that was required for ICAM-1 
transcription (Ginis et al., 2002). 
4.01 Inhibition of NF-κB in astrocytes as a therapy for CNS injury 
As described in the previous Chapters, more severe astrogliosis has been associated with 
increased secondary neuronal damage and more extensive axon-growth inhibitory glial 
scarring. This association between the severity of the astrocytic inflammatory response 
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and tissue damage has led to research on NF-κB inhibition targeted specifically to 
astrocytes as a therapy for CNS injury. Inhibition of NF-κB in transgenic mice, bearing a 
dominant negative form of IκBα under the control of an astrocyte-specific GFAP 
promoter, resulted in decreased white matter damage and lesion size, followed by 
improved functional recovery after contusive spinal cord injury (Brambilla et al., 2005b; 
Brambilla et al., 2009). Decreased astrocytic expression of the pro-inflammatory 
chemokines, CXCL10 and CCL2, transforming growth factor-β2 and the chondroitin 
sulphate proteoglycans (CSPGs), neurocan and phosphacan accompanied the 
improvements in the injury response. Transforming growth factor-β2 regulates glial scar 
formation (Lagord et al., 2002), while secretion of neurocan and phosphacan and other 
CSPGs into the extracellular matrix is considered to contribute to the axon growth 
inhibitory environment of the glial scar (Properzi et al., 2005; Carter et al., 2008; Shen et 
al., 2008). In addition, transgenic mice with astrocyte-specific inhibition of NF-κB had 
less STAT2 upregulation in astrocytes, CCL2 expression and leukocyte infiltration in 
response to injury than wild-type mice (Khorooshi et al., 2008). Similarly, transgenic 
mice expressing an astrocyte-specific constitutively active form of the calcium-dependent 
phosphatase, calcineurin, exhibited less p65 NF-κB-dependent glial inflammation and 
neuronal death following penetrating brain injuries (Fernandez et al., 2007a). TNF-α 
activated the calcium-dependent phosphatase, calcineurin to induce inflammatory gene 
transcription in astrocytes through the NF-κB and NFAT pathways. However, at the later 
stages of injury responses, IGF-1 also recruited calcineurin in reactive astrocytes to 
inhibit NF-κB/NFAT activation. Calcineurin-dependent dephosphorylation of IκB by 
IGF-1 protected IκB against TNF-α initiated phosphorylation and subsequent 
translocation of NF-κB to astrocyte nuclei, suggesting a probable mechanism for the 
therapeutic anti-inflammatory effects of IGF-1 (Pons and Torres-Aleman, 2000). Three 
different inhibitors, SC-514, BAY 11-7082 and caffeic acid phenyl ester, which block 
distinct steps in the NF-κB pathway, attenuated the release of NO, TNF-α and chemokine 
receptor CXCL2 respectively from activated astrocytes and NO production was 
diminished in TNF-α knockout astrocytes (Phulwani et al., 2008). Inhibition of NF-κB by 
BAY 11-7082 and SN-50 also blocked the iNOS upregulation and subsequent NO 
production responsible for astrocyte swelling (Sinke et al., 2008). It therefore appears that 
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targeted inactivation of NF-κB in astrocytes may prevent the initiation of processes 
involved in the progression of inflammation and secondary cellular damage after injury. 
 
4.02 OEC transplants and astrogliosis  
Although as described in Chapter 1, there has been extensive research on OEC 
transplantation therapy for CNS injury, the molecular, cellular and tissue repair 
consequences of this therapy remain uncertain (reviewed by Chuah et al., 2010). It has 
been suggested that transplanted OECs could promote neuronal repair by their production 
of growth factors, by re-myelinating axons or by forming a permissive tract for axon 
growth across lesions. Another possibility is that transplanted OECs could moderate 
astrogliosis to provide a more permissive environment for axon regeneration at injury 
sites. The lack of boundary formation between astrocytes and co-cultured or transplanted 
OECs suggest that OECs may have a moderating effect on astrogliosis and glial scar 
formation (Lakatos et al., 2000; Lakatos et al., 2003a; Li et al., 2005b). Although there is 
divergent evidence concerning the behaviour and therapeutic efficacy of transplanted 
OECs, many studies report the amelioration of astrogliosis and glial scarring (Ramon-
Cueto et al., 2000; Takami et al., 2002; Nieto-Sampedro, 2003; Plant, 2003; Ramer et al., 
2004b). Since the severity of astrocytic inflammatory activation and glial scarring are key 
determinants of the extent of secondary neuronal damage and subsequently, the capacity 
for axon regeneration, this amelioration of astrogliosis by transplanted OECs could be an 
important component of any therapeutic effects. Improved axon regrowth in response to 
co-cultured or transplanted OECs has been associated with decreased GFAP upregulation 
by reactive astrocytes (Lopez-Vales et al., 2004; Li et al., 2005b; Richter et al., 2005; 
Lopez-Vales et al., 2006a), decreased astrocytic production of axon growth-inhibitory 
CSPGs (Leaver et al., 2006; Lopez-Vales et al., 2006a), prevention of the formation of a 
GFAP and CSPG enriched glial scar boundary (Ramer et al., 2004b) and prevention of 
the development of a fibrotic scar with basal laminae (Li et al., 2005b; Teng et al., 2008). 
Further evidence suggests that transplanted OECs may modulate the IL-1β, COX-2 and 
iNOS expression components of the inflammatory response at CNS injury sites to induce 
an initially more intense but shorter duration inflammation that moderates glial scarring 
and improves tissue repair (Lopez-Vales et al., 2004; Lopez-Vales et al., 2006b). 
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4.03 Research rationale 
4.03.0 Do OECs moderate the inflammatory activation of astrocytes? 
Although previous research provides some evidence that transplanted OECs may 
moderate astrogliosis and improve the permissiveness of the glial scar to axon growth, 
the evidence has been somewhat variable and inconsistent. This study was intended to 
further investigate the possibility that OECs could moderate the inflammatory responses 
of astrocytes with potentially beneficial consequences for recovery from CNS injury. NF-
κB activation is a key early event in CNS injury responses leading to astrogliosis and as 
shown in Chapter 3, PMA/ionophore robustly induces rapid translocation of p65 NF-κB 
to astrocyte nuclei. This treatment model was therefore utilised to determine whether 
OECs could directly moderate astrocyte inflammatory activation. There has been no 
previous investigation into the direct effects of OECs on the initiation of astrocyte 
activation. The effects of OECs on astrocyte activation were compared with the effects of 
microglia and meningeal fibroblasts because both cell types interact with astrocytes 
during CNS injury responses. CNS injury rapidly activates microglia, stimulating their 
production of IL-1β, TNF-α, IL-6 and other inflammatory mediators (Davalos et al., 
2005; Haynes et al., 2006; Hanisch and Kettenmann, 2007) that can promote astrogliosis 
and the development of the glial scar (Meeuwsen et al., 2003a; Bolin et al., 2005; John et 
al., 2005). Invading meningeal fibroblasts can interact with reactive astrocytes to 
exacerbate glial scarring by enhancing extracellular matrix protein deposition and 
forming axon-growth inhibitory basal laminae layers (Sandvig et al., 2004; Laabs et al., 
2005; Teng et al., 2008). In addition, olfactory meningeal fibroblasts in OEC cultures 
may promote OEC migration and modulate interactions between OECs and astrocytes to, 
perhaps paradoxically, prevent the formation of inhibitory basal laminae in glial scars (Li 
et al., 2005b; Teng et al., 2008). Comparisons were also made between the effects of 
PMA/ionophore on NF-κB translocation in astrocytes, OECs, microglia and meningeal 
fibroblasts, since this treatment model has not previously been used to investigate NF-κB 
translocation in these cell types and their activation would be relevant to responses at 
CNS injury sites. 
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4.03.1 Do OECs moderate inflammatory gene transcription by astrocytes? 
If OECs were found to moderate NF-κB translocation in astrocytes it was considered 
important to demonstrate that there was a corresponding moderating effect on the 
astrocytic transcription of NF-κB-regulated inflammatory genes relevant to CNS injury. 
NF-κB regulates transcription of granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Schreck and Baeuerle, 1990; Tsuboi et al., 1994; Brettingham-Moore et al., 
2005a), which is rapidly upregulated following CNS injury together with other pro-
inflammatory cytokines (Kaltschmidt et al., 1993; Franzen et al., 2004; Frugier et al., 
2009).  GM-CSF produced by astrocytes and microglia can promote proliferation and 
differentiation of microglia and recruited peripheral immune cells to phagocytic and 
antigen-presenting phenotypes (Hayashi et al., 1993; Re et al., 2002; Schermer and 
Humpel, 2002; Koguchi et al., 2003) with beneficial effects on wound-healing (Ellison et 
al., 1999; Schwartz, 2003; Jones et al., 2005; Kurpius et al., 2007). However, high levels 
of GM-CSF released by astrocytes can stimulate microglia to produce cytotoxic levels of 
TNF-α, IL-1β and IL-6 (Zaheer et al., 2007) that can exacerbate inflammation and 
astrogliosis (Guillemin et al., 1996; Lenzlinger et al., 2001; Meeuwsen et al., 2003a; John 
et al., 2005). Moderation of astrocytic GM-CSF production could therefore limit neuronal 
damage and improve tissue repair after CNS injury. GM-CSF regulates the production, 
differentiation and function of myeloid cells (Schreck and Baeuerle, 1990; Tsuboi et al., 
1994; Brettingham-Moore et al., 2008) and has been well-characterised as a target gene 
for NF-κB following activation by PMA/ionophore in lymphocytes (Holloway et al., 
2003; Brettingham-Moore et al., 2005a; Brettingham-Moore et al., 2008). However, 
PMA/ionophore stimulation of NF-κB translocation and induction of GM-CSF 
transcription have not previously been investigated in astrocytes. Therefore, to determine 
whether OECs could moderate NF-κB-dependent inflammatory gene expression in 
astrocytes, the effects of OECs and microglia on GM-CSF transcription in astrocytes 
were investigated following stimulation of astrocytic NF-κB translocation with 
PMA/ionophore.  
 
 
 
 140
4.04 Specific aims 
 
1. Determine whether PMA/ionophore induces NF-κB translocation in OECs, 
microglia and meningeal fibroblasts. 
 
2. Compare the effects of OECs, microglia and meningeal fibroblasts on NF-κB 
translocation in astrocytes. 
 
3. Determine whether OECs moderate NF-κB translocation in astrocytes in vitro. 
 
4. Determine whether OECs moderate GM-CSF transcription in astrocytes. 
 
5. Compare the effects of OECs and microglia on GM-CSF transcription in astrocytes. 
 
4.1 Materials and Methods 
4.10 Cell culture 
Astrocytes, OECs, microglia and meningeal fibroblasts were cultured on 18mm 
coverslips in 12-well culture plates, as described in Chapter 2. Direct co-cultures of 
astrocytes and OECs, astrocytes and microglia or astrocytes and fibroblasts were obtained 
by harvesting cells from flasks by trypsinisation and re-plating onto 18 mm coverslips in 
12-well plates at approximately equal densities (104/cell type). After growth to 
confluence, this procedure typically resulted in co-cultures containing about 70% 
astrocytes. Astrocyte/OEC co-cultures were also prepared by establishing OEC cultures 
on cell culture inserts incorporating polyethylene terephthalate membranes with 400 nm 
pores (Becton Dickinson) and later transferring these to culture plate wells containing 
previously established astrocyte cultures on coverslips. 
 
4.11 Immunocytochemistry 
Following experimental treatments, monocultures were immunostained following the 
previously described protocols for p65 NF-κB and a cell marker protein: GFAP for 
astrocytes, p75NTR for OECs and CD11b for microglia. The purity of sample fibroblast 
cultures was verified by immunostaining for fibronectin and GFAP to show that cells 
were predominantly fibronectin positive/GFAP negative fibroblasts. However, fibroblast 
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cultures used in experiments were delineated with phalloidin staining of actin filaments 
rather than immunostaining for fibronectin, which is secreted and often formed an 
adherent layer on the PLL-coated coverslips (Fig. 2.7). All co-cultures were 
immunostained for NF-κB and GFAP to identify activated astrocytes. The identity of 
OECs, microglia and fibroblasts in the co-cultures with astrocytes was inferred from 
immunostaining of the monocultures from which they were derived and from the 
morphology revealed by NF-κB immunoreactivity in cells that did not express GFAP in 
each type of co-culture. Nuclei in all cells were counter-stained with Hoechst blue.  
 
 4.12 Comparisons of NF-κB translocation 
 Immunostained cultures were imaged as described in Chapter 2 and the resulting 
fluorescence microscope images were used for comparisons of nuclear relative to 
cytoplasmic NF-κB immunoreactivity intensity between:  
 
1. astrocyte/OEC, astrocyte/fibroblast and astrocyte/microglia co-cultures stimulated 
with PMA/ionophore (Fig. 4.0) 
 
2. cultures of astrocytes, OECs, microglia and fibroblasts stimulated with 
PMA/ionophore (Fig. 4.1) 
 
3. astrocytes in astrocyte-, OEC- or microglia-conditioned medium (Fig. 4.3) 
 
4. astrocytes in DMEM, OEC- or microglia-conditioned medium stimulated with 
PMA/ionophore (Fig. 4.4) 
 
5. astrocytes pre-incubated for 24 hours with OECs on tissue culture inserts or       
astrocytes alone, with both culture types then stimulated by incubation in 
microglia-conditioned medium in the presence or absence of PMA/ionophore 
(Figs.  4.5, 4.6) 
 
6. astrocytes stimulated with PMA/ionophore or microglia-conditioned medium in 
the presence or absence of insulin-like growth factor-1 (Millipore) (Fig. 4.7).  
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4.13 Quantitative analysis of cell activation  
Astrocyte activation in monocultures was quantified using HCA-Vision© software as 
described in Chapter 3. Astrocyte activation in co-cultures, in comparisons between co-
cultures and other treatments and activation of other cell types were scored manually 
because of differences in the NF-κB immunoreactivity intensity between the different cell 
types. By either method, cells were scored as activated only when their nuclear NF-κB 
immunoreactivity was visibly more intense than the cytoplasmic NF-κB 
immunoreactivity. At least eight images (selected randomly as described previously) 
showing ~120 cells/image from 2-3 separate cell cultures were analysed to generate 
means for each treatment group. Data were analysed for significant differences between 
treatment group means by ANOVA and post-hoc Tukey tests. 
 
4.14 Quantitative RNA analysis by real-time PCR  
4.14.0 RNA isolation from treatment samples 
Astrocyte cultures in 6-well culture plates were treated with 20ng/mL PMA/ 250nM 
ionophore in DMEM, OEC CM or microglia CM for 4, 8, 12, 18 or 24 h with untreated 
cultures in DMEM as comparison controls. Total RNA was isolated using Tri-Reagent 
(Sigma) according to the manufacturer’s protocol. Briefly, culture wells were washed 
with PBS after removal of culture medium was removed from culture wells and cells 
lysed with the addition of 1 mL Tri-Reagent to each well. Wells were scraped to remove 
any remaining adherent material and after 5-10 minutes samples were removed into 
eppendorfs and stored at -80oC. Samples were thawed at room temperature and 200 μL 
chloroform added to each sample tube with vigorous shaking for 15 seconds. After 15 
minutes incubation at room temperature, samples were centrifuged at 13000rpm for 20 
minutes and the upper clear aqueous phase containing the RNA transferred to new 
eppendorfs. 500μl of isopropanol was added to each sample, mixed by inversion, RNA 
precipitated by overnight incubation at -20oC (or -80oC for 30 minutes), centrifuged at 
13000rpm for 20 minutes at room temperature, the supernatant removed, 1mL 75% 
ethanol added to each pellet and mixed by vortexing followed by centrifugation at 
13000rpm for 20 minutes at room temperature. The supernatant was then removed, the 
pelleted RNA air-dried at room temperature over several minutes and re-suspended in 
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50μL MilliQ water with vortexing followed by incubation at 65oC for 5 minutes. Samples 
were then consolidated by brief centrifugation at 13000 rpm and the purity and RNA 
content of each sample measured on a Nanodrop Spectrophotometer (ND-1000). 2μL 
undiluted aliquots of each sample were used for the measurements and RNA content was 
quantified by measuring the optical density at 260nm. Optical density was measured to 
preclude protein contamination of RNA samples with a 260nm:280nm fluorescence ratio 
of ≥ 1.8 indicating sufficient RNA purity. The RNA sample solutions were then snap 
frozen in liquid nitrogen and stored at –80oC. 
 
4.14.1 cDNA synthesis 
1μg of each RNA sample was used to synthesise cDNA by reverse transcription using 
Superscript II Reverse Transcriptase (Life Technologies). All samples for each 
experiment were processed simultaneously with each sample reaction in a separate 
eppendorf tube. Any remaining genomic DNA was degraded by incubation with DNase 
prior to reverse transcription. Sufficient RNA solution to provide 1μg of RNA for each 
sample was added to 2μl of 5x first strand buffer (Invitrogen), 1μl of DNase (Sigma) and 
sufficient MilliQ water for a total volume of 10μL. The solution was incubated at 37oC 
for 30 minutes and the DNase then inactivated by heating to 75oC for 5 minutes. 1μl of 
1μg/ml oligodT primer (Invitrogen) and 3.5μl of water were added, reactions incubated at 
70oC for 10 minutes and then chilled on ice to promote oligodT binding to RNA poly-A 
tails. 2μL of 5x first strand buffer, 2μl of 0.1M DTT (Invitrogen), 1μl of 10mM dNTPs 
(Promega) and 0.5μl of Superscript reverse transcriptase (Invitrogen) was then added, 
each reaction incubated at 42oC for 50 minutes for transcription and the transcriptase then 
inactivated by heating to 70oC for 15 minutes. Master mixes of sufficient volume were 
prepared for each of the above incubation steps and equally aliquotted to each sample 
tube, to minimise cross-contamination between samples. The resulting cDNA samples 
were stored at –80oC. 
 
4.14.2 Real time PCR 
Primers were designed using Primer 3 (http://frodo.wit.mit.edu/cgi-bin/primer3/ ) and 
sequences obtained from the NCBI website (http://www.ncbi.nlm.nih.gov/). Primers were 
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designed to have melt temperatures of about 60ºC and to generate product sizes of about 
100 base pairs. The lypophilised oligonucleotide primers (Sigma) were diluted to 100μM 
with sterile MilliQ water and then, in separate tubes, 5μM for working stocks. Real time 
quantification of DNA amplification was achieved using a QuantiTect SYBR Green PCR 
kit (Qiagen) on a Rotor-Gene 2000 real-time cycler (Corbett Research), as described 
previously (Brettingham-Moore et al, 2005). PCR was conducted using the rattus 
norvegicus (rat) GM-CSF primers, sense: 5'-CCCGCCTGAAGCTATACAAG-3' and 
antisense: 5'-AGTGGCTGGCTATCATGGTC-3' in parallel with the rat GAPDH primers, 
sense: 5'-TGCCACTCAGAAGACTGTGG-3' and antisense: 5'-GGATGCAGGGATGA- 
TGTTCT-3', to normalize for differences in cDNA synthesis and RNA input. GAPDH 
was used as a loading control for Western blotting of astrocyte samples in Chapter 3 and 
did not appear to be regulated by the treatment conditions.  The cDNA was diluted 1:5 
for real time PCR and a 5μl aliquot used in each reaction. The other reagents were 
prepared as a master mix to minimise cross contamination, in the following proportions: 
12.5 μL SYBR green, 1.5μL forward primer (5μM), 1.5μL reverse primer (5μM) and 
4.5μL RNase-free water, for a total reaction volume of 25μL. A no template control, 
where the 5μl of sample cDNA was replaced with 5μl of RNase free water, was prepared 
for each run to detect any contaminating DNA. The PCR cycling conditions were as 
follows for all samples: melt at 95oC held for 15 minutes, 40 cycles of 95oC hold for 15 
seconds followed by 60oC hold for 60 seconds with data acquired to cycling channel 1, 
melt from 60-95oC holding for 5 seconds after each 1oC increase with data acquired to 
melt channel 1. Analysis of PCR product melt curves for a single peak and product 
visualization by agarose (2%) gel electrophoresis with ethidium bromide staining 
indicated that PCR generated single products of the expected size (81 base pairs for GM-
CSF, 85 base pairs for GAPDH). Threshold values from the amplification plots derived 
from the acquired cycling data were converted to copy number by generating a standard 
curve using purified GM-CSF and GAPDH PCR products. Three separate culture 
samples analysed in separate PCR amplifications were used for each culture condition 
and time-point. Data were analysed for significant differences between treatment group 
means by ANOVA and post-hoc Tukey tests. 
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4.14.3 DNA purification and standard curves 
Real time PCR DNA products were purified by ethanol precipitation to remove other 
reaction components. Each PCR reaction solution (25µl) was added to a microcentrifuge 
tube containing 3µl of 3M sodium acetate (pH~6, Ajax chemicals) and 75µl of 100% ice 
cold ethanol (Sigma), incubated for 24 hours at -20ºC to precipitate DNA, centrifuged at 
13,000 rpm for 5 minutes at 4ºC and the DNA pellet washed in 70% ice cold ethanol.  
The DNA was then vacuum dried for 5-10 minutes and resuspended in 30µL of MilliQ 
water by vortexing after heating to 65ºC. The DNA concentration of sample solutions 
was determined from their measured optical density at 260nm, known product size and 
the calculated number of DNA product copies. Solutions were serially diluted to produce 
8 standard solutions containing 109-102 copies/µl of PCR product.  These standards of 
known copy number were then quantified by real time PCR as described above to 
generate standard curves of copy number plotted against threshold value. 
 
4.2 Results 
4.20 OECs moderate activation of co-cultured astrocytes both in the absence and   
presence of PMA/ionophore 
One-hour combined PMA/ionophore treatment was used to compare the activation 
responses of astrocytes that were co-cultured with OECs, fibroblasts or microglia and 
astrocyte monocultures (Fig. 4.0A). PMA/ionophore treatment induced significant 
increases in the percentages of activated astrocytes in all cultures (p < 0.001) (Fig. 4.0) 
similar to those previously seen in astrocyte monocultures (Fig. 3.1). The results 
suggested a moderating effect of OECs on astrocyte inflammation with significantly 
fewer activated astrocytes occurring in astrocyte/OEC co-cultures (Fig. 4.0B, C, H) than 
in co-cultures of astrocytes with fibroblasts (Fig. 4.0D, E, H) or microglia (Fig. 4.0F, G, 
H) and astrocyte monocultures for both untreated (astrocyte/OEC, 0.7±0.3%; 
astrocyte/fibroblasts, 9.8±3.63 %; astrocyte/microglia, 30.9±2.3%; astrocytes, 7.3±1.8%; 
p < 0.001) and PMA/ionophore-treated cultures (astrocytes/OECs, 34.6±4.4%; 
astrocytes/fibroblasts, 55.3±5.3%; astrocytes/microglia, 53.0±4.7%; p < 0.01; astrocyte 
monocultures, 62.1±1.8%; p < 0.001). There were significantly more activated astrocytes  
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in the untreated astrocyte/microglia co-cultures than for untreated astrocyte/fibroblast, 
astrocyte/OEC co-cultures or astrocyte monocultures (Fig. 4.0H) (p < 0.001). However, 
percentages of activated astrocytes were not significantly different between untreated 
astrocyte monocultures and astrocyte/fibroblast co-cultures or between astrocyte 
monocultures and astrocyte/microglia or astrocyte/fibroblast co-cultures after the increase 
in activation induced by PMA/ionophore. PMA/ionophore also appeared to activate some 
microglia (asterisks, Fig. 4.0F, G) and fibroblasts (asterisks, Fig. 4.0D, E) in the co-
cultures. However, OECs in the co-cultures did not appear to be activated by 
PMA/ionophore despite displaying strong cytoplasmic immunoreactivity for NF-κB 
(asterisks and arrows, Fig. 4.0B, C). 
 
4.21 PMA/ionophore activates all cell types except OECs  
The apparent differences in activation of the different cell types in the co-cultures were 
further investigated by comparing their NF-κB translocation responses to 
PMA/ionophore using monocultures of astrocytes, microglia, meningeal fibroblasts and 
OECs. Microglia had a higher basal level of activity, there being significantly more 
activated cells in the untreated cultures of microglia (Fig. 4.1C, I) than for the other cell 
types (p < 0.001) (Fig. 4.1A, E, G, I). PMA/ionophore induced significant increases in 
activation for astrocytes (p < 0.001) (Fig. 4.1B, I), microglia (p < 0.05) (Fig. 4.1D, I) and 
meningeal fibroblasts (p < 0.001) (Fig. 4.1F, I) to levels that were not significantly 
different for these three cell types (p > 0.05) (Fig. 4.1I). In contrast, PMA/ionophore did 
not activate OECs (Fig. 4.1H). Although OECs displayed bright cytoplasmic NF-κB 
immunoreactivity in the untreated (Fig. 4.1G) and treated (Fig. 4.1H) cultures, OEC 
nuclear immunoreactivity was never observed to be brighter than the cytoplasmic 
immunoreactivity. Apparent faint NF-κB immunoreactivity within the nuclear regions of 
OECs (asterisks, Fig. 4.1G, H) was probably due to overlying cytoplasmic 
immunoreactivity because it was not distributed evenly throughout the nuclear region, 
was absent when nuclei could be distinguished without overlying cytoplasm (arrows, Fig. 
4.1G, H) and was not altered by PMA/ionophore treatment (Fig. 4.1H). Consequently, 
OECs were deemed to be not activated by PMA/ionophore.  
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Figure 4.0 Comparison of astrocyte activation in co-cultures with OECs, microglia or 
meningeal fibroblasts. A: Co-cultures of astrocytes with OECs, astrocytes with meningeal 
fibroblasts or astrocytes with microglia and for control comparison, astrocyte monocultures, were 
treated with PMA/ionophore or were untreated. B-G: Cultures were immunostained for NF-κB 
(red) and GFAP (green), with nuclei counterstained using Hoechst blue. The majority of nuclei in 
the images belong to GFAP positive astrocytes except in B where there are some dense clusters of 
OECs (asterisks). There appeared to be more NF-κB positive astrocyte nuclei in the untreated 
astrocyte/microglia co-cultures (F) than for the other untreated co-cultures (B, D). Although 
PMA/ionophore increased astrocyte activation in all cultures (C, E, G), there was fewer activated 
astrocytes in the astrocyte/OEC co-cultures (C). Bright cytoplasmic NF-κB staining occurred in 
OEC cell bodies (asterisks in B, C) and processes (arrows in B, C). NF-κB immunoreactivity in 
OEC nuclei in the co-cultures appeared to be of low intensity before (asterisks in B) and after 
treatment (asterisks in C) while PMA/ionophore increased nuclear NF-κB immunoreactivity for 
fibroblasts (asterisks in D, E) and microglia (asterisks in F, G). Scale bar is 100 μm. H: 
Quantitative analysis of astrocyte activation in co-cultures with OECs, microglia or meningeal 
fibroblasts and astrocyte monocultures. PMA/ionophore (P/I) induced significant increases in 
astrocyte activation in all cultures (p < 0.001). There were significantly fewer activated astrocytes 
in astrocyte/OEC co-cultures than in astrocyte/microglia or astrocyte/fibroblast co-cultures either 
in the absence (p < 0.001) or presence of PMA/ionophore treatment (p<0.01 or p<0.001 for 
astrocyte monocultures). There were also significantly more activated astrocytes in the untreated 
astrocyte/microglia co-cultures than in the other untreated cultures (p<0.001). Percentages are 
means ± SEM, n = 15; ** p<0.01, *** p<0.001. 
 
 149
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 150
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 PMA/ionophore activates all cell types except OECs. Cultures of each cell type 
were treated with PMA/ionophore and untreated cultures provided comparison controls. Cultures 
were immunostained for NF-κB (red), and cell specific proteins (green); GFAP for astrocytes (A, 
B), CD11B for microglia (C, D) and p75NTR for OECs (G, H). Meningeal fibroblasts (E, F) were 
delineated with phalloidin staining of cytoskeletal actin filaments (green). Nuclei were stained 
with Hoechst blue (HB). More intense nuclear immunoreactivity for NF-κB following activation 
by PMA/ionophore occurred for astrocytes (B), microglia (D) and meningeal fibroblasts (F) but 
not for OECs (H). After PMA/ionophore treatment, some microglia appeared to be highly 
activated, displaying rounded morphologies with intense NF-κB and CD11B immunoreactivity 
(arrowheads in D). OECs displayed bright to moderate intensity cytoplasmic NF-κB 
immunoreactivity in cell bodies and processes with no difference in the NF-κB immunoreactivity 
between untreated (G) and PMA/ionophore treated (H) cultures. Where cytoplasmic NF-κB 
immunoreactivity was intense there was faint nuclear immunoreactivity (asterisks in G and H) 
probably due to overlying cytoplasmic immunoreactivity. This was confirmed by fortuitously 
orientated OECs that allowed Hoechst blue-stained nuclei, devoid of NF-κB, to be distinguished 
from adjacent bright cytoplasmic NF-κB immunoreactivity (arrows in G and H). Scale bar is 50 
μm. I: Quantitative analysis of PMA/ionophore (P/I) activation of astrocytes, microglia and 
meningeal fibroblasts. There were significantly more activated microglia than astrocytes or 
fibroblasts in the untreated cultures (p < 0.001). PMA/ionophore induced significant increases in 
activation of the three cell types (p < 0.05 for microglia; p < 0.001 for astrocytes and fibroblasts). 
Results for OECs were not graphed since they had no NF-κB positive nuclei. Data were analysed 
by 2-way ANOVA and post-hoc Tukey’s multiple comparison test. Percentages are means ± 
SEM, n = 15. Asterisks denote significant differences: * p < 0.05, *** p < 0.001. 
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Contaminating fibroblasts in some OEC cultures were also activated by PMA/ionophore 
(Fig. 4.2) and if counter-staining with p75NTR had not been used to identify OECs (Fig. 
4.1G, H; Fig. 4.2B, green in D) it would have been possible for activated p75NTR- 
negative fibroblasts (Fig. 4.2A, B, D) to have been misinterpreted as activated OECs. 
 
4.22 Microglia release soluble factors that activate astrocytes  
Microglia had a relatively high level of basal activity in the culture conditions (Fig. 4.1C, 
I) and when co-cultured with microglia, about 31% of astrocytes were already activated 
before PMA/ionophore treatment (Fig. 4.0F, H). Astrocyte cultures were therefore 
incubated with microglia-conditioned medium (CM) (Fig. 4.3E, F) for 30 minutes, 1 hour, 
2 hours or 3 hours to test whether soluble factors released by activated microglia could 
have been responsible for the previously observed activation of co-cultured astrocytes. 
Astrocytes were also incubated with media conditioned by OECs and astrocytes for 
comparisons (Fig. 4.3A-D). Incubation with astrocyte CM and OEC CM induced small 
significant increases in astrocyte activation within 30 minutes (10.2±1.3 % and 9.9±2.1 % 
respectively; p < 0.05 which represented increases of about 5% from levels prior to the 
medium change. However these responses were significantly much less than the increase 
induced by microglia CM (38.4±4.1 %; p < 0.001) (Fig. 4.3G). Activation remained 
significantly higher in the presence of microglia CM at 1 hour (59.3±4.5 %; p < 0.001) 
and 2 hours (20.4±2.4 %; p < 0.01) after the medium changes. Significantly more 
astrocytes were activated following the 1 hour of incubation with microglia CM than 
after about 4 days of co-culture with microglia (p < 0.01) (Figs. 4.1H, 4.3G). Activation 
had returned to basal levels for all cultures by 3 hours after the medium changes. 
Therefore, the data indicated that microglia-derived soluble factors activated astrocytes in 
a similar manner to PMA/ionophore with NF-κB translocation induced mainly within the 
first hour of exposure to either treatment. Since these results indicated that medium 
change alone could induce some activation, astrocytes were pre-incubated in media for 
24 hours prior to reagent treatments to eliminate any possible confounding effect. 
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Figure 4.2 Contaminating fibroblasts in OEC cultures. The images represent an OEC culture 
with contaminating fibroblasts after 1 hour of PMA/ionophore treatment. Cells were 
immunostained for NF-κB (A and red in D) and counterstained for P75NTR (B and green in D) to 
identify OECs. Nuclei were stained with Hoechst blue (C and blue in D). Bright cytoplasmic NF-
κB immunoreactivity in OEC cell bodies and processes (A) co-localised with p75NTR (B and D). 
Faint cytoplasmic immunoreactivity in fibroblasts (asterisks in A) occurred in p75NTR negative 
regions (asterisks in B and D). OEC nuclei occupy regions of low intensity NF-κB 
immunoreactivity (e.g. 1, 2, and 3 in A-D) ringed by brighter cytoplasmic immunoreactivity. 
OEC nuclei and cytoplasm sometimes overlapped with fibroblasts (e.g. 1 and 2) or with other 
OECs (e.g. 3). Fibroblast nuclei were usually larger than OEC nuclei and the majority were NF-
κB positive (vertical arrows in A, C and D). Two NF-κB negative fibroblast nuclei are in the 
centre of the images (long horizontal arrow in C and D). A small nucleus with intense Hoechst 
blue staining (X in C and D) and low NF-κB immunoreactivity (X in A) probably represents an 
apoptotic fibroblast. Scale bar is 50 μm. 
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Figure 4.3 Microglia CM activates astrocytes. Astrocytes were incubated for 30 minutes, 1 
hour, 2 hours or 3 hours in medium conditioned for 24 hours by astrocyte (A, B), OEC (C, D) or 
microglia cultures (E, F). Cultures were immunostained for NF-κB (A, C, E and red in B, D, F) 
and GFAP (green in B, D, F). Nuclei were counterstained with Hoechst blue (B, D, F). Only 
astrocytes incubated in microglia-conditioned medium (CM) had noticeably increased activation 
as indicated by high levels of nuclear NF-κB immunoreactivity (E, F). Scale bar is 100 μm. G: 
Quantitative analysis of astrocyte activation by CM. Incubation with microglia CM induced a 
highly significant increase in astrocyte activation within 30 minutes (p < 0.001). Although 30 
minutes and 1 hour of incubation with astrocyte CM and OEC CM induced small significant 
increases in astrocyte activation (p < 0.05) these were significantly less than the large increase in 
activation induced by microglia CM (p < 0.001). After 2 hours of incubation, astrocyte activation 
had returned to basal levels except for astrocytes incubated with microglia CM where activation 
remained significantly higher (p < 0.01) until 3 hours after the medium change. Data were 
analysed by 2-way ANOVA and post-hoc Tukey’s multiple comparison test. Percentages are 
means ± SEM, n = 12. Asterisks denote significant differences: * p < 0.05, ** p < 0.01, *** p < 
0.001. 
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4.23 OECs release soluble factors that moderate astrocyte activation  
4.23.0 OEC CM moderates astrocyte activation by PMA/ionophore 
The effects of media conditioned by OECs or microglia on astrocyte activation were then 
compared to investigate whether soluble factors released by the OECs could have 
mediated the moderation of astrocyte activation by the co-cultured OECs. Astrocyte 
cultures were incubated in OEC CM, microglia CM or DMEM for 24 hours and then 
activated with PMA/ionophore (Fig. 4.4A). The OEC- and microglia-conditioned media 
had similar effects on PMA/ionophore-induced astrocyte activation as occurred when 
astrocytes were co-cultured with these same cell types. There were significantly fewer 
astrocytes activated by PMA/ionophore for cultures incubated in OEC CM (31.3±2.5 %; 
Fig. 4.4B, C, F) than for cultures incubated in microglia CM (58.6±1.6 %; Fig. 4.4D, E, F) 
or DMEM (56.4±2.6 %; Fig. 4.4F) (p < 0.001). There was no significant difference in 
PMA/ionophore induced astrocyte activation between cultures pre-incubated 24 hours 
with microglia CM and those pre-incubated with DMEM (p > 0.05). Comparisons 
revealed that the moderating effects of OEC CM on astrocyte activation were similar to 
those resulting from co-culture of astrocytes with OECs (Figs. 4.1H, 4.4F), suggesting 
that the effects of the co-cultured OECs were mediated substantially by soluble factors 
released by the OECs.  
 
4.23.1 Soluble factors released by OECs moderate astrocyte activation by 
PMA/ionophore and microglia CM 
Results in Fig 4.3G showed that like PMA/ionophore, soluble activating factors derived 
from microglia had most effect on astrocytes within the first hour of exposure. Therefore, 
perhaps due to the rapid depletion or de-activation of the microglia-derived factors, pre-
incubation for 24 hours with microglia CM did not enhance PMA/ionophore induction of 
NF-κB translocation in astrocytes. It is also possible that PMA/ionophore and the 
microglia-derived factors exerted their effects through similar intracellular pathways and 
that the observed ~55-60 % of astrocytes activated was the maximum possible for these 
stimuli. Astrocytes proliferate and differentiate in culture and may not all be 
synchronously responsive to activating stimuli. To differentiate between these two 
alternatives and because astrocytes can be activated by multiple stimuli following CNS 
 156
injury, we wanted to determine whether soluble factors derived from OECs were able to 
moderate activation of astrocytes by microglia in both the presence and absence of 
PMA/calcium ionophore (Fig. 4.5).  OEC cultures were established on permeable 
nitrocellulose membranes that were later inserted into culture wells above astrocyte 
cultures, 24 hours prior to the cultures being treated with microglia CM, PMA/ionophore 
or simultaneously with both stimuli (Fig. 4.5A). Pre-incubation with OECs on inserts 
resulted in significant decreases from about 58% to 22% of astrocytes being activated by 
microglia CM, PMA/ionophore or simultaneously by both treatments (p<0.001) (Fig. 
4.5F). These results confirmed that a soluble factor released by OECs moderated the 
astrocyte activation induced by either PMA/ionophore or by microglia CM and that there 
was no additional activation of astrocytes when stimulation with microglia CM was 
combined with PMA/calcium ionophore. Therefore the percentage of synchronously 
activated astrocytes approximated the maximum measurable for these stimuli under the 
culture conditions. Most importantly, under all the treatment conditions tested, OECs 
were able to attenuate the activation of astrocytes. The observed small differences in the 
apparent OEC-mediated moderation of astrocyte activation could have been related to the 
different duration of exposure of astrocytes to soluble factors released by OECs and 
possible interactions between astrocytes and OECs allowed by the different treatment 
models. In the OEC/astrocyte co-cultures, astrocytes were exposed to soluble factors 
released by the OECs for several days prior to treatment and these untreated co-cultures 
had fewer activated astrocytes than any other cultures. However, following 
PMA/ionophore treatment there were significantly fewer activated astrocytes for 
astrocytes co-cultured with OECs on tissue culture inserts (Fig. 4.5F), which separated 
the two cell types by about 4mm, than for either astrocytes in direct co-culture with 
astrocytes (Fig. 4.0H) or astrocytes incubated in OEC CM  (Fig. 4.4F) ( p < 0.05).  
 
4.23.2 Combined treatment with PMA/ionophore and microglia CM activated some 
OECs 
Immunostaining of OEC cultures on inserts (Fig. 4.6) used during astrocyte treatments 
confirmed that as found previously (Fig. 4.1G, H) PMA/ionophore (Fig. 4.6C, D and, in 
addition, microglia CM (Fig. 4.6A, B) did not induce NF-κB translocation in OECs.  
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Figure 4.4 OEC CM moderates activation of astrocytes by PMA/ionophore. Astrocytes in 
DMEM and astrocytes pre-incubated in medium conditioned by OECs or microglia were 
stimulated with PMA/ionophore (A). Cultures were immunostained for NF-κB (B, D and red in C, 
E) and GFAP (green in C, E). Nuclei were counterstained with Hoechst blue (C, E). Following 
treatment with PMA/ionophore more astrocytes in microglia-conditioned medium (CM) (D, E) 
had intense nuclear NF-κB immunoreactivity than astrocytes in OEC CM (B, C). Scale bar is 100 
μm. F: Quantitative analysis of astrocyte activation after 1 hour incubation with PMA/ionophore 
in OEC CM, microglia CM or DMEM. There was significantly less astrocyte activation induced 
by PMA/ionophore in OEC CM than when in microglia CM or DMEM (p < 0.001). There was no 
significant difference in activation of astrocytes by PMA/ionophore in DMEM or microglia CM 
(p > 0.05). Data were analysed by ANOVA and post-hoc Tukey’s multiple comparison test. 
Percentages are means ± SEM, n = 24. Asterisks denote significant differences: *** p < 0.001. 
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Figure 4.5 OECs moderate astrocyte activation by incubation in microglia CM and/or 
PMA/ionophore. A: Astrocytes pre-incubated for 24 hours with OECs on inserts and astrocyte 
monocultures were treated for 1 hour with PMA/ionophore, microglia-conditioned medium (CM) 
or simultaneously with PMA/calcium ionophore and microglia CM. Astrocytes from 
monocultures (B, C) and astrocytes from co-cultures with OECs on inserts (D, E) were 
immunostained for NF-κB (B, D, and red in C, E) and GFAP (green in C, E). Nuclei were 
counterstained with Hoechst blue (C, E). Less PMA/ionophore-treated astrocytes had bright 
nuclear NF-κB immunoreactivity in the presence of OECs (D, E). Scale bar is 50 μm.  F: 
Quantitative analysis of astrocyte activation for astrocyte/OEC co-cultures and astrocyte 
monocultures. In the presence of co-cultured OECs on inserts, significantly fewer astrocytes 
(p<0.001) were activated by either separate or combined treatments with PMA/ionophore and 
microglia CM. Percentages are means ± SEM, n = 24; *** p<0.001.  
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Figure 4.6 NF-κB is not activated in OECs. OECs on inserts used for incubation with 
astrocytes cultures were immunostained for NF-κB (A, C, E and red in B, D, F), and p75NTR 
(green in B, D, F), with nuclei counterstained with Hoechst blue (B, D, F). OEC nuclei remained 
devoid of NF-κB immunoreactivity following separate treatments with microglia CM (A, B) and 
PMA/ionophore (C, D). A small percentage of OECs (4.2±1.4%, n = 12) had predominantly 
nuclear localisation of NF-κB immunoreactivity (arrow in E, F) after simultaneous treatment with 
microglia CM and PMA/ionophore. Pores in the insert membranes can be seen in some images 
(asterisks C, D). Scale bar is 50 μm.   
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Interestingly however, a small percentage (4.2±1.4%) of the co-cultured OECs on inserts 
were activated after 1 hour of the combined treatment with PMA/ionophore and 
microglia CM, as indicated by more intense nuclear than cytoplasmic NF-κB 
immunoreactivity (arrow, Fig. 4.6E, F). 
 
4.23.3 Insulin-like growth factor-1 may contribute to the moderation of astrocyte 
activation by OECs 
OECs express a number of growth factors including insulin-like growth factor-1 (IGF-1) 
(Gudino-Cabrera and Nieto-Sampedro, 2000), which has been shown to inhibit the NF-
κB dependent production of inflammatory mediators in astrocytes (Fernandez et al., 
2007a).  Immunoreactivity for IGF-1 occurred throughout the cell bodies and processes 
of the cultured OECs (Fig. 4.7 A, B).  Addition of 500ng/mL IGF-1 in the culture 
medium resulted in significant decreases (p<0.05) in the percentage of astrocytes 
activated by PMA/calcium ionophore (43.8±3.3) or microglia CM (45.0±3.0).  Therefore, 
IGF-1 is a probable component of the OEC-derived soluble factors that could contribute 
to their moderating effect on astrocyte activation. Significantly more astrocytes (p<0.01) 
were activated by both PMA/ionophore and microglia in the presence of IGF-1 (Fig. 4.7C) 
than in the presence of co-cultured OECs on inserts (Fig. 4.6F), implying that IGF-1 
alone is not sufficient to account for the moderating effect of OECs on astrocyte 
activation. 
 
4.24 OECs moderate GM-CSF transcription by activated astrocytes 
Real-time PCR was used to compare transcription of mRNA for the NF-κB-dependent 
pro-inflammatory cytokine, GM-CSF, in astrocytes incubated for 4, 8, 12, 18 and 24 
hours with PMA/ionophore in OEC CM, microglia CM or unconditioned medium 
(DMEM), to determine whether the moderation of astrocyte activation by OECs was 
associated with decreased GM-CSF production (Fig. 4.8). GM-CSF mRNA transcripts 
increased for 8 hours of PMA/ionophore treatment in astrocytes cultured in OEC CM or 
DMEM to a maximum (~5 fold) that was significantly less than for astrocytes in 
microglia CM (~7 fold; p < 0.05) where transcripts continued to increase until 12 hours 
(Fig. 4.8). GM-CSF transcripts had decreased substantially for astrocytes in OEC CM by  
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Figure 4.7 IGF-1 moderates astrocyte activation. A: Immunoreactivity for insulin-like growth 
factor-1 (IGF-1) occurs in the perikaryon and processes of OECs. B: Merged immunoreactivity 
image shows IGF-1 (red), p75NTR to identify OECs and Hoechst blue nuclear counterstaining. 
Scale bar is 50 μm. C: Astrocyte activation was compared, with and without the addition of 
500ng/mL IGF-1, for astrocytes in DMEM and astrocytes incubated for 1h with PMA/ionophore 
or microglia CM. Addition of IGF-1 resulted in significantly fewer astrocytes (p<0.05) being 
activated by incubation with either PMA/ionophore or microglia CM. Percentages are means ± 
SEM, n = 18; * p<0.05. 
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Figure 4.8 Quantitative real time PCR comparison of GM-CSF mRNA transcription in 
response to PMA/ionophore for astrocytes cultured in OEC CM, microglia CM or DMEM. 
Data were graphed as GM-CSF mRNA copies relative to copies of GAPDH mRNA for each 
sample. PMA/ionophore induced significant increases in GM-CSF transcription to a  maximum at 
8h (p < 0.001) for astrocytes in OEC CM or DMEM, while for astrocytes in microglia CM there 
was a further increase in GM-CSF transcription to significantly higher levels at 12 hours (p < 
0.05). After 18-24 hours of incubation, GM-CSF transcription in astrocytes cultured in OEC CM 
had diminished to significantly lower levels than for astrocytes in microglia CM (p < 0.001) or 
DMEM (p < 0.01). Data were analysed by 2-way ANOVA and post-hoc Tukey’s multiple 
comparison test. Results are means ± SEM, n = 3. Asterisks denote significant differences: * p < 
0.05, ** p < 0.01, *** p < 0.001. 
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Figure 4.9 C-Rel immunoreactivity in astrocytes and OECs. Untreated astrocytes (A, B) 
and astrocytes stimulated with microglia CM for 1 hour (C, D) or PMA/ionophore for 1 hour 
(E, F) or 24 hours (G, H) were immunostained for c-Rel NF-κB (red in A-H) and GFAP 
(green in B, D, F, H), with nuclei counter-stained with Hoechst blue (A-L). OECs on inserts 
used for co-culture with astrocytes during stimulation with microglia CM (I, J) and 
PMA/ionophore (K, L) were immunostained for c-Rel (red in I-L) and p75NTR (green in J, L). 
C-Rel immunoreactivity was of low intensity and predominantly cytoplasmic in astrocytes 
and OECs under all conditions. Note: c-Rel immunoreactivity was imaged at ~4x the 
exposures used for imaging p65 NF-κB immunoreactivity in astrocytes. Scale bar is 50 μm. 
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the later time-points of 18 and 24 hours of treatment and were significantly less than for 
astrocytes in microglia CM (p < 0.001) or DMEM (p < 0.01). After 24 hours of treatment 
GM-CSF transcripts for astrocytes in OEC CM were not significantly different from 
untreated astrocytes whereas GM-CSF transcripts remained significantly elevated for 
astrocytes in microglia CM (p < 0.001) or DMEM (p < 0.01). There were also 
significantly more transcripts for astrocytes in microglia CM than in DMEM at 18 and 24 
hours (p < 0.05). 
 
4.25 Astrocyte activation by PMA/ionophore or microglia did not involve c-Rel 
Full activation of the GM-CSF gene in T-cells requires translocation to nuclei of both the 
c-Rel and p65 NF-κB isoforms (Brettingham-Moore et al., 2005a). Immunoreactivity for 
c-Rel was only observed at very low levels in the cultured astrocytes and occurred 
predominantly in the cytoplasm (Fig. 4.9). The intensity and distribution of c-Rel 
immunoreactivity was not altered following 1 hour of incubation with microglia CM (Fig. 
4.9C, D) or PMA/ionophore (Fig,. 4.9E, F), or 24 hours incubation with PMA/ionophore 
(Fig. 4.9G, H).  Combining these stimuli with co-cultured OECs on inserts or IGF-1 also 
had no effect on c-Rel immunoreactivity in astrocytes (data not shown). C-Rel 
immunoreactivity in the OECs on inserts used for co-culture experiments was also of low 
intensity and unaffected by treatments (Fig. 4.9I-L).  
 
4.26 Microglial activation of NF-κB and pre-conditioning of astrocyte cultures 
The activation of astrocytes by microglia implied that, if not already activated during 
dissection and trypsinisation, astrocytes would become activated during the preparation 
of the cortical cultures due to the presence of microglia in the un-purified cultures. 
Immunostaining of the un-purified cortical cultures for NF-κB confirmed that strong 
activation of astrocytes, progenitor cells, microglia and fibroblasts occurred in these 
cultures (Fig. 4.10), possibly implying that the later responses to activating stimuli were 
more representative of astrocytes that have been pre-conditioned to injury than astrocytes 
in normal adult cortical tissue. However, it is uncertain whether any such pre-
conditioning effect would persist through the later passaging and within the purified 
astrocyte monocultures. Although the cultured cortical astrocytes do have strong GFAP  
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Figure 4.10 Inflammatory activation during cortical cell culture. A: Nuclear 
immunoreactivity for NF-κB (red) indicates that the majority of cells are 
activated in primary cortical cell cultures. Mature astrocytes have networks of 
cytoplasmic GFAP (green) while immature astrocytes (arrows) have thin radial 
GFAP-positive processes. The morphology revealed by cytoplasmic NF-κB 
immunoreactivity sometimes identified GFAP-negative cells as microglia 
(asterisks) or progenitor cells (plus signs). GFAP-negative cells with larger 
nuclei are probably fibroblasts. B: Ionized calcium binding adapter molecule 1 
(Iba1) immunoreactivity (red; pink nuclei) identifies numerous activated 
microglia (Ito et al, 1998) in the cortical cultures. Counter-staining of nuclei with 
Hoechst blue (HB) identifies Iba1-negative cells, comprising astrocytes, 
progenitors and fibroblasts. Scale bar is 50μm. 
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immunoreactivity that is more similar to reactive astrocytes than adult cortical astrocytes 
in vivo this could be due to the absence of the usual cellular interactions and the different 
mode of cell-substrate attachment in vitro, rather than being an indication of astrocyte 
inflammation. However, the quiescence of astrocytes in the untreated cultures is not 
inconsistent with the possibility of earlier pre-conditioning, because transient NF-κB 
activation can directly and indirectly activate gene transcription that leads to permanently 
altered phenotypes. Pre-conditioning can confer resistance to later inflammatory 
stimulation due to the upregulation of anti-inflammatory factors in response to a 
moderate pre-conditioning stimulus (Ginis et al., 2002; Bright and Mochly-Rosen, 2005; 
Lehotsky et al., 2009; Lu et al., 2009; Ridder and Schwaninger, 2009). This response acts, 
at least in part, as a negative feedback mechanism to limit inflammatory activation and 
includes the upregulation of IκB proteins that bind and inactivate NF-κB dimers.  
 
4.3 Discussion 
4.30 OECs release a soluble factor that moderated astrocyte inflammatory activation  
The regulation of inflammatory genes in astrocytes, microglia and fibroblasts by NF-κB 
is a key determinant of CNS injury responses (Baeuerle and Henkel, 1994; Schneider et 
al., 1999; Kracht and Saklatvala, 2002; Chen and Greene, 2004b). PMA/ionophore 
stimulation appeared to be a relevant treatment model for investigating these 
inflammatory responses since it strongly induced translocation of NF-κB to nuclei of 
astrocytes, microglia and meningeal fibroblasts and increased astrocytic transcription of 
the pro-inflammatory cytokine, GM-CSF. Interestingly, PMA/ionophore did not appear 
to induce NF-κB translocation in OECs and this may have implications for the efficacy of 
OECs in CNS injury therapy. Importantly, a soluble factor released by OECs moderated 
both the NF-κB translocation and GM-CSF transcription components of astrocyte 
activation. PMA/ionophore and soluble factors released by microglia stimulated NF-κB 
translocation in a similar manner in astrocytes and OECs moderated the translocation 
induced by either stimulus. Furthermore, prior to PMA/ionophore treatment, astrocytes 
co-cultured with OECs remained quiescent while monocultures and co-cultures with 
microglia and fibroblasts had significantly more astrocytes exhibiting predominantly 
nuclear localisation of NF-κB. This moderation of astrocyte reactivity represents a 
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possible mechanism whereby transplanted OECs could facilitate neural repair after CNS 
injury. The mediation of these potentially beneficial effects by a soluble factor released 
from OECs is of particular relevance to the therapeutic potential of OEC transplants. If 
the therapeutic effects are principally mediated by a soluble factor then debate concerning 
the migratory capacity of transplanted OECs within the injured CNS (Ramon-Cueto et al., 
1998; Ramon-Cueto et al., 2000; Resnick et al., 2003, Ruitenberg et al., 2002; Lu et al., 
2006) may be less relevant. A soluble anti-inflammatory factor released by the 
transplanted OECs could potentially ameliorate injury responses at a distance from the 
transplant site, dependent on the concentration gradient generated and the distance the 
soluble factor could diffuse before inactivation in vivo. Furthermore the release of anti-
inflammatory factors by transplanted OECs near the lesion could avoid the systemic 
immune suppression problems associated with intravenous methylprednisolone treatment 
(Bracken and Holford, 2002; Kronvall et al., 2005; Sorensen, 2008). Isolation of the 
relevant soluble factors released by the OECs would assist research into these 
possibilities. 
 
4.31 Restriction of NF-κB activation in OECs may confer therapeutic benefits 
4.31.0 OEC activation and innate immunity 
Surprisingly, OECs, unlike astrocytes, microglia and fibroblasts were not activated by 
PMA/ionophore or microglia-conditioned medium. Although this result was unexpected 
it suggests the possibility that OECs transplanted into CNS lesions may at least remain 
inactivated and not have pro-inflammatory actions. It may be that the soluble anti-
inflammatory factor released by OECs that ameliorated inflammatory NF-κB 
translocation in astrocytes had the even stronger effect of eliminating NF-κB 
translocation in the OECs. This could be a consequence of stoichiometric factors such as 
the diffusion rate of the soluble factor or its intracellular rate of inactivation. OECs may 
also have high constitutive expression levels of IκBs, the primary negative regulators of 
NF-κB, which could explain the lack of response to a variety of stimuli, possibly 
including multiple inflammatory cytokines in the microglia-conditioned media. Another 
possible explanation is that OECs exert additional paracrine or contact-mediated anti-
inflammatory effects on adjoining cells in confluent cultures. Similar mechanisms could 
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serve to maintain a supportive environment for neuronal survival within OEC 
ensheathments in the olfactory tract. OECs do express fractalkine, which could have 
imparted a contact-dependent component to the anti-inflammatory activity (Ruitenberg et 
al., 2008), since it is a membrane-bound chemokine that has been shown to exert 
neuroprotective anti-inflammatory effects (Cardona et al., 2006; Held-Feindt et al., 2010; 
Lauro et al., 2010). Although PMA/ionophore stimulation of OECs has not previously 
been studied, Escherichia coli (E. coli) induced NF-κB translocation to nuclei in a subset 
of p75NTR-positive OECs in cultures derived from peripheral olfactory mucosal and CNS 
olfactory bulb tissue (Vincent et al., 2007). Bacterial activation of OECs has been 
associated with nitric oxide production, inflammatory cytokine secretion, toll-like 
receptor (TLR) expression and phagocytic behaviour, supporting a postulated innate 
immune function of OECs that could prevent the spread of infections along the peripheral 
olfactory tract into the CNS (Vincent et al., 2007; Harris, 2008; Leung et al., 2008; Harris 
et al., 2009). The constitutive periodic replacement of olfactory neurons throughout life 
and the acceleration of this replacement following pathogenic invasion provides a 
primary defence mechanism against pathogenic invasion of the CNS through the 
olfactory tract (Carr and Farbman, 1993; Bauer et al., 2003; Chen et al., 2005a; Borders 
et al., 2007a; Leung et al., 2007). TLR activation can induce innate immune responses of 
variable intensity within the CNS, involving interactions between complement cascades, 
reactive oxygen species, NF-κB activation, chemokines expression and the recruitment of 
leukocytes and activation of macrophages (Lee and Lee, 2002; Akira and Sato, 2003; 
Konat et al., 2006; Frangogiannis, 2007). The absence of NF-κB translocation in OECs 
following PMA/ionophore treatment in this study allows the possibility that OECs could 
have evolved a specific moderate innate immune response to pathogens. Moderate 
inflammatory responses have been associated with increased expression of growth factors 
that promote axon growth (Lenzlinger et al., 2001; Laird et al., 2008). A moderate 
inflammatory response by OECs in response to residual pathogens could both stimulate 
axon regrowth from regenerating olfactory neurons (Borders et al., 2007b) and provide an 
additional targeted defence against pathogens being carried into the CNS by the 
regrowing axons.  
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4.31.2 Toll-like receptors and innate immunity 
The unresponsiveness of OECs to PMA/ionophore is not inconsistent with a role in 
innate immune responses involving TLR activation by pathogens. Unlike 
PMA/ionophore treatment, TLR stimulation of inflammatory gene expression via NF-κB 
activation does not involve PKC- and calcium-dependent intracellular signalling 
pathways (Lee and Lee, 2002; Akira and Sato, 2003; Takeda et al., 2003; Konat et al., 
2006). TLRs are expressed by most cells including astrocytes, microglia, 
oligodendrocytes and neurons and they play an important role in CNS innate and 
adaptive immune responses to pathogens and injury (Lee and Lee, 2002; Bowman et al., 
2003; Janssens and Beyaert, 2003; Carpentier et al., 2005; Konat et al., 2006; Hanisch et 
al., 2008). TLRs are responsive to bacteria and viruses and their activation induces 
increased expression of IL-1β, TNF-α, IFN-γ, IL-6 and other inflammatory cytokines and 
chemokines (Bsibsi et al., 2002; Lee and Lee, 2002; Konat et al., 2006; Hanisch et al., 
2008), which can then induce immune and glial cell differentiation leading to adaptive 
immune responses (Carpentier et al., 2005; Town et al., 2005; Glezer et al., 2007; 
Voskuhl et al., 2009). Pre-conditioning of astrocytes through activation of NF-κB by 
TNF-α or bacterial lipopolysaccharide (LPS) stimulation of TLRs can result in 
neuroprotective tolerance to ischemia and the pre-conditioning with TNF-α induces 
tolerance to subsequent LPS exposure (Phulwani et al., 2008). However, TLR activation 
has also been associated with chronic immune activation and neurodegeneration 
(Maslinska et al., 2004; Chakravarty and Herkenham, 2005; Lehnardt et al., 2008). It is 
conceivable that TLR activation in transplanted OECs could also induce a tolerance to 
ischemia. Whether this would be more beneficial than TLR activation in resident 
astrocytes and microglia could depend on the timing of OEC transplantation and the 
inflammatory conditions in the lesion. It would therefore be interesting to extend this 
research to compare the effects of OECs on PMA/ionophore and bacterial stimulation of 
NF-κB translocation in astrocytes. 
 
4.31.1 OEC cultural differences 
It is also possible that NF-κB is less readily activated in the CNS olfactory bulb OECs 
used in this study than in peripheral mucosal OECs. Robust immune responses can cause 
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detrimental secondary neuronal damage within the CNS and perhaps for this reason, 
olfactory bulb OECs are not readily activated by either E. coli or PMA/ionophore.  The 
subset of OECs where NF-κB was activated in the previous study (Vincent et al, 2007) 
may have represented the mucosal OECs in the mixed mucosal and bulbar OEC cultures. 
However, select groups of OECs along specific olfactory nerve tracts from the lamina 
propria into the outer layers of the olfactory nerve layer in the olfactory bulb express 
TLR4, which is activated by gram-negative bacteria (Vincent et al, 2007). It is also 
possible that the subset of activated cells in these cultures were contaminating Schwann 
cells since these occur in the peripheral olfactory tract, express p75NTR and have similar 
morphologies to OECs. It would therefore be interesting to compare the responses to 
bacterial and PMA/ionophore stimulation of separate cultures of lamina propria OECs, 
olfactory bulb OECs and Schwann cells. Functional differences have been reported 
between peripheral and CNS OECs used in transplants (Kumar et al., 2005; Richter et al., 
2005), although these differences may primarily have been due to different proportions of 
contaminating fibroblasts in the cultures (Lakatos et al., 2003b; Kumar et al., 2005; 
Ibanez et al., 2007; Teng et al., 2008). The fascicles of olfactory sensory axons and their 
surrounding OECs are enclosed by basal laminae and overlying fibroblasts along the 
trajectories of the nerve fascicles through the peripheral olfactory system to the olfactory 
bulb where the fibroblasts separate from the fascicles to form a meningeal glia limitans 
around the bulb (Boyd et al., 2003; Li et al., 2005b). Fibroblasts are therefore a common 
contaminating cell in OEC cultures (Ito et al., 2006a), with the propensity to proliferate 
more rapidly than OECs (Gibbons et al., 2007). Hence, it is essential that behaviours 
ascribed to OECs be correlated with positive identification using a distinguishing marker 
protein to identify OECs as demonstrated in this study, where PMA/ionophore activated 
contaminating p75NTR-negative fibroblasts and not p75NTR-positive OECs.  
 
4.31.2 Are multiple stimuli required for OEC activation? 
Rather than peripheral and CNS OECs representing different cell populations, it may be 
that any immune function of OECs specifically targets invasive pathogens. Co-culture 
with microglia significantly enhanced the activation of OECs by E. coli, presumably due 
to the release of inflammatory cytokines resulting from simultaneous activation of the co-
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cultured microglia by E. coli (Vincent et al, 2007). It was therefore interesting, in this 
study, that although OECs were not activated by separate stimulation with 
PMA/ionophore or microglia-conditioned medium, a small percentage of the OECs on 
culture inserts were activated by simultaneous application of these stimuli. TNF-α 
promotes oligodendrocyte apoptosis in multiple sclerosis (Penkowa and Hidalgo, 2001; 
Espejo et al., 2002) by strongly activating NF-κB via oligodendrial p75NTR (Ladiwala et 
al., 1998). TNF-α released by activated microglia could induce NF-κB translocation in 
OECs by a similar mechanism. Bacteria could activate OECs both directly and through 
stimulation of TNF-α release by microglia. In this study, astrocytes were activated by 
microglia-conditioned medium possibly due to the presence of IL-1β or other cytokines 
released by the microglia, to which OECs may have been unresponsive. If OECs were 
insensitive to these inflammatory cytokines it could confer benefits for OEC transplant 
therapies. This possibility warrants a thorough investigation of the effects of IL-1β, TNF-
α and other pro-inflammatory factors on NF-κB translocation and the expression of anti-
inflammatory factors by OECs. The anti-inflammatory actions of OECs that were 
identified in this study through their moderating effects on astrocyte activation could also 
have direct neuroprotective effects both in the context of OEC transplant therapy for CNS 
injury and during the normal development and regeneration of olfactory neurons. 
 
4.32 Microglia and PMA/ionophore similarly activated astrocytes  
Microglia in monocultures had a high basal level of activation in the culture conditions 
consistent with their postulated surveillance role in normal CNS tissue and rapid 
inflammatory responses to a variety of abnormal extracellular conditions. Presumably 
and not surprisingly, conditions in the cell cultures were sufficiently abnormal to induce 
the observed microglial activation. Consequently, culture medium conditioned by 
microglia or co-culture with microglia rapidly activated astrocytes, probably because of 
pro-inflammatory cytokines secreted by the activated microglia. This similarity of 
astrocyte activation by PMA/ionophore and microglia further substantiated the 
physiological relevance of the reagent treatment. Activated microglia are known to 
secrete IL-1β, IL-6, TNF-α and other pro-inflammatory cytokines, which stimulate 
further activation of NF-κB in astrocytes and immune cells, thereby increasing the 
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amplitude and duration of inflammation (Yamamoto and Gaynor, 2001; Saklatvala, 2007; 
Block et al, 2007). Astrocyte activation was significantly lower in untreated 
astrocyte/microglia co-cultures than in astrocyte monocultures after 1 hour of incubation 
in microglia-conditioned medium, possibly because, in the several days prior to reagent 
treatment, astrocytes in the co-cultures could have released factors that inhibited 
activation of microglia (Wilms et al, 1997; Schilling et al, 2001) in the unstimulated co-
cultures. Furthermore, PMA/ionophore directly increased NF-κB translocation to nuclei 
in both astrocytes and microglia, presumably leading to increased expression of pro-
inflammatory factors by both microglia and astrocytes in the co-cultures. 
 
4.33 OECs could moderate astrocyte activation induced by multiple stimuli  
Following CNS injury, NF-κB-regulated astrocyte inflammation can be induced directly 
by factors such as glutamate (Abe and Saito, 2001; Matute et al., 2006) and ATP (Neary 
and Kang, 2005; Weisman et al., 2005; Chen et al., 2006b) released from damaged cells, 
or indirectly in response to cytokines, such as IL-1β and TNF-α, secreted by activated 
microglia and other immune cells (Norris et al., 1994; Meeuwsen et al., 2003a; 
Brahmachari et al., 2006; Kim et al., 2006). Importantly, in addition to being 
unresponsive to PMA/calcium ionophore, OECs substantially moderated astrocyte 
activation whether induced by PMA/calcium ionophore and/or microglia-derived factors. 
This represents a plausible mechanism for the promotion of neural repair by OEC 
transplants since astrocyte-specific NF-κB inhibition results in decreased axonal damage, 
smaller lesion size, decreased inhibitory CSPG deposition in glial scars and improved 
functional recovery after spinal cord injury (Brambilla et al., 2005a).  
 
4.34 Insulin-like growth factor-1 may have contributed to the moderation of astrocyte 
activation 
Astrocyte activation was similarly moderated by direct co-culture with OECs, co-culture 
with OECs separated by tissue culture inserts or incubation in culture medium 
conditioned by OECs, indicating that the moderating effect was due to a soluble factor 
released by the OECs. There are many soluble cellular products in the CNS, including N-
acetyl aspartate (Rael et al., 2004b), proliferation-related acidic leucine-rich protein 
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(Shen et al., 2009), IL-10 (Cheng et al., 2009), insulin-like growth factor-1 (IGF-1) 
(Butovsky et al., 2005), prostaglandins (Zhang et al., 2008) and glucocorticoids (Sorrells 
and Sapolsky, 2007), with NF-κB-inhibiting and anti-inflammatory actions. IGF-1 is one 
possible candidate for mediating the moderating effect of OECs on NF-κB translocation, 
since it is a secreted soluble factor expressed by OECs (Gudino-Cabrera and Nieto-
Sampedro, 2000; Rojas-Mayorquín et al., 2010) and it has been shown to inhibit the NF-
κB-dependent production of the inflammatory mediators, inducible nitric oxide synthase 
and cyclo-oxygenase in astrocytes (Fernandez et al., 2007a). IGF-1 exerts 
neuroprotective effects in both white and gray matter under different detrimental 
conditions, including ischemic stroke (Guan and Gluckman, 2009; Kooijman et al., 2009). 
The anti-inflammatory action of IGF-1 is highly relevant to this study since it has been 
shown to prevent the translocation of NF-κB to astrocyte nuclei by inhibiting the 
degradation of IκB induced by TNF-α (Pons and Torres-Aleman, 2000). In addition, 
IGF-1 promotes the differentiation of neuronal precursors into olfactory sensory neurons 
(Mason et al., 2003) and OEC-conditioned medium induced increased expression of IGF-
binding protein in neural precursor cells (Rojas-Mayorquin et al., 2008). This research 
confirmed the expression of IGF-1 by OECs and indicated that while IGF-1 may be a 
contributing factor, it was insufficient to account in full for the inhibition of NF-κB 
translocation in astrocytes by the OEC-derived soluble factors. It is not improbable that 
multiple factors released by OECs could differentially regulate NF-κB by interacting with 
different molecules in the inflammatory pathway. Identification of these factors and their 
specific roles could allow anti-inflammatory therapies targeted at specific molecules. The 
involvement of IGF-1 or other soluble factors released by OECs in the moderation of 
astrocyte activation could be further investigated using transgenic knockout or gene 
knockdown models, by blocking the effects of soluble factors with specific reagents or 
with antibodies against the soluble factors and their specific receptors. Commercially 
available cytokine and growth factor assays or micro-arrays could be used to screen for 
possible mediating factors by comparing the expression profiles of cells and medium 
from unstimulated and PMA/ionophore-stimulated astrocyte and OEC mono- and co-
cultures.  
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4.35 OECs did not eliminate astrocyte activation 
4.35.0 Moderate activation of astrocytes has beneficial effects 
OECs moderated, but did not eliminate, NF-κB-mediated astrocyte activation and this 
may present an advantage for neural repair. Drastic suppression of astrocytic activation 
leading to abolition of astrogliosis has been associated with increased neural damage 
(Bush et al., 1999; Faulkner et al., 2004). Although presenting barriers to axon regrowth, 
glial scars may also serve to protect perilesional tissue from the cytotoxic conditions 
ensuing from strong immune responses in the lesion (Sofroniew, 2005; Fitch and Silver, 
2008; Sofroniew, 2008; Voskuhl et al., 2009). Similarly, while reactive astrocytes and 
fibroblasts may inhibit axon regrowth by depositing CSPGs and interacting to form basal 
laminae at glial scars, they also secrete neurotrophic factors (Meeuwsen et al., 2003b; 
Laird et al., 2008). Moderation of astrocyte activation by transplanted OECs could 
therefore inhibit CSPG deposition and basal laminae formation to improve the axon 
growth-permissiveness of the glial scar while maintaining and contributing (Woodhall et 
al., 2001) to neurotrophin production.  
 
4.35.1 OEC moderation of astrocyte activation could prevent excessive cytokine and ROS 
production  
A previous study has suggested that transplanted OECs may have a biphasic effect, 
initially promoting and later inhibiting inflammatory responses (Lopez-Vales et al., 2004). 
This biphasic effect could be related to a requirement for specific pathogens or microglia-
derived cytokines to induce the inflammatory activation of OECs. High levels of TNF-α 
and IL-1β can have neurotoxic consequences while at lower levels both cytokines can 
also exert neuroprotective and neurotrophic effects (Feuerstein et al., 1994; John et al., 
2005; Gosselin and Rivest, 2007; Lambertsen et al., 2009; Whitney et al., 2009). 
Microglia are a major source of TNF-α (Meme et al., 2006; Clausen et al., 2008; Kaushal 
and Schlichter, 2008; Tuttolomondo et al., 2008; Lambertsen et al., 2009) and astrocytic 
NF-κB inhibition did not alter levels of this cytokine (Brambilla et al, 2005). However, 
IL-1β is another key cytokine regulating CNS injury responses (John et al, 2005) and 
OEC transplantation into injured spinal cords was associated with initial increases and 
later decreases in the post-injury levels of IL-1β, iNOS and astrocyte activation (Lopez-
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Vales et al, 2004). Although OEC survival was not monitored after transplantation, the 
transplanted OECs could possibly have limited lesion size and the spread of secondary 
damage by at first contributing to strong acute immune responses initiated by microglia 
in the lesion and later moderating the inflammatory responses of perilesional reactive 
astrocytes. OEC moderation of astrocyte activation could also have the therapeutic effect 
of inhibiting the production of cytotoxic ROS. Both PMA activation of PKC and calcium 
influx induced by ionophore or ATP activated NF-κB-dependent generation of ROS by 
NADPH oxidase in cultured astrocytes (Abramov et al., 2005). If not detoxified by 
superoxide dismutase, excess superoxide generated by NADPH oxidase may combine 
with NO generated by iNOS to generate highly cytotoxic peroxynitrite (Forman and 
Torres, 2001). Moderation of astrocyte activation by transplanted OECs could therefore 
enhance neuronal survival and axon regrowth by moderating peroxynitrite production in 
perilesional reactive astrocytes, following resolution of the initial acute immune cell 
response.  
 
4.36 Meningeal fibroblasts did not moderate astrocyte activation  
In this study, co-culture with OECs inhibited activation of astrocytes, supporting the 
notion that interactions between astrocytes and transplanted OECs may prevent the 
development of axon growth-inhibitory boundaries as occurs in response to invading 
meningeal fibroblasts (Teng et al, 2008) or transplanted Schwann cells (Fairless et al, 
2004; Nieto-Sampedro, 2003). In addition, while PMA/ionophore strongly activated 
meningeal fibroblasts, co-culture of astrocytes with fibroblasts did not alter 
PMA/ionophore-induced activation of astrocytes. The similarity of PMA/ionophore-
induced astrocyte and fibroblast activation is consistent with the interaction between 
reactive astrocytes and activated meningeal fibroblasts that leads to the formation of axon 
growth-inhibitory basal laminae in the glial scar (Logan et al., 1999; Bundesen et al., 
2003; Sandvig et al., 2004). However, some studies have indicated that OEC/fibroblast 
co-cultures are more beneficial than OEC monocultures as therapeutic transplants after 
CNS injury, possibly because the fibroblasts promote the migration of OECs to form 
axon-growth permissive conduits across lesions (Li et al., 2005b; Teng et al., 2008). 
Alternatively, fibroblasts could promote the migration of peripheral Schwann cells into 
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lesions, leading to the promotion of axon-growth and remyelination (Lakatos et al., 
2003b; Boyd et al., 2004). Testing the effects of OECs on NF-κB translocation and 
inflammatory gene transcription in fibroblasts using the experimental model employed in 
this study could shed further light on interactions between fibroblasts and therapeutically 
transplanted OECs. 
 
4.37 OECs moderated pro- inflammatory GM-CSF transcription in astrocytes 
4.37.0 PMA/ionophore stimulated GM-CSF transcription in astrocytes  
Although increases in nuclear levels of NF-κB are associated with increased production 
of pro-inflammatory cytokines and more severe inflammation, it remained uncertain 
whether the significant moderation of NF-κB translocation to astrocyte nuclei by OECs 
had functional significance. The PMA/ionophore-induced astrocytic NF-κB translocation 
was associated with increased transcription of the pro-inflammatory cytokine, GM-CSF, 
as found in T cells (Schreck and Baeuerle, 1990; Brettingham-Moore et al., 2005a), 
where the increased transcription has been conclusively demonstrated to involve 
translocation to nuclei and DNA-binding of p65 NF-κB (Schreck and Baeuerle, 1990; 
Tsuboi et al., 1994; Holloway et al., 2003; Brettingham-Moore et al., 2008). There was 
only a transient peak in NF-κB transcription that occurred from 30 minutes to 1 hour after 
stimulation of astrocytes with PMA/ionophore whereas GM-CSF transcription was not 
significantly activated until 4 to 8 hours after stimulation, by which time NF-κB was 
inactive. However, this delay between NF-κB translocation and gene transcription is not 
unusual (Hoffman et al., 2002; Holloway et al., 2003; Brettingham-Moore et al., 2008). 
Even transient NF-κB activation for 15 to 30 minutes following stimulation by a brief 
pulse of the inflammatory cytokine, TNF-α, has been demonstrated to induce increased 
transcription of the chemokines, RANTES and IP-10, 4 to 8 hours later (Hoffman et al., 
2002). The 5- to 7-fold increase in astrocytes was not as dramatic as that induced by 
PMA/calcium ionophore (~200-fold) in T cells (Brettingham-Moore et al., 2005b). 
However, the abundance and location of astrocytes in the injury penumbra, facilitates 
their major contribution to the inflammatory mediators at CNS lesions (Swanson et al., 
2004; Panickar and Norenberg, 2005) including GM-CSF, which regulates the 
proliferation and immune activation of microglia (Xiao et al., 2002; Koguchi et al., 2003).  
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4.37.1 The comparative activating effects of ionophore and PMA differ between 
astrocytes and lymphocytes   
In T cells, PMA alone induced GM-CSF transcription more strongly (20-fold) than 
ionophore alone (~4-fold), with the increased transcription in response to both reagents 
being dependent on PKC. Only PMA induced translocation of NF-κB to nuclei in T cells, 
whereas ionophore induced calcineurin-dependent translocation of NFAT (Brettingham-
Moore et al., 2005a). Although the separate effects of PMA and ionophore on GM-CSF 
transcription were not investigated in this study, ionophore alone induced NF-κB 
translocation to astrocyte nuclei more strongly than PMA alone. Interestingly, the 4-fold 
increase in T cell GM-CSF transcription induced by ionophore was just below the 5 to 7-
fold range of the increase in GM-CSF transcription induced by combined 
PMA/ionophore in astrocytes, where PMA had only a relatively small effect on NF-κB 
translocation. There are differences in NF-κB activity between immune cells involved in 
adaptive and innate immune responses (Baeuerle and Henkel, 1994) and it would be 
interesting to investigate whether the divergent responses of T cells and astrocytes to 
PMA/calcium ionophore are more generally indicative of differences in the activation of 
immune and non-immune cells. 
 
4.37.2 C-Rel was not involved in GM-CSF transcription in astrocytes  
The large synergistic increase in GM-CSF transcription induced 4-6 hours after 
PMA/ionophore treatment in T cells was associated with chromatin remodelling to 
improve access of transcription machinery to the gene promoter region (Brettingham-
Moore et al, 2005). The chromatin remodelling was dependent on de novo synthesis and 
translocation of c-Rel NF-κB and to a lesser extent, NFATc, to T cell nuclei, following 
the earlier translocation of p65 NF-κB. The weak immunoreactivity for c-Rel in 
astrocytes under all treatment conditions suggested that it was probably not involved in 
the activation of astrocytes by PMA/ionophore or microglia. However, this result requires 
confirmation with immunostaining and ideally CHIP assays at the later time-points of 4 
to 8 hours after treatments, when transcription peaked in lymphocytes. The absence of c-
 181
Rel activity may explain the short duration of the activation mediated by p65 NF-κB and 
the relatively modest increase in GM-CSF transcription in astrocytes. 
 
4.37.3 Moderation of GM-CSF production by OECs could attenuate inflammation  
Importantly, the moderation of PMA/ionophore-induced NF-κB translocation to astrocyte 
nuclei by soluble factors released from OECs was accompanied by significantly 
moderated GM-CSF transcription in the cultured astrocytes. This result was consistent 
with the view that OEC transplants could act to moderate the severity and duration of 
inflammation, since high levels of GM-CSF have been associated with more severe 
inflammation and cytotoxic levels of pro-inflammatory cytokines and ROS (Zaheer et al., 
2007). The NF-κB-regulated cytokines and ROS can also stimulate further NF-κB 
activation in astrocytes and immune cells to exacerbate and prolong inflammation 
(Pawate et al., 2004; Jia-Yi et al., 2006; Ridder and Schwaninger, 2009). While NF-κB 
translocation is necessary for robust inflammatory responses, full activation of 
inflammatory genes also requires the recruitment of co-activators and may involve 
interactions between NF-κB subunits, inhibitor of κB proteins, inflammatory gene 
products and other signalling pathways (Baeuerle and Henkel, 1994; Chen and Greene, 
2004; Hayden and Ghosh, 2004). The lower peak in astrocytic GM-CSF transcription at 
8-12 hours after stimulation in OEC-conditioned medium compared to microglia-
conditioned medium and the attenuation of transcription at later time-points in 
comparison with both microglia-conditioned medium and unconditioned medium was 
consistent with OECs having ameliorated a sustained increase in GM-CSF transcription 
that has been associated with the recruitment of co-activators to the gene promoter region 
in T cells (Brettingham-Moore et al., 2005a). GM-CSF transcription was significantly 
elevated from 12 to 24 hours for astrocytes exposed to microglia-conditioned medium 
compared to astrocytes in OEC-conditioned or unconditioned medium. This suggested 
that cytokines or other factors released by microglia may have had an additional effect on 
transcription through a pathway independent of NF-κB, since microglia did not have a 
measurable additive effect on PMA/ionophore stimulation of NF-κB translocation. 
However, there may have been a stronger mean activation of NF-κB in individual 
astrocytes, not detectable as a difference in the percentage of activated astrocytes, which 
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led to the stronger and more sustained effects of PMA/ionophore on transcription in 
microglia-conditioned medium. 
 
4.38 Were the cultured astrocytes pre-conditioned to injury? 
A variety of pre-conditioning treatments have been shown to moderate inflammatory 
responses and tissue damage to subsequent CNS injuries (Liu et al., 2000; Carmel et al., 
2004; Drozdz et al., 2006; Ambros et al., 2007; Bigdeli et al., 2009; Lehotsky et al., 2009) 
and the tolerance to ischemia is dependent on PKC and NF-κB activation during the pre-
conditioning in many treatment models (Ginis et al., 2002; Bright and Mochly-Rosen, 
2005; Lu et al., 2009; Ridder and Schwaninger, 2009). The Chapter 4 results show that 
the cultured astrocytes in this research were activated in the presence of co-cultured 
microglia and by soluble factors that microglia released into conditioned medium. 
Astrocytes were found to be similarly activated in the presence of activated microglia in 
the unpurified cortical cultures during the preparation of cultures for later 
experimentation. Even changes of media were demonstrated to significantly activate 
astrocytes and activation of immediate early genes in response to media changes has been 
previously demonstrated in epithelial cells (Yang et al., 2006). Consequently, cultured 
astrocytes may represent a pre-conditioned cell population that are resistant to further 
inflammatory activation except in response to strong stimuli, such as PMA and ionophore. 
Pre-conditioning could explain why there was only relatively modest upregulation of the 
cytokine, GM-CSF, associated with the PMA/ionophore stimulation of NF-κB in the 
cultured astrocytes. Unlike mature cortical astrocytes in vivo, cultured cortical astrocytes 
express high levels of GFAP, consistent with their having undergone activation during 
culture, leading to the development of a reactive phenotype. Any stimuli strong enough to 
induce re-activation of the cultured astrocytes may also induce apoptosis and 
accompanying degradation of GFAP and other proteins. In addition, high levels of 
nuclear IκB in the cultured astrocytes due to earlier activation of NF-κB could explain the 
rapid cycle of NF-κB activation and deactivation (Brown et al., 1993; Sun et al., 1993; 
Zabel et al., 1993; Baeuerle and Henkel, 1994) in response to PMA and ionophore 
stimulation.  
 
 183
4.39 Conclusions 
This research provided evidence that a soluble factor released by OECs moderated both 
the NF-κB translocation and GM-CSF transcription components of astrocyte activation. 
This moderation of astrocyte reactivity represents a plausible mechanism whereby 
transplanted OECs enhance neuronal survival and increase the likelihood of neural repair 
after CNS injury. Investigation of the direct effects of OECs on neuronal responses using 
the in vitro model of inflammatory activation established by this research could provide 
further insight into these possibilities. PMA/ionophore stimulated translocation of NF-κB 
to nuclei of microglia and meningeal fibroblasts, in addition to astrocytes and increased 
astrocytic transcription of the pro-inflammatory cytokine, GM-CSF, providing further 
evidence of the relevance of the treatment model to the investigation of inflammatory 
responses following CNS injury. Furthermore, stimulation with PMA/ionophore and by 
soluble factors released from microglia induced NF-κB translocation to a similar extent in 
astrocytes and OECs moderated the translocation induced by either stimulus. The 
similarity of the activating effects of microglia and PMA/ionophore supports the 
physiological relevance of the in vitro activation model, since activated microglia 
participate and interact with astrocytes during the inflammatory response to CNS injury. 
Co-culture with OECs also appeared to maintain astrocytes in a more quiescent state 
prior to PMA/ionophore treatment than found in astrocyte monocultures or co-cultures 
with microglia and fibroblasts. In addition, the NF-κB translocation response in OECs 
displayed apparent insensitivity to PMA/ionophore and microglia-conditioned medium. 
Insensitivity to these stimuli may indicate a resistance to injury-induced pro-
inflammatory signals that could be an advantage for therapeutic transplants of OECs after 
CNS injury. Although the moderation of GM-CSF transcription by OECs supported the 
physiological relevance of the moderation of astrocytic NF-κB translocation, testing the 
effects of OECs on astrocytic transcription of other NF-κB-dependent pro-inflammatory 
mediators, particularly IL-1β, TNF-α, IL-6, iNOS, COX-2 and chemokines, could 
provide stronger evidence. Assays for cytokines and ROS, and Western blots or real-time 
quantitative RNA analysis for expression of proteins associated with astrogliosis, such as 
GFAP and CSPGs, could also provide useful evidence concerning the possible 
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therapeutic efficacy and mechanisms for the observed moderation of astrocytic NF-κB 
translocation by OECs. 
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CHAPTER 5:  
OECs and astrocyte apoptosis 
 
5.0 Introduction 
5.00 Apoptosis and CNS injury 
Ischemia following the disruption of blood supply by CNS injury results in insufficient 
oxygen and glucose delivery to maintain cellular homeostasis and consequently leads to 
necrotic or apoptotic cell death through multiple mechanisms including excitotoxicity, 
acidosis, ionic dysregulation and oxidative stress (Bright and Mochly-Rosen, 2005; 
Doyle et al., 2008; Harting et al., 2008; Broughton et al., 2009; Candelario-Jalil, 2009). 
Rapid energy depletion, mitochondrial collapse and ion pump failure result in large 
increases in intracellular calcium and extracellular potassium (Swanson et al., 1997; 
Hansson and Ronnback, 2004; Doyle et al., 2008; Broughton et al., 2009; Candelario-
Jalil, 2009). Cell swelling, lysis and extensive necrotic cell death follow within minutes 
in the lesion core where the restriction of blood flow and associated ischemia is most 
severe. Collateral blood supply can help maintain tissue viability in the injury penumbra 
where the severity of ischemia and the timing of reperfusion are major determinants of 
cell survival. Cell death occurs less rapidly in the penumbra and is more likely to be 
through regulated apoptosis than necrosis. Waves of peri-infarct depolarisation emanating 
from excitotoxicity in the lesion core, diffusion of glutamate and potassium, and the 
production of reactive oxygen species, particularly in response to reperfusion, can 
increase penumbral damage by promoting apoptosis. Further regulation of apoptosis 
occurs through interaction between the inflammatory responses of neurons, glia and 
migratory immune cells involving intracellular signalling pathways and secreted 
inflammatory mediators. Inflammation following CNS injury can lead to increased 
apoptotic cell death that may continue for months. This temporally delayed second wave 
of programmed cell death in the ischemic penumbra can cause tissue damage that 
exceeds the initial injury and contributes significantly to functional deficits (Swanson et 
al., 1997; Doyle et al., 2008; Rami et al., 2008). The delayed nature of the penumbral 
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apoptotic cell death and its regulation by multiple intracellular and extracellular factors 
provides an attractive feasible target for therapeutic strategies (Broughton et al., 2009).  
 
5.01 Excessive intracellular calcium levels induce apoptosis 
The failure of mitochondrial ATP production in the hypoxic conditions following CNS 
injury prevents the plasma membrane Ca2+ ATPase from maintaining the usual low 
intracellular calcium ion concentrations necessary for normal cell functions (Pivovarova 
et al., 2004; Jemmerson et al., 2005; Nguyen and Jafri, 2005; Christophe and Nicolas, 
2006). Excitoxicity resulting from elevated extracellular glutamate levels allows further 
influx of calcium into neurons through activation of N-methyl-D-aspartate (NMDA) 
receptors and increased calcium permeability of alpha-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) receptors.  The rise in intracellular calcium 
levels during ischemia activates numerous calcium-dependent proteases, lipases and 
DNases resulting in damage to essential cell structures and cell death by necrosis or 
apoptosis. Activated caspases directly promote apoptosis (Beer et al., 2001; Faubel and 
Edelstein, 2005; Verkhratsky, 2007; Nakka et al., 2008; Broughton et al., 2009) and can 
also cleave and inactivate  the plasma membrane Ca2+ ATPase to exacerbate the elevation 
of intracellular calcium levels (Schwab et al., 2002). Activation of the calpain family of 
calcium-dependent cysteine proteases can induce apoptosis by cleavage of caspases, 
cleavage and release of apoptosis inducing factor from mitochondria or, less directly, by 
cleavage of metabotropic glutamate receptors, ion channels, calcineurin and other 
intracellular targets (Du et al., 1999; Ray, 2006; Zhu et al., 2007; Bevers et al., 2009; 
Leon et al., 2009). While the uptake of calcium ions by mitochondria provides an 
important buffering mechanism to maintain normal intracellular calcium levels 
(Kannurpatti et al., 2000; Carafoli, 2002; Clapham, 2007), excessive accumulation of 
calcium by mitochondria plays a crucial role in delayed neuronal death after CNS injury 
(Liu, 1997; Brustovetsky et al., 2002; Pivovarova et al., 2004; Jemmerson et al., 2005; 
Wang and Youle, 2009). Mitochondrial calcium overload leads to increased permeability 
of the inner mitochondrial membrane, swelling of the matrix and outer membrane rupture, 
releasing respiratory chain cytochrome c into the cytosol where it initiates apoptosis by 
activating caspases. Cytochrome c can also be released by the formation of a permeability 
 187
transition pore in the mitochondrial outer membrane, an event that is regulated by the 
Bcl-2 family of proteins (Brustovetsky et al., 2002; Soane et al., 2007; Leon et al., 2009; 
Robertson et al., 2009; Wang et al., 2009a). Oxidative phosphorylation is calcium-
dependent and increases in mitochondrial calcium levels of viable cells in the injury 
penumbra can increase oxidative phosphorylation and the associated ROS production 
(Perez-Pinzon et al., 2005; Loh et al., 2006; Szeto, 2006; Busija et al., 2008; Niizuma et 
al., 2009; Wang et al., 2009a). The resultant high levels of nitric oxide, superoxide and 
peroxynitrite can damage mitochondrial and cellular molecules triggering signalling 
mechanisms that culminate in apoptosis. 
  
5.02 Does NF-κB promote apoptosis? 
5.02.0 NF-κB promotes growth and differentiation 
As a key regulator of inflammatory responses, NF-κB controls transcription of genes that 
promote immune cell survival, proliferation and differentiation (Baeuerle and Henkel, 
1994; Baldwin, 1996; Yamamoto and Gaynor, 2001; Ridder and Schwaninger, 2009). 
Activation of NF-κB is therefore generally considered to be anti-apoptotic with p65-
deficient cells being more susceptible to apoptosis and constitutive NF-κB activation 
being involved in the abnormal growth and proliferation of tumour cells (Wang et al., 
1996; Ridder and Schwaninger, 2009). NF-κB directly activates anti-apoptotic genes 
including TNF receptor-associated factors, inhibitors of apoptosis and Bcl-2 proteins, 
which inhibit TNFα-induced apoptosis, block the activation of caspases and prevent 
cytochrome c release from mitochondria respectively (Wang et al., 1996; Wang et al., 
1999; Weaver et al., 2003; Groesdonk et al., 2007; Plesnila et al., 2007; Rami et al., 
2008). NF-κB also promotes transcription of cyclin D1, which promotes cell cycle 
progression (Guttridge et al., 1999). Despite these known anti-apoptotic effects, NF-κB 
activation associated with the severe ischemia following CNS injury contributes to cell 
death and increases tissue damage (Ridder and Schwaninger, 2009) and the NF-κB-
dependent cytokines, IL-1β and TNF-α can induce apoptosis (Chao et al., 1995; Yokota 
et al., 2000; Li et al., 2001; Ortis et al., 2006; Gosselin and Rivest, 2007). These 
conflicting effects may to some extent be related to variations in the sensitivity of 
different cell types to various inflammatory stimuli and NF-κB activation (Baeuerle and 
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Henkel, 1994; Ridder and Schwaninger, 2009). However, suppression of NF-κB in both 
neurons and astrocytes has been demonstrated to decrease tissue damage and enhance 
recovery after CNS injury (Schneider et al., 1999; Brambilla et al., 2005b; Zhang et al., 
2008; Brambilla et al., 2009). In contrast, delayed neuronal apoptosis after brain injury 
has been shown to involve inhibition of NF-κB by the pro-apoptotic transcription factor, 
p53 (Plesnila et al., 2007) and NF-κB activation during TNFα-induced inflammation 
promotes astrocyte survival (Ginis et al., 2002; Quinones et al., 2008).  
 
5.02.1 NF-κB transcriptional effects depend on the severity and duration of activation  
It appears likely that the variable effects of NF-κB on apoptosis relate to the strength and 
duration of activation and interactions with other inflammatory signalling molecules 
(Baichwal and Baeuerle, 1997; Yamamoto and Gaynor, 2001; Ridder and Schwaninger, 
2009). Preconditioning by inducing a brief period of sublethal ischemia protects against a 
subsequent severe ischemic insult  (Blondeau et al., 2001; Ginis et al., 2002; Carmel et al., 
2004; Dhodda et al., 2004; Noguchi et al., 2007; Bigdeli et al., 2009; Lehotsky et al., 
2009). The neuroprotection conferred by preconditioning is dependent on NF-κB and can 
be induced by treatment with the NF-κB-regulated pro-inflammatory cytokine, TNFα 
(Ginis et al., 2002; Bigdeli et al., 2009; Guo et al., 2009; Ridder and Schwaninger, 2009). 
The moderate transient activation of NF-κB during preconditioning apparently favours 
the transcription of anti-apoptotic and neuroprotective factors that can then moderate the 
effects of the strong sustained activation of NF-κB that occurs during severe ischemia. 
Sustained NF-κB activation induces production of ROS and inflammatory cytokines that 
can induce apoptosis through intrinsic and extrinsic pathways (Clemens et al., 1998; 
Ginis et al., 2002; Hoffman et al., 2002; Dhodda et al., 2004; Loh et al., 2006; Ortis et al., 
2006). High levels of pro-inflammatory mediators increase blood flow and disrupt the 
BBB resulting in increased oedema, ionic imbalance and recruitment of leukocytes 
(Lopez-Neblina et al., 2005; Harukuni and Bhardwaj, 2006; Nakka et al., 2008). The 
consequent amplification of inflammation prolongs NF-κB activation and increases 
delayed apoptotic cell death. Interestingly, the transcription factor, CEBP homologous 
protein, which can synergise with NF-κB to promote inflammatory gene expression, is 
upregulated in cultured astrocytes in response to hypoxia and hypoglycaemia but only 
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induces apoptosis when the upregulation is sustained and not when the upregulation is 
transient (Benavides et al., 2005). 
 
5.02.2 NF-κB family members have differing transcriptional effects  
Differential expression and activation of NF-κB family members may also contribute to 
the variable effects on neuronal apoptosis with p65 activation promoting apoptosis and c-
Rel activation protecting neurons against ischemia by inducing anti-apoptotic gene 
expression (Pizzi et al., 2009; Sarnico et al., 2009; Valerio et al., 2009). However, the 
transcriptional effects of NF-κB family members vary with cell type and c-Rel activation 
can also promote apoptosis and is required for sustained activation of inflammatory gene 
transcription in lymphocytes (Baldwin, 1996; Cogswell et al., 2003; Brettingham-Moore 
et al., 2005a; Bednarski et al., 2009). 
 
5.03 Neurons are more susceptible to ischemic apoptosis than astrocytes 
Neurons are more susceptible to ischemia-induced apoptosis than astrocytes because they 
are subject to excitotoxicity, have exceptionally high energy demands and are particularly 
vulnerable to oxidative stress (Pivovarova et al., 2004; Doyle et al., 2008; Broughton et 
al., 2009; Forder and Tymianski, 2009; Guo et al., 2009; Niizuma et al., 2009). The much 
greater resistance of astrocytes to ischemic damage substantially relates to their neuronal 
metabolic support role (Takuma et al., 2004; Panickar and Norenberg, 2005; Laird et al., 
2008; Wang and Bordey, 2008). Astrocytes have large stores of the metabolic substrates, 
glycogen, glutamate and glutamine that enable the maintenance of metabolic activity for 
1-2 hours in the absence of glucose and a greater capacity than neurons to utilise fatty 
acids and ketone bodies for metabolism. Elevated extracellular glutamate and calcium 
levels ensue from cell death and damage during CNS injury and the consequent 
excitotoxic stimulation of neurons leads to uptake of excessive calcium and consequently 
apoptotic or necrotic neuronal death (Kannurpatti et al., 2000; Johnston, 2005; 
Verkhratsky, 2007; Villmann and Becker, 2007; Candelario-Jalil, 2009). Astrocytes 
protect neurons against excitotoxicity by taking up the excess calcium and glutamate both 
following CNS injury and as a normal physiological function (Kim et al., 1994; 
Verkhratsky and Steinhauser, 2000; Simard and Nedergaard, 2004; Panickar and 
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Norenberg, 2005; Girouard and Iadecola, 2006; Iadecola and Nedergaard, 2007; Wang 
and Bordey, 2008). Commensurate with their physiological role in maintaining 
extracellular ionic homeostasis, astrocytes have superior calcium buffering capacity to 
neurons and are accordingly less susceptible to apoptosis (Cornell-Bell et al., 1992; 
Venance et al., 1997; Verkhratsky et al., 1998; Lee et al., 2000; Verkhratsky, 2006; 
Burgos et al., 2007b).Compared to neurons, astrocytes have higher levels of glutathione, 
ascorbic acid, anti-apoptotic proteins, such as Bcl-2, and the anti-oxidant enzymes, 
catalase, superoxide dismutase (SOD) and glutathione peroxidase to protect against free 
radical damage (Eddleston and Mucke, 1993; Penkowa and Hidalgo, 2000; Swanson et 
al., 2004; Acarin et al., 2005; Chen et al., 2006b; Jia-Yi et al., 2006). TNF family ligands 
are important inducers of apoptosis in the CNS from which astrocytes are protected by 
their constitutive calcium/calmodulin kinase II activity (Song et al., 2006). Furthermore, 
TNFα induces expression of the calcium-binding protein, calbindin-D, which protects 
astrocytes against apoptosis induced by elevated intracellular calcium in response to 
calcium ionophore or amyloid β-peptide (Wernyj et al., 1999).  
 
5.04 Astrocyte apoptosis can be induced in vitro 
Despite their protective mechanisms, apoptosis can been readily induced in cultured 
astrocytes (reviewed by Takuma et al., 2004; Giffard and Swanson, 2005) using a variety 
of in vitro models of ischemia (Yu et al., 2001; Xu et al., 2004; Benavides et al., 2005; 
Chen et al., 2005c; Chu et al., 2008) and other treatments related to CNS injury including 
acidosis (Swanson et al., 1997; Giffard and Swanson, 2005), oxidative stress (Takuma et 
al., 1999; Bonini et al., 2004) inflammatory cytokines (Song et al., 2006) and elevation of 
intracellular calcium levels induced by hypoxia (Kintner et al., 2007), calcium ionophore 
(Wernyj et al., 1999) or thapsigargin (Takuma et al., 1999).   Astrocyte apoptosis has also 
been identified following ischemic (Li et al., 1995; Beer et al., 2001) or contusive (Kaya 
et al., 1999; Moroni, 2008) brain injury. Apoptosis is more difficult to confirm in vivo 
(Giffard and Swanson, 2005) because of the high cell density of the tissue together with 
variable cell morphologies and nuclear sizes. In addition, apoptotic cells and fragments 
are removed by macrophages in the lesion and surrounding tissue. Identification of 
astrocytes by their expression of GFAP may have led to an underestimation of astrocyte 
 191
apoptosis following CNS injury. GFAP is normally only expressed at low levels in grey 
matter astrocytes preventing the correct identification of apoptotic astrocytes in the early 
stages of injury responses. The upregulation of GFAP by reactive astrocytes does not 
become pronounced until several days after injury and is probably accompanied by the 
induction of anti-apoptotic factors (Swanson et al., 2004; Takuma et al., 2004; Giffard 
and Swanson, 2005). 
 
5.05 Astrocytes are essential for neuronal survival after CNS injury 
The normal physiological functions of astrocytes, including the clearance of extracellular 
glutamate and its conversion to glutamine, maintenance of extracellular ionic and pH 
homeostasis, coupling of cerebral blood flow to neuronal activity, provision of metabolic 
substrates for neurons and ROS scavenging are obviously crucial to neuronal function 
and survival (Swanson et al., 2004; Takuma et al., 2004; Panickar and Norenberg, 2005; 
Iadecola and Nedergaard, 2007; Kintner et al., 2007; Wang and Bordey, 2008). After 
CNS injury astrocyte survival is a critical determinant of neuronal survival and the 
maintenance of tissue viability in the lesion penumbra. Enhanced glutamate uptake due to 
upregulation of glutamate transporters by reactive astrocytes may limit neuronal 
excitotoxic damage. Production of antioxidants such as ascorbate, glutathione and 
metallothionein by reactive astrocytes can detoxify high levels of ROS that could 
otherwise damage neurons and induce apoptosis (Neal et al., 1996; Penkowa et al., 1997; 
Swanson et al., 2004; Wakida et al., 2007). Reactive astrocytes also secrete 
neuroprotective factors, such as erythropoietin (Diaz et al., 2005; Wakida et al., 2007) 
and glial cell line-derived growth factor (Choi-Lundberg and Bohn, 1995; Widenfalk et 
al., 2001; Lin et al., 2006; Chu et al., 2008) that can activate neuronal NF-κB to induce 
transcription of anti-apoptotic proteins. However, strongly activated astrocytes release 
high levels of nitric oxide, chemokines, matrix metalloproteases and the pro-
inflammatory cytokines, TNFα and IL-1β that can contribute to neuronal death and 
promote recruitment of leukocytes, which may further intensify the inflammatory 
response (Feuerstein et al., 1994; Chen et al., 2001b; Domanska-Janik et al., 2001; 
Meeuwsen et al., 2003a; Swanson et al., 2004; John et al., 2005; Gosselin and Rivest, 
2007). 
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5.06 Research rationale 
Since astrocyte survival and reactivity following CNS injury are crucial determinants of 
neuronal survival, OEC-mediated protection of astrocytes against apoptosis is a possible 
mechanism for the beneficial effects of OEC transplant therapy. Conditioned medium 
from OECs has been previously reported to protect PC12 cells from 6-OHDA induced 
apoptosis in an in vitro model of Parkinson’s disease (Feng et al., 2008), although the 
identity of the cultured OECs was not confirmed in this research. Furthermore, the 
described OEC culture method involved passaging to remove fibroblasts, which is likely 
to have had the opposite effect, since fibroblasts survive passaging better than OECs. In 
Chapter 3, PMA and ionophore induced NF-κB activation in astrocytes and at high doses, 
ionophore appeared to induce apoptosis. In Chapter 4, OECs moderated PMA and 
ionophore-induced NF-κB activation in astrocytes. Moderate transient activation of NF-
κB appears to be protective against ischemia-induced neuronal apoptosis, while strong 
sustained activation of NF-κB appears to promote apoptosis (Ridder and Schwaninger, 
2009). Therefore, the moderation of NF-κB activation by OECs could inhibit the 
astrocyte apoptosis associated with ionophore treatment. OEC moderation of ionophore-
induced apoptosis would be highly relevant for CNS injury therapy, since ionophore 
induces elevation of intracellular calcium, a key factor in CNS injury responses and the 
initiation of apoptosis (Gwag et al., 1999; Clapham, 2007; Doyle et al., 2008; Guo et al., 
2009). Hence, this component of the research investigates ionophore-induced astrocyte 
apoptosis and its potential moderation by soluble factors released from OECs. OEC 
effects on apoptosis were compared with the effects of microglia and fibroblasts for 
additional controls and because soluble factors from microglia activated astrocytic NF-κB 
similarly to PMA and ionophore. The apoptotic effects of ionophore on OECs and 
astrocytes were also compared because transplanted OECs in vivo would be subject to the 
same post-injury conditions as astrocytes and PMA/ionophore did not activate NF-κB in 
OECs.  
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5.07 Specific aims 
 
1. Investigate astrocyte apoptosis in response to ionophore. 
 
2. Determine whether OECs moderate ionophore-induced astrocyte apoptosis. 
 
3. Compare the effects of microglia, meningeal fibroblasts and OECs on astrocyte 
apoptosis. 
 
4. Compare the apoptotic effects of ionophore on OECs and astrocytes. 
 
5.1 Method 
5.10 Comparisons of apoptosis by nuclear condensation 
Apoptosis was assayed by measuring the percentage of cells with condensed nuclei in the 
following experiments:  
 
1. untreated astrocytes and astrocytes stimulated with 20ng/mL PMA combined with 
500nM ionophore for 1, 3, 6 or 24 hours (Fig. 5.1)  
2. astrocytes stimulated with 20ng/mL PMA combined with 500nM or 1μM 
ionophore for 8 hours (Fig. 5.2) 
3. astrocytes stimulated with 20ng/mL PMA, 1μM ionophore or combined 20ng/mL 
PMA and 1μM ionophore for 8 hours (Fig. 5.3) 
4. astrocytes incubated in OEC CM, microglia CM or DMEM for 30 hours with and 
without 1μM ionophore for the final 6 hours (Fig. 5.3) 
5. OECs that were untreated or stimulated for 3 hours with 60nM, 125nM, 500nM or 
1μM ionophore (Fig. 5.9) 
 
5.11 Measurement of nuclear condensation in astrocytes and OECs 
Astrocytes or OECs were cultured on 18mm coverslips in 12-well culture plates as 
described in Chapter 2. Following treatments, cells were fixed, immunostained for GFAP 
(astrocytes) or p75NTR (OECs) and NF-κB, with Hoechst blue 33342 (Molecular Probes) 
counterstaining of nuclei and imaged as described for immunocytochemistry in Chapter 2. 
The images of Hoechst blue stained astrocyte nuclei were used to assess apoptosis by 
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nuclear condensation. Cells with relatively small, brightly stained nuclei were scored as 
apoptotic (plus signs in Figs. 5.2, 5.3 and 5.4). Merged immunoreactivity images 
confirmed that condensed nuclei were associated with apoptotic cells displaying 
cytoplasmic condensation and degradation of cytoplasmic protein. 8 images were used to 
generate group means and data were analysed by Student’s t-test or, where possible, 
ANOVA and post hoc Tukey tests.  
 
5.12 Comparisons of astrocyte apoptosis by TUNEL assay 
Initially TUNEL assays were conducted using fluorescence microscopy to optimise 
treatment conditions prior to assays using flow cytometry. Astrocytes were cultured and 
treated on 18mm coverslips in 12-well culture plates for comparisons using fluorescence 
microscopy and in 25cm2 culture flasks for comparisons using flow cytometry. Astrocyte 
apoptosis was compared by TUNEL assay after the following treatments, using 
fluorescence microscopy:  
 
1. 500nM ionophore for 4, 6 or 8 hours (Fig. 5.5). 
2. 125nM, 250nM, 500nM or 1μM ionophore for 8 hours (Fig. 5.6). 
 
and using flow cytometry: 
 
3. 1μM ionophore for 8 hours and untreated astrocytes (Fig. 5.7). 
4. incubation for 32 hours in astrocyte CM, OEC CM, fibroblast CM microglia CM 
and all treated with 1μM ionophore for the final 8 hours (Fig. 5.8). 
 
5.13 TUNEL assay for detection of apoptotic astrocytes 
The Apo-BrdU™ kit (Calbiochem®), a two colour terminal deoxynucleotide transferase 
dUTP nick end labelling (TUNEL) assay, labelled DNA breaks in apoptotic nuclei with 
fluorescein and total cellular DNA in all nuclei with propidium iodide. The labelling 
procedure illustrated in the flow diagram (Fig. 5.0) followed the kit protocol with minor 
modifications, as follows: 
 
Astrocytes for flow cytometry analysis were detached from 25cm2 culture flasks by 
washing with 2mL warm Versene to inhibit cell-substrate binding by chelating calcium 
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Figure 5.0 Flow chart for Apo-BrdU™ kit TUNEL staining protocol. The Apo-
BrdU™ kit (Calbiochem®), a two colour Terminal deoxynucleotide transferase dUTP 
Nick End Labelling (TUNEL) assay, labelled DNA breaks with fluorescein and total 
cellular DNA with propidium iodide. Astrocytes and kit control lymphocytes were 
stained for detection of apoptotic cells by flow cytometry and fluorescence microscopy. 
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ions followed by treatment with 1mL 0.75% trypsin in HBSS. Detached astrocytes were 
resuspended in 2mL DMEM-10S to halt trypsinisation, combined with the medium 
removed from the flask before trypsinisation that may have contained previously 
detached apoptotic cells, centrifuged at 300g for 5 minutes and resuspended in 2% (w/v) 
paraformaldehyde in pH 7.4 PBS at a concentration of ~106 cells/mL for 30-60 minutes 
on ice to cross-link DNA. Samples were centrifuged at 300g for 5 minutes and washed 
with PBS twice, cells resuspended in the residual PBS by gentle vortexing, diluted to 
~106 cells/mL with ice-cold 70% (v/v) ethanol to permeabilise cell membranes and stored 
overnight at -20OC. Normal lymphocytes and apoptotic lymphocytes that had been fixed 
and permeabilised using the above protocol were provided with the kit as negative and 
positive controls respectively. Kit control and astrocyte cell suspensions were swirled to 
resuspend cells and 1 mL aliquots containing ~106 cells/mL were transferred to 15mL 
centrifuge tubes (Becton Dickinson) and centrifuged at 300g for 5 minutes and the 
ethanol removed carefully by aspiration. Samples were resuspended in 1 mL wash buffer 
and centrifuged at 300g for 5 minutes twice before resuspending in 50 μL of DNA 
fragment (TUNEL) labelling solution that to ensure equal concentrations of reagents for 
each sample was prepared as a master mix, as follows: 
 
                    DNA LABELLING SOLUTION            1 Sample       10 Samples 
                   _______________________________________________________ 
                    Reaction Buffer                                        10 μL              100 μL 
                    Terminal deoxynucleotide transferase    0.75 μL             7.5 μL 
                    Br-dUTP                                                     8 μL                80 μL 
                    Distilled H2O                                          32.25 μL         322.5 μL 
                   _______________________________________________________                    
                    Total Volume                                             51 μL             510 μL 
                   _______________________________________________________ 
                    
Samples were incubated with the DNA labelling solution for 3 hours at 37OC on a shaker 
to keep cells in suspension. Labelling solution was then removed by twice adding 1 mL 
of rinse buffer, centrifuging at 300g for 5 minutes and removing the supernatant by 
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aspiration. To stain Br-dUTP labelled DNA fragments, cells were then resuspended in 
100 μL of fluorescein isothiocyanate (FITC)-conjugated anti-BR-dUTP solution that was 
also prepared as a master mix, as follows: 
 
                             ANTIBODY SOLUTION            1 Sample        10 Samples 
                            ___________________________________________________ 
                             FITC-anti-Br-dUTP                          5 μL                 50 μL 
                             Rinse Buffer                                    95 μL                950 μL 
                            ___________________________________________________ 
                             Total Volume                                  100 μL             1000 μL 
                            ___________________________________________________ 
 
The samples were incubated with the antibody solution for 1 hour, at room temperature 
on a shaker, in the dark (by wrapping sample tubes in aluminium foil). For the final 30 
minutes of the antibody incubation 500 μL of buffer containing propidium iodide to label 
all DNA in the samples and RNase A to degrade any mRNA in the samples was added to 
each sample. Samples were kept in the dark and analysed within 3 hours by flow 
cytometry. Astrocytes for analysis by fluorescence microscopy were fixed, permeabilised 
and stained while remaining adherent to 18 mm glass coverslips in 12-well culture plates. 
Coverslips were removed from culture plates and placed on wax-filled culture plate lids 
for the DNA labelling and antibody incubation steps and only required 100 μL/sample 
additions of the propidium iodide/RNase buffer. Coverslips were then rinsed in distilled 
water, mounted on glass slides using Permafluor™ aqueous mounting medium 
(Immunotech, France), stored in the dark and imaged within 6 hours. 
 
5.14 Fluorescence microscopy analysis of TUNEL stained samples 
Specimens were viewed on a fluorescence microscope (Olympus BX50) for image 
capture with an Optronics Magnafire camera. Adobe Photoshop© was used to merge sets 
of 2 images showing propidium iodide (red) and TUNEL staining with fluorescein 
isothiocyanate (FITC; green) (Fig. 5.5). Nuclei that stained with both propidium iodide 
and FITC appeared yellow in the merged images and were scored as apoptotic. Eight 
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images were used to generate group means and data were analysed by ANOVA and post 
hoc Tukey tests.  
 
5.15 Flow cytometry analysis of TUNEL stained samples 
Samples were run on a Coulter Elite EST flow cytometer (Miami, USA) and excited with 
a 488 nm argon laser that induced propidium iodide to fluoresce at 623 nm and 
fluorescein at 520 nm without any requirement for fluorescence compensation. The 
intensity of fluorescence at each wavelength was simultaneously acquired by the flow 
cytometer software as stained nuclei passed the detector. Each detected event was plotted 
on a log FITC fluorescence intensity versus log propidium iodide fluorescence intensity 
graph (Figs. 5.7 and 5.8) for each sample using Windows Multiple Document Interface 
(WinMDI©) for flow cytometry analysis, Version 2.9 (Copyright© Joseph Trotter, 
available free online at (http://facs.scripps.edu/software.html). DNA in apoptotic cells 
was expected to be stained by both propidium iodide and fluorescein. Therefore events 
plotting in the upper right quadrant of each graph were deemed to represent apoptotic 
nuclei. Using the positive and negative control graphs (Fig. 5.7), quadrant grids (x = 488, 
y = 232) were selected to provide the best separation of the dual-stained apoptotic nuclei 
and were applied to graphs of each sample to enable calculation of the percentages of 
apoptotic astrocytes. 6 samples from separate cultures were used for each treatment in the 
comparison between ionophore-treated and untreated astrocytes in DMEM (Fig. 5.7) and 
3 samples from separate cultures for comparisons between ionophore-treated astrocytes 
in the conditioned media (Fig. 5.8). Kit negative and positive controls were included in 
each TUNEL assay experiment to verify that the staining protocol had been effective. 
Data were analysed by ANOVA and post hoc Tukey tests. 
 
5.2 Results 
5.20 PMA/ionophore induced time-dependent astrocyte apoptosis 
NF-κB activation may lead to apoptosis of neurons and glia contributing to the 
pathogenesis of CNS injury. Since PMA/ionophore activated NF-κB in astrocytes, this 
treatment was further investigated for possible effects on astrocyte apoptosis. The images 
of Hoechst blue staining of nuclei and immunostaining for GFAP and NF-κB revealed 
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that from 3 to 24 hours following treatment with 20ng/mL PMA combined with 500nM 
ionophore, increasing numbers of astrocytes displayed morphology changes consistent 
with apoptosis (Fig. 5.1). As previously described, NF-κB translocated to astrocyte nuclei 
after 1 hour of treatment without any obvious changes in cytoplasmic or nuclear size or 
morphology (Xs in Fig. 5.1E-H). However after 3 hours or more of treatment many 
astrocytes showed signs of apoptosis, including irregular, condensed nuclei with intense 
Hoechst staining (e.g. plus signs in Fig. 5.1I-P) together with cytoplasmic condensation 
and depolymerisation of GFAP. Many nuclei also had punctate Hoechst staining (e.g. 
asterisks in Fig. 5.1Q-T; enlarged in Fig. 6.1V) indicating fragmentation of nuclear DNA, 
an unambiguous marker of apoptosis. The morphology changes that accompanied 
cytoplasmic condensation progressed from stellate to blebby as processes appeared to 
become detached from the substrate. Astrocytes with the most condensed nuclei appeared 
to revert to a flattened morphology delineated by fragmented GFAP immunoreactivity 
while NF-κB immunoreactivity was lost from the cytoplasm, although there was often a 
faint remnant in the nuclear region (e.g. Xs in Fig. 5.1R). Quantitative analysis of the 
percentage of apoptotic astrocytes, as indicated by nuclear condensation, (Fig. 5.1U) 
showed that the 3% of untreated astrocytes were apoptotic and there was no significant 
change after 1 hour of PMA/ionophore treatment (p > 0.05). The percentage of apoptotic 
astrocytes had increased significantly after 3 hours (18.66±0.95%; p < 0.001), with 
further significant increases after 6 and 24 hours of treatment (p < 0.001), by which time 
the large majority of astrocytes were apoptotic (78.67±3.39%).  
 
5.21 PMA/ionophore-induced astrocyte apoptosis depended on ionophore 
concentration 
Different PMA and ionophore doses were used during the investigation of astrocyte 
activation and although there was no measurable increase in the induction of NF-κB 
translocation, there did appear to be increased apoptosis with higher ionophore 
concentrations (Fig. 5.2). Comparisons of Hoechst-stained astrocyte nuclei (Fig. 5.2I) 
showed that there were significantly more apoptotic astrocytes (plus signs in A-H) with 
1μM ionophore (74.56±6.35%) than with 500nM ionophore (41.82±5.41%) in 8 hour 
combined PMA/ionophore treatments (p < 0.001). Similar alterations of normal astrocyte  
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Figure 5.1 PMA/ionophore induces time-dependent astrocyte apoptosis. Apoptosis was 
compared for untreated astrocytes (A-D) and astrocytes treated with 20ng/mL PMA combined with 
500nM ionophore (PI) for one (E-H), three (I-L), six (M-P) or 24 hours (Q-T). Immunostaining for 
GFAP (A, E, I, M, Q and green in D, H, L, P, T) was used to identify astrocytes and NF-κB (B, F, J, 
N, R and red in D, H, L, P, T) to identify activated astrocytes. Nuclei were counterstained with 
Hoechst blue (HB) (C, G, K, O, S and blue in D, H, L, P, T).  Only a few astrocytes had nuclei with 
NF-κB immunoreactivity more intense than in the cytoplasm in untreated (Xs in A-D) and 6 hour 
PMA/ionophore-treated cultures (Xs in M-P). In the untreated astrocytes, GFAP and NF-κB 
immunoreactivity was uniformly distributed in the cytoplasm and nuclei were large and ovoid, with 
uniform Hoechst staining of nuclear DNA. Following 1 hour of PMA/ionophore treatment there 
was intense NF-κB immunoreactivity in many nuclei (Xs in E-H) without any noticeable change in 
cytoplasmic or nuclear morphology and Hoechst staining. After 3 and 6 hours of treatment, many 
astrocytes appeared apoptotic (plus signs I-P) with condensed nuclei and cytoplasm, accompanied 
by depolymerisation of GFAP. Astrocytes with cytoplasmic NF-κB immunoreactivity have stellate 
morphologies but in cells with more condensed nuclei, cytoplasmic NF-κB is absent, there is 
sometimes faint nuclear NF-κB immunoreactivity (asterisks in I-L) and morphologies are flattened 
or blebby. Two large nuclei near the centre of images M-P (asterisks) with punctate Hoechst 
staining belong to astrocytes in the early stages of apoptosis. The flattened astrocytes exhibited 
detachment and condensation of processes with only faint nuclear NF-κB immunoreactivity. After 
24 hours of treatment, most astrocytes are apoptotic with depolymerised GFAP and blebby or 
flattened morphologies. Nuclei are either condensed or irregularly-shaped and many have punctate 
Hoechst staining of DNA (e.g. asterisks in Q-T) clearly illustrated in the enlargement (V) of the 
indicated area in S. Astrocytes with the least condensed nuclei (arrows in Q-T) retain some 
cytoplasmic NF-κB immunoreactivity while in others there are faint remnants of NF-κB staining in 
nuclei (e.g. Xs in R). U: Quantitative analysis of astrocyte apoptosis. Astrocytes with condensed 
nuclei were scored as apoptotic. There was a significant increase in the percentage of apoptotic 
astrocytes following PMA/ionophore treatment for 3 hours (p < 0.001) with further significant 
increases after 6 and 24 hours of treatment (p < 0.001). Data were analysed by ANOVA with post-
hoc Tukey’s multiple comparison tests. Percentages are means ± SEM, n = 8. Asterisks denote 
significant differences: *** p < 0.001. 
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Figure 5.2 Astrocyte apoptosis induced by PMA/ionophore depends on ionophore 
concentration. Astrocytes were treated with 20ng/mL PMA combined with 500nM or 1μM 
ionophore for 8 hours. Immunostaining for GFAP (A, E and green in D, H) was used to 
identify astrocytes and NF-κB (B, F and red in D, H) to identify activated astrocytes. Nuclei 
were counterstained with Hoechst blue (HB) (C, G and blue in D, H). A few activated 
astrocytes with intense nuclear NF-κB immunoreactivity retained normal nuclear and 
cytoplasmic morphologies (broad arrows in A-H) while others had condensed nuclei and 
cytoplasm (long arrows in A-H). Apoptotic astrocytes were more frequent following 
treatment with 1μM ionophore (D-H) and were characterised by condensed nuclei (plus signs 
in A-H) accompanied by condensed cytoplasm as revealed by intense GFAP 
immunoreactivity (A, D, E, H). Initially cytoplasmic NF-κB immunoreactivity increased as 
cytoplasm condensed in apoptotic cells but with increasing nuclear condensation there was a 
loss of NF-κB immunoreactivity (B, F). Scale bar is 50 μm. I: Quantitative analysis of 
astrocyte apoptosis. Astrocytes with condensed nuclei were scored as apoptotic. There were 
significantly more apoptotic astrocytes following treatment with PMA combined with 1μM 
ionophore than for PMA combined with 500nM ionophore (p < 0.001). Data were analysed 
by Student’s t-test. Percentages are means ± SEM, n = 8. Asterisks denote significant 
differences: *** p < 0.001. 
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 (broad arrows in A-H) morphology and immunostaining to those seen previously (Fig. 
5.1) accompanied apoptosis. Apoptotic astrocytes had condensed cytoplasm (long arrows 
in Fig. 5.2A-H) resulting in intense GFAP and, initially, NF-κB immunoreactivity while 
at later stages cytoplasmic NF-κB immunoreactivity was absent (Fig. 5.2A-H).  
 
5.22 Ionophore alone induced astrocyte apoptosis  
The relative effects of separate and combined treatments with PMA and ionophore on 
astrocyte apoptosis were then investigated (Fig. 5.3), since NF-κB translocation preceded 
apoptosis and was induced more strongly by ionophore than PMA. Comparisons of 
astrocyte apoptosis using Hoechst staining of nuclei (Fig. 5.3G) revealed that after 8 
hours of treatment with 20ng/mL PMA there was no significant difference from the low 
levels of apoptosis in untreated cultures (p > 0.05).  However, there were large significant 
increases in the percentage of apoptotic astrocytes (plus signs in Fig. 5.3B, C, E and F) 
after treatment for 8 hours with 1μM ionophore or combined PMA/ionophore (p < 0.001). 
Although there was more apoptosis with the combined treatment (76.19±8.43%) than for 
ionophore alone (58.48±4.94%), the difference was not quite significant (p = 0.054). 
 
5.23 OECs and microglia did not modulate ionophore-induced astrocyte apoptosis 
The effects of media conditioned by OECs or microglia on the ionophore-induced 
astrocyte apoptosis were then investigated (Fig. 5.4) since OECs had moderated 
PMA/ionophore-induced NF-κB translocation in astrocytes and microglia had induced 
NF-κB translocation in a similar manner to PMA/ionophore. Again using Hoechst 
staining of nuclei for comparisons of astrocyte apoptosis (Fig. 5.4E), no significant effect 
on astrocyte apoptosis was found in response to 6 hour incubations with OEC or 
microglia CM (p > 0.05). Although treatment for 6 hours with 500nM ionophore did 
significantly increase apoptosis (p < 0.001), there was again no effect attributable to 
OECs or microglia, since no significant difference was found in the percentage of 
apoptotic astrocytes (p > 0.05) whether treated with ionophore in DMEM (35.93±2.10%), 
OEC CM (34.83±1.73%) or microglia CM (35.84±1.50%). 
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Figure 5.3 Ionophore induces astrocyte apoptosis. Astrocytes were treated for 8 hours with 
20ng/mL PMA (A, D), 1μM ionophore (B, E), combined PMA/ionophore (C, F) or were 
untreated. Immunostaining for GFAP (green) identified astrocytes and NF-κB (red) indicated 
astrocyte activation (D-F). Nuclei were counterstained with Hoechst blue (HB) (A-C and blue 
in D-F). Few astrocytes had high levels of nuclear NF-κB immunoreactivity (asterisks in B, E) 
after 8 hours of PMA treatment. Many ionophore and PMA/ionophore treated astrocytes 
appeared apoptotic with condensed nuclei (plus signs in B, C, E, F) and cytoplasm as 
revealed by GFAP immunoreactivity (E, F). Scale bar is 50 μm. G: Quantitative analysis of 
astrocyte apoptosis. Astrocytes with condensed nuclei were scored as apoptotic. There were 
significantly more apoptotic astrocytes following ionophore or PMA/ionophore treatment 
than for PMA-treated or untreated astrocytes (p < 0.001). Data were analysed by ANOVA 
and post-hoc Tukey’s multiple comparison test. Percentages are means ± SEM, n = 12. 
Asterisks denote significant differences: *** p < 0.001. 
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Figure 5.4 Comparison of ionophore-induced apoptosis for astrocytes incubated in 
OEC CM, microglia CM or DMEM. Astrocytes were treated with 1μM ionophore in 
DMEM (B), OEC CM (C) or microglia CM (D), or incubated in DMEM (A), OEC CM 
or microglia CM without ionophore. Cultures were fixed and immunostained for GFAP 
and NF-κB, 6 hours after ionophore stimulation. Nuclei were counter-stained with 
Hoechst blue (A-D). Apoptotic cells had condensed nuclei with bright Hoechst staining 
(plus signs) and were far more frequent following ionophore treatment in all media. Scale 
bar is 100 μm. E: Quantitative analysis of astrocyte apoptosis. Astrocytes with condensed 
nuclei were scored as apoptotic. There were significantly more apoptotic astrocytes 
following ionophore treatment than for untreated astrocytes in all media (p < 0.001). 
There was no significant difference in the percentage of apoptotic astrocytes in DMEM, 
OEC CM or microglia CM before or after ionophore treatment (p > 0.05). Data were 
analysed by ANOVA and post-hoc Tukey’s multiple comparison test. Percentages are 
means ± SEM, n = 18. Asterisks denote significant differences: *** p < 0.001. 
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5.24 TUNEL staining reveals time-dependent ionophore-induced DNA fragmentation 
in astrocytes. 
Nuclear size can increase as cells grow, varies at different stages of cell cycles and 
nuclear condensation occurs during both necrotic and apoptotic cell death. Therefore, 
further experiments were conducted using a Terminal deoxynucleotide transferase dUTP 
Nick End Labelling (TUNEL) assay to confirm that the ionophore-induced nuclear 
condensation was a consequence of astrocyte apoptosis. The TUNEL assay could also 
potentially allow a less subjective and more efficient analysis of apoptotic cells using 
flow cytometry. Initial assay optimisation experiments (Figs. 5.5 and 5.6) were analysed 
by fluorescence microscopy before proceeding to flow cytometry analysis. The Apo-
BrdU™ TUNEL assay kit labelled DNA in all nuclei with propidium iodide (Fig. 5.5A, 
D and G) and DNA fragments in apoptotic nuclei with FITC (Fig. 5.5B, E and H). 
Therefore normal nuclei appeared red and apoptotic nuclei appeared yellow in the 
merged fluorescence images (Fig. 5.5C, F, I and Fig. 5.6A-D). Although some apoptosis 
was detected by nuclear condensation in untreated cultures and at significantly higher 
levels after 3 hours of PMA/ionophore treatment, no nuclei with FITC-labelled DNA 
fragments were detected using the TUNEL assay after 2 or 4 hours of treatment with 
500nM ionophore (Fig. 5.5J). However, many FITC-labelled nuclei, indicative of 
apoptosis, were clearly identifiable by 6 hours after treatment (33.5±4.82% of astrocytes) 
and this was similar to the percentage of apoptotic astrocytes detected by nuclear 
condensation using Hoechst staining for the same treatment (Fig. 5.4; 35.93±2.10%). By 
8 hours after treatment, the percentage of apoptotic astrocytes detected by the TUNEL 
assay was 44.48±6.80%, although this increase was not significant (p > 0.05), reflecting 
the considerable variation in the results between different cultures for similar treatments. 
The result at 8 hours was similar to the percentage of apoptotic astrocytes detected by 
Hoechst staining for treatment for the same time period with 500nM ionophore combined 
with PMA (Fig. 5.2; 41.82±5.41%) and less than for 1μM ionophore alone (Fig. 5.3; 
58.48±4.94%). 
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Figure 5.5 Time-dependent DNA fragmentation in ionophore-treated astrocytes. Astrocytes 
were treated with 500nM ionophore for two (data not shown), four (A-C), six (D-F) or eight (G-I) 
hours and then stained using an Apo-BrdU™ kit (Calbiochem). The kit provided dual labelling of 
nuclei with propidium iodide (A, D, G and red in C, F, I) and FITC (B, E, H and green in C, F, I) 
after permeabilising cell membranes with 70% (v/v) ethanol. Propidium iodide stained DNA in 
all cells while DNA fragments in nuclei of apoptotic cells were also labelled using Br-dUTP 
followed by incubation with FITC conjugated anti-Br-dUTP. Therefore nuclei of normal cells 
appeared red and nuclei of apoptotic cells appeared yellow in the merged images (C, F, I). There 
was some non-specific FITC staining (green; arrows in A-I) that was not associated with nuclei or 
incubation time. Apoptotic nuclei were detected only after 6 or 8 hours of incubation with only 
background levels of FITC immunoreactivity after 4 hours of incubation (B). Scale bar is 50 μm. 
J: Quantitative analysis of astrocyte apoptosis. Astrocytes with nuclei that appeared yellow in the 
merged images were scored as apoptotic. No astrocytes were apoptotic after 4 hours incubation 
and therefore significantly more astrocytes were apoptotic after longer incubations (p < 0.001). 
There was no significant difference in the percentage of apoptotic astrocytes for 6 and 8 hour 
incubations (p > 0.05). Data were analysed by ANOVA and post-hoc Tukey’s multiple 
comparison test. Percentages are means ± SEM, n = 8. 
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Figure 5.6 Ionophore-induced astrocyte apoptosis is concentration-dependent. 
Astrocytes were treated with 125nM (A), 250nM (B), 500nM (C) or 1μM (D) ionophore 
for 8 hours and stained with propidium iodide (PI; red) and TUNEL labelled with FITC 
(green) using the Apo-BrdU™ kit. A-D: In the merged images, normal nuclei were 
stained only with propidium iodide and appeared red while apoptotic nuclei were 
condensed and appeared yellow due to TUNEL/FITC labelling of DNA fragments. 
Apoptotic nuclei increased in frequency with increasing ionophore concentration. Scale 
bar is 100 μm. E: Quantitative analysis of astrocyte apoptosis. Astrocytes with nuclei that 
appeared yellow in the merged images were scored as apoptotic. The percentage of 
apoptotic astrocytes increased significantly and exponentially with each increase in 
ionophore concentration (p < 0.001, y = 4.8x2.02, R2 = 0.9996).  The data could also have 
represented a linear increase in apoptosis with ionophore concentration (R2 = 0.9763). 
Data were analysed by ANOVA, linear and polynomial regressions and post-hoc Tukey’s 
multiple comparison test. Percentages are means ± SEM, n = 8. Asterisks denote 
significant differences: *** p < 0.001. 
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5.25 Astrocyte apoptosis was ionophore concentration-dependent 
Apoptosis was then compared by TUNEL assay for astrocytes treated with a 125nM (Fig. 
5.6A), 250nM (Fig. 5.6B), 500nM (Fig. 5.6C) and 1μM (Fig. 5.6D) ionophore for 8 hours. 
Only 4.82±0.88% of astrocytes were apoptotic with 125nM ionophore (Fig. 5.6E), similar 
to the levels identified in untreated cultures by nuclear condensation (Figs. 5.1, 5.3 and 
5.4; 3.05±1.26% to 4.64±0.59%). The percentage of apoptotic astrocytes increased 
significantly (p < 0.001) in an exponential manner (y = 4.8x2.02, R2 = 0.9996) with each 
increase in ionophore concentration (19.49±2.81% for 250nM, 46.11±6.68% for 500nM 
and 77.51±5.33% for 1μM), although the data also fitted well with a linear increase (R2 = 
0.9763). 
 
5.26 Flow cytometry assay of apoptosis in ionophore-treated astrocytes  
Untreated astrocytes and astrocytes treated with 1μM ionophore were then TUNEL 
assayed using flow cytometry, together with the kit negative control normal lymphocytes 
and positive control apoptotic lymphocytes (Fig. 5.7). Particles detected by the flow 
cytometer were plotted on log FITC fluorescence (520nm) intensity against log 
propidium iodide fluorescence (623nm) intensity graphs and the graphs divided into 
quadrants using the same co-ordinates (x = 488, y = 232) for each graph (Fig. 5.7A-D). 
The graphs confirmed that dual propidium iodide/FITC labelled apoptotic nuclei from the 
positive control plotted in the upper right quadrants of the graphs, indicating both high 
propidium iodide and high FITC fluorescence. Normal nuclei from the positive and 
negative controls plotted in the upper left quadrant, indicating high propidium iodide 
fluorescence but low FITC fluorescence. As expected there were significantly more 
apoptotic nuclei detected by this method for the positive control lymphocyte samples 
(46.60±4.05%; p < 0.001; Fig. 5.7E). Applying the same quadrants selected for the kit 
control graphs to the graphs for astrocytes indicated that significantly more apoptotic 
nuclei were detected for the ionophore-treated astrocyte cultures (53.20±4.11%) than for 
the untreated astrocytes (p < 0.01). The percentage of apoptotic nuclei detected was 
similar for the kit positive controls and ionophore-treated astrocytes. The low percentage 
of apoptotic nuclei detected in the kit negative controls (3.89±0.94%) was similar to that 
detected using fluorescence microscope imaging of the untreated astrocytes with either  
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Figure 5.7 Analysis of astrocyte apoptosis by flow cytometry. Apoptosis was compared for 
Apo-BrdU™ kit lymphocyte negative (A) and positive (B) controls and astrocytes that were 
untreated (C) or treated for 8 hours with 1μM ionophore (D). All samples including the kit 
controls were TUNEL labelled with FITC and propidium iodide stained using the Apo-BrdU™ 
kit and analysed by flow cytometry with excitation at 488 nm. Each detected event was plotted on 
a scale of log FITC fluorescence (520 nm) intensity against log propidium iodide fluorescence 
(623 nm) intensity (A-D) and the graphs divided into quadrants using the same co-ordinates (x = 
488, y = 232) for each graph. The kit controls confirmed that, as predicted, apoptotic nuclei 
plotted in the upper right quadrant of the graphs (A, B). More astrocyte nuclei plotted in the upper 
right quadrant following ionophore treatment (C, D). E: Quantitative analysis of astrocyte 
apoptosis. Detected events plotting in the upper right quadrants of the log FITC/log propidium 
iodide graphs were scored as apoptotic cells. There were significantly more apoptotic 
lymphocytes in the kit positive control samples than in the negative controls (p < 0.001). 
Similarly, there were significantly more apoptotic astrocytes in the ionophore-treated samples 
than in the untreated astrocyte samples (p < 0.01). Data were analysed by ANOVA and post-hoc 
Tukey’s multiple comparison test. Percentages are means ± SEM, n = 4. 
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Figure 5.8 Flow cytometric comparison of ionophore-induced apoptosis in astrocytes 
incubated in astrocyte CM, OEC CM, fibroblast CM or microglia CM. Apoptosis was 
compared for astrocytes incubated in astrocyte CM (A), OEC CM (B), fibroblast CM (C) or 
microglia CM (D) after treatment for 8 hours with 1μM ionophore. Samples were TUNEL labelled 
with FITC and propidium iodide stained using the Apo-BrdU™ kit and analysed by flow cytometry 
with excitation at 488 nm. Detected events were plotted on log FITC intensity/ log propidium 
iodide intensity graphs for each sample and as previously (Fig. 6.7), divided into quadrants (A-D). 
E: Quantitative analysis of astrocyte apoptosis. Detected events plotting in the upper right quadrants 
of the log FITC/log propidium iodide graphs were scored as apoptotic cells. There was no 
significant difference in the percentage of apoptotic astrocytes in the different media following 
ionophore treatment (p > 0.05). Data were analysed by ANOVA and post-hoc Tukey’s multiple 
comparison test. Percentages are means ± SEM, n = 4. 
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Figure 5.9 Ionophore rapidly induces OEC apoptosis. Apoptosis was compared for 
OECs that were untreated (A, B) or stimulated for 3 hours with 60nM (C, D), 125nM (E, 
F), 500nM (G, H) or 1μM (I, J) ionophore. OECs were immunostained for p75NTR (green 
in B, D, F, H, J) and NF-κB (red in B, D, F, H, J), and nuclei were counterstained with 
Hoechst blue (A, C, E, G, I and blue in B, D, F, H, J). Apoptotic cells were identified by 
condensed nuclei (red plus signs in A-J) and were associated with condensed cytoplasm, 
detachment from the substrate and loss of p75NTR and NF-κB immunoreactivity (B, F, H, 
J). Few OECs appeared apoptotic in untreated or 60nM ionophore treated cultures but 
apoptosis increased with increasing ionophore concentration until the majority of OECs 
appeared apoptotic with 1μM ionophore. Scale bar is 50μm. K: Quantitative analysis of 
OEC apoptosis. OECs with condensed nuclei were scored as apoptotic. Less than 5% of 
OECs were apoptotic in untreated or 60nM ionophore treated cultures. With each 
following increase in ionophore concentration, there was a significant increase in the 
percentage of apoptotic OECs (p < 0.001, 60nM to125nM; p < 0.01, 125nM to 500nM; p 
< 0.001, 500nM to 1μM). Data were analysed by ANOVA and post-hoc Tukey’s multiple 
comparison test. Percentages are means ± SEM, n = 8. Asterisks denote significant 
differences: ** p < 0.01, *** p < 0.001. 
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the TUNEL assay or Hoechst staining of nuclei. However, TUNEL assay by flow 
cytometry detected a significantly much higher percentage of apoptotic nuclei for 
untreated astrocytes (26.18±3.20%; p < 0.001). For the 1μM ionophore-treated astrocytes, 
similar levels of apoptosis were detected by flow cytometric TUNEL assay 
(53.20±4.11%) and fluorescence microscopy of Hoechst staining (58.48±4.94%) but 
higher levels were detected by fluorescence microscopic analysis of the TUNEL assays 
(77.51±5.33%).  
 
5.27 Flow cytometry did not detect any modulation of ionophore-induced astrocyte 
apoptosis by OECs, fibroblasts or microglia 
Apoptosis was then compared by flow cytometric TUNEL assay for astrocytes treated for 
8 hours with 1μM ionophore in medium conditioned by astrocytes, OECs, fibroblasts or 
microglia (Fig. 5.8). Rather than fresh DMEM, astrocyte CM was the control for 
comparison with the media conditioned by the other cell types, as it was possible that 
depletion of nutrients from media by cells during conditioning could contribute to the 
induction of apoptosis. Detected events were plotted on log FITC fluorescence (520nm) 
intensity against log propidium iodide fluorescence (623nm) intensity graphs (Fig. 5.8A-
D) and using the same co-ordinates as previously (Fig. 5.7), events in the upper right 
quadrant were scored as apoptotic astrocytes. The detected events graphed as in Figs. 5.7 
and 5.8 reached the preset recordable maximum of 20,000 for all the kit control samples 
whereas for the astrocyte samples, detected events varied between 1278 and 9728 and 
averaged 4745. Significantly more apoptotic astrocytes were detected after ionophore 
treatment (p < 0.001) independent of the medium conditions, there being no significant 
differences (p > 0.05) in the percentages of apoptotic astrocytes that ranged from 
50.35±3.49% for astrocytes in OEC CM to 57.55±2.57% for astrocytes in microglia CM 
(Fig. 5.8E).  This result agreed with the results from Hoechst staining of 500nM 
ionophore-treated astrocytes in OEC CM and microglia CM (Fig. 5.4), where there was 
also no significant effect attributable to the conditioned media. 
 
5.28 Ionophore rapidly induced apoptosis of OECs 
Although PMA/ionophore did not induce NF-κB translocation in OECs, apoptosis 
appeared to be occurring much sooner after treatment in OEC cultures than in astrocyte 
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cultures for the same ionophore dose. Consequently, ionophore concentration-dependent 
OEC apoptosis was investigated using the images of immunostaining from OEC 
activation experiments. Apoptosis was compared in OEC cultures that were untreated or 
treated for 3 hours with 60nM, 125nM, 500nM or 1μM ionophore (Fig. 5.9). Apoptotic 
cells were identified by condensed nuclei and were associated with condensed cytoplasm, 
detachment from the substrate and loss of p75NTR and NF-κB immunoreactivity (Fig. 
5.9A-J). Less than 5% of OECs were apoptotic in untreated or 60nM ionophore treated 
cultures (Fig. 5.9K) but thereafter with each increase in ionophore concentration there 
was a significant increase in the percentage of apoptotic OECs to 19.31±2.62% at 125nM 
(p < 0.001), 33.91±2.80% at 500nM (p < 0.01) and 60.16±5.20% at 1μM (p < 0.001). At 
the higher ionophore concentrations, as apoptosis increased, many OECs appeared to 
have detached from the substrate displaying sinusoidal processes and a tendency to form 
clumps (Fig. 5.9H, J). Few OECs remained attached to coverslips preventing any analysis 
following treatment with 125nM to 1μM ionophore for 6 to 8 hours. Similar levels of 
apoptosis were found in astrocyte cultures at these longer treatment durations (Figs. 5.4, 
5.6) as found after only 3 hours of treatment for OECs.  
 
5.3 Discussion 
5.30 Ionophore induced astrocyte apoptosis 
In addition to activating astrocytes by inducing NF-κB translocation, PMA/ionophore 
robustly induced astrocyte apoptosis within 6 to 8 hours of treatment. Ionophore more 
strongly induced NF-κB translocation than PMA and appeared to be entirely responsible 
for the induction of apoptosis, with the usual stimulus dose of 20ng/mL PMA alone not 
inducing any increase in astrocyte apoptosis. There was a trend towards increased 
apoptosis with combined PMA/ionophore compared with ionophore alone, although this 
was not investigated over a range of PMA and ionophore doses. It is possible that 
stimulation of oxidative phosphorylation and metabolism through stimulation of protein 
kinase C and calcium signalling pathways by combined PMA/ionophore could promote 
ROS production and increase the susceptibility of astrocytes to the apoptotic effects of 
ionophore-induced increases in intracellular calcium levels.  
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5.31 Hoechst nuclear staining and TUNEL assays detected similar levels of astrocyte 
apoptosis 
Similar results were obtained using Hoechst staining of nuclei and TUNEL staining with 
microscopy or flow cytometry. However, flow cytometry detected far fewer cells in 
astrocyte samples than in the control lymphocyte samples from the TUNEL kit. This was 
presumably due to loss of astrocytes by disintegration or adherence to plastic tubes 
during sample preparation and suggested that flow cytometry may not be a suitable 
method for adherent cells, such as astrocytes. A further problem with the flow cytometric 
method was the necessity for removing the adherent cells from culture flasks by 
trypsinisation, which itself induces some apoptosis. This probably explains the 
significantly higher level of apoptosis found in untreated astrocyte cultures by flow 
cytometry compared with microscopy and could have obscured any treatment differences 
in apoptosis. While TUNEL staining provided less ambiguous detection of apoptotic cells 
than Hoechst staining, both methods yielded similar results and only detected apoptosis at 
a relatively late stage in the process. Apoptosis assays that detect cytochrome c release 
from mitochondria or alterations of the plasma membrane could detect apoptosis at 
earlier stages. These methods could possibly provide results that are more accurate by 
avoiding the loss of detached cells that occurs at later stages of apoptosis in vitro. 
 
5.32 Ionophore-induced astrocyte apoptosis may be independent of NF-κB 
translocation 
The apoptotic effect of ionophore was dose-dependent with large increases in the 
percentage of apoptotic astrocytes from basal levels of apoptosis with 125nM ionophore 
to the large majority of astrocytes becoming apoptotic with 1μM ionophore after 8 hours 
of treatment. To some extent, these results were consistent with the view that stronger 
activation of NF-κB can promote apoptosis. Although there was no significant difference 
in astrocyte activation across the range of ionophore concentrations tested there did 
appear to be more intense nuclear NF-κB immunoreactivity at higher ionophore 
concentrations. Elevation of intracellular calcium by ionophore treatment induces 
apoptosis and this mechanism may have induced astrocyte apoptosis independent of 
ionophore stimulation of NF-κB translocation. The apoptotic effects of ionophore 
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occurred within 8 hours of treatment, too soon for any substantial protein expression 
changes deriving from the NF-κB activation, implying that the induction of apoptosis and 
NF-κB translocation were most probably independent effects. Furthermore, although 
there was no systematic investigation of the apoptotic time-course, morphological 
indications of apoptosis did occur at much earlier time-points. 
 
5.33 OECs, microglia and fibroblasts did not modulate astrocyte apoptosis 
There was no evidence for the modulation of astrocyte apoptosis by medium conditioned 
by microglia, OECs or fibroblasts. Microglia-conditioned medium induced NF-κB 
translocation in astrocytes in a similar manner to PMA/ionophore but did not induce 
apoptosis in astrocytes or modulate the ionophore-induced apoptosis. This result provided 
strong evidence that the activation of NF-κB and induction of apoptosis in astrocytes 
were independent processes within the experimental conditions utilised in this research. 
Pro-inflammatory cytokines released by activated microglia, particularly Il-1β and TNF-
α, are the probable components of the microglia-conditioned medium that activate NF-
κB in astrocytes. Unlike ionophore, these cytokines do not directly promote increased 
intracellular calcium levels and the microglia-conditioned medium did not promote 
apoptosis, inferring that the initiating factor for astrocyte apoptosis was elevated 
intracellular calcium levels rather than NF-κB translocation. It is also possible that 
microglia-conditioned medium preferentially stimulated the expression of anti-apoptotic 
NF-κB-dependent genes in astrocytes, since TNF-α can promote the expression of anti-
apoptotic factors that protect against ionophore-induced calcium influx (Wernyj et al., 
1999) and NF-κB activation can promote the expression of factors that protect against 
TNF-α-induced apoptosis (Groesdonk et al., 2007; Rami et al., 2008). However, the 
composition of the microglia-conditioned medium is unknown and it did not inhibit the 
ionophore-induced apoptosis. Excessive intracellular calcium resulting from ischemia is a 
crucial determinant of neuronal apoptosis following CNS injury (Verkhratsky, 2006, 
2007; Doyle et al., 2008; Nakka et al., 2008; Broughton et al., 2009) and this research 
suggests that the same probably applies to astrocytes. Modification of the 
PMA/ionophore treatment model by varying the ionophore dose and extracellular 
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calcium levels could possibly mimic injuries of different severity or different regions in 
the injury penumbra. 
 
5.34 OECs are more susceptible to ionophore-induced apoptosis than astrocytes 
The moderation of NF-κB translocation by OECs was not accompanied by any 
corresponding evidence of the moderation of ionophore-induced astrocyte apoptosis by 
OEC-conditioned medium. This result was again consistent with separate pathways 
regulating ionophore-induced NF-κB translocation and ionophore-induced apoptosis in 
astrocytes. In addition to not protecting astrocytes from the ionophore-induced apoptosis, 
OECs were themselves significantly more susceptible to the apoptotic effects of 
ionophore than astrocytes. Apoptosis was induced more rapidly and at lower ionophore 
doses in OECs than in astrocytes. This susceptibility to apoptosis in response to calcium 
influx may have implications for the use of OECs as therapeutic implants because 
extracellular calcium levels are elevated following cellular and vascular damage by CNS 
injury. Although microglia-conditioned medium did not induce apoptosis in astrocytes, it 
would be informative to determine whether OECs were also susceptible to apoptosis in 
response to factors released by microglia. In addition to testing the effects of microglia-
conditioned medium, it would be relevant to test the effects of pro-inflammatory 
cytokines, such as TNF-α and IL-1β, on OEC apoptosis, since these are produced by 
activated microglia, astrocytes and peripheral macrophages at CNS injury sites. For 
similar reasons, comparisons between the responses of OECs and astrocytes to reactive 
oxygen species could provide further insight into the responses of transplanted OECs at 
injury sites. 
 
 
5.35 Conclusions 
Astrocytes are less susceptible than neurons to apoptosis following CNS injury partly due 
to their superior glutamate and calcium buffering capacity (Cornell-Bell et al., 1990; Kim 
et al., 1994; Verkhratsky et al., 1998; Verkhratsky, 2006; Iadecola and Nedergaard, 2007; 
Wang and Bordey, 2008). However, the severe disruption of extracellular homeostasis 
following CNS injury can overcome even the calcium buffering capacity of astrocytes, 
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leading to disruption of mitochondrial membranes and the initiation of apoptosis 
(Swanson et al., 1997; Takuma et al., 1999; Matute et al., 2002). Thus, ionophore-
induced astrocyte apoptosis represents a useful model of astrocyte apoptosis ensuing 
from CNS injury. The greater resistance of astrocytes to the ionophore-induced apoptosis 
suggests that they have superior calcium buffering to OECs. Consequently, OECs 
transplanted into ischemic regions of CNS lesions, where there are high levels of 
extracellular calcium ions, glutamate and ATP could become apoptotic due to excessive 
calcium influx. Disruption of the surviving vasculature during OEC transplantation could 
re-initiate ischemia and in vivo research may be required to determine the optimal timing 
and location for transplanting OECs. It may be preferable to introduce therapeutic OEC 
transplants away from the ischemic core of injuries and, as far as possible, without 
disrupting the surviving vasculature. However, correct location of OEC transplants to 
allow interaction with astrocytes and possibly migration of OECs in a suitable direction 
for axon regeneration may also be necessary to promote axon regrowth (Raisman, 2000; 
Li et al., 2005b; Teng et al., 2008). Once inflammation subsides, any remnant lesion 
cavity may be the ideal location for OEC transplantation and moderate inflammation 
induced by the transplant procedure may stimulate cellular mobilisation and neurite 
sprouting. It is perhaps relevant to these observations that OECs transplanted directly into 
corticospinal cord lesion cavities, 8 weeks after injury, promoted spinal cord repair and 
some recovery of motor function but had no beneficial effect when misplaced a few 
hundred microns dorsal to cavities (Keyvan-Fouladi et al., 2003). However, ionophore 
directly transports calcium ions across membranes down the concentration gradient 
(Mitani and Otake, 1978; Fasolato and Pozzan, 1989; Dedkova et al., 2000) and in the 
absence of this reagent, the relationship between extracellular calcium levels and 
excessive calcium influx would depend on the expression and function of calcium 
channels and pumps in OECs. 
  
ATP and glutamate released from olfactory neurons can evoke calcium signalling in 
OECs with similarities to the calcium signalling that occurs in astrocytes in response to 
neural activity (Rieger et al., 2007). Other evidence based on measurements of 
intracellular calcium ion concentrations suggest that OECs have unusual calcium 
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dynamics, including high resting intracellular calcium ion levels and the absence of 
voltage-gated calcium channels (Hayat et al., 2003). These features of OEC biology may 
explain their vulnerability to ionophore-induced calcium influx and in this regard, it 
would be informative to investigate the comparative expression of calcium channels and 
pumps in OECs and astrocytes using immunocytochemistry. OEC susceptibility to 
apoptosis may relate to a normal physiological role during the turnover and replacement 
of olfactory neurons. Rather than becoming activated by physiological challenges, OECs 
surrounding olfactory nerve fascicles could undergo apoptosis, thus initiating apoptosis 
and replacement of the olfactory neurons. This could represent a defence mechanism 
against the spread of infections along the olfactory tract into the CNS, when an 
inflammatory challenge is too severe for any protective anti-inflammatory or innate 
immune functions of OECs. However, it is uncertain whether OECs are replaced or, 
instead, axons regrow within channels formed by surviving OECs, during olfactory 
neuron turnover. Further investigation of OEC responses to other inflammatory and 
apoptotic stimuli could shed light on the physiological and therapeutic importance of the 
susceptibility of OECs to ionophore-induced apoptosis.  
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CHAPTER 6:  
Summary and further research 
 
6.0 A mechanism for the therapeutic effects of OEC transplants 
The unique regenerative capacity of olfactory neurons has led to research related to the 
use of olfactory ensheathing cell (OEC) transplantation as a therapy for CNS injury, 
including this study. While there is considerable evidence for improved CNS tissue repair 
in response to OEC transplants, some evidence is inconsistent and debate continues 
regarding the possible mechanisms for the reported therapeutic effects. Chapter 4 of this 
thesis shows that OECs can moderate the inflammatory activation of astrocytes in vitro 
and explains how this represents a plausible mechanism that could contribute to improved 
neuroprotection and tissue regeneration in response to OEC transplantation after CNS 
injury. Briefly, strong inflammatory activation of astrocytes in response to CNS injury 
increases production of pro-inflammatory mediators leading to increased neuronal 
damage and the formation of a glial scar, which presents a major impediment to axonal 
regeneration. NF-κB is a key regulator of inflammatory genes and is essential for these 
robust inflammatory responses. Chapter 4 shows that soluble factors released from OECs 
moderated NF-κB translocation in astrocytes in vitro. OECs also moderated astrocytic 
transcription of the NF-κB-dependent pro-inflammatory cytokine, GM-CSF, confirming 
the physiological relevance of the moderation in NF-κB translocation. Hence, if 
transplanted OECs had a similar moderating effect on astrocyte inflammatory activation 
in vivo, this mechanism could both enhance both neuronal survival and axon regrowth 
following CNS injury.  In addition to this major research finding, the study: 
 
• identified insulin-like growth factor 1 (IGF-1) as a possible component of the 
OEC-derived factors that could contribute to the anti-inflammatory effects  
• identified a resistance of OECs to inflammatory stimuli  
• optimised a protocol for growing highly purified OEC cultures that can be used 
for transplantation and related research 
•  established an effective in vitro model of astrocyte inflammatory activation  
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• identified a susceptibility of OECs to apoptosis induced by calcium ion influx, 
which may have implications for the timing and location of therapeutic OEC 
implants in the injured CNS. 
 
6.1 Was the in vitro research with cultured OECs relevant?  
6.10 The in vitro research paradigm 
Chapter 2 of this thesis established protocols for the preparation of high purity OEC 
monocultures from olfactory bulbs suitable for research into OEC biology and OEC 
transplantation therapy for CNS injury. In vitro cell culture provides a simplified research 
paradigm that may help to identify useful therapeutic targets by revealing relevant 
underlying components of the complex responses to injury in CNS tissue. This 
justification of the cell-culture research paradigm self-evidently requires the capability 
for preparing cultures that are demonstrably monocultures of specific cell types relevant 
to the intended research (Crang and Blakemore, 1997; Szabo et al., 1997; Silva et al., 
1998; Yang and Hernandez, 2003). However, it is difficult to prepare 100% 
homogeneous primary cell monocultures from live tissue and in addition, definitions and 
identification of specific cell types may be uncertain (McCarthy and De Vellis, 1980; 
Morrison and de Vellis, 1981; Crang and Blakemore, 1997). Although pure monocultures 
can be prepared using clonal cell lines, they do not have identical phenotypes to the 
primary cells from which they derive (Kikuchi et al., 1993; Gendron et al., 2003; Kim et 
al., 2006). Therefore, research findings relating to tissue responses based on cell line 
cultures may be of questionable relevance.  
 
6.11 Are there important differences between olfactory bulb and lamina propria OECs? 
6.11.0 Mucosal and bulbar OEC cultures 
OEC cultures for experiments were prepared using only olfactory bulb tissue since these 
cultures consisted predominantly of Schwann cell-like OECs, were less likely to contain 
contaminating Schwann cells (Kawaja et al., 2009) and had fewer contaminating 
fibroblasts (Ruitenberg et al., 2005). Sourcing OECs from the more accessible peripheral 
lamina propria tissue would obviously be preferable for autologous transplantation 
(Ramer et al., 2004b; Feron et al., 2005; Mackay-Sim et al., 2008). However, this 
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research using OECs from the olfactory bulbs remains relevant, since bulbar and laminar 
propria OECs are believed to represent a single population of cells with a common origin 
in the olfactory placode (Doucette, 1993; Chuah and West, 2002; Au and Roskams, 2003). 
A subpopulation of horizontal basal cells in the epithelium of the olfactory mucosa 
appears to be the source of OEC progenitors (Carter et al., 2004). During development, 
the immature OECs probably migrate along the peripheral olfactory tract and into the 
olfactory bulbs as they ensheath bundles of olfactory neuron axons along this entire tract 
(Doucette, 1990, 1993b). The different mode of ensheathment of olfactory neurons in the 
peripheral olfactory tract and the olfactory bulbs, together with the possibility of 
immature OECs in cultures from the mucosa, led to research comparing therapeutic 
transplants of OECs cultured from mucosal and bulbar tissue (Richter et al., 2005). 
However, differences between cultures of mucosal and bulbar OECs appear to arise 
predominantly from the different proportions of contaminating cells (Au and Roskams, 
2003; Jani and Raisman, 2004; Kumar et al., 2005; Krudewig et al., 2006; Smith et al. 
2002). Mucosal OEC cultures contain more fibroblasts while bulbar OEC cultures 
contain more astrocytes. The mucosal cultures are reported to continue proliferating for 
longer than the bulbar cultures possibly due to the presence of OEC progenitors or the 
influence of fibroblast-derived growth factors. However, purified mature OECs from 
either source tissue have similar antigenic profiles and abilities to promote neurite growth 
in vitro. Recent comparative gene expression profiling of OECs from olfactory bulb and 
olfactory mucosa identified more genes associated with neurogenesis, angiogenesis, 
inflammation and hematopoiesis in the olfactory bulb OECs and more extracellular 
matrix  and tissue repair related genes in the olfactory mucosal OECs (Guerout et al., 
2010). This result is consistent with the identification of potentially neuroprotective anti-
inflammatory factors expressed by olfactory bulb-derived OECs in this research and 
allows for the possibility that OECs from each source could have therapeutic effects 
through somewhat different mechanisms. However, these differences may again have 
been due to more contamination of mucosal cultures by fibroblasts and of bulbar cultures 
by astrocytes, since fibroblast growth factor was more prominent in the mucosal OEC 
profile and GFAP was more prominent in the bulbar OEC samples. Unfortunately, none 
of the genetic profiling studies on OECs (Vincent et al., 2005; Pastrana et al., 2006; 
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Franssen et al., 2008; Guerout et al., 2010) make comparisons with fibroblasts, which this 
and other studies (Smith et al. 2002; Jani and Raisman, 2004; Kumar et al., 2005; 
Krudewig et al., 2006) identify as the most frequent contaminating cell type in OEC 
cultures. If the differently expressed genes in mucosal relative to bulbar OEC cultures 
were also more highly expressed by fibroblasts, it would imply that relatively greater 
fibroblast contamination of the mucosal cultures could account for the differences. 
Further research is clearly required to determine the most effective method for obtaining 
purified cultures and comparative phenotyping of OECs from either source tissue, and of 
the relative efficacy of these cells as therapeutic transplants. A culture method based on 
the differential adhesion of OECs and contaminating cell types (Nash et al., 2002; Smith 
et al. 2002; Jani and Raisman, 2004; Kumar et al., 2005; Krudewig et al., 2006; Sasaki et 
al., 2006) combined with the mitotic inhibitor, cytosine-β-D-arabinofuranoside, used to 
deplete contaminating cells in this study, could possibly enable the reliable production of 
highly purified OECs from either of the source tissues. 
 
6.11.1 Therapeutic transplantation of mucosal and bulbar OECs 
Furthermore, transplants of OECs cultured from CNS olfactory bulbs (Lakatos et al., 
2003a; Sasaki et al., 2006; Lopez-Vales et al., 2007; Mackay-Sim et al., 2008), peripheral 
lamina propria (Ramer et al., 2004b; Mackay-Sim, 2005; Richter et al., 2005) or pooled 
tissue from both sources (Chuah et al., 2004; Teng et al., 2008) have all been reported to 
improve recovery from CNS injury. Some of the conflicting results in studies using either 
mucosal or bulbar OEC transplants have been attributed to possible phenotypic 
differences between the OECs (Ramer et al., 2004a) and there is some evidence that 
mucosal OECs are more beneficial when transplanted after CNS injury (Richter et al., 
2005). However, other studies could not replicate this finding (Ramer et al., 2004a; Lu et 
al., 2006) and the reported differences between peripheral and bulbar OECs may have 
been due to the presence of contaminating fibroblasts in the mucosal cultures (Jani and 
Raisman, 2004; Kumar et al., 2005; Mackay-Sim, 2005). Ramer et al., 2004 used Thy1.1 
mediated lysis to remove fibroblasts from the mucosal cultures and a p75NTR 
immunopanning method to purify the bulbar cultures and the different methods could 
have resulted in different proportions of contaminating cells in the cultures. Schwann 
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cells are present in the peripheral olfactory tract and, in common with OECs, express 
p75NTR, while both cell types also express Thy1.1, albeit at lower levels than fibroblasts 
(Smith et al. 2002; Jani and Raisman, 2004; Kumar et al., 2005; Krudewig et al., 2006). 
Thy1.1 mediated lysis and p75NTR or O4 antigen immunopanning have been found to be 
ineffective methods for eliminating contaminating cells from OEC or Schwann cell 
cultures (Smith et al. 2002; Jani and Raisman, 2004; Ratner et al., 2006; Kawaja et al., 
2009) and other researchers have reported the difficulty of eliminating fibroblasts from 
mucosal OEC cultures (Ruitenberg et al., 2006; Teng et al., 2008). Therefore, variable 
numbers of fibroblasts, Schwann cells and astrocytes could have been transplanted along 
with OECs in the many studies whether using these purification methods (Barnett et al., 
1993; Ramon-Cueto and Nieto-Sampedro, 1994; Ramon-Cueto et al., 1998, 2000; Plant 
et al., 2002, 2003; Ruitenberg et al., 2003; Ramer et al., 2004a, b; Lu et al, 2006), no 
specific purification procedure (Feron et al, 2005; Deng et al., 2006) or intentionally 
unpurified OEC cultures (Li et al., 1998, 2003; Sonigra et al., 1999; Lakatos et al., 2003; 
Teng et al., 2008). The possible therapeutic contribution of fibroblasts inadvertently 
introduced during OEC transplantation has led to research suggesting that transplants of 
OECs combined with meningeal fibroblasts are reportedly more beneficial in axonal 
repair and regeneration than transplants of OECs alone (Lakatos et al., 2003b; Li et al., 
2005; Teng et al., 2008) and this current research project suggests that lamina propria 
cultures may be more susceptible to fibroblast contamination. Therefore, reported 
differences in the therapeutic efficacy of OECs from the lamina propria and olfactory 
bulbs may have arisen merely from the different contributions of contaminating cells to 
the cultures from each tissue source. This question regarding the cellular composition of 
cultures used for transplants underlines the importance of directly identifying the cell 
types responsible for measured effects. The immunohistochemical method for measuring 
cellular inflammatory activation utilised in this research had the advantage of enabling 
simultaneous identification of cell type by counterstaining with antibodies against 
specific marker proteins.  Even if OECs from the olfactory bulbs represent a separate 
population, this research project could provide important evidence concerning this cell 
population for comparison with other studies using OECs cultured from the olfactory 
mucosa. Similarly, any lingering uncertainty about whether OECs constitute a separate 
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cell type or are a variant of non-myelinating Schwann cells may ultimately have little 
relevance for their therapeutic value. The constant turnover and regeneration of olfactory 
neurons and progenitors in the olfactory epithelium implies a probable role for OECs in 
the regeneration and allows their harvesting from the olfactory system for autologous 
transplant without causing undue trauma or disruption of normal function. Identification 
of the proteins responsible for the therapeutic effects of OECs may eventually lead to the 
development of OEC-based transgenic cell lines expressing a variety of beneficial 
molecules for CNS injury transplantation therapy. 
 
6.2 The in vitro astrocyte activation model 
6.20 Further investigation of the effects of NF-κB translocation in astrocytes 
 Phorbol myristate acetate (PMA) and calcium ionophore (PMA/ionophore) consistently 
induced rapid robust translocation of p65 NF-κB from the cytoplasm to the nucleus in 
astrocytes, providing an effective in vitro model of astrocyte inflammatory activation that 
is highly relevant for CNS injury research. Immunocytochemistry allowed simultaneous 
detection of NF-κB subcellular localisation with counterstaining for GFAP to identify 
astrocytes, thus providing simple, direct, unambiguous detection of the astrocyte 
activation. The treatment model is highly relevant for CNS injury research because the 
PMA/ionophore activation of NF-κB, through the PKC and calcium signaling pathways, 
simulates inflammatory activation during CNS injury responses. Specific inhibitors and 
activators of signaling molecules, genetically modified cells and protein constructs could 
be utilised in this treatment model to help decipher the mechanisms for the anti-
inflammatory effects of OECs. Microglia-conditioned medium promoted NF-κB 
translocation similarly to PMA/ionophore in astrocytes, supporting the physiological 
relevance of the reagent treatment, since cytokines and other factors released by 
microglia contribute to inflammatory responses after CNS injury. However, the 
composition of the conditioned medium was unknown and may have varied between 
cultures. Specific inflammatory cytokines, particularly IL-1β and TNF-α, and other 
known microglia-derived factors would be more informative treatments for further 
investigation of the mechanisms of NF-κB activation in astrocytes and the anti-
inflammatory effects of OECs. Although there was no significant difference in NF-κB 
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translocation for ionophore doses from 125nM to 1μM and PMA doses from 20ng/mL to 
200ng/mL, the protocol for measuring NF-κB translocation did not take into account any 
differences in NF-κB immunoreactivity intensity in nuclei above an arbitrary threshold. 
While it is uncertain whether there would be any functional importance to such 
differences, it is plausible that more intense immunostaining would indicate more NF-κB 
had translocated to the nucleus and this could result in greater enhancement of 
transcription. For similar reasons, although nuclear NF-κB immunoreactivity intensity 
was lower than the arbitrary detection threshold at time-points following the peak 
response, nuclear NF-κB could have remained higher than levels prior to treatment and 
may have been sufficient to maintain increased gene transcription. This could explain 
why combining PMA/ionophore with microglia-conditioned medium had an additive 
effect only on GM-CSF transcription and not on the measured NF-κB activation. 
However, it is also plausible that factors in the microglia-conditioned medium promoted 
transcription through pathways independent of NF-κB activation. Western blotting of 
nuclear and cytoplasmic fractions of astrocytes and/or chromatin immunoprecipitation 
assay for NF-κB subunits (Butler et al., 2002; Brettingham-Moore et al., 2005a) in 
conjunction with the immunocytochemistry could provide a more accurate indication of 
relative activation levels in the cultures. While, the stimulation of GM-CSF transcription 
in astrocytes by PMA/ionophore supported the physiological relevance of the NF-κB 
translocation, a causal relationship between these effects should ideally be confirmed 
using specific inhibition of NF-κB. Stronger evidence of the physiological relevance of 
the NF-κB translocation could be gained by measuring transcription of the numerous 
other NF-κB-dependent pro-inflammatory mediators produced by astrocytes, particularly 
IL-1β, TNF-α, IL-6, iNOS, COX-2 and chemokines. Assays for cytokines, nitric oxide 
and reactive oxygen species, together with Western blots for expression of proteins 
associated with astrogliosis, such as GFAP and CSPGs, could provide further relevant 
corroborative evidence. Testing the effects of OECs on these additional parameters could 
reveal more detail relevant to the therapeutic effects of OEC transplants that may assist in 
isolating therapeutic molecules.  
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6.21 Implications for the timing and location of therapeutic OEC implants 
Most importantly, Chapter 4 showed that soluble factors released by OECs significantly 
moderated NF-κB translocation in astrocytes, whether it was induced by PMA/ionophore 
or microglia. Chapter 5 shows that in addition to activating NF-κB, calcium influx 
induced by ionophore treatment promoted apoptosis in a dose-dependent manner. The 
apoptotic effect of ionophore appeared to be independent of NF-κB activation, since 
unlike NF-κB translocation, the astrocyte apoptosis was unaffected by soluble factors 
from either OECs or microglia. Interestingly, although PMA/ionophore and microglia did 
not activate NF-κB in OECs, they were more susceptible to ionophore-induced apoptosis 
than astrocytes. This finding further supports the independence of ionophore-induced NF-
κB activation and apoptosis, and implies that the therapeutic success of OEC implants 
may depend on the severity of inflammation at the implantation site. For the in vitro 
experiments, astrocytes were exposed to co-cultured OECs or OEC-conditioned medium 
for at least 24 hours before activation to allow establishment of the cultures and to avoid 
any confounding effects of abrupt media changes. This pre-incubation could be 
interpreted as a caveat against the anti-inflammatory effects of OECs being replicated 
when transplanted directly into inflamed CNS tissue. However, establishment of the OEC 
cultures, particularly in co-culture with astrocytes, could be likened to implantation of 
OECs into the CNS. The experimental findings suggest that as long as the OECs survived 
transplantation they could, once established, exert the same anti-inflammatory influence 
seen in vitro. The transient and asynchronous pattern of NF-κB activation in the cultured 
astrocytes is particularly relevant to this question, since it implies that not all astrocytes 
would be equally activated at the time of implantation. Whether OECs could moderate 
the responses of astrocytes where NF-κB was pre-activated or could only prevent the 
spread of inflammation to quiescent astrocytes would depend on the mechanism for their 
anti-inflammatory effects. The lack of response to PMA/ionophore and microglia implies 
that is unlikely implanted OECs would be activated by inflammatory mediators released 
by microglia or by other factors evoked by CNS injury that stimulate PKC or calcium ion 
influx. Therefore, implanted OECs would probably be able to maintain the quiescent in 
vitro phenotype to enable the moderation of astrocyte inflammatory activation 
surrounding the implantation site.  However, OECs were more susceptible to ionophore-
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induced apoptosis and could become apoptotic due to excessive calcium influx if 
transplanted into ischemic regions of CNS lesions where there are high levels of 
extracellular calcium ions, glutamate and ATP. Previous research showing that tissue 
repair and functional recovery required precise transplantation of OECs into corticospinal 
tract lesion cavities (Keyvan-Fouladi et al., 2003) may have been partly related to this 
susceptibility of OECs to calcium influx-induced apoptosis.  Furthermore, disruption of 
the surviving vasculature during OEC transplantation could re-initiate ischemia and in 
vivo research may be required to determine the optimal timing and location for 
transplanting OECs. Both the OEC moderation of astrocyte activation and the absence of 
OEC inflammatory activation imply that if transplanted OECs survive, they are likely to 
enhance neuronal survival by moderating inflammation. Once the initial severe ischemia 
due to a CNS injury has subsided, any remnant lesion cavity may present the ideal 
location for OEC implantation. OEC implantation could fill the cavity with non-
inflammatory, axon growth-promoting cells without disrupting the blood supply. 
Transplanted OECs could release IGF-1 and other soluble factors to moderate 
inflammation in the surrounding reactive astrocytes. The anti-inflammatory effects could 
protect neurons, promote neurogenesis and may also promote infiltration of the scar 
tissue by the OECs, to possibly form a permissive conduit for axon-growth through the 
glial scar and across the lesion. It may be that the inclusion of fibroblasts and/or Schwann 
cells with the transplanted OECs would be required to create the necessary aligned 
substrate for substantial axon regrowth (Ruitenberg et al., 2006; Bunge, 2008; Ruitenberg 
and Vukovic, 2008; Teng et al., 2008). With regard to the anti-inflammatory effects of 
OECs identified by this research, it is interesting that a combination treatment of 
methylprednisolone and OECs for corticospinal tract lesion in rats was shown to be 
significantly more effective than methylprednisolone alone and OECs alone were almost 
as effective as the combined treatment in improving axonal regeneration and improved 
neurological outcomes (Nash et al, 2002). This result is not inconsistent with the 
possibility that the anti-inflammatory effect of OECs identified in this study is replicated 
by transplanted OECs and confers a therapeutic effect of similar magnitude to that of 
methylprednisolone. While the therapeutic effects of methylprednisolone are probably 
due to its anti-oxidant activity, transplanted OECs could indirectly moderate the 
 230
production of reactive oxygen species, through their anti-inflammatory effects on 
astrocytes, to achieve similarly beneficial effects. If so, utilising these anti-inflammatory 
properties by transplanting OECs near the lesion, could avoid the systemic immune 
suppression problems (Bracken and Holford, 2002; Kronvall et al., 2005; Sorensen, 2008) 
associated with intravenous treatments, such as methylprednisolone. Dependent on the 
survival time of transplanted OECs, they could also provide a physiological dose of the 
therapeutic factors, targeted precisely to the injury site for an extended period. While the 
in vitro research showed that OECs could moderate astrocyte activation induced by 
microglia-derived factors, there was no investigation of direct OEC effects on the 
activation of microglia. Further investigation of NF-κB activation during interactions 
between neurons, astrocytes, OECs, activated microglia and peripheral macrophages, 
which all participate in CNS injury responses and coexist in the olfactory system, could 
provide additional evidence on the therapeutic potential of OECs and their normal 
physiological role in the olfactory system.  
 
6.22 Identification of active components of the OEC-derived soluble factors 
Identification of the active components responsible for the OEC moderation of astrocyte 
activation could allow the development of molecular therapies that would avoid the 
potential complications of apoptosis and the re-initiation of ischemia associated with cell 
transplantation. However, the physical interaction between OECs, astrocytes and axonal 
growth cones may be an important component of the therapeutic mechanism of 
transplanted OECs. In addition, there may be a range of protective factors produced by 
OECs, with some possibly limited to paracrine effects requiring close proximity to the 
target tissues. OECs do express fractalkine, the only known membrane-bound chemokine, 
which mediates its effects by binding to the specific CX3CR1 receptor that is expressed 
by microglia, macrophages and other peripheral leukocytes (Cardona et al., 2006; 
Ruitenberg et al., 2008). Constitutive neuronal fractalkine expression has been shown to 
exert neuroprotective anti-inflammatory effects on microglia (Cardona et al., 2006; Held-
Feindt et al., 2010; Lauro et al., 2010). OEC and olfactory neuronal expression of 
fractalkine could have similar constitutive anti-inflammatory actions on microglia and 
macrophages in the olfactory tract (Ruitenberg et al., 2008). Fractalkine expression could 
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therefore contribute a contact-dependent component to the anti-inflammatory activity of 
transplanted OECs. Although the effect of the soluble anti-inflammatory factor inferred 
by this research was maintained in conditioned medium it could be rapidly inactivated by 
other factors following in vivo OEC transplantation. Insulin-like growth factor 1 (IGF-1) 
was identified as a factor expressed by OECs that could contribute to the anti-
inflammatory effects. IGF-1 is expressed by macrophages, reactive astrocytes, neurons 
and microglia in damaged tissue following traumatic brain injury in rats and appears to 
regulate gliosis and axonal sprouting in both an autocrine and paracrine manner (Walter 
et al., 1997). Interestingly, some of the neuroprotective effects of estradiol may be 
mediated by its promotion of IGF-1 production by astrocytes (Kipp and Beyer, 2009). 
Previous research indicates that IGF-1 recruitment of calcineurin can inhibit NF-κB and 
nuclear factor of activated T-cells (NFAT) activity resulting in the moderation of the 
inflammatory activation of astrocytes by TNF-α (Fernandez et al., 2007a; Perez-Ortiz et 
al., 2008). IGF-1 may similarly have moderated a calcium signalling-dependent 
component of the astrocyte activation induced by PMA/ionophore and microglia in this 
research. It would therefore be interesting to investigate the involvement of calcineurin 
and NFAT using the in vitro astrocyte activation model. In the olfactory system, IGF-1 
induces neuronal precursors to differentiate into olfactory sensory neurons and has 
similar effects in the developing CNS (Drago et al., 1991; McCurdy et al., 2005). IGF-1 
also promotes remyelination by regulating the proliferation and differentiation of 
oligodendrocyte progenitors (Drago et al., 1991; Mason et al., 2003), has neuroprotective 
effects in CNS white and grey matter under different detrimental conditions and improves 
long-term function after focal brain injury following cerebroventricular, intravenous or 
intranasal administration (Guan and Gluckman, 2009; Kooijman et al., 2009). Although 
in Chapter 4, the effect of IGF-1 was insufficient to fully account for the anti-
inflammatory effects of OECs, these previously reported effects are similar to those 
reported for OECs. It is also interesting to note that the lipoprotein receptor, megalin is 
involved in some of the neuroprotective effects of exogenous IGF-1 and its transport into 
the brain (Carro et al., 2005). Antioxidant production by OECs could also have 
contributed to the anti-inflammatory effects. High levels of antioxidants, including 
superoxide dismutase, glutathione peroxidase, catalase, ascorbate and alpha-tocopherol 
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are present in the rat nasal cavity presumably to protect cells against oxidative stress 
during immune responses to pathogens (Reed et al., 2003) and may be produced by OECs. 
Treatment with an agent that upregulated glutathione production was recently shown to 
protect against oxidative stress and peryoxynitrite-mediated protein nitration after 
traumatic brain injury (Reed et al., 2009). Understanding the biological actions and 
intracellular pathways involved in the effects of identified therapeutic molecules will be 
important for identifying targets, optimising treatments and for recognising probable 
side-effects and limitations. The development of clonal cell lines based on the OEC 
phenotype that express a range of therapeutic molecules could provide any required 
physical interaction for tissue repair in addition to enhanced production of factors that 
moderate inflammation and promote tissue repair.  
 
6.23 NF-κB dimer activity and transcription 
Astrocyte activation was measured using localisation of p65 NF-κB in this research 
because activity during CNS injury responses has been reported to involve mainly 
p65/p50 NF-κB dimers (Schneider et al., 1999; Hang et al., 2006; Ridder and 
Schwaninger, 2009). There was only low cytoplasmic immunoreactivity for c-Rel NF-κB 
in the cultured astrocytes and no translocation occurred in response to treatments, 
supporting the relevance of using p65 immunoreactivity for measuring activation. In T 
cells, PMA alone induced GM-CSF transcription more strongly (20-fold) than ionophore 
alone (~4-fold), with the increased transcription in response to both reagents being 
dependent on PKC (Brettingham-Moore et al, 2005). Only PMA induced translocation of 
NF-κB to nuclei in T cells, whereas ionophore induced calcineurin-dependent 
translocation of NFAT. Although the separate effects of PMA and ionophore on GM-
CSF transcription were not investigated in this study, ionophore alone induced NF-κB 
translocation to astrocyte nuclei more strongly than PMA alone. Interestingly, the 4-fold 
increase in T cell GM-CSF transcription induced by ionophore was just below the 5- to 7-
fold range of the increase in GM-CSF transcription induced by combined 
PMA/ionophore in astrocytes, where PMA had only a relatively small effect on NF-κB 
translocation.  The synergistic increase in GM-CSF transcription evoked by combined 
PMA and ionophore stimulation of T cells involved de novo synthesis and translocation 
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of c-Rel NF-κB to nuclei following the earlier translocation of p65 NF-κB (Brettingham-
Moore et al, 2005). Somewhat contrary to these findings, a weaker but more prolonged 
inflammatory activation has more generally been associated with c-Rel translocation in 
comparison to p65 NF-κB, which may relate to a less effective dissociation of c-Rel-
DNA complexes by IκB than for p65 or c-Rel promotion of the transcription of genes that 
suppress IκB activity (Baeuerle and Henkel, 1994). During adaptive immune responses, 
antigens induce NF-κB activation in T lymphocytes leading to the production of pro-
inflammatory cytokines and cytotoxic levels of ROS to assist the clearance of pathogens 
by macrophages. NF-κB is a constitutively active nuclear protein in mature B cells, 
which produce antibodies and also secrete IL-1β and TNF-α (Sen and Baltimore, 1986; 
Baeuerle and Henkel, 1994; Kaltschmidt et al., 1994; Wietek and O'Neill, 2007) but, 
unlike T cells, do not produce GM-CSF. Nuclear NF-κB in B cells mainly consists of c-
Rel/p50 dimers while the p50/p65 dimers are mainly cytoplasmic (Baeuerle and Henkel, 
1994; Baldwin, 1996; Chen and Greene, 2004a), consistent with the requirement for 
nuclear localisation of both p65 and c-Rel for enhanced GM-CSF transcription in T cells 
(Brettingham-Moore et al., 2008). Astrocytes have been implicated in both the cytokine 
production and antigen-presenting components of innate immune responses (Sasaki and 
Nakazato, 1992; Dong and Benveniste, 2001; Carpentier et al., 2005; Bsibsi et al., 2006) 
and macrophages produce similar inflammatory mediators to astrocytes, including M-
CSF, G-CSF, GM-CSF, TNF-α, IL-1β, IL-6, chemokines and iNOS, in response to NF-
κB activation during innate and adaptive immune responses (Muller et al., 1993; Baeuerle 
and Henkel, 1994; Muller et al., 1997). The relatively modest increase in GM-CSF 
transcription in astrocytes is consistent with the absence of c-Rel involvement and the 
moderation of transcription by OECs was possibly due to the direct inhibition of p65 NF-
κB translocation. It would therefore be informative to investigate whether OECs 
moderate the separate effects of PMA and ionophore on NF-κB translocation and GM-
CSF transcription in astrocytes and the possible involvement of protein synthesis, 
calcineurin, NFAT and chromatin remodelling in these events. 
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6.24 Does NF-κB activity reveal a hierarchy of immune functions?  
The different activity of NF-κB family members in the different cell types suggests there 
may be a related hierarchy of immune activity, with c-Rel constitutively active in mature 
B-cells for continuous antibody production, inducible c-Rel and p65 activity in T-cells 
for antigen-specific adaptive immune responses and only inducible p65 activity in 
astrocytes for their innate immune responses. These responses are probably at least 
partially regulated by variable expression levels of the IκB isoforms, which are the 
primary regulators of NF-κB activity (Suyang et al., 1996; Hoffman et al., 2007; Rao et 
al., 2010). IκBβ is degraded more slowly than IκBα in response to inflammatory stimuli 
and is re-synthesised in a hypophosphorylated form that stably binds to p65:c-Rel NF-κB 
heterodimers that cannot be inhibited by free IκBα. Unlike phosphorylated IκBβ or IκBα, 
hypophosphorylated IκBβ does not mask the nuclear localization signal or DNA binding 
domain of NF-κB. Hence, in response to persistent stimuli the newly synthesized 
hypophosphorylated IκBβ can form stable IκBβ:NF-κB complexes that enter the nucleus 
where they can bind to DNA and maintain prolonged expression of inflammatory genes. 
The results of this and previous studies suggest that OECs have only a relatively muted 
innate immune response (Vincent et al., 2007; Harris et al., 2008; Harris et al., 2009). 
Separate treatments with PMA/ionophore or microglia did not activate NF-κB in OECs. 
Even when the treatments were combined less than 5% of OECs showed nuclear 
localisation of p65 immunoreactivity. Therefore, it could prove informative to investigate 
IκB isoform expression in OECs. Perhaps OECs have high levels of constitutive IκBα 
expression and low levels of IκBβ expression, which could impart a resistance to NF-κB 
activation. This could be mediated by OEC expression of factors, such as G-protein-
coupled receptor kinases, which can promote nuclear accumulation of IκBα (Sorriento et 
al., 2008). The resultant high levels of nuclear IκBα impaired protection against 
apoptosis in endothelial cells and inhibited NF-κB activation, TNF-α production and 
inflammation, consistent with the lack of NF-κB activation and susceptibility to apoptosis 
in OECs. IGF-1 has been previously shown to inhibit TNF-α stimulation of NF-κB 
translocation in astrocytes by activating the calcium-dependent phosphatase, calcineurin, 
to dephosphorylate IκBα (Pons and Torres-Aleman, 2000). The enhanced 
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dephosphorylation of IκBα protects it against TNF-α-induced phosphorylation and 
removal from the inactivated NF-κB dimers, thus inhibiting NF-κB translocation to 
nuclei for gene transcription. IGF-1 probably inhibited NF-κB translocation in response 
to PMA/ionophore and microglia-conditioned medium by the same mechanism, 
especially considering that ionophore and thapsigargin strongly induced NF-κB 
translocation in the cultured astrocytes in a similar manner to microglia-conditioned 
medium and TNF-α is a likely component of the conditioned medium. IGF-1 expression 
was detected in OECs and could have exerted a stronger inhibitory effect on OECs than 
astrocytes because of higher expression levels of IGF-1 receptors or other factors in the 
NF-κB signalling pathway, including IκBα. Interestingly, the synthetic glucocorticoid 
dexamethasone also inhibits TNF-α stimulation of NF-κB activation via IκB, in this case 
by upregulating IκB gene transcription (Scheinman et al., 1995). If OEC moderation of 
NF-κB activation in astrocytes is also mediated by effects on IκB it would lend some 
support to the possibility that OECs could provide a targeted anti-inflammatory treatment 
that is as effective as systemic glucocorticoid treatment, without the risks of systemic 
immunosuppression. 
 
6.25 Is OEC innate immunity targeted at invasive pathogens? 
OECs may have an innate immune response targeted specifically at pathogens migrating 
along the olfactory tract from the mucosa into the CNS (Harris et al., 2008; Leung et al., 
2008; Harris et al., 2009). However, fewer OECs showed nuclear localisation of p65 NF-
κB in response to Escherichia coli (E. coli) than astrocytes or microglia, although similar 
to the finding in this study, there was more activation by E. coli when OECs were in co-
culture with microglia (Vincent et al., 2007). OECs also had a muted inflammatory 
response to Staphylococcus aureus (S. aureus) with only minimal upregulation of iNOS 
associated with weak nuclear p65 immunoreactivity, which could have been partly due to 
growth factors in the culture medium, contaminating cells in the culture and overlapping 
cytoplasmic immunoreactivity (Harris et al., 2009). This lesser response to S. aureus may 
represent a greater tolerance to these Gram-positive bacteria that are more commonly 
present on the facial skin and olfactory mucosa than E. coli. A muted innate immune 
response in OECs could serve to protect olfactory neurons against the neurotoxic effects 
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of severe inflammation. OECs produce the chemokines Gro1 and MCP-1 in culture 
(Vincent et al., 2005b) and these could attract macrophages to sites of pathogen 
accumulation. Fractalkine is another chemokine that is produced by OECs, as well as by 
olfactory sensory neurons in the olfactory tract, that is known to have an important role in 
recruiting macrophages (Ruitenberg et al., 2008). The moderation of inflammatory 
responses by IGF-1 and other factors released by OECs could protect olfactory neurons 
and restrict inflammation to the macrophage-occupied region outside the ensheathed 
olfactory neuron fascicles. However, if the infection progressed, dual stimulation by pro-
inflammatory cytokines released from activated macrophages and binding of pathogens 
to TLRs could activate OECs to initiate an inflammatory response within the axon 
fascicles. Apoptosis of neurons could then occur due to their susceptibility to 
inflammation preventing spread of the infection into the CNS. Neuronal death would 
release calcium ions, glutamate and ATP, which could induce OEC apoptosis because of 
their susceptibility to calcium influx. Release of Gro1, IGF-1 and other factors from 
surviving or apoptotic OECs could then initiate progenitor proliferation and 
differentiation in the olfactory epithelium for olfactory neuron renewal. It is possible that 
the immune behaviour of OECs alters as they mature after differentiating from 
progenitors in the olfactory epithelium while accompanying and then ensheathing 
developing or regenerating olfactory axons. Previous studies on immune function in 
OECs have utilised cultures from combined lamina propria and olfactory bulb tissue 
(Vincent et al., 2007; Harris, 2008; Leung et al., 2008; Harris et al., 2009). A sub-
population of more motile immature OECs derived from progenitor cells in the lamina 
propria epithelial tissue during culture could have been principally responsible for the 
immune responses observed in these studies. OECs have been observed migrating 
together with developing olfactory neuron axons (Doucette, 1989; Tennent and Chuah, 
1996). Although there is no evidence of increased OEC motility or proliferation 
following zinc sulphate irrigation injury, with olfactory neuron regeneration and axon 
regrowth apparently occurring within the existing channels formed by the intact OEC 
ensheathments (Williams et al., 2004), this experimental treatment may not accurately 
replicate the response to pathogens. In addition, signaling through olfactory neuronal 
CX3CL1 (fractalkine) to recruit monocyte-derived macrophages and possibly to promote 
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progenitor cell proliferation and differentiation in the olfactory epithelium, appears to be 
an important process in olfactory sensory neuron renewal (Ruitenberg et al., 2008). 
Another possibility is that the sub-population of activated cells were contaminating 
Schwann cells from the peripheral olfactory tract tissue used for the cultures.  
Comparison of NF-κB activation in OECs and Schwann cells could help to clarify this 
possibility. Research on immune responses in mixed cultures containing OECs and 
olfactory neurons at different stages of maturity and related in vivo research on the 
olfactory system could help to further elucidate the immune functions of OECs.  
 
6.26 Correlating astrocyte activation levels with the potential for CNS repair  
As discussed throughout this thesis, moderate inflammatory astrocyte activation probably 
leads to conditions that are conducive to axonal regeneration and CNS tissue repair, 
whereas both severe inflammation and complete inhibition of astrogliosis have 
detrimental effects. It is therefore noteworthy that the moderate levels of astrocyte 
activation following the moderation of PMA/ionophore-induced activation by OECs were 
similar to those following treatment with either metallothionein 2A or PMA. Exogenous 
metallothionein 2A strongly promotes axonal regeneration lending support to the view 
that these moderate levels of astrocyte activation are favourable for CNS repair. Phorbol 
esters, such as PMA were first identified as tumour promoters that induce excessive 
growth and inhibit apoptosis by chronically activating calcium-dependent protein kinase 
(PKC) (Jaken, 1990; Marquez et al., 1992; Szallasi et al., 1996; Ventura and Maioli, 2001; 
Papp et al., 2003).  PKC activates NF-κB via phosphorylation of IKK (Fig. 1.1) (Baeuerle, 
1998; Huang et al., 2003; Amos et al., 2005; Hull et al., 2006) and the moderate levels of 
NF-κB translocation induced by PMA, metallothionein 2A and by PMA/ionophore in the 
presence of OECs may represent activation through this PKC pathway that could lead to 
the transcription of neuroprotective and growth-promoting genes. In contrast, excessive 
calcium ion influx following CNS injury has detrimental effects on cells as illustrated by 
the dose-dependent calcium ionophore-induced apoptosis described in Chapter 5. The 
stronger activation of astrocytes by ionophore or combined PMA/ionophore may 
stimulate calcium signalling pathways that combine with the PKC pathway to more 
strongly induce NF-κB translocation. Simultaneously activated MAPK pathways could 
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synergise with NF-κB to promote increased transcription of pro-inflammatory factors that 
can increase CNS tissue damage. These possibilities reinforce the need to compare the 
transcriptional effects of the different levels of astrocyte activation in response to these 
treatments and the moderating effects of OECs.  
  
6.3 In vivo OEC implantation research 
6.30 Implanted OECs survive in the lesion 
The research in this thesis aimed to provide insight into possible mechanisms that may 
contribute to improved tissue repair in response to OEC transplantation following CNS 
injury. Any findings of the research ultimately require testing in vivo and some progress 
has been made towards this goal using a focal cortical needle-stick injury model (Fig. 6.0) 
(King et al., 1997; Chung et al., 2003). This preliminary in vivo research, outlined below, 
has produced some promising results as well as revealing some potential sources of error 
that should be considered for future research. Carboxy-fluorescein diacetate succinimidyl 
ester (CFDA-SE) staining of implanted OECs confirmed that many remained viable 7 
days after implantation in the lesion, since the fluorescent label is only inherited by 
daughter cells after cell division, is not transferred to adjacent cells in a population and is 
rapidly degraded in dead cells (Lyons and Parish, 1994; Bracher et al., 2007; Quah et al., 
2007; Weischenfeldt and Porse, 2008). Some of the implanted cells infiltrated the 
reactive astrocytes surrounding the lesion, although the majority remained in the lesion 
within the boundary formed by the GFAP-positive astrocyte processes aligned along the 
border of the lesion (Fig. 6.0 B-D). Some weak GFAP immunostaining could have been 
expected in the implanted OECs, although it may not have been visible at the exposures 
used for these images. Additional high magnification, longer exposure images of the cells 
in the lesion, together with a nuclear stain, could help to positively identify, delineate and 
demonstrate the viability of these cells. There are always some fibroblasts in the OEC 
cultures and it is possible that these preferentially survived and proliferated during the 7 
days after implantation. For this reason, it would be desirable to conduct immunostaining 
against, for example, p75NTR and S100, for which OECs immunostain more intensely 
than for GFAP, in conjunction with the CFDA-SE staining, to confirm the presence of 
surviving OECs in the implants. 
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6.31 Measuring the injury response 
 This needle-stick injury was ~0.5mm deeper than intended and cavities formed at the 
base of the lesion (Fig. 6.0B-C) probably due to blood vessel damage and consequent 
severe local ischemia. Despite this relatively severe injury, the GFAP immunoreactivity 
around the lesion was not as intense or extensive as following a 1.5mm deep lesion in a 
control saline-injected lesion, where there was no apparent blood vessel damage or lesion 
cavity (Fig. 6.1A). This promising result could be due to the moderation of astrocyte 
inflammatory activation by the implanted OECs as found in the in vitro model. Obviously, 
this requires confirmation with additional animals and ideally immunostaining, Western 
blotting and real-time PCR evidence for the moderation of NF-κB activation, 
inflammatory gene expression, astrogliosis and glial scarring. It is possible that any 
cellular implant is preferable to an open injury cavity and the implantation of other cell 
types such as astrocytes, fibroblasts and microglia could provide useful comparisons with 
the OEC transplants. Small variations in the position and orientation of the needle-stick 
injury can result in large variations in the extent of injury due to blood vessel damage 
(Fig. 6.1B) independent of any intentional treatment effects. This variation would 
obviously be a confounding effect with seriously detrimental consequences for the 
validity of the research if the initial injuries were assumed to be equivalent for 
comparisons between controls and/or treatment groups. Consequently, animals should all 
be of the same age and size. Furthermore, great care and skill is required in positioning 
animals correctly in the surgical stereotax, location of the injury site, drilling through the 
skull, performing the needle-stick injury (Fig. 6.1) and suturing the wound. 
Metallothionein 1/2 upregulation reaches a peak at 2 to 4 days post-injury (Fig. 6.2) and 
is another potential indicator of astrocyte inflammatory activation (Penkowa et al., 1997; 
Campagne et al., 2000; Trendelenburg et al., 2002; Chung et al., 2008) and the severity of 
injury. Immunoreactivity for ferritin identifies activated macrophages (King et al., 2001; 
Huang and Ong, 2005) in the lesion and penumbra (Fig. 6.2). Western blotting of cortical 
samples revealed increased GFAP expression in the samples from injured compared to 
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Figure 6.0 A focal cortical injury with implanted OECs. Carboxyfluorescein diacetate 
succinimidyl ester-stained (CFDA, green in B-D) OECs were implanted at the time of injury into 
a 2mm deep cortical needle-stick injury in an adult male rat. Markedly increased GFAP 
immunoreactivity occurred around the injury (B-D) contrasting with the low immunoreactivity 
throughout the uninjured hemisphere (A). GFAP-expressing astrocyte processes align with the 
lesion border (C and D). There are two large cavities at the base of the lesion (C) probably due to 
blood vessel damage. The majority of the implanted OECs occupy the lesion but some have 
infiltrated the reactive astrocytes in the lesion penumbra (asterisks in C and arrows in D). Some 
CFDA-stained cells have elongated morphologies that resemble in vitro OEC morphologies (Os 
in D). Scale bar is 200μm. 
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Figure 6.1 Vascular damage increases lesion size. All three cortical needle-stick injuries 
(location shown by large arrows in A, B and C) received control saline injections at the time 
of injury. Tissue was dissected and fixed 7 days after injury, then sectioned and 
immunostained for GFAP (red). A small variation in the location of the injuries caused 
vascular damage and a large lesion cavity 7 days after injury (B). A descending arteriole is to 
the left of the lesion in A (small arrows). Large concave lesions on the cortical surface can be 
caused by heat and abrasion while drilling through the skull and become filled with 
coagulated blood and immune cells (asterisks in B), which are often lost from the section 
during processing (A).  This unintentional drill damage can cause more damage than the 
needle-stick and is potentially a major confounding factor in this injury model.  
Improvements in the drilling technique enabled needle-stick injuries with little surface injury 
(C) and consequently a much more restricted region of increased GFAP immunoreactivity 
around the lesion. Scale bar is 500μm. 
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Figure 6.2 Metallothionein 1/2 and ferritin expression at 4 days post-injury. 
Immunoreactivity for metallothionein 1/2 (MT1/2, green) is increased in astrocytes in the 
lesion penumbra, 4 days after a cortical needle-stick injury (large arrow). Ferritin 
immunoreactivity (red) identifies activated macrophages, which occupy the needle-stick 
lesion and a large concave lesion caused by drilling through the skull. More sparsely 
distributed activated macrophages also occur in the penumbral tissue. These may represent 
both activated microglia migrating towards the lesion and macrophages from blood migrating 
into the injured CNS tissue from the lesion. Nuclei are counter-stained with Hoechst blue 
DNA stain (HB). Several descending blood vessels can be clearly distinguished in the section 
(small arrows) and the needle-stick lesion intersects the largest of these. Scale bar is 500μm. 
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uninjured hemispheres (Fig. 6.3).  The relative differences in GFAP expression are also 
dependent on the size of the tissue sample relative to the region of altered protein 
expression and the extent to which increased GFAP immunoreactivity represents 
increased expression rather than merely changes in phosphorylation and polymerisation 
status. Changes in protein expression may also refect changes in cellular composition 
within the sample region and immunostaining of equivalent regions would help to clarify 
this possibility.  
 
6.32 Measuring CNS tissue repair and functional recovery  
The measures described above can provide valuable information regarding the likelihood 
of beneficial effects from OEC implantation and the mechanisms for any such effects. 
However, the therapeutic goal of this research is to demonstrate improvements in 
neuronal regeneration and functional recovery. Immunoreactivity for phosphorylated 
neurofilaments has been used as an indicator of neurite sprouting (King et al., 1997; 
Maxwell et al., 1997; Dickson et al., 2000). The most intense immunoreactivity (Fig. 6.4) 
for phosphorylated neurofilaments co-localises with microtubule-associated protein 2 
(MAP2) immunoreactivity (Fig. 6.4G and H) in damaged axons on the lesion border (Fig. 
6.4F). If this intense SMI312 staining does unequivocally represent neurite sprouting, it implies 
there must be massive sprouting of abortive neurites into the lesion. A less marked increase in 
phosphorylated neurofilament immunoreactivity occurs in the lesion penumbra and 
injuries where the lesion appears to be due primarily to the needle-stick (Fig. 6.4A-C). 
This phosphorylated neurofilament immunoreactivity in relatively intact tissue may 
represent neurite sprouting or axonal restructuring, although immunoreactivity is also 
increased in regions that were damaged during sectioning of the fixed tissue (Fig. 6.4D 
and E). Higher resolution confocal microscopy and axonal growth cone markers, such as 
GAP 43 (Dickson et al., 2000; King et al., 2001; Cafferty et al., 2004), may be required to 
demonstrate improvements in axonal regeneration. Spinal cord and brain injury models 
where distinct axonal tracts are lesioned may be more amenable to assessing both axon 
regeneration and any functional improvements in motor or cognitive behaviour resulting 
from OEC implantation. 
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Figure 6.3 Cortical injury increases GFAP expression. Rats were euthanised 7 days post-
injury, brains removed and a 4mm section that included the lesion (small arrow in A) cut (dashed 
lines in A) through the entire brain. The injured and uninjured hemisphere portions of the section 
were separated and the cortical portions peeled from the hindbrain (B). A 4x4mm section of the 
cortex centred on the injury site and an equivalent section from the uninjured hemisphere (dashed 
lines in B) were cut and processed for Western blotting (C). All samples are from the same 
control saline-injected, cortical needle-stick injured rat. Blot lanes alternate between uninjured 
and injured hemisphere samples. Stronger protein bands indicate increased GFAP expression in 
injured hemispheres relative to uninjured hemispheres. B actin loading control lanes indicated 
similar amounts of total protein were loaded in each lane. 
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Figure 6.4 Phosphorylated neurofilament and MAP 2 immunoreactivity in injured neurons. 
Cortical sections were immunostained using antibodies against phosphorylated neurofilaments 
(SMI312, green) and microtubule-associated protein 2 (MAP2, red) 7 days after needle-stick 
injuries. Nuclei are counter-stained with Hoechst blue (HB). In injuries where the lesion 
corresponds closely to the needle-stick (A) neuronal death in the lesion results in a loss of MAP2 
immunoreactivity and the lesion appears as a dark region in the image (small arrows in A). The 
section is on the border of the lesion and there is overlying increased MAP2 and SMI312 
immunoreactivity in neurites in the lesion border more clearly seen in the enlarged images (B and 
C). The phosphorylated neurofilaments appear to commence around layer 3 of the cortex (C) and 
extend towards layer 1 and the dorsal surface (B). The phosphorylated neurofilament 
immunoreactivity within the relatively intact tissue does not coincide with the MAP2 
immunoreactivity. A similar pattern and increase in immunoreactivity occurs in cortical tissue 
damaged after fixation during sectioning (D and E). Where there is more extensive tissue damage 
(F) intense immunoreactivity for phosphorylated neurofilaments (F and G) co-localises with 
MAP2 immunoreactivity (F, G and H) in a tangled mass of neurites. Scale bar is 250μm.  
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6.4 Conclusion 
This thesis provides evidence for a moderating effect of OECs on astrocyte inflammatory 
activation that could contribute to improved tissue repair following CNS injury in 
response to transplanted OECs. An apparent resistance of OECs to inflammatory 
activation and a susceptibility to apoptosis in response to inflammation-related calcium 
influx have implications for OEC interaction with neurons and other cells in their normal 
olfactory neuron support role and for transplanted OECs. Continuing research utilising 
the in vitro model established by this research complemented by the additional in vitro 
and in vivo research described above will further elucidate OEC biology and the 
mechanisms for their therapeutic effects.  
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